Learning to Dance  in the Rain: Stories of Young People taking Antipsychotic Medication by Ramdour, Sonia Jane
  
Learning to Dance in the Rain:  Stories of Young 
People taking Antipsychotic Medication 
 
 
by 
 
Sonia Ramdour 
 
 
 
 
A thesis submitted in partial fulfilment for the requirements for the 
degree of Doctor of Philosophy at the University of Central 
Lancashire 
 
March 2016 
 
 
 
 
2 
 
 
 STUDENT DECLARATION FORM  
 
 
Concurrent registration for two or more academic awards  
I declare that while registered as a candidate for the research degree, I have 
not been a registered candidate or enrolled student for another award of the 
University or other academic or professional institution  
 
 
Material submitted for another award  
I declare that no material contained in the thesis has been used in any other 
submission for an academic award and is solely my own work  
 
 
 
Signature of Candidate:  
 
 
 
Type of Award:  Doctor of Philosophy  
 
 
School:   School of Nursing 
 
 
3 
 
 
 
 
 
 
 
 
This thesis is dedicated in loving memory of my 
father 
 
 
Chandra Ramdour 
4 
 
Abstract  
Early intervention to promptly identify and treat psychosis limits the duration of 
untreated psychosis and improves patient outcome.  Despite evidence to 
support efficacy, approximately 50% of young people do not take antipsychotic 
medication as prescribed.  This research was designed to explore factors which 
may promote and deter teenage adherence with antipsychotic medication. 
Initially intended as a quantitative study, the research pragmatically shifted to a 
qualitative design following recruitment difficulties.  Narrative inquiry and auto-
photography were used to obtain stories from ten young people prescribed 
antipsychotic medication as a teenager.  Participants collected images 
illustrative of their medication journey, discussing these images and their 
medication stories at interview. 
Analysis of data uncovered a metastory of a journey from darkness to 
brightness.  In darkness, symptoms predominated bringing fear, isolation and 
unpredictability.  As medication took effect, stories became brighter evidencing 
hope, happiness and productivity.  Four stories linked to medication adherence 
emerged; namely endurance, motivation, control and resentment. Underpinning 
sub-stories included the endurance of resisting symptoms, taking medication 
long term and dealing with medication side effects.  Sub-stories of motivations 
related to being well, being a ‘normal’ teenager and having a brighter future. 
Control was evident in the positive choices made, degree of openness and level 
of independence exerted. Young people often resented the fact that they were 
ill and were prescribed medication. They felt different from their peers.  The 
main motivation for young people to take prescribed medication was to be well.   
Poor adherence was most commonly due to forgetfulness.  
My findings suggest young people balance positive stories of motivation and 
control against negative stories of endurance and resentment when making 
decisions about medication.  Adherence is dynamic as the balance of positive 
and negative stories constantly shifts. Staff should explore individual stories of 
motivation, control, resentment and endurance frequently, to better understand 
and promote medication adherence. 
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CHAPTER ONE.  INTRODUCTION 
In presenting this narrative research of the medication stories of young people 
prescribed antipsychotic medication in their teenage years, I have chosen firstly 
to describe the journey which led to my interest in pharmacy, healthcare and 
more specifically mental health.  I then describe my reasons for the research 
topic chosen, including further information about my PhD journey and how this 
progressed.  Finally, I provide an outline of how my thesis is then presented.  
Throughout I have included reflective entries considering how my past 
experiences had the potential to influence my own position within the research 
undertaken.  
1.1. The Start of My Journey 
On reflection the start of my journey began in childhood, living with my parents 
and younger sister in Preston.  My mother did not work whilst I was a young 
child but later went to teacher training college whilst I was at primary school.  
Post-qualification she worked teaching children who were mentally and 
physically disabled.  My father moved to the United Kingdom from Mauritius at 
the age of 17 and subsequently trained as a nurse.  He was both a registered 
general and mental health nurse.  My father worked in a number of mental 
health specialties over the years, however, I only ever remember him working 
on older adult mental health wards.   
I strongly believe that both parents having a background working with people 
with mental health and learning difficulties influenced my views and career 
choices.  As a child, my sister and I would accompany my father to work during 
the school holidays when childcare was difficult to arrange.  During our early 
childhood my father worked at the local mental health hospital, a large thriving 
community catering for hundreds of patients and my memories of visits to the 
hospital as a child are still vivid.  One occasion springs to mind where my sister 
and I were particularly scared of an ‘old lady’ on the ward who was shouting and 
distressed.  I remember us both sharing a big armchair and huddling into it 
thinking that she then would not notice us.  Apart from that one occasion, I just 
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remember being around the patients both on the wards and in the hospital 
grounds whilst we played and remember feeling comfortable rather than uneasy 
in this setting.  My sister and I also used to regularly attend the social functions 
held at the school where my mother worked, including the school discos where 
we would dance with the students.  I think that this exposure to those with 
mental health and learning difficulties at a young age gave me a greater 
appreciation of the difficulties some faced, but also meant that I felt comfortable 
with people who were diagnosed with mental health and physical or learning 
disabilities.  
I decided whilst at high school that I wanted to become a pharmacist as I 
enjoyed science subjects, particularly chemistry.  I ended up moving to 
Liverpool at the age of eighteen to start a pharmacy undergraduate degree 
course.  Course content was limited in the area of mental health, however, we 
were lucky to receive exposure to the different fields of pharmacy during the 
course.  I was clear having worked in these various fields, that a career as a 
hospital pharmacist would give me most job satisfaction as it provided greater 
opportunity to utilise my clinical training, influence patient care and outcomes 
and work alongside other healthcare professionals.  I finished my degree in 
1990, and started my pre-registration placement at a local hospital.  During my 
pre-registration year I rotated through the various directorates and was lucky to 
spend four weeks on a mental health rotation.  This mental health placement 
was back at the mental health hospital where my father had worked when I was 
at primary school and, given that it was in the days before the vast majority of 
long stay patients were discharged to community placements, there were still 
many wards located across the vast estate supporting large numbers of 
patients.  The mental health pharmacist routinely attended consultant ward 
rounds and it was clear from the start that she was influencing and supporting 
decisions and choices around medication.  She also spent a lot of time talking 
to patients and understanding their medication histories.  It was immediately 
apparent to me that she was a valued and important member of the 
multidisciplinary team.  This mental health placement sparked my interest in the 
field and this continues to this day.  I see the impact, both positive and negative, 
that medication has on patients and am passionate about the important role a 
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pharmacist plays in supporting patients and staff in making decisions about 
medication choices.   
Following my pre-registration year I became a resident pharmacist, working 
shifts to ensure seven day cover and continuing to rotate through the various 
hospital specialities.  Such was my love of mental health pharmacy, I always 
asked if I could cover the mental health wards when the mental health 
pharmacist was on annual leave.   
After a couple of years, I then moved to another hospital where again I asked to 
cover the mental health wards on a permanent basis whilst also rotating through 
other areas.  It was also at this stage in my working career that I completed a 
Postgraduate Diploma in Psychiatric Therapeutics wishing to further my 
knowledge in the field.  My father by now was also working at the same hospital 
as senior nurse manager for the older adult mental health unit.  We did not work 
routinely together, however I would on occasion bump into him on the wards 
when I was reviewing the prescription charts.  Whilst we used to talk about work 
a lot, this tended to be very general.  We never had lengthy discussions about 
medication adherence or mental illness.  In 1996, an opportunity arose to 
specialise as a mental health pharmacist and I leapt at this opportunity.  Since 
then I have worked on acute, adult, older adult, secure, rehabilitation and young 
people’s wards as well as providing services to all associated community 
teams.  The majority of my clinical time has been spent on adult, older adult and 
secure mental health wards with less time spent on the young people’s wards or 
in the community teams.   
1.2. Deciding Upon a Research Topic 
Despite my limited exposure to young people with mental illness, I have always 
been aware that delays in effective treatment and poor medication adherence 
risk adverse outcomes. I was therefore keen to explore and understand this in 
more detail.  This prompted my initial interest in undertaking research with 
young people in Early Intervention Services for mental health.   
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Colleagues spoke of the difficulties in undertaking research with young people 
as they are sometimes perceived as difficult to engage (Rhee et al., 2008, 
Nguyen et al., 2014).  Whilst married, I have no children and so this also means 
that I do not spend considerable periods of time in the presence of young 
people.  I have contact with teenagers through friends and family, however, this 
is much more different than living with young people and understanding things 
such as how they interact, behave and communicate.  I was from the outset 
aware that I may not fully understand the terminology in common use and would 
need to clarify any points of understanding. However, I felt that this would not 
unduly disadvantage my undertaking this research as I would be able to ask 
staff routinely working with young people for any advice should this be needed.   
Throughout my career in mental health I have always thought that medication 
adherence was important.  On occasions, I have been prescribed courses of 
medication which I have not completed, or have missed doses of medication 
such as antibiotics and prophylactic antimalarial medication. Given this, some 
might question my statement that medication adherence is important, I would 
hope however that should I ever be prescribed medication for my mental health, 
I would fully adhere to this.  This is because of my personal experiences of 
possible outcomes when medication adherence is poor and the subsequent 
distress it can cause to family members.  Whilst there is no history of mental 
illness in my immediate family, I do have two more distant family members 
diagnosed with mental health problems in adulthood.  I became more involved 
in the support of one family member whilst she was an inpatient, and have also 
provided support to her siblings in response to their distress that she was not 
taking her medication.  When she was in hospital I went with my parents to visit 
her, and during the visit my father and I spent some time discussing how 
important it was to take medication to stay well.  This was in response to 
concerns from staff and my father that she would not take medication post-
discharge.  From this conversation, I know that my father also shared my view 
that medication adherence was important.   
I hope that my clinical experience working as a mental health pharmacist has 
afforded me some understanding of why people might not want to take 
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medication. I have also extensively read the literature on this issue.  I have seen 
the deleterious effects on physical health that has resulted from antipsychotic 
use in some people, and have on occasions recommended that particular 
medication is changed in response to side effects significantly impacting on a 
person’s physical health and wellbeing.  I feel that whenever medication is 
proposed, comprehensive information needs to be provided.  This needs to be 
appropriate so the recipient is able to understand and process this information 
to enable an informed choice about whether to take medication.  I think that 
patients should be fully involved in discussions about medication so that they 
can be partners in the decision about which antipsychotic medication is 
prescribed.  If they are unable to do this at the time due to their mental health, 
their involvement should be revisited at a later date. Whilst I appreciate that 
there are multi-modal approaches to treatment, my view is that medication is 
the cornerstone of treatment for psychosis complementing psychological and 
psychosocial interventions.  Some would consider that I follow a ‘medical model’ 
in my role, and I accept this.  I do, however, appreciate that other healthcare 
professionals would argue against adopting a medical model approach feeling 
that social and psychological factors are more important that the biological.   
My passion for mental health and strong conviction that medication plays a vital 
role in the management of mental illness and improved outcomes for patients 
drove my desire to conduct research in this area to further enhance knowledge.  
Given my interest in medication adherence, and awareness that delays in 
instituting effective treatments for first episode psychosis (FEP) can have an 
adverse effect on patient outcome, I decided that this was the field in which I 
wanted to conduct my research.  I felt that in undertaking this research, there 
was potential to strengthen the limited research literature base. The knowledge 
obtained could then influence medication interventions and approaches taken 
with young people who are being prescribed antipsychotic medication for the 
first time.  Whilst my clinical experience has predominantly been with adults with 
chronic psychosis, I instinctively felt that different drivers to take or refuse 
antipsychotic medication may be present in this younger age group with first 
presentation psychosis.  I wondered whether peer pressure from other 
teenagers may influence medication decisions given that teenagers are often 
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easily swayed by the views of others.  In a similar vein, I also wondered whether 
teenagers would be influenced by depictions of mental illness and antipsychotic 
medication in the media. 
1.3. My PhD Journey 
Having decided to research medication adherence in young people with 
psychosis, I then had to decide on my research questions.  Initially I decided 
that I wanted to explore the factors staff, young people and their carers felt 
supported and detracted from adherence with antipsychotic medication. This 
would enable an assessment of whether the views across the three groups 
were similar or discrepant.  The findings could then be compared with the 
published research outlining factors affecting adherence in children with chronic 
mental and physical health conditions.   
I firstly considered whether focus groups would be a way of engaging staff, 
young people and their carers and gathering qualitative data on medication 
adherence.  There was a facility within the University of Central Lancashire 
which specialised in running innovative and creative focus groups and I held 
some exploratory meetings to consider the different options available.  
Following these meetings I was interested in using Lego Serious Play©, a form 
of Lego bricks designed to be used by adults, to model more serious themes.  
To explore the feasibility of this, a meeting was held with the child and 
adolescent mental health (CAMHS) workers based in the early intervention 
service.  Feedback received at this meeting was that some patients were 
reticent about being involved in a group and would prefer participation on an 
individual basis.  The fact that their parents may also be involved in the study 
was seen as a drawback for some teenagers’ participation in focus groups.  
During this stage, I also met with a professor at the University of Central 
Lancashire, whose particular research focus is with young people who are ill.  
She also indicated that sometimes young people just feel that they have little to 
contribute to a particular topic, are reluctant to travel to a place of unfamiliarity 
and speak in front of people they do not know.  Based on this feedback I 
therefore decided to discount the use of focus groups and sought alternative 
means of engagement.   
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Having decided against using focus groups, I explored other avenues for 
engaging staff, young people and carers.  I was keen to use technology as 
researchers working with children and young people suggested that this was an 
effective way of engaging this age group.  I therefore chose to take a 
quantitative approach, developing and distributing a survey to obtain further 
information about medication adherence in this patient population.  The 
intention was ultimately to develop and ratify a tool to assess medication 
adherence in children and young people, utilising the survey data obtained in 
the tool design.  Despite numerous attempts to garner a sufficient response 
from suitable candidates, I received only a handful of responses from patients 
and their carers.  This was disappointing as my predominant desire in 
undertaking this research was to understand the views of young people 
themselves.  Without this, I felt that the research would have less utility in 
supporting clinical interventions to promote medication adherence.  Given the 
poor survey response rate by carers and young people, I spent a long time 
considering why the survey had failed to garner sufficient interest from young 
people and their carers so I could contemplate other avenues by which to 
gather information.  My explorations of research in young people then 
uncovered the possibility of using visual methodologies to effectively engage 
young people in qualitative research.  I found references to the use of narrative 
research, where stories are used as source data.  I felt that young people may 
be more interested in the research if they were asked to tell their story about 
taking medication using photographs, media images or drawings.  In line with 
the requirements of my ethics approval, I was reliant on care co-ordinators to 
initially identify suitable participants.  I therefore attended several meetings with 
staff working in Early Intervention Services, inpatient services for young people 
as well as several support groups for young people with psychosis.  Posters 
advertising the research were also displayed in buildings where young people 
attended outpatient appointments.  Despite all of these efforts recruitment was 
particularly slow.  I feel that this was because there were several research 
projects being undertaken within the teams and so the young people were 
perhaps involved in other research projects.  Additionally, care coordinators had 
lots of competing priorities and so advertising my research in their busy 
schedules was perhaps less of a priority.  Thankfully there were several care 
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coordinators and a couple of consultant psychiatrists who were particularly 
supportive, and due to the efforts of these people I managed to recruit 12 young 
people to the research with 10 young people completing data generation. 
A further surprise and source of frustration was that despite allowing four weeks 
to complete the data collection phase this invariably took longer, and required 
numerous emails, phone calls and text messages on my part to ensure that the 
photographs were returned.  In hindsight, I feel that I had been very naive in 
expecting teenagers who were busy at school and college, and who were at 
times mentally unsettled, to independently return the photographs without 
prompting.   
Because of my concerns about getting sufficient numbers of participants, I 
decided to submit a substantial amendment to allow recruitment of people who 
were over 18, on the condition that they had taken medication at some point 
between the ages of 14 and 18.  In the end, there were only two participants 
who fell into this category, both being twenty years of age.  The other eight 
young people who completed the research were between the ages of 14 and 
18. 
Having completed the recruitment and analysed the data obtained, I then 
completed the writing of my PhD thesis, the structure of which will now be 
outlined. 
1.4. The Structure of my PhD Thesis  
Following on from this introductory chapter, Chapter Two provides an overview 
of psychosis in childhood before discussion the concept and relevance of 
duration of untreated psychosis (DUP).  Information is also provided about the 
use of medication in psychosis describing psychosis in children and young 
people.  Chapter Three then presents further detail on medication adherence 
and includes the search strategy supporting the integrative literature review of 
factors affecting medication adherence in FEP.  Chapter Four is a stand-alone 
chapter dedicated to the survey research.  Whilst initially debating whether the 
survey should be included in a thesis given the research is a qualitative 
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exploration of young people’s stories of taking antipsychotic medication, the 
survey research with staff uncovered valuable information.  This included, for 
example, the finding that nursing staff rate the impact of substance misuse, 
interference with goal attainment, fear of hospital admission and family views on 
medication adherence lower than prescribers.   Whilst the survey research 
represented a detour in my qualitative research journey, I have dedicated 
Chapter Four to this detour, as the survey findings provide a means of 
contrasting staff and young people’s views within the discussion chapter.  It also 
facilitates deliberation about whether staff views may impact on the 
effectiveness of clinical interventions to promote teenage adherence with 
antipsychotic medication. In Chapter Five, I outline the qualitative methodology 
used for my PhD study stating my research aim and questions, describing the 
underpinning research framework, before explaining in more detail how the 
research was undertaken.  Chapter Six provides an overview of the participants, 
whilst Chapter Seven details the findings of the narrative research undertaken 
with young people. Chapter Eight is dedicated to a discussion about the 
research findings and how this augments current literature in the field. Finally, in 
Chapter Nine I outline my original contribution to research, strengths and 
limitations of the study, implications for clinical practice and suggest areas for 
further research.   
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CHAPTER TWO.  BACKGROUND 
2.1. Introduction 
The purpose of this chapter is to give an overview of psychotic illness in 
children and adolescents before focusing on the role of medication in treatment. 
I start by presenting an overview of psychotic illness in children and young 
people considering prevalence rates, prodromal states and subsequent 
transition to psychosis.  The concept of Duration of Untreated Psychosis (DUP) 
is outlined, with particular reference to factors affecting DUP and the impact this 
has on outcomes.  Information is provided about medication prescribed to treat 
psychotic symptoms with consideration given to the effectiveness of 
antipsychotic medication in FEP.  Finally, I discuss adherence to antipsychotic 
medication paying specific attention to the assessment of adherence, rates of 
adherence to antipsychotic medication in FEP and consequences of poor 
medication adherence. 
Whilst recent guidance has suggested that Schizophrenia should be the 
preferred  term for those fulfilling diagnostic criteria for the condition (Cantwell et 
al., 1999), I have opted to use the term psychosis throughout this thesis.  This is 
because psychosis is the term I would most commonly use when speaking to 
young people about antipsychotic medication.  I accept that some young people 
find it helpful to understand their experiences in the context of a particular 
diagnosis, however others find being labelled with schizophrenia stigmatising, 
confusing and distressing (Cantwell et al., 1999). For this reason I prefer to use 
the term psychosis, unless the person themselves refers to their illness as 
schizophrenia.  This also mirrors the terminology used by colleagues working 
within the Early Intervention Service (EIS). 
2.2. Psychosis in Childhood. 
Before considering the topic of medication adherence in FEP, it is important to 
have an understanding of the prevalence and presentation of psychosis in 
childhood.    Available information suggests prevalence rates of approximately 
1.6 to 1.9 per 100,000 child population (Gillberg, 1984, Burd and Kerbeshian, 
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1987, Hellgren et al., 1987, Gillberg, 2000).  Prevalence starts to increase 
sharply from the age of 14, with peak prevalence in the late teens and early 20s 
(Gillberg et al., 1986, Thomsen, 1996).  Prior to the emergence of full blown 
psychotic symptoms in young people, prodromal symptoms are often evident. 
Defined as “early or premonitory symptoms of a disease or disorder” (Campbell, 
1989), these symptoms may develop following a period of acute stress, distress 
or physical illness (Lincoln et al., 2011).  Symptoms characteristic of a prodrome 
include marked withdrawal, impairment in role functioning, peculiar behaviour, 
impaired personal hygiene, blunted or inappropriate emotional response, 
speech disturbances, odd beliefs or magical thinking, unusual perceptual 
experiences and marked lack of initiative, interest or energy (American 
Psychiatric Association, 1987).  Low mood, withdrawal, sleep disturbance and 
changes in appetite are most commonly reported (Herz and Melville, 1980, 
Birchwood et al., 1989).  Following the emergence of non-psychotic prodromal 
symptoms, frequent and excessive emotional displays may precede the 
development of overt psychotic symptoms (Docherty et al., 1978). Psychotic 
symptoms include ‘positive symptoms’ such as thought disorder, paranoid 
delusions and hallucinations, as well as ‘negative symptoms’ such as marked 
apathy, blunted or incongruent emotions and social withdrawal (Wing and 
Brown, 1970).  Progression of prodromal symptoms to frank psychosis usually 
occurs over a period of less than four weeks (Herz and Melville, 1980, 
Birchwood et al., 1989, Jorgensen, 1998), although the prodrome may last up to 
one year (Padmavathi et al., 1998). 
Most of the disabling consequences of psychosis, in particular effects on social 
outcomes, develop before the onset of psychotic symptoms (Jones et al., 1993, 
Hafner et al., 1995, Yung et al., 1996).  Early prodromal symptoms of mood, 
sleep and appetite disturbance as well as social withdrawal may spontaneously 
remit without intervention or, alternatively, develop into a disorder which may or 
may not be a psychotic episode (Gaebel et al., 1993).  Thus, an emerging 
psychotic episode is extremely difficult to diagnose until the end of a pre-
psychotic stage (Hafner et al., 1995, McGorry et al., 1995).   
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Studies have reported transition rates from prodromal to psychotic states of up to 
50% (Klosterkotter et al., 2001, Miller et al., 2002, Yung et al., 2003, Haroun et 
al., 2006). A recent meta-analysis predicted transition in those at high risk of 
psychosis as 18% after 6 months, 22% after 12 months, 29% after 24 months, 
and 36% after 36 months of follow-up (Fusar-Poli et al., 2012). More recently, 
transition rates appear to be declining, with one centre in Victoria, Australia 
estimating a 20% year on year reduction (Yung et al., 2007).  It has been 
suggested that these declining transition rates may be secondary to the benefits 
of early intervention treatment strategies, a greater likelihood of “false positives” 
because people are seeking help earlier, or benefits of adjunctive treatment with 
anxiolytics and antidepressants in the prodromal phase (Yung et al., 2007).  
Whilst treatment of prodromal symptoms with antipsychotic medication may 
appear logical, ethically it causes some dilemmas.  This is because it may result 
in unnecessary treatment of some patients whose prodrome would not have 
developed into a psychotic illness (Yung and McGorry, 1997, Rosen, 2000, 
Cornblatt et al., 2001, McGlashan, 2001, Corcoran et al., 2005).  Randomised 
controlled trials have suggested potential benefits to treatment of medication in 
the prodrome (McGorry et al., 2002, McGorry et al., 2013), although positive 
benefits of medication did not always reach statistical significance (McGlashan et 
al., 2006). A recent meta-analysis concluded that preventive interventions, such 
as psychological and pharmacological treatment, in those at ultra-high risk of 
developing psychosis can reduce the risk of onset of the disorder by 52% to 54% 
after 12 months and by 35% to 37% in the longer term (van der Gaag et al., 
2013).  It was estimated that treatment of nine people in a prodromal state for 12 
months would prevent conversion to FEP in one person (van der Gaag et al., 
2013). What is clear, is that the early years following transition from prodrome to 
psychosis form a critical period, because of the likelihood of a rapid deterioration 
in functioning and poor recovery rates in the longer term, if psychosis is not 
adequately treated (Birchwood et al., 1998, Crumlish et al., 2009).  EIS in the UK 
developed in recognition of the need to facilitate early detection of emerging 
psychotic symptoms, reduce delays to first treatment and provide consistent 
intervention during the critical period following initial diagnosis (Joseph and 
Birchwood, 2005).  This strategy to support prompt and effective treatment is 
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crucial to limit duration of untreated psychosis and maximise positive outcomes, 
as will now be outlined. 
2.3. Duration of Untreated Psychosis (DUP) 
DUP is defined as the time from manifestation of the first psychotic symptom to 
initiation of adequate antipsychotic drug treatment (Norman and Malla, 2001).  
Whilst estimation of DUP might seem straightforward on the basis of this 
definition, variations in how the onset of psychotic symptoms is defined, 
judgements as to when presentation switches from unusual or eccentric to 
psychotic, the degree of recall by patients (which in itself may be influenced by 
psychotic symptoms experienced), as well as recall of carers are all potential 
confounding variables (Häfner et al., 1993, Browne et al., 2000).  The time at 
which DUP ends also varies in studies and can include the point at which 
antipsychotic medication is initiated, or the time at which adequate treatment 
according to particular criteria is reached (Larsen et al., 1996, Edwards et al., 
1998, Haas et al., 1998, Craig et al., 2000).  Despite these difficulties, it has been 
estimated that once psychotic symptoms appear the average DUP is between 
one (Loebel et al., 1992) and two (Larsen et al., 1996) years. A literature review 
was undertaken of factors affecting DUP.  A number of themes emerged which 
will now be presented.   
2.3.1. Factors Affecting Duration of Untreated Psychosis 
Studies conducted in different countries have found variation in DUP across 
developed and developing countries.  Studies have shown that prolonged DUP in 
developing countries is more likely where those with psychosis are living with 
extended families due to delays in seeking treatment (Padmavathi et al., 1998, 
Srinivasan et al., 2001).  Cultural differences in familial recognition of illness can 
also delays access to treatment in developing countries (Srinivasan et al., 2001).   
Migration to another country has been linked to a prolonged DUP (Sterk et al., 
2010, Boonstra et al., 2012b, Apeldoorn et al., 2014, Nerhus et al., 2015).  Other 
factors associated with prolonged DUP include male gender  (Loebel et al., 1992, 
Larsen et al., 1996, Larsen et al., 1998, Johannessen et al., 1999, Melle et al., 
2004, Chang et al., 2011, Fridgen et al., 2013, Apeldoorn et al., 2014) and 
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younger age at onset of psychotic symptoms (Johannessen et al., 1999, Craig et 
al., 2000, Bechard-Evans et al., 2007, Schimmelmann et al., 2008, Apeldoorn et 
al., 2014).  Also of relevance is a family history of admission to a mental health 
ward (Verdoux et al., 1998), stigma (Corrigan, 2004, Tanskanen et al., 2011, 
Sadeghieh Ahari et al., 2014), insidious illness onset (Kalla et al., 2002, Chen et 
al., 2005a, Morgan et al., 2006, Compton et al., 2008) and greater severity of 
illness at the point of admission (Verdoux et al., 1998, Johannessen et al., 1999) 
which are all associated with a longer DUP.  Lack of insight (Larsen et al., 1998, 
Drake et al., 2000), presence of negative symptoms (Larsen et al., 1996, Browne 
et al., 2000) and persecutory delusions (McGorry et al., 1996) also predict 
prolonged DUP.  Poor educational attainment (Verdoux et al., 1998, Sadeghieh 
Ahari et al., 2014), pre-morbid functioning (Childers and Harding, 1990, 
Addington and Addington, 1993, Bailer et al., 1996, Fresán et al., 2003, Melle et 
al., 2004, Schimmelmann et al., 2008), neuropsychological and cognitive function 
(Kolakowska et al., 1985, Keshavan et al., 2003) and poor occupational, social 
and global functioning (Larsen et al., 1996, Verdoux et al., 1998, Johannessen et 
al., 1999, Kalla et al., 2002, Melle et al., 2004) also contribute adversley to DUP.   
Some studies have failed to find links between DUP and age of onset (Haas and 
Sweeney, 1992, Loebel et al., 1992, Beiser et al., 1993, Häfner et al., 1993, 
Larsen et al., 1996, Haas et al., 1998, Drake et al., 2000, Morgan et al., 2006), 
age of first admission (Craig et al., 2000), ethnicity (Craig et al., 2000, Anderson 
et al., 2014), gender (Haas et al., 1998, Craig et al., 2000, Ho et al., 2000, Cascio 
et al., 2012) or marital status (Haas et al., 1998, Craig et al., 2000).  Poor 
premorbid functioning (Ho et al., 2000, Chen et al., 2005a, Apeldoorn et al., 
2014), socioeconomic status (Haas et al., 1998), educational or occupational 
attainment (Craig et al., 2000, Morgan et al., 2006, Bechard-Evans et al., 2007, 
Compton et al., 2008, Compton et al., 2011) or dose of antipsychotic on 
admission (Haas et al., 1998) have also been shown to be insignificant predictors 
of DUP.   
It is clear from this review that there are many potential confounders of DUP. I will 
now outline why a prolonged DUP is of clinical relevance, and why EIS 
proactively tries to limit DUP.   
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2.4. Impact of Duration of Untreated Psychosis on Outcomes 
Whatever the causes of a prolonged DUP, this is of clinical importance because 
of the potential link to poorer prognosis and outcomes (Larsen et al., 2000, 
Bottlender et al., 2003, Keshavan et al., 2003).   There is however no clear 
consensus in the literature about whether prolonged DUP inevitably results in 
poor outcomes. Whilst many studies do highlight an association, some studies do 
not demonstrate significant links (Kolakowska et al., 1985, Linszen et al., 1998, 
Barnes et al., 2000, Craig et al., 2000). 
2.4.1. Symptom Control  
Studies have sought to assess the impact of DUP on global, positive, negative or 
affective symptoms.  A randomised study known as the OPUS trial, named so in 
recognition of the intensive early treatment programme it provides, showed that 
participants with longer treatment free periods displayed more psychotic 
symptoms at both baseline and follow up (Jeppesen et al., 2008).  In Drake et 
al.’s (2000) study DUP was the strongest predictor of symptom severity after 6-12 
weeks treatment, even when controlling for severity of symptoms at baseline 
(Drake et al., 2000). This is in contrast to other studies which concluded that DUP 
had no effect on the course of psychotic symptoms (Linszen et al., 1998, Ho et 
al., 2000). 
Focusing specifically on positive symptoms, these have been demonstrated as 
more enduring (McGorry et al., 1996, Szymanski et al., 1996, Bottlender et al., 
2003, Jeppesen et al., 2008, Crumlish et al., 2009) and severe (Haas et al., 1998, 
Bottlender et al., 2000, Norman and Malla, 2001, Addington et al., 2004, Harris et 
al., 2005, Barnes et al., 2008, Hill et al., 2012, Wing Chung et al., 2012) in those 
with prolonged DUP.  However, other studies have failed to confirm the 
association (Barnes et al., 2000, Browne et al., 2000, Craig et al., 2000, de Haan 
et al., 2000). 
Studies have also shown a significant association between prolonged DUP and 
more severe negative symptoms at first presentation or admission (Larsen et al., 
1996, Haas et al., 1998), at discharge (Haas et al., 1998, Bottlender et al., 2000) 
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and at one year (McGorry et al., 1996, Larsen et al., 2000, Barnes et al., 2008, 
Galderisi et al., 2013), 10 year (Waddington et al., 1995), 12 year (Hill et al., 
2012) and 15 year (Bottlender et al., 2003) follow up.  One study found this 
association in women but not men (Scully et al., 1996).  In contrast, other studies 
failed to find a significant association between prolonged DUP and severity of 
negative symptoms (Barnes et al., 2000, Browne et al., 2000, Craig et al., 2000, 
Addington et al., 2004, Harris et al., 2005, Jeppesen et al., 2008, Melle et al., 
2008, Crumlish et al., 2009, Wing Chung et al., 2012).  
Studies have also found a positive association between prolonged DUP and 
presence of affective symptoms (Binder et al., 1998), including depression 
(Edwards et al., 1998). 
Whilst evidence is conflicting in relation to the impact of DUP on symptom 
control, the only systematic review conducted to date, which controlled for the 
impact of poor pre-morbid functioning, demonstrated a significant relationship at 
12 months between longer DUP and all symptoms be they positive, negative or 
affective symptoms (Marshall et al., 2005).  Another meta-analysis concluded that 
a prolonged DUP was associated with more severe negative symptoms, but not 
positive symptoms, at baseline (Perkins et al., 2005).  This finding linking DUP to 
severity of negative symptoms has also been replicated in other meta-analyses 
(Boonstra et al., 2012a, Penttilä et al., 2014).  The analysis by Penttilä et al. 
(2014) also found a significant effect of a prolonged DUP on severity of positive 
symptoms. 
2.4.2. Remission 
As well as an effect on symptom control, several studies have also shown an 
adverse association between prolonged DUP and recovery or remission rates.  A 
longer DUP has been shown to lengthen the time to achieve remission (Loebel et 
al., 1992, Edwards et al., 1998, Díaz et al., 2013) and lower the rates of remission 
and recovery (McGorry et al., 1996, Barnes et al., 2000, Crumlish et al., 2009, Hill 
et al., 2012, Tang et al., 2014).  Larsen et al.’s (2000) study of 43 patients with 
first episode psychosis found that those who were not in remission had a DUP 
three times greater than those in remission (Larsen et al., 2000). Other studies 
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have however failed to confirm a link between DUP and likelihood of, or time to, 
remission (Wiersma et al., 1998, Robinson et al., 1999, Craig et al., 2000, Ho et 
al., 2000).  The systematic review conducted by Marshall et al., (2005) showed a 
significant impact between prolonged DUP and lower rates of remission.  This 
was replicated in a further meta-analysis (Penttilä et al., 2014).    
2.4.3. Readmission 
When considering the effect of prolonged DUP on readmission rates, a study of 
228 patients with first-admission schizophrenia randomised to five different arms 
(psychotherapy, milieu therapy, ECT, drug alone or drug plus psychotherapy) 
demonstrated the advantages of early drug treatment.  Those initially treated with 
medication or ECT had a better clinical, social and psychological outcome (May 
et al., 1981).  Those who initially received non-drug treatments and stayed in 
hospital less than six months had subsequent higher readmission rates to 
hospital, indicating that an initial good response to non-drug treatments did not 
necessarily lead to better outcomes (Wyatt, 1991).  Other studies have linked 
prolonged DUP to increased rates of re-admission in the subsequent two years 
(Wyatt et al., 1997, Qin et al., 2014) but fewer days spent in hospital over the next 
ten years (Penttilä et al., 2013). A retrospective study looking at readmissions 
over a 16 year to 33 year period also found that prolonged DUP significantly 
increased the number of readmissions in the very long term (Primavera et al., 
2012). A recent meta-analysis concluded however that the association between 
prolonged DUP and hospital admission was insignificant (Penttilä et al., 2014).   
2.4.4. Relapse 
As well as increasing time spent in hospital, studies have shown that prolonged 
DUP increases relapse rates (Crow et al., 1986, Rabiner et al., 1986). Others 
have concluded that DUP has no effect on worsening of illness (Barnes et al., 
2000) or risk of relapse at one year (Linszen et al., 1998), five year (Robinson et 
al., 1999) and 15 year follow up (Wiersma et al., 1998). The evidence is therefore 
contradictory as to whether DUP impacts on relapse rates. 
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2.4.5. Social Functioning 
Other studies have shown that DUP can lead to poorer social functioning and 
attainment (Inoue et al., 1986, Larsen et al., 1996, Harris et al., 2005, Barnes et 
al., 2008, Crumlish et al., 2009, Hill et al., 2012, Qin et al., 2014) as well as 
poorer social integration (Drake et al., 2000) and limited social circles (Helgason, 
1990, Tirupati et al., 2004, Jeppesen et al., 2008). A greater likelihood of 
homelessness and solitary living has also been demonstrated (Barnes et al., 
2000).  A systematic review and meta-analysis also evidenced the link between 
prolonged DUP and adverse social outcomes at months 6 and 12, but these 
ceased to be significant at month 24 (Marshall et al., 2005).  The association 
between DUP and social functioning was also found in a later meta-analysis 
(Penttilä et al., 2014).  Other studies however failed to show a significant 
association between prolonged DUP and social outcome (de Haan et al., 2000, 
Verdoux et al., 2001a) or independent living (Hill et al., 2012). 
2.4.6. Occupational Functioning 
Studies have also assessed the impact of a prolonged DUP on employment and 
occupational functioning.  One meta-analysis concluded that a prolonged DUP 
did not impact on subsequent employment (Penttilä et al., 2014).  Studies have 
however been mixed with some supporting an association between prolonged 
DUP and poorer employment prospects (Harris et al., 2005, Norman et al., 
2007, Schimmelmann et al., 2008, Wing Chung et al., 2012), and others 
concluding that this was not significant (de Haan et al., 2003, Jeppesen et al., 
2008, Hill et al., 2012).  One study found that a prolonged DUP was associated 
with a significantly greater number of days spent at work over a ten year follow-
up period (Penttilä et al., 2013). 
2.4.7. Neurocognitive Functioning 
Reviewing studies examining the effects of DUP on neurocognitive functioning, 
the majority have found no link (Binder et al., 1998, Barnes et al., 2000, Hoff et 
al., 2000, Norman et al., 2001, Ho et al., 2003, Addington et al., 2004, Rund et 
al., 2004, Rund et al., 2007, Barnes et al., 2008, Goldberg et al., 2009).  A 
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meta-analysis also failed to demonstrate an association between prolonged 
DUP and baseline neurocognitive function (Perkins et al., 2005).  Two studies 
reported deficits in particular aspects of neurocognitive tests such as 
comprehension and executive functioning (Amminger et al., 2002, Joyce et al., 
2002), whilst others evidenced poorer memory and attention in those with a 
longer DUP (Barnes et al., 2000, Cuesta et al., 2012). It has been suggested 
that DUP can affect specific executive functions of abstract thinking and 
perception and this may contribute to poorer social problem solving and 
adaptability within the community (Barnes et al., 2000). 
2.4.8. Global Functioning 
As well as considering the impact of DUP on social, occupational and 
neurocognitive functioning, it is important to reflect on how DUP affects global 
functioning. A prolonged DUP has been associated with poorer overall 
functioning in the pre-admission period (Larsen et al., 1996), during admission 
(Haas et al., 1998, Bottlender et al., 2002), at discharge (Bottlender et al., 2000) 
and in one year (McGorry et al., 1996, Larsen et al., 2000), two year (Wyatt et al., 
1997, Keshavan et al., 2003, Fraguas et al., 2014) and 12 year (Hill et al., 2012) 
follow up studies. One study assessing 58 first episode patients, fifteen years 
after first admission found lower levels of global functioning even after controlling 
for potentially confounding variables (Bottlender et al., 2003).  Another study 
retrospectively assessing global functioning over a minimum of sixteen years 
follow up also showed that longer DUP predicted poorer global functioning in the 
long term (Primavera et al., 2012).  A systematic review (Marshall et al., 2005)  
and meta-analysis (Penttilä et al., 2014) have also confirmed the association 
between prolonged DUP and poor global functioning.  However, global 
functioning was not significantly affected by DUP at two year follow up in a further 
study (Craig et al., 2000). 
2.4.9. Quality of Life 
As prolonged DUP has potentially adverse consequences across a number of 
different variables, it is not unreasonable to think that prolonged DUP may have 
an adverse effect on quality of life.  Poorer scores on quality of life assessment 
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tools have been evidenced at first presentation (Browne et al., 2000), one year 
(McGorry et al., 1996, Carbone et al., 1999), eight year (Harris et al., 2005), 12 
year (Hill et al., 2012) and 20 year (Helgason, 1990) follow up.  McGorry et al., 
(1996) found that DUP accounted for 15% of the variance in quality of life scores. 
This effect on quality of life is also supported by the findings of one systematic 
review (Marshall et al., 2005), but not in the other meta-analysis (Penttilä et al., 
2014).  One study assessing impact of early detection and reduced DUP on 
quality of life did not however find subjective or objective differences in quality of 
life assessed by living situation, activities of daily living, family relationships, 
social relationships, finances, occupational and educational factors, legal and 
safety issues or health (Melle et al., 2005). 
2.4.10. Response to Medication 
Other studies have looked specifically at the impact of DUP on response to 
antipsychotic treatment.  It has been shown that limiting DUP shortens the time to 
medication response, and increases the likelihood of symptomatic response and 
remission (Larsen et al., 2000, Verdoux et al., 2001a, Malla et al., 2002b, Perkins 
et al., 2005, Barnes et al., 2008).   A study to assess the impact of DUP on 
response to both delusions and hallucinations to medication found that whilst a 
prolonged DUP was associated with a longer time to improvements in delusional 
symptoms, this was not the case with hallucinations (Gunduz-Bruce et al., 2005). 
Another study found that after six months of treatment, impact on positive 
symptoms was lessened in those with a prolonged DUP, although this was not 
the case for negative symptoms (Szymanski et al., 1996). 
Putting this into context, Lieberman et al. (2003) estimated that for every extra 
year of untreated psychosis, the odds of response were reduced by 15%. The 
Lieberman Study was a comparison of clozapine versus chlorpromazine in 
treatment-naive first episode patients, and as clozapine is only licensed for 
treatment resistant schizophrenia it could be argued that use of clozapine in this 
study was not reflective of clinical practice (Lieberman et al., 2003a).  It has also 
been suggested that halving the duration of untreated psychosis would increase 
likelihood of medication response by 18% (Perkins et al., 2004).  Evidence 
presented therefore suggests that prolonged periods without treatment leads to 
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more severe symptoms, which subsequently prove more resistant to treatment 
with antipsychotic medication.  A few studies have however failed to confirm a 
link between lengthy DUP and prolonged time to, and reduced rates of, treatment 
response (Kolakowska et al., 1985, Barnes et al., 2000, Craig et al., 2000, Ho et 
al., 2000). 
2.4.11. Other Factors 
For completeness, I have also included factors where single studies assessed 
the impact on antipsychotic medication adherence in FEP.  A single study 
showed that a prolonged DUP was linked to greater behavioural disturbance, 
including potentially threatening behaviour to the life of self or others, 
inappropriate or bizarre sexual behaviour, damage to property or other behaviour 
deemed bizarre or inappropriate (Johnstone et al., 1986).  A further study found 
that a prolonged duration of untreated psychotic symptoms was linked to a 
greater risk of suicide in the two years subsequent to first hospitalisation 
(Verdoux et al., 2001b). The only study assessing the impact of DUP on illicit 
substance use failed to find a link between DUP and substance misuse (Barnes 
et al., 2000).  Another study concluded that prolonged DUP was associated with 
a longer initial admission to hospital (Penttilä et al., 2013). 
In summary, evidence has been presented linking lengthy periods of untreated 
psychosis to poorer symptom control with medication.  Delayed treatment also 
predicts a lengthier time to treatment response. Negative symptoms are likely to 
be more entrenched and remission rates lower, adversely impacting social and 
functional capabilities.  Whilst many studies highlight an adverse effect of a 
prolonged DUP on clinical, social and vocational outcomes this is not a 
unanimous finding as some studies failed to demonstrate an association.  Having 
presented background information about the presentation of a first episode 
psychosis, the focus of the literature review will now move to medication in the 
treatment of psychosis. 
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2.5. Medication in the Treatment of Psychosis 
For reasons already outlined, one of the key aims of EIS is to proactively 
engage with young people and their carers, ideally in the prodromal phase, 
instituting effective treatments once a first episode psychosis is evident thereby 
minimising DUP and limiting adverse outcomes (Birchwood, 2002).  Whilst 
holistic treatment involves psychosocial and psychological intervention, a key 
treatment intervention in psychosis is the prescribing of antipsychotic 
medication to target and treat psychotic symptoms.  To achieve long term, full 
functional recovery it has been shown that early functional gains in response to 
symptomatic remission need to be demonstrated (Ãlvarez-Jimenez et al., 2012).  
Limiting DUP by prompt instigation of effective antipsychotic treatment provides 
a means of limiting adverse outcomes in respect of functioning, symptom 
control, quality of life and occupational or vocational attainment. Before 
considering the efficacy of antipsychotic medication, it is however important to 
briefly outline the history of antipsychotic medication and terminology in 
common use.  
Antipsychotic medication has been available since the introduction of 
chlorpromazine in 1952 (Delay et al., 1952).  Since then, numerous 
antipsychotic drugs have been developed and launched extending the 
pharmacological options for the management of psychosis.  Chlorpromazine 
and antipsychotic medications with a similar mode of action and profile of 
receptor blockade have in the past been deemed ‘typical’ antipsychotics but are 
now classified as first generation antipsychotics (FGAs). More recently 
marketed antipsychotics were initially termed ‘atypical antipsychotics’, but are 
now referred to as second generation antipsychotics (SGAs). There is no 
consensus definition as to what constitutes a SGA, however, they are 
considered to be a group of drugs which are less likely to cause extrapyramidal 
side effects (NICE, 2002a, NICE, 2002b). The antipsychotic drugs amisulpride, 
aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, sertindole, 
risperidone and zotepine comprise the group of SGAs.   
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The National Institute for Clinical Excellence (NICE) technology appraisal on the 
use of the atypical antipsychotics and the clinical guideline for the management 
of schizophrenia, first published in 2002, recommended the use of SGA 
medication for all those newly diagnosed with the psychotic illness 
schizophrenia (NICE, 2002a, NICE, 2002b).  This was due to a lower incidence 
of extrapyramidal side effects and hyperprolactinaemia with the SGAs, and 
purported greater efficacy in treating negative symptoms.  This advice 
subsequently changed in recognition of the potential for SGAs  to induce weight 
gain and metabolic syndrome, with the latest guidance now requiring joint 
decision making by the healthcare professional and patient based on discussion 
and information about side effect profiles of the different antipsychotic 
medications (NICE, 2009a, NICE, 2014).   
This change of direction was driven by two key studies comparing effectiveness 
of FGAs and SGAs.  The Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) study was a large, long term study comparing 
effectiveness of the FGA perphenazine against four SGAs (olanzapine, 
risperidone, quetiapine and ziprasidone) in 1493 patients across 53 sites in the 
USA.  It was a ground breaking study as it was the first such study to be 
conducted independently of pharmaceutical industry sponsorship.  The 
conclusion reached was that perphenazine was as effective as, and 
comparatively tolerable to, the SGAs. (Lieberman et al., 2005).  A further large, 
randomised, controlled, pragmatic study funded independently of 
pharmaceutical sponsorship was conducted in the United Kingdom.  The Cost 
Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) 
drew similar conclusions to the CATIE study, in that SGAs did not markedly 
differ from FGAs when assessing quality of life, effectiveness and adherence 
rates (Jones et al., 2006).   
A SGA which differs from the rest of the group is clozapine, as this is the only 
antipsychotic medication licensed for the management of treatment resistant 
schizophrenia.  First marketed in the mid-1970s, it was subsequently withdrawn 
following a number of deaths in Finland.  Further investigation uncovered that 
these deaths occurred secondary to development of the white blood cell 
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disorders neutropenia and agranulocytosis (Amsler et al., 1977). Clozapine was 
subsequently re-launched with a requirement for mandatory full blood count 
monitoring in response to findings of a landmark study.  This study showed 
superior efficacy of clozapine in treatment resistant schizophrenia (Kane et al., 
1988).  To this day, clozapine remains the gold standard for treatment resistant 
schizophrenia, where treatment resistance is defined as failure to respond to, or 
tolerate, a therapeutic trial of two antipsychotic medications one being a SGA 
(NICE, 2014). Clozapine was excluded as a treatment option in phase 1 CATIE 
and CUtLASS studies, but became the focus of investigation in the respective 
phase two trials.  Phase two of the CATIE trial comprised recruits from phase 
one who had to discontinue the original study medication because of poor 
symptom control.  In the study, participants entered one of two treatment arms, 
clozapine or an alternative SGA (olanzapine, quetiapine and risperidone).  
Those receiving clozapine were more likely to still be on the same treatment at 
the end of the trial, and to have benefitted from a greater reduction in symptoms 
(McEvoy et al., 2006b).  In CUtLASS 2, a sample of 136 participants meeting 
criteria for treatment resistance were randomised to receive clozapine or an 
alternative SGA selected by the clinician.  Symptomatic improvement in mental 
health was significantly associated with use of clozapine over the other SGAs 
(Lewis et al., 2006).  There is therefore a strong evidence base for the use of 
clozapine in treatment resistant illness as this is more likely to result in an 
improvement in symptoms.  
In those aged 15-17 years, a technology appraisal published by NICE 
recommended the initial use of risperidone for psychosis as risperidone is 
licensed for use in this age group.  Use of aripiprazole was suggested in cases 
where risperidone was not appropriate for the individual patient (NICE, 2011a).  
In 2013, NICE published a clinical guideline for psychosis and schizophrenia in 
children and young people (NICE, 2013).  Summarising recommendations 
around antipsychotic medication, the advice issued was that children and young 
people with FEP should be offered antipsychotic medication alongside 
psychological therapy.  The guideline advocated that the choice of initial 
antipsychotic medication should be made jointly between healthcare 
professionals, the young person and their parents or carers, following a 
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discussion about the likely benefits and propensity of individual drugs to cause 
metabolic, extrapyramidal, cardiovascular, hormonal and other side effects.  
The NICE clinical guideline suggested that the initial dose should be at the 
lower end of the recommended range for children if the medication was licensed 
in this population, otherwise a dose at the lower end of the range for adults 
should to be initiated before gradually increasing the dose.  Once the optimum 
dose was reached, they recommended prescribing of a therapeutic dose of 
medication for 4-6 weeks before assessing efficacy. The use of multiple 
antipsychotics was to be avoided except for short periods when changing from 
one antipsychotic to another.  The importance of baseline and ongoing 
monitoring for the emergence of adverse side effects, regular review of efficacy 
and comprehensive documentation of discussion and decisions around 
medication was also emphasised.  In treatment resistant cases, the NICE 
guideline advised practitioners to review the diagnosis, establish that 
medication had been taken as prescribed and that psychological interventions 
had been provided and undertaken, and to consider whether other factors such 
as substance misuse, physical comorbidities or other prescribed medication 
could be contributing to poor response.  Following such a review, clozapine was 
to be recommended for children and young people with treatment resistant 
illness, with subsequent consideration of clozapine augmentation with a second 
antipsychotic if required (NICE, 2013).   
There are, therefore, a number of national guidelines supporting the use of 
antipsychotic medication as an effective treatment option in the management of 
a psychotic illness, with adherence to the same maximising the likelihood of 
symptomatic improvement. 
When specifically considering antipsychotic treatment in those with first episode 
psychosis, short and long term studies have shown that introduction of 
antipsychotic medication will, in the majority of instances, bring about prompt 
improvement in psychotic symptoms (May et al., 1981, Emsley, 1999, Sanger et 
al., 1999, Malla et al., 2001, Lieberman et al., 2003a, Lieberman et al., 2003b, 
Schooler et al., 2005, Robinson et al., 2006, Zhang et al., 2013).  Those in an 
initial phase of a psychotic illness are likely to be more responsive than those in 
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chronic stages of the illness (Robinson et al., 1999), and such responses often 
result from use of much lower doses of medication (Oosthuizen et al., 2004, 
Robinson et al., 2005, Kahn et al., 2008, Josiassen et al., 2010).  Meta-
analyses of antipsychotic medication in children and young people also confirm 
efficacy of medication in this age group (Armenteros and Davies, 2006, 
Kennedy et al., 2007). 
Whilst effective treatment of a first episode psychosis will hopefully lead to 
complete symptomatic and functional recovery, relapse risk remains high with 
more than 90% of patients relapsing within five years of recovery from a first 
episode illness (Wiersma et al., 1998, Robinson et al., 1999, Gitlin et al., 2001).  
Whilst the majority of studies highlight a protective effect of antipsychotic 
medication in reducing relapse risk (Szymanski et al., 1996, Robinson et al., 
1999, Verdoux et al., 2000, Coldham et al., 2002, Üçok et al., 2004, Chen et al., 
2010, Alvarez-Jiménez et al., 2011, Caseiro et al., 2012), this is not a universal 
finding (Craig et al., 2000, Harrigan et al., 2003).   
In summary, antipsychotic medication is an effective intervention for symptoms 
of psychotic illness irrespective of the stage of illness.  It is also an important 
strategy in reducing risk of relapse.  Prompt and effective antipsychotic 
treatment is crucial, and inherent in this is ensuring the young person adheres 
to their antipsychotic medication.   
2.6. Assessing Medication Adherence 
Having considered the background for treatment with antipsychotic medication, 
the focus now moves to medication adherence in young people with FEP.  This 
first requires consideration of the different ways in which adherence is defined 
and assessed in research literature.   
2.6.1. Classification of Adherence 
Three terms are routinely used in the study of patient acceptance of medication 
and treatment, namely compliance, concordance and adherence.  
Compliance has been defined as: 
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 “the extent to which a person’s behaviour coincides with the 
medical advice given”  (Haynes et al., 1979)  
More recently, this term has fallen out of favour as it implies a degree of passivity 
in terms of obeying the advice given by a prescriber (Bebbington, 1995). 
Practitioners are now advised to use the terms concordance or adherence in 
preference to compliance.   
Concordance has been defined as: 
“an agreement reached after negotiation between a patient and 
health care professional that respects the beliefs and wishes of the 
patient in determining whether, when and how medicines are to be 
taken” (RPSGB, 1997).   
This definition is based around respect for the patient’s agenda and creates 
openness between the patient and the prescriber.  There is recognition within this 
definition that concordance cannot be imposed upon a patient. 
Adherence is the term most recently advocated and has been defined as: 
“the extent to which patients follow the instructions they are given 
for prescribed treatments” (Haynes et al., 2000)  
This definition is intended to be non-judgemental without inferring blame on either 
the patient, prescriber or treatment and allows for flexibility in the level of 
adherence (Haynes et al., 2000). Thus, this term is intended to support ongoing 
dialogue about adherence between practitioner and patient, acknowledging that 
adherence may vary with time and circumstance. 
Non-adherence has been further defined as:  
“the failure to enter a treatment programme, premature termination 
of therapy and incomplete implementation of instructions, including 
prescriptions” (Nose et al., 2003b) 
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The definitions quoted above are essential when examining the factors that affect 
adherence and interventions that are used to improve adherence. Adherence can 
be defined in terms of a quantitative measure of the percentage of prescribed 
doses taken.  This approach is reasonable because in real life situations it is 
likely that most patients will either intentionally or unintentionally miss doses of 
medication, thereby requiring an element of pragmatism and flexibility by the 
practitioner when discussing medication adherence.  Some studies have used an 
80% cut-off to determine that a patient is adherent, some a 75% cut-off and 
others a 50% cut-off (Velligan et al., 2006).  In effect, this means that the same 
patient could be categorised differently across two different studies depending on 
the operational definition of adherence employed.  Some studies have used 
statistical measures such as the mean amount of medication taken over a 
specific time period, and it has been proposed that this measure should always 
be included to allow studies to be compared (Velligan et al., 2006).  The problem 
with use of a mean percentage is that the time period over which adherence is 
measured can also vary across studies impacting on subsequent medication 
adherence.  What is clear is that a lack of consensus about how to define 
medication adherence in research exists and impacts on the conclusions that can 
be drawn. 
2.6.2. Measurement of Adherence 
A further complication is that there are different quantitative or qualitative means 
of measuring adherence, each with its own advantages and draw backs.   
Quantitative measures of adherence including pill counts, prescription refill rates, 
mechanical or electronic monitoring, chart reviews and measurement of blood or 
urine medication levels have all been shown to have limitations. Pill counts and 
prescription refill rates imply that a person has taken the medication collected 
when they may in fact be discarding it. Chart reviews for inpatients are also not 
100% accurate as patients are adept at concealing medication should they not 
wish to take it. The measurement of blood and urine levels, whilst appearing to 
convey an accurate assessment, can be open to manipulation by the patient as 
adherence behaviour may change when patients know that a sample is due. The 
measurement methods can also bring bias as some laboratory tests are only 
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effective at picking up very recent non-adherence. They will indicate the presence 
or absence of medication or metabolites but will not give any indication of partial 
adherence.  There can also be significant inter-patient variation in rates of 
metabolism and volumes of distribution. These variations will affect the level of 
drug in either blood or urine and may affect the assessment of adherence. 
Quantitative means of calculating a measure of adherence are also available 
using electronic systems and databases.  Some of the more commonly used 
formulas employed in medication databases and clinical systems are the 
medication possession ratio (MPR), proportion of days covered (PDC), refill 
compliance rate (RCR), continuous measure of medication gaps (CMG) and the 
continuous multiple interval measure of oversupply (CMOS). Studies evaluating 
adherence rates in individuals using these measures have found that results 
differ for an individual depending on the measure used (Ahn et al., 2008, Karve et 
al., 2009, Martin et al., 2009).   
As well as electronic data about prescription re-fills, electronic monitoring of the 
opening of containers holding medication provides another quantitative measure 
of adherence.  One of the most common forms of electronic monitoring is the 
Medication Event Monitoring System (MEMS).  This employs a specific 
medication bottle cap to generate records of the date and time the medication 
bottle is opened. Whilst seemingly more accurate than other objective measures 
of adherence such as pill counts and refill records, it could be argued that prior 
knowledge of the requirement to return electronic monitors for assessment 
purposes may lead to greater degrees of compliance than is usual, resulting in a 
degree of bias. Likewise, removal of an electronic cap from the medication bottle 
does not guarantee that the tablet or capsule has been swallowed (Velligan et al., 
2006).  
Recent advances have seen the first application for a digital medicine, filed in 
2015 with the USA Food and Drug Administration (FDA).  This digital medicine 
application relates to tablets of the SGA aripiprazole, each embedded with an 
ingestible sensor. The sensor communicates with a wearable sensor patch and 
a medical software application allowing for an estimation of adherence.  The 
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adherence data, with patient consent, can then be shared with healthcare 
professionals (Proteus Digital Health, 2016).     
Qualitative measures including patient self-reports, health care professional and 
carer reports, patient interviews, clinical impressions and past medication taking 
have also been used to measure adherence. Evidence suggests that 
assessments by health care professionals are the least reliable of these 
measures, with one study concluding that physicians over-estimated adherence 
in 65% of patients whose blood sample analysis showed adherence to be poor 
(Borras et al., 2007).  Another study found that clinicians failed to detect two 
thirds of patients who self-reported poor adherence (Hui et al., 2006a).  The 
limitations of these measures are similar to those for the quantitative measures 
e.g. reliance on accurate recording and reporting (Farmer, 1999), and factors 
such as the time the reporter spends with the patient and their degree of 
involvement in the delivery of care, as well as a potential for poor response to 
medication to be misinterpreted as poor adherence (Velligan et al., 2006).   
Patient self-report is the most common subjective, qualitative measure of 
adherence (Velligan et al., 2006). Whilst some have concluded that self-report 
may overestimate the extent of adherence (Jonsdottir et al., 2010, Lee et al., 
2011), others have concluded that self-report provides an accurate reflection of 
medication adherence (Haukka et al., 2007).  Byerly et al. (2007) sought to 
compare adherence rates using MEMS with self-reports of adherence by patient, 
clinician and research assistant.  Prescriber and patient evaluations of non-
adherence (7% and 5% respectively) were much lower than non-adherence 
estimates by the MEMS and research assistants (57% and 54% respectively) 
suggesting an overestimation of adherence by both prescribers and patients.  
(Byerly et al., 2007).   
It is reasonable to conclude that whilst different measures of adherence exist, all 
have their limitations.  A further means of assessing adherence is through the 
use of adherence tools and I now consider these tools in more detail. 
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2.6.3. Medication Adherence Tools 
Adherence tools have been developed to assess self-reported attitudes to 
medication known to potentially impact on adherence.  Such tools include the 
Drug Attitude Inventory [DAI] (Hogan et al., 1983), the Medication Adherence 
Questionnaire [MAQ] (Morisky et al., 1986), the Medication Adherence Rating 
Scale [MARS] (Thompson et al., 2000) and the Attitudes to Neuroleptic 
Treatment Questionnaire [ANT] (Kampman et al., 2000).  Other tools available 
to support the assessment of adherence include the Rating of Medication 
Influences Scale [ROMI] (Weiden et al., 1994), the Personal Evaluation of 
Transition in Treatment [PETiT] (Voruganti and Awad, 2002), the Brief 
Evaluation of Medication Influences and Beliefs Scale [BEMIB] (Dolder et al., 
2004) and the Subjective Well Being Under Neuroleptic Treatment Scale [SWN] 
(Naber et al., 2005).  These tools measure a variety of different attitudes to, and 
effects of, medication including insight into illness and the need for treatment, 
positive and negative aspects of medication on mood, social and emotional 
wellbeing, experience of side effects and views of medication. Initial validation 
of these scales was undertaken predominantly in adults. Exceptions to this were 
the validation of the ROMI which included first presentation patients, and the 
ANT the youngest participant of whom was 16 years old.  Townsend et al.’s 
(2009) study sought to evaluate whether the DAI  would be suitable for use in 
an adolescent population experiencing a range of mental health disorders such 
as psychosis, attention deficit hyperactivity disorder and depression.  This study 
found that the factor structure for the adolescent population only demonstrated 
a ‘fair’ correlation with that of the adult population, suggesting that adolescents’ 
and adults’ views, attitudes and experiences of taking psychotropic medication 
may differ (Townsend et al., 2009). Whilst there are numerous adherence tools 
available, some studies have also raised issues with consistency across tools, 
with the potential for adherence of the same individuals to be categorised 
differently depending on the scale used (Kikkert et al., 2008, Kikkert et al., 
2011).  This suggests that such tools should not be the sole basis for 
judgements about medication adherence.   
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2.6.4. Summary 
In conclusion, there is no gold standard measure of adherence as all have 
particular limitations.  It has therefore been proposed that all studies of 
medication adherence should incorporate at least two different measures, one 
of which should be an objective measure such as pill counts, electronic 
monitoring, prescription refill records or blood analysis (Velligan et al., 2006).  
Having presented a general overview of medication adherence and its 
assessment, I will not present information on rates of medication adherence in 
FEP. 
2.7. Rates of Medication Adherence in First Episode 
Psychosis 
Whilst acknowledging some of the difficulties in determining adherence with 
medication, studies have attempted to assess medication adherence rates in 
first episode psychosis. A systematic review, published in 2011, concluded that 
around 30% of first episode participants stop taking second generation 
antipsychotic medication in the first nine months of treatment (Miller et al., 
2011).  This review considered all cause discontinuation of medication including 
a deliberate decision by the patient or prescriber to change or stop antipsychotic 
medication, thereby over-estimating discontinuation due to poor adherence.   
Considering studies which focus purely on non-adherence rather than all cause 
discontinuation rates, varying results have been obtained.  Studies conducted 
over a 12 month period have demonstrated non-adherence rates of 45% 
(Rabinovitch et al., 2009), 49% (Le Quach et al., 2009), 59% (Coldham et al., 
2002) and 70% (McEvoy et al., 2007).  Longer studies conducted over a two 
year period demonstrated lower rates of non-adherence  of 14.5% (Malla et al., 
2008) and 25% (Gearing and Charach, 2009).  These variations will in part be 
due to differences in methods for assessing adherence and adherence 
definitions however, depending on the reference source accessed, non-
adherence with medication in first episode psychosis is estimated as anywhere 
between 14.5% (Malla et al., 2008) and 70% (McEvoy et al., 2007).  This 
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particularly wide reference range makes comparisons and generalisations 
problematic.   
2.8. Consequences of Poor Adherence with Antipsychotic 
Medication 
Thus far, it is evident that medication adherence can be problematic in first 
episode patients, although calculated rates of non-adherence vary depending 
on the research study examined.  Poor antipsychotic medication adherence is 
currently the only consistent predictor of relapse with a high predictive power 
(Robinson et al., 1999, Chen et al., 2005b, Uçok et al., 2006, Caseiro et al., 
2012).  A systematic review and meta-analysis concluded that poor medication 
adherence increased the risk of psychotic relapse four-fold (Alvarez-Jimenez et 
al., 2012). Further studies have shown the negative impact of poor medication 
adherence on remission rates and time to remission (Strakowski et al., 1998, 
Malla et al., 2006, Malla et al., 2008, Petersen et al., 2008),  psychopathology, 
social and vocational outcomes, hospitalisation and symptomatic remission 
(Verdoux et al., 2000, Coldham et al., 2002, Malla et al., 2002a, Petersen et al., 
2008, Barbeito et al., 2013).  One study found that dose reduction or 
discontinuation resulted in higher functional recovery, but not symptomatic 
recovery, when compared with maintenance antipsychotic treatment 
(Wunderink et al., 2013) suggesting some possible benefits to medication 
reduction.  Other studies have also shown that discontinuation of medication 
may lead to increased cannabis use (Hides et al., 2006), poor insight (Lepage 
et al., 2010a) and disengagement with services (Chan et al., 2014b).  
Interestingly in the study by Lepage et al. (2010), positive symptoms of 
psychosis improved significantly with time for partially and poorly adherent 
groups as well as the fully adherent group, perhaps highlighting benefits of 
other treatment options and the possibility that some patients might not need to 
take medication consistently to achieve some benefit.  Negative symptoms 
however deteriorated in those who were partially or non-adherent in this study 
(Lepage et al., 2010a).   
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It is therefore reasonable to conclude that poor adherence with antipsychotic 
medication has significant personal, social and economic sequelae with non-
adherence increasing the risk of hospitalisation and use of other healthcare 
facilities, increasing lengths of hospital stay and likelihood of relapse, and 
reducing recovery rates.  Evidence also suggests it may have indirect 
influences on quality of life and insight in a first episode population.  These all 
contribute to increasing treatment costs, and come at personal cost to the 
service user and their carers.  It is therefore important to consider factors that 
increase the likelihood of poor antipsychotic adherence in FEP, so we can 
identify those at potential risk and consider interventions which may promote 
adherence.   
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CHAPTER THREE.  AN INTEGRATIVE REVIEW 
OF THE LITERATURE ON FACTORS AFFECTING 
ANTIPSYCHOTIC MEDICATION ADHERENCE IN 
FIRST EPISODE PSYCHOSIS 
3.1.  Introduction  
Having outlined the importance of antipsychotic medication in reducing DUP 
and improving outcomes and presented initial information on medication 
adherence this chapter focuses specifically on factors affecting antipsychotic 
medication adherence in FEP. Firstly, I set out the details of the integrative 
literature review I undertook on medication adherence and present the 
approach used to identify and select relevant papers. I then present information 
on factors influencing antipsychotic medication adherence, as determined by 
the integrative review.  Finally, views from healthcare professionals, carers and 
patients about influences on medication adherence in this cohort are provided.   
3.2.  The Literature Search 
I started my PhD by conducting a literature search of adherence to 
antipsychotic medication.  Having retrieved a large number of articles, I realised 
that I needed to take a more structured approach to ensure retrieval of high 
quality, relevant articles.  There are different approaches to undertaking 
literature reviews and the choice depends on the topic area and the nature of 
knowledge and literature available. Careful decisions therefore needed to be 
taken about the choice of review undertaken. Due to the need to undertake a 
robust review that reviewed, critiqued and synthesised relevant literature of a 
limited but growing evidence base, I chose to undertake an integrative literature 
review (Torraco, 2005, Whittemore and Knafl, 2005).   Integrative literature 
reviews are the broadest type of literature review, of particular relevance to the 
science and delivery of healthcare, enabling inclusion of research grounded in 
diverse methodologies with the potential to play a substantial role in evidence 
based practice for nursing (Whittemore and Knafl, 2005).  They are of relevance 
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where the topic of investigation is a new and emerging concept (Torraco, 2005), 
as is the case with teenage antipsychotic medication adherence.  Having 
previously looked into the evidence base around medication adherence as part 
of my clinical practice, I discovered that research around adherence with 
antipsychotic medication predominantly centres on an adult population with 
chronic psychoses such as schizophrenia.  Research considering medication 
adherence issues in children focuses on study of physical health conditions 
such as asthma, diabetes and childhood human immunodeficiency virus (HIV).  
Where childhood mental health conditions are researched this usually involves 
attention deficit hyperactivity disorder (ADHD) or depression, with very little 
consideration of adherence issues pertinent to antipsychotic medication.  This 
prompted my desire to conduct research into this area and conduct an 
integrative literature review to explore adherence with antipsychotic medication 
in young people with FEP.  I felt that an integrative literature review was ideally 
suited to the topic being researched and the infancy of available research 
literature.  It would strengthen my knowledge of relevant literature, thereby 
supporting an informed research study and conceptualisation of the parameters 
to be researched.  An integrative review also provides a framework to deliver a 
literature review incorporating well-defined search parameters, explicit search 
terms, carefully chosen databases and clear criteria for assessment of the 
quality of the papers retrieved.  
I conducted an integrative review of the literature using the computerised 
databases MEDLINE, Cumulative Index of Nursing and Allied Health Literature 
(CINAHL Complete) and PsycINFO to obtain key papers about medication 
adherence in young people with psychosis.  These databases were chosen as 
collectively they provided the most comprehensive source of medicine, nursing, 
allied healthcare and mental health literature.  The Boolean search terms 
(concordance OR adherence OR compliance) AND (“first episode psychosis” 
OR (psychosis AND (children OR adolescen*)) AND (medication OR medici*) in 
the abstract were used to access relevant references.  Given the changing 
terminology in the field it was important to include the terms compliance, 
concordance and adherence as all have been preferred terms over different 
periods of time. I felt that use of broad search terms would capture most of the 
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appropriate references in a limited field; however I also had to acknowledge that 
limitations exist in computerised searches such that inconsistent search 
terminology and indexing problems might yield only around 50% of eligible 
studies (Whittemore and Knafl, 2005).  For this reason, I also analysed 
reference lists of retrieved reports to obtain additional articles of relevance not 
captured by the initial literature search (backward searching). I also looked at 
papers which had subsequently referenced the included paper to assess 
whether any of these met the inclusion criteria (forward searching).   
The search was restricted to English Language, published, peer reviewed 
articles.  I chose to limit the search to papers published from the year 1995 to 
current date.  My reason for choosing articles from the year 1995 onwards was 
that the National Health Service (NHS) Plan, recognising the benefits of early 
intervention for FEP and requiring 50 early intervention teams to be established 
in the United Kingdom (UK), was published in 2000.  Limiting my search from 
five years before this date would therefore also capture references from early 
implementers of EIS services.  Clear inclusion and exclusion criteria were 
created to ensure that only relevant papers with sufficient quality were included 
in the review. Primary reference sources were obtained in preference to 
inclusion of review articles.  
Inclusion criteria: articles were included 
 If the article topic related to medication adherence in early psychosis, 
more specifically medication adherence rates, factors influencing 
medication adherence in children and adolescents, outcomes following 
both good and poor adherence with medication, measurement of 
adherence in children and adolescents or strategies to improve 
medication adherence in the population of interest.   
Exclusion criteria: articles were excluded: 
 If they did not meet the inclusion criteria described 
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 If they focused on other mental health disorders in children and 
adolescents where antipsychotic medication is not a mainstay of 
treatment e.g. ADHD or depression.   
 If they centred on medication adherence in physical illness e.g. HIV, 
asthma or diabetes mellitus.  
 Where articles incorporated a range of different psychotropic 
medications e.g. antipsychotics, antidepressant and stimulant 
medication, and presentation of results did not allow data for 
antipsychotic medication to be interrogated separately.  
 Where a range of treatments e.g. medication and psychological 
interventions were considered and results were assessed as a whole.   
 Where an assessment of medication adherence was undertaken, yet the 
article failed to clearly define how participants were assigned to the 
different medication adherence groups or to describe the means of 
measuring adherence. 
A flowchart of the search strategy is included as Figure 3.1.   
Initially 338 articles were obtained, 10 of which were duplicates. I then reviewed 
the 328 abstracts for relevance using the previously described inclusion and 
exclusion criteria.  Following the abstract review, 69 full text articles were 
sourced.  On reading these full text articles and critically appraising them using 
schedules from the Critical Appraisal Skills Programme (CASP, 2010) , 21 
papers met the criteria for inclusion.  Reference lists of these 21 full text articles 
were also reviewed and following a review of abstracts this revealed an 
additional 70 articles for full text assessment; of these, 17 were retained.  
Forward searching of references sourced a further 19 articles for full text 
assessment; of these 7 were retained.  Thus, the final review included a total of 
45 papers.   
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Figure 3.1.  Flow Chart of Literature Search 
 
For reference, a summary of included papers considering factors affecting 
medication adherence is included (Table 3.1) before presenting information 
about emerging themes from the integrative review.    
Database Search- CINAHL, MEDLINE & PSYCHINFO 
(concordance OR adherence OR compliance) AND (“first episode psychosis” OR 
(psychosis AND (children OR adolescen*)) AND (medication OR medici*) from the 
year 2000 onwards 
 
328 papers obtained.   
328 abstracts reviewed.  259 abstracts discarded leaving 69 articles for full assessment 
69 full text articles assessed.   
Review of reference lists generated an additional 70 full text articles for assessment.   
Forward Searching generated an additional 19 articles for full text assessment 
158 full text articles assessed in total 
113 Papers excluded.   
Review aticles ( 35 ) 
Inclusion Criteria  ( 31 )  
 Patient Population  ( 26 )   
Critical Appraisal  ( 7  ) 
  Whole group analysis  ( 7)  
 Adherence definition  ( 5  )  
Adherence assessment  ( 2 ) 
 
 
45 Papers retained 
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Table 3.1.  Factors Affecting Adherence with Antipsychotic Medication in Children, Adolescents and First Episode Psychosis 
Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Barbeito et al. 
(2013) 
Prospective, eight year 
cohort study. 
92 consecutive 
admissions to a 
psychiatric ward in a 
general hospital in 
Victoria, Spain. 
Good adherence: score of 
4 on the Morisky-Green 4 
item scale. 
Comparison of baseline 
and follow up scores 
classified patient 
adherence as always 
good, always bad, 
improving from bad to 
good or deteriorating from 
good to bad. 
Self-report. Poorer adherence associated with family 
history of psychosis, lower global 
functioning at baseline, fewer depressive 
symptoms, increased alcohol intake at 
baseline, involuntary first admission to 
hospital, cannabis use during follow up. 
Cannabis and tobacco use at baseline 
were not significant predictors of 
adherence. 
Single site.  No objective 
measure of adherence. 
Recruitment from a 
hospital ward only. 
Chen et al. 
(2005b) 
Prospective, three year 
follow up, cohort study. 
93 patients 
consecutively 
diagnosed with FEP in 
Hong Kong. 
Adherent : at least 75% 
compliance rate. 
Self-report. 
Informant report. 
Cognitive functioning not significant. No objective measure of 
adherence.  30% lost to 
follow-up. 
Coldham et al. 
(2002) 
Prospective, follow up 
cohort study over 12 
months. 
186 patients in the 
Calgary Early 
Psychosis Programme. 
Non-adherence: Stops 
medication for months at 
a time or doesn’t take 
medication. 
Inadequate adherence: 
misses doses but never 
for longer than a few 
weeks at a time. 
Good adherence: Rarely 
or never misses doses. 
Rating by primary rater 
from: 
Prescription chart review  
Case manager rating.   
Referred to a secondary 
rater where ratings 
differed. 
Gender, substance misuse or diagnosis 
not significant. Non-adherent group were 
younger, had a younger age of onset and 
poorer pre-morbid functioning.  At baseline 
and follow-up they had poorer insight and 
quality of life and were consuming more 
alcohol and cannabis. 
Family involvement was significantly 
associated with good adherence. 
Akathisia and extrapyramidal side effect 
(EPSEs) were not a significant predictor. 
Most significant predictors were younger 
age, poor pre-morbid functioning, low 
levels of family support and use of 
cannabis at follow up. 
Retrospective analysis of 
adherence.  Subjective 
measures only.  Single 
site. 
Faridi et al. 
(2012) 
Prospective, follow up, 
cohort study over 12 
months. 
48 patients with FEP 
admitted to specialist 
EIS service in Montreal 
with concurrent active 
use of cannabis. 
Adherent: Taking more 
than 75% of prescribed 
doses. 
Self-report. 
Case manager report.  
Family report. 
Those continuing and ceasing to take 
cannabis became less adherent in the first 
six months.  By 12 months, 40% of those  
ceasing cannabis became adherent again, 
much lower than the 92% becoming 
adherent whilst continuing to consume 
cannabis . 
 
Relatively small sample.   
Single site.  No objective 
measure of adherence. 
 
61 
 
Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Gearing and 
Charach 
(2009) 
Retrospective, follow-up, 
longitudinal, cohort study 
of patients discharged on 
antipsychotic medication 
between Jan 1999 and 
Oct 2003. 
65 patients from six 
child and adolescent 
psychiatric inpatient 
units in Ontario, 
Canada. 
Adherent: Following 
physicians instructions 
about medication. 
Parental Report. Ten times more likely to adhere if 
discharged on concurrent antidepressants 
or mood stabiliser. 
DUP showed trend towards statistical 
significance.  Age, gender, family history of 
depression and decreased social support 
did not affect adherence. 
Retrospective design. 
Information gathered from 
health records and 
parental report- relies on 
accurate and 
comprehensive records 
and parental memory over 
the preceding two years.  
All patients were 
discharged on one of 
three antipsychotic 
medications, olanzapine, 
risperidone or quetiapine.  
Single measure of 
adherence. 
No objective measure of 
adherence. 
Hill et al. 
(2010) 
Prospective, four year, 
follow up, cohort study.  
171 patients in a region 
in Ireland. 
Adherent: at least 75% 
compliance with 
prescribed doses. 
Self-report. Poor adherence linked to alcohol and drug 
misuse at baseline and at follow up, 
greater degree of symptoms, poor insight, 
poor global functioning, negative 
medication attitudes, longer DUP and 
more frequent hospital admissions over 
the four years. 
Single measure of 
adherence.  No objective 
measure of adherence. 
Adherence only assessed 
at baseline and four years 
and not at intervening 
periods.  The study does 
not therefore capture 
changes in adherence 
with time. 
Hon (2012) Grounded Theory Study. 12 patients in an Early 
Intervention Service in 
Southern England. 
This was a views study 
and it therefore relied on 
personal reflections about 
what affected adherence 
with antipsychotic 
medication. 
Self-report. Medication variance was driven by three 
factors: 
Quality of life (living a normal life, being in 
control, freedom to choose, independence 
social relationships. 
Health Status (impact of illness, efficacy 
and side effects of medication). 
Discernment (knowledge and information, 
self-assessment, personal experiences). 
Single, inner city site. 
Researcher worked in the 
team so this might have 
introduced some  bias.  
All patients in the study 
were prescribed 
aripiprazole.  Results may 
have differed with other 
antipsychotic medications.  
Single measure of 
adherence. 
No objective measure of 
adherence. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Hui et al. 
(2006b) 
Prospective, cohort study.  229 patients from two 
early psychosis clinics 
in Hong Kong. 
Poorly adherent: if they 
indicated on the scale 
that they forgot to take 
medication or had 
stopped it of their own 
accord. 
Self-report using an 
abridged version of the 
Medication Adherence 
Rating Scale. 
Clinician questionnaire 
based on the Medication 
Adherence Rating Scale. 
Feeling embarrassed was significantly 
associated with stopping medication.  
Patient embarrassment was under-
recognised by clinicians.  Taking 
medication only when well was related to 
stopping but not forgetting to take 
medication.  Feeling worse without 
medication was significantly linked to 
forgetting to take medication but not 
stopping medication.  Feeling medication 
was beneficial was not associated with 
forgetting or stopping medication.  In early 
psychosis the groups who forgot and 
stopped medication appeared distinct with 
few reporting both.  38% of patients 
reported forgetting their medication. 
No objective measures of 
adherence.  Partially 
funded by pharmaceutical 
company. 
Kamali et al. 
(2006) 
Prospective, six month, 
follow up, cohort study. 
60 patients discharged 
from a psychiatric 
hospital in Dublin, 
Ireland. 
Adherent: at least 75% 
compliance over 
preceding three months. 
Self-report. Poor adherence associated with greater 
positive symptom scores (grandiosity most 
predictive), alcohol misuse, substance 
misuse, poor insight (particularly if no 
substance misuse present).  Insignificant 
factors: age, gender, admission status. 
 
40% of the initial sample 
did not attend follow up. 
Insight assessed using 
the single item on the 
Positive and Negative 
Syndrome Scale 
(PANSS).  Relatively 
small sample from a 
single service.  Single 
measure of adherence. 
No objective measure of 
adherence. 
Kampman et 
al. (2002) 
Prospective, cohort study.  59 patients in a single 
site in Finland. 
Self-report of adherence 
categorised as regular, 
irregular, occasional use 
or failure to use 
medication at all. 
 
Medical record review 
which included: 
Self-report. 
Details of failure to collect 
a prescription at the 
expected time. 
Increased risk of poor adherence with 
males, younger patients with limited social 
activities, greater total PANSS score and a 
low score in the positive symptom 
subscale. 
Retrospective collection of 
adherence data from 
medical records only. 
Three month follow-up 
period.  Weak definition of 
adherence.  Single site.  
Relatively small sample. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Lecomte et al. 
(2008) 
Cross sectional study.  118 patients with early 
psychosis from four 
sites in Canada. 
Medication rating as 
follows: 
1=Not taking medication 
as directed and no 
intention to. 
2= Not taking medication 
as directed but 
considering doing so. 
3= Not taking medication 
as directed but am going 
to start taking it. 
4= Consistently taking 
medication as directed. 
Also asked on a scale of 
1-100 how often they 
forgot to take medication, 
altered the dose, or 
intentionally missed a 
dose to suit need. 
 
Self-report. Predictors of poor adherence were being 
male, having a history of legal problems, 
presence of more positive symptoms, 
witnessing violence as a child and a 
personality trait of high agreeableness. 
No significant difference found for insight 
or substance misuse 
91% reported always 
taking their medication as 
directed, they asked 
answers to the 
supplementary questions 
about forgetting, changing 
or altering dose and 
created three sub-groups 
i) perfect medication 
adherence with no 
changes in dose ii) 
medium adherence with 
less than 50% changes in 
dose iii) Poor adherence 
with no medication at all 
or changes in dose more 
than 50% of the time.  
This is a low delineator 
between good and 
medium adherence. 
Single measure of 
adherence.  No objective 
measure of adherence. 
Lepage et al. 
(2010b) 
Six month, case control 
study.  
160 patients in an EIS 
service in Montreal and 
35 controls. 
 
5 point Likert scale used: 
4= fully adherent. 
3= partially adherent. 
2 or below= poorly 
adherent. 
 
 
Case manager report 
based on: 
Patient interview 
Prescription review  
Pill count. 
Age, gender, education and patient or 
parental socioeconomic status was 
insignificant.  Type of antipsychotic 
medication was not significant.   
Verbal, performance or full scale IQ did not 
impact medication adherence. 
Single site study. 
Environmental or 
motivational issues were 
not considered.  Some 
participants were living 
with family which might 
have influenced 
adherence.  Did not 
control for other factors 
which might have affected 
adherence e.g. substance 
misuse.   
Numbers of controls much 
lower than patients. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Le Quach et 
al. (2009) 
Two year, randomised 
controlled trial.  
547 patients in two 
sites in Denmark 
(Copenhagen and 
Aarhus). 
Poor adherence: 
prescribed but not 
started, prescribed but 
discontinued, unregulated 
medication, symptomatic 
but poor motivation to 
take medication. 
Good adherence: 
medication taken as 
prescribed, not prescribed 
medication but not 
symptomatic. 
Self-report. 
Staff report. 
Case note review. 
Prescription chart review. 
Negative medication attitudes and lack of 
dual parental upbringing were the 
strongest predictors after two years of poor 
adherence.  Poor insight at year 1, no 
vocational education and lack of a relative 
to interview at baseline were significant. 
After one year, negative medication 
attitudes, poor illness insight at baseline, 
substance abuse, no vocational education, 
young age and high global functioning 
predicted poor adherence. 
Lack of clarity about some 
of the adherence 
categories e.g. 
unregulated medication.   
Assumptions made about 
adherence in those not 
prescribed medication, 
depending on whether 
they were symptomatic or 
not. 
 
 
Malla et al. 
(2002a) 
One year, prospective, 
cohort study. 
66 patients in a 
programme to promote 
early recognition, 
comprehensive 
assessment and 
treatment.  Urban 
population in Canada. 
Compliance rated on a 
four point scale 
depending on whether 0-
25%, 25-50%, 50-75% or 
75-100% were taken in 
the previous month. 
 
Consensus rating based 
on: 
Self-report 
Carer report 
Clinician report 
Poor adherence associated with lower 
social relations and activities of daily living. 
Approximately one-third of 
patients were excluded 
from analysis due to 
incomplete data. 
Single site. 
McEvoy et al. 
(2006a) 
Two year, randomised, 
double-blind, controlled 
trial. 
251 patients over 14 
study centres in North 
America and Western 
Europe. 
Poor adherence: failure to 
take any medication over 
a seven day period. 
Pill count. 
Self-report. 
Higher levels of insight into psychiatric 
illness and need for medication predicted 
adherence. 
 
 
Patients were prescribed 
either olanzapine or 
haloperidol.  Patients had 
high baseline levels of 
insight which might have 
reflected in the results.  
Medication supplied free 
of charge which might 
have influenced 
adherence behaviours.  
Drug company 
sponsored. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Miller et al. 
(2009) 
Prospective, one year, 
cohort study 
112 patients from two 
services in New York 
enrolled in the 
Preventing Morbidity in 
First Episode 
Schizophrenia Study.   
 
Adherent if medication 
was taken at least 50% of 
the time. 
 
Self-report. 
Clinician report. 
Carer report. 
Plasma level monitoring. 
 
Cannabis use associated with poor 
adherence. 
Study was to compare 
effectiveness of two 
antipsychotics, this was 
therefore secondary 
analysis of study data. 
Study participants may 
not be representative of 
many patients with FEP.  
Low threshold for 
adherence.  Study 
focused purely on 
cannabis and did not 
consider other illicit 
substances which may 
have been consumed. 
Montreuil et 
al. (2012) 
Prospective, six month, 
cohort study. 
81 patients. Adherent if more than 
75% of full doses were 
taken for each month of 
the study. 
Self-report. 
Clinician report. 
Carer report. 
Pill count. 
Good case manager rated working 
alliance, but not patient-related alliance, 
was predictive of good adherence. 
Single centre study. Study 
did not assess side 
effects of medication 
which may influence 
adherence and 
therapeutic alliance. 
Working alliance only 
rated by clinicians. 
Mutsatsa et 
al. (2003) 
Prospective, cohort study. 101 patients in West 
London. 
Seven point Compliance 
Rating Scale (CRS). 
Good adherence: rating 
of 5 or above on the CRS. 
Poor adherence:  rating of 
4 or below on the CRS. 
Clinician report. 
Carer report. 
Prescription chart review. 
Case note review. 
Age, gender, substance or alcohol misuse, 
type of antipsychotic, ESPSEs or non-
neurological side effects did not 
significantly affect adherence.  Subjective 
wellbeing ratings were also not linked to 
adherence behaviours. 
Poor adherence was significantly linked to 
negative and disorganisation syndromes 
and poor total insight, illness awareness 
and recognition and need for treatment 
scores. Negative attitudes to medication 
(as measured by the Ratings of Medication 
Influences [ROMI] scale) were significantly 
associated with poorer adherence. Insight 
and negative attitudes to medication were 
most significant predictors of poor 
adherence accounting for 27% of the 
variance. 
 
Single centre study. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Novak-Grubic 
and Tavcar 
(2002) 
Prospective, naturalistic, 
one year, follow up, 
cohort study. 
 
56 patients in a single 
site in Slovenia. 
Adherent: Strict 
adherence to medication 
regimen. 
Self-report.  
Carer report. 
Socio-demographic variables e.g. age,  
living situation, marital, educational & 
occupational status, severity of EPSEs, 
type of medication, attitude to 
hospitalisation and length of stay were not 
significantly associated with adherence.  
Diagnosis of schizophrenia rather than 
schizophreniform or schizoaffective 
disorder, poor insight at discharge and 
more severe positive symptoms on 
admission were associated with poor 
adherence. 
Sample all male. All 
initially admitted to a 
psychiatric intensive care 
unit which might reflect 
severity of illness or risk. 
Substance misuse was an 
exclusion criteria. Single 
site. Relatively small 
sample. Insight assessed 
from a single item in the 
PANSS questionnaire. 
Rigid definition of 
adherence. No objective 
measure of adherence. 
Opjordsmoen 
et al. (2010) 
Four year, cohort study.  217 consecutive 
admissions to three 
hospitals in Norway. 
Adherent: taking 
prescribed medication.  
Self-report. Involuntary admission had no impact on 
treatment adherence. 
Perceived coercion not 
assessed. Admission 
based on legislation in 
Norway.  23.1% refused 
consent. Definition of 
adherence not 
comprehensive. No 
objective measure of 
adherence. 
Perkins et al. 
(2006) 
Two year, randomised, 
double blind, clinical trial. 
254 patients over 14 
study centres in North 
America and Western 
Europe. 
Non-adherent: refusal to 
continue taking any 
antipsychotic, start of the 
first seven day gap in 
medication (or the first 
four day gap if within the 
first 12 weeks of the 
study). 
Pill count. Age, gender, duration of illness, social 
support, diagnosis, ethnicity, alcohol, drug 
or cannabis use and negative aspects of 
treatment e.g. side effects, interference 
with life goals, embarrassment not 
associated with adherence.  Belief in the 
need for treatment and benefits of 
medication was associated with 
adherence.  Clinician rated akathisia, but 
not parkinsonian side effects, were 
associated with non-adherence.  
Increased BMI also significant for non-
adherence over a seven day period.  Non-
adherence was 1.5 times greater with 
haloperidol than olanzapine but was 
mediated in part by other associations e.g. 
negative aspects of medication.  Less 
improvement in positive symptoms and 
psychopathology linked to non-adherence. 
Secondary analysis from 
a clinical trial to assess 
efficacy of olanzapine vs. 
haloperidol. Results 
obtained from a clinical 
trial rather than a 
naturalistic setting.  Single 
measure of adherence. 
Social support was the 
perceived rather than 
actual level of social 
support. 
67 
 
Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Pogge et al. 
(2005) 
Follow up, prospective, 
cohort study. 
86 patients discharged 
from a private 
psychiatric hospital in 
New York on 
olanzapine or 
risperidone. 
Adherent: currently (over 
the past week) taking 
medication as directed. 
Non-adherent: patient 
made the decision to stop 
medication on their own. 
Discontinued: medication 
stopped at the request of 
parent or prescriber 
Self-report by patient 
through telephone 
interview.   
If patient was not a 
reliable historian a parent 
was approached. 
Predictors of adherence were substance 
abuse, rapid weight gain during 
hospitalisation, failure to comply with 
individual therapy post discharge and 
being younger. Gender, ethnicity, 
diagnoses other than substance misuse, 
efficacy of medication, positive symptoms, 
side effects of EPSEs, memory changes, 
akathisia, sedation, anticholinergic side 
effects and perceived weight gain were not 
significant variables. 
Risperidone or olanzapine 
not always prescribed for 
psychosis.  Follow up 
adherence phone call 
occurred anytime 
between 3 and 18 months 
post-discharge.  Patients 
were asked about current 
adherence so the design 
would not have picked up 
variable adherence 
patterns over time. Power 
calculation included but 
sample size was 
insufficient to detect 
differences between 
olanzapine and 
risperidone groups. Single 
site. No objective 
measure of adherence. 
Rabinovitch 
et al. (2009) 
Follow up, longitudinal, 
six month, cohort study. 
 
102 consecutive 
admissions with FEP to 
the Prevention and 
Early Intervention 
Programme for 
Psychoses (PEPP) in 
Montreal, diagnosed 
with schizophrenia 
spectrum disorder or 
affective psychosis. 
Adherent: Over 75% of 
prescribed doses were 
taken during the study 
period. 
Formal interview with a 
trained rater.  
Adherence information 
obtained from the 
interview, case manager 
records of visits. 
Rated measure highly 
correlated with pill counts 
on a sample of 51 
patients. 
No significant difference for gender, age of 
admission, DUP, IQ, premorbid 
adjustment, diagnosis, substance misuse, 
level of baseline depressive symptoms, 
weight gain, EPSE’s, disorganisation, 
psychomotor poverty or reality distortion 
syndrome. 
Level of social support and early 
medication acceptance were significant 
predictors of adherence. 
Social support was case 
manager rated.  In a 
smaller sample, social 
support was rated by the 
patient and the findings in 
terms of social support 
were not replicated. 
Poor records of weight 
acknowledged in first two 
months when most weight 
gain is likely to occur.  
Patients from a single 
service received intensive 
support and treatment 
programme. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Rabinovitch 
et al. (2013) 
Follow up, longitudinal, 
cohort study. 
81 FEP patients in the 
PEPP. 
Good adherence: taking 
over 75% of prescribed 
doses over the previous 
month. 
Patient Report. 
Clinician Report. 
Family Report. 
Pill counts used to 
determine a consensus 
measure of adherence. 
Baseline social support was associated 
with initial adherence, but not with 
changes in adherence over time. 
Increased social support over time 
associated with a decrease in adherence, 
irrespective of insight and substance 
misuse. Significant correlation with mean 
insight scores. Trend with lifetime 
substance use disorder. No relationship 
with sex, marital status or level of 
psychopathology. 
Patients subject to an 
intensive support and 
treatment programme.  
Might not be replicated in 
those receiving differing 
standards and means of 
care. 
Robinson et 
al. (2002) 
Prospective, one year, 
follow up, cohort study.  
118 new admissions to 
an inpatient hospital in 
New York. 
Poor adherence: failure to 
take medication for a 
period of at least one 
week. 
Self-report. 
Carer report. 
Clinician report. 
Poor adherence associated with poor 
premorbid, cognitive and executive 
functioning.  Poor adherence associated 
with Parkinsonian side effects.   
Following first relapse, lower parental 
social class, poor education attainment, 
side effects and discontinuation of 
medication during the initial treatment 
phase were associated with poor 
adherence.  Premorbid social functioning, 
DUP, diagnosis, symptom severity and 
family attitudes were not significant. 
Early study.  Data 
collection period was 
1989-1996.  No objective 
measure of adherence. 
Single site.  Secondary 
study. 
Segarra et al. 
(2012) 
Prospective, one year 
cohort study. 
577 patients recruited 
from 19 centres in 
Spain. 
Good adherence: rating 
of 4 on the Morisky-Green 
scale with corroborative 
information from other 
sources . 
Self-report. 
Carer report. 
Prescription review. 
Pill count. 
 
Greater insight and higher levels of 
education were associated with better 
adherence at follow up.  Treatment with a 
long acting injection was associated with 
higher rates of adherence. 
10.3% were on long-
acting antipsychotics and 
up to 47% were on a 
combination of long-acting 
and oral antipsychotics. 
The high proportion of 
patients on long-acting 
injections meant that 
adherence rates were 
high.  This may not be 
representative of other 
samples.  22% drop out 
rate. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Sleath et al. 
(2010) 
Retrospective, cohort 
study.  
64,775 patients 
identified from a 
database detailing 
claims for prescription 
costs in Georgia and 
North Carolina in the 
United States of 
America (USA). 
Adherent: at least one 
prescription was collected 
and the Proportion of 
Days Covered (PDC) by a 
prescription was 80%. 
Proportion of days 
covered using 
prescription collection 
data. 
Black children were less adherent than 
white children, or those of unknown race.  
Black children in North Carolina were more 
adherent than those in Georgia.  Black 
boys were less adherent than black girls. 
Single measure of 
adherence.  No 
confirmation that 
medication was 
subsequently consumed.   
The database only 
records data from 
pharmacies receiving 
reimbursement via 
Medicaid. 
Steger et al. 
(2012) 
Follow up, six month, 
cohort study. 
216 patients in the 
PEPP service in 
Montreal. 
Adequate adherence: 
taking more than 75% of 
doses.   
Inadequate adherence: 
taking 75% or fewer 
prescribed doses. 
Self-report.  
Case manager report. 
Early resolution of negative, but not 
positive, symptoms associated with 
inadequate adherence.  Those whose 
negative symptoms had resolved at 3 
months were less likely to be adequately 
adherent at 6 months. Late resolution of 
positive and negative symptoms did not 
affect adherence rates.  Baseline insight 
was significantly associated with later 
adherence. Diagnostic category was 
significant.  Those with affective psychosis 
were more adherent than those with a 
schizophrenia spectrum disorder.  Age, 
gender, marital status, DUP, diagnosis, 
substance misuse did not influence three 
month adherence in those with early 
resolution of negative symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded patients with 
missing data were more 
likely to be inadequately 
adherent.  Potential for 
sample bias.  Single 
service study.  No 
objective measure of 
adherence.  
Pharmaceutical company 
sponsored. 
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Reference Study Design/duration Participant 
Descriptors 
Definition of adherence Measurement of 
adherence 
Results Study Limitations 
Tunis et al. 
(2007) 
 
Naturalistic, randomised, 
open-label trial. 
440 patients across 21 
sites in the USA. 
Adherent:  Remaining on 
the initial antipsychotic for 
at least 180 days, with no 
treatment gaps greater 
than 14 days. 
Secondary analysis of 
antipsychotic persistence 
at 90 and 270 days was 
also undertaken. 
ROMI Scale. Antipsychotic persistence associated with 
initial prescription of olanzapine rather 
than risperidone, no comorbid substance 
misuse, positive relationships with staff 
and fulfilment of life goals.   
Patient persistence was on average 46 
days longer when the initial prescription 
was olanzapine and 44 days longer when 
there was no misuse of substances.  
Patients were twice as likely to have 
persisted for 180 days if there was a 
strong therapeutic alliance or where 
medication was supporting fulfilment of life 
goals.  Perceived daily benefit and fear of 
relapse were rated as the most influential 
factor for adherence, followed by side 
effect relief, fulfilment of life goals, 
deference to authority, positive relation 
with clinical staff, outside positive influence 
about medication, outside opinion that 
current medication is better and outside 
pressure by staff.   
Two most influentially rated factors, 
perceived daily benefit and fear of relapse 
did not mirror the most influential factors 
for persistence on actual assessment. 
Only two antipsychotics 
were prescribed to 
patients.  Higher level of 
monitoring within the 
study, even though it was 
conducted in a naturalistic 
setting, might have 
influenced responses and 
behaviours.  Researchers 
were employed by the 
pharmaceutical company 
manufacturing 
olanzapine.  Single 
measure of adherence. 
Uçok et al. 
(2006) 
Observational, one year, 
follow up, cohort study. 
74 patients admitted 
with FEP in Turkey. 
 
Non-adherent: less or no 
medication was taken for 
ten consecutive days. 
Self-report. 
Carer report. 
Higher ratings of suspiciousness on the 
Brief Psychiatric Rating Scale (BPRS) at 
discharge, was linked to poor adherence 
at follow-up. 
All patients had been 
treated for their first 
episode in an inpatient 
clinic rather than the 
community which may 
have suggested more 
severe illness at 
commencement.  No 
objective measure of 
adherence. 
Verdoux et al. 
(2002) 
Two year, follow up, 
cohort study. 
35 consecutive 
admissions to a 
psychiatric hospital in 
Bordeaux fulfilling 
inclusion criteria. 
Poor adherence: 
medication was stopped 
completely against 
medical advice for at least 
two weeks over a six 
month interval. 
Self-report.  
Informant reports. 
Poorer cognitive flexibility was associated 
with good adherence.   
No associations with verbal fluency, 
attention, visual-motor capabilities, verbal 
and visual memory. 
 
Single site.  No objective 
measure of adherence. 
This summary of relevant papers highlights that the research studies have, in 
the main, been small scale and have utilised many different designs.  
Definitions of adherence are extremely inconsistent across published papers, 
and assessment of adherence has been via a number of different strategies 
although self-report appears most prevalent.  All these variables make 
comparison of studies and conclusions about findings extremely difficult.  The 
variability in approach also highlights a need to agree a gold standard for 
defining and assessing medication adherence in research. Despite these 
limitations, further information is now provided about factors affecting 
medication adherence.  These factors are presented in six different 
subcategories; patient, social- and economic, health system or health team, 
condition, treatment and other factors affecting medication adherence.  This 
mirrors five of the dimensions proposed by the World Health Organisation 
(WHO) for several physical health conditions such as hypertension, 
tuberculosis, asthma, cancer and HIV (World Health Organisation, 2003), 
however for psychosis I struggled to assign some research findings to the 
categories of  patient, social- and economic, health system or health team, 
condition or treatment factors presented for physical illness, requiring addition of 
an ‘other’ category. 
3.3. Patient Related Factors Affecting Adherence  
Patient related factors which may impact on antipsychotic adherence in FEP 
include age, ethnicity, gender, insight, patient attitudes and personality traits.  
3.3.1.   Age 
EIS caters for a wide age group, in recognition of the fact that first episode 
psychosis can present at any age in children and young adults.  It is therefore 
important to consider whether age may influence adherence behaviours.  Most 
studies concluded that age was not significant (Novak-Grubic and Tavcar, 2002, 
Mutsatsa et al., 2003, Kamali et al., 2006, Perkins et al., 2006, Gearing and 
Charach, 2009, Lepage et al., 2010a, Segarra et al., 2012, Steger et al., 2012, 
Chan et al., 2014a).  A younger participant age was linked to poor adherence in 
a small number of studies (Coldham et al., 2002, Kampman et al., 2002, Pogge 
et al., 2005, Le Quach et al., 2009).   
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3.3.2. Ethnicity 
The evidence base considering the effects of ethnicity on medication adherence 
in FEP is limited, however two studies have shown no impact on medication 
adherence (Pogge et al., 2005, Perkins et al., 2006).  Sleath et al. (2010) found 
that black children in North Carolina and Georgia were significantly more likely 
to take their medication less than 80% of the time compared to white children or 
those classified as ‘unknown race’ (Sleath et al., 2010).  Reviewing suicides 
within a year of first contact with mental health services, it was found that the 
incident of non-adherence with medication was higher amongst ethnic minority 
groups compared to a white population (Hunt et al., 2003).  In another study 
greater adherence rates were found in white, rather than non-white, race in the 
twelve months following a first admission for affective psychosis (Strakowski et 
al., 1998).  There is a suggestion therefore that in some ethnic minority groups 
rates of medication adherence are lower, but paucity of data prevents firm 
conclusions being drawn. 
3.3.3. Gender 
Another important demographic variable to consider is the effect of gender on 
medication adherence.  The majority of studies have failed to find a link 
between gender and medication adherence (Coldham et al., 2002, Mutsatsa et 
al., 2003, Pogge et al., 2005, Kamali et al., 2006, Perkins et al., 2006, Gearing 
and Charach, 2009, Rabinovitch et al., 2009, Hill et al., 2010, Lepage et al., 
2010a, Steger et al., 2012, Rabinovitch et al., 2013, Chan et al., 2014a). A few 
studies have concluded that males with FEP were less likely to take medication 
as prescribed (Kampman et al., 2002, Lecomte et al., 2008). In Sleath et al.’s 
(2010) study black girls were more likely to adhere with medication than black 
boys; however, considering the sample as a whole boys were more adherent 
(Sleath et al., 2010). 
3.3.4. Insight 
Another patient factor requiring consideration is insight.  Insight in mental illness 
is a multifactorial phenomenon driven by psychological, neuropsychological and 
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organic factors (Ouzir et al., 2012).  Due to the nature of psychotic illness, 
insight is often lacking and is a common feature of the illness (McFarland et al., 
2009).  Differing definitions of insight have existed over the years and include 
the ability to perceive clearly or deeply; the faculty of seeing into inner character 
or underlying truth; intuitive understanding of the significance of an event or 
action; an understanding of relationships that sheds light on a problem; self-
knowledge; and a sudden, penetrating understanding of a complex problem or 
situation (Silberman, 2014).  Because of the negative impact poor insight has 
on patient outcome (Chan et al., 2014a), it is important to assess and measure 
this using available insight tools.  The Insight and Treatment Attitudes 
Questionnaire (ITAQ) assesses the patient’s attitudes or beliefs about whether 
they are suffering from a mental illness, and subsequently whether this requires 
treatment (McEvoy et al., 1981). The Schedule for the Assessment of Insight 
(SAI) measures subjective recognition of mental illness, compliance with 
treatment and appropriate recognition of psychotic phenomena by the 
respondent (David et al., 1990). The Scale to Assess Unawareness of Mental 
Disorder (SUMD) considers awareness and attribution of illness, current and 
retrospective assessment of recognition of a mental disorder, the effects of 
medication and the consequences and specific signs of mental illness (Amador 
et al., 1993).  Finally, the Birchwood self-report insight scale for psychosis 
focuses on general attributions about illness, specific attributions about 
symptoms and the perceived need for treatment (Birchwood et al., 1994).   
The literature provides support for the fact that poor insight into illness and 
medication impacts negatively on medication adherence (Coldham et al., 2002, 
Novak-Grubic and Tavcar, 2002, Mutsatsa et al., 2003, Kamali et al., 2006, 
McEvoy et al., 2006a, Perkins et al., 2006, Le Quach et al., 2009, Hill et al., 
2010, Segarra et al., 2012, Steger et al., 2012, Chan et al., 2014a).  Isolated 
studies have failed to show an association between insight and adherence (de 
Haan et al., 2007, Lecomte et al., 2008), however this is outweighed by the 
amount of evidence supporting an association. 
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Having considered the effect of insight on medication adherence, it is also 
important to consider whether factors such as premorbid adjustment and 
personality features have a bearing on medication adherence. 
3.3.5. Premorbid Adjustment 
Initially I debated whether pre-morbid adjustment was a patient related or 
condition related factor.  Premorbid adjustment is defined as “the degree to 
which a subject had fulfilled the appropriate expectations for his or her sex and 
age before the onset of the illness” (Phillips, 1953).  On the basis of this 
definition, I decided premorbid adjustment was a patient-related, rather than an 
illness related factor as it related to a period preceding illness onset.  Poor pre-
morbid functioning has been associated with poor adherence in one study 
(Coldham et al., 2002), but not in another study (Rabinovitch et al., 2009). 
3.3.6. Personality Traits 
Studies have also found that personality traits may provide an indicator of 
medication adherence.   Hostility and uncooperativeness (de Haan et al., 2007), 
high agreeableness (Lecomte et al., 2008) and suspiciousness (Uçok et al., 
2006) have been linked to poor adherence.  Embarrassment at the need to take 
medication was associated with poor adherence in one study (Hui et al., 
2006a), but not in another study (Perkins et al., 2006). 
3.3.7. Other Patient Related Factors 
Finally, I will outline other patient related factors that have been suggested, in 
single studies, to be of relevance to medication adherence.  Patient 
discernment as determined by knowledge and information, self-assessment and 
personal experience was one of three factors driving medication adherence in a 
grounded theory study conducted with patients prescribed the antipsychotic 
medication aripiprazole (Hon, 2012).  Subjective wellbeing was also shown not 
to be important to medication adherence (Mutsatsa et al., 2003).   
As well as patient factors, it is important to consider social and economic factors 
which may influence adherence in FEP. 
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3.4. Social and Economic Related Factors Affecting 
Adherence 
In considering social and economic factors impacting on adherence, specific 
attention is drawn to the relevance of social support, including marital status, 
educational factors and socioeconomic situations. 
3.4.1. Social Support 
Given the relatively young age at which first episode psychosis can present, 
patients may still be living at home particularly if they are still of school age.  It is 
therefore relevant to consider the impact family and social support has on 
medication adherence.  Poor family involvement and social support has been 
shown to adversely affect medication adherence (Coldham et al., 2002, Le 
Quach et al., 2009, Rabinovitch et al., 2009), although other studies did not 
come to the same conclusions (Perkins et al., 2006, Gearing and Charach, 
2009).  In a later study conducted by Rabinovich et al. (2013), good social 
support networks were modestly associated with good medication adherence 
however  increased levels of social support over time were associated with 
declining adherence rates (Rabinovitch et al., 2013).  Whilst this initially appears 
counterintuitive, it may be that increased social support means that patients no 
longer feel that they need medication.   Studies have also found that a lack of 
social activities can result in poorer adherence (Kampman et al., 2002, Malla et 
al., 2002a), however pre-morbid social functioning had no association with poor 
adherence in another study (Robinson et al., 2002). 
It is important when considering these studies to acknowledge that the means 
of categorising family involvement varied across the studies.  The methods 
utilised included involvement of family members in the early intervention 
programme, contact with family workers within the team, completion of required 
family assessments, availability for interview, lack of support or contact with a 
key relative and case manager rated support. Some of these could be 
considered weak proxy indicators of familial support and this may have 
influenced the findings.   
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Marital status might also be viewed as a proxy indicator of social support, 
however studies have not shown an association between marital status and 
medication adherence (Novak-Grubic and Tavcar, 2002, Steger et al., 2012, 
Rabinovitch et al., 2013).   
3.4.2. Other Social and Economic Related Factors 
Considering other studies which have included social and economic related 
factors, educational status (Novak-Grubic and Tavcar, 2002, Lepage et al., 
2010a), intelligence scores (Rabinovitch et al., 2009, Lepage et al., 2010a), 
patient or parental socioeconomic status (Lepage et al., 2010a), living situation 
(Novak-Grubic and Tavcar, 2002), family history of depression (Gearing and 
Charach, 2009) and occupational status (Novak-Grubic and Tavcar, 2002) have 
been shown not to impact on medication adherence.  One study found that lack 
of vocational education was associated with poor adherence (Le Quach et al., 
2009). Other studies have suggested that poor education attainment predicts 
poor adherence after an initial relapse (Robinson et al., 2002, Segarra et al., 
2012).  It has also been suggested that lower parental social class (Robinson et 
al., 2002), family history of psychosis (Barbeito et al., 2013), a history of legal 
problems (Lecomte et al., 2008) and witnessing violence during childhood 
(Lecomte et al., 2008) can be predictive of poor adherence.   
Having presented the evidence for social and economic-related mediators of 
adherence, the next dimension of health system- or health team- related factors 
will be addressed. 
3.5. Health System or Health Team Related Factors Affecting 
Adherence 
There are a number of health system- or health team- related factors which may 
affect medication adherence.  These include healthcare systems, associated 
insurance policies, poor staff knowledge, ease of access to medication and 
relationships with healthcare professionals, staff (Whittemore and Knafl, 2005).  
There is limited information about heath team- or health system- related factors 
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which impact antipsychotic medication adherence in FEP, which I will now 
present. 
3.5.1. Therapeutic Alliance 
When considering health team factors impacting on medication adherence, it is 
important to consider whether relationships between practitioners and patients 
influence subsequent adherence with antipsychotic medication.  Studies have 
shown that poor therapeutic alliance (Tunis et al., 2007) and negative initial 
interactions with staff (de Haan et al., 2007) do adversely affect medication 
adherence.  In one study case manager, but not patient, ratings of therapeutic 
alliance was found to be predictive of adherence (Montreuil et al., 2012). 
3.5.2. Admission Status 
Involuntary admission to hospital is another health system-related variable 
which has the potential to affect medication adherence. Although adherence to 
medication improved in the eight years following a first involuntary hospital 
admission (Barbeito et al., 2013), other studies have shown the opposite to be 
true (Kamali et al., 2006, Opjordsmoen et al., 2010).  One study comparing 
adherence rates in an inpatient or outpatient setting concluded that the 
treatment setting at baseline had no impact on subsequent adherence (Hill et 
al., 2010).   
3.5.3. Other Health Related Factors 
Health system or team factors can also have an impact on the amount of 
information about both illness and medication a patient receives.  Studies have 
shown that provision of information about illness and medication positively 
influences adherence with medication (Hon, 2012, Chan et al., 2014a).   
Contrasting these findings, another study showed that admission length and the 
patients’ feelings and attitudes to the admission were not a significant mediator 
of adherence (Novak-Grubic and Tavcar, 2002).  Irrespective of the potential 
impact on adherence, national guidelines recognise the importance of patient-
centred care and encourage healthcare professionals to involve patients in 
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discussions about medication where this is appropriate (NICE, 2009a, NICE, 
2009b, NICE, 2013, NICE, 2014). 
3.6. Condition Related Factors Affecting Adherence 
Whilst there is little literature addressing health system and health team related 
factors affecting antipsychotic adherence in FEP, the same cannot be said of 
condition-related factors as the evidence base is more expansive.  Factors 
considered include diagnosis, DUP, symptoms, cognitive and global functioning 
and substance misuse. 
3.6.1. Diagnosis 
Antipsychotic medication may be used for a number of conditions such as first 
episode psychosis, schizophrenia, schizoaffective disorder or bipolar affective 
disorder.   A study showed that adherence is higher in those with a diagnosis of 
schizophrenia rather than schizophreniform or schizoaffective disorder (Novak-
Grubic and Tavcar, 2002), whilst another found that a diagnosis of 
schizophrenia as opposed to  affective psychosis predicted poorer adherence 
rates (Steger et al., 2012).  The majority of studies have however concluded 
that diagnosis has no bearing on medication adherence (Coldham et al., 2002, 
Robinson et al., 2002, Pogge et al., 2005, Perkins et al., 2006, Miller et al., 
2009, Rabinovitch et al., 2009, Hill et al., 2010) 
3.6.2. Duration of Untreated Psychosis 
Given the negative outcomes already linked to a prolonged DUP, it is not 
unreasonable to question whether there is also an association between DUP 
and medication adherence.  A prolonged DUP showed a trend to poor 
adherence in a study by Gearing and Charach (2009), and a significant 
association in another study (Hill et al., 2010).  Other studies  have shown that 
DUP (Robinson et al., 2002, Rabinovitch et al., 2009, Steger et al., 2012) and 
duration of illness (Perkins et al., 2006) are insignificant. 
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3.6.3. Symptomatology 
Ongoing positive and negative symptoms of psychosis may also affect whether 
somebody takes their medication as prescribed.  Higher positive symptom 
scores have been linked to poor adherence (Novak-Grubic and Tavcar, 2002, 
Kamali et al., 2006, Perkins et al., 2006, Lecomte et al., 2008, Hill et al., 2010).  
In a study by Kampman et al. (2002), whilst a low positive subscale score on 
PANSS was linked to poor adherence, a high total score was also associated 
with poor adherence showing the adverse effect negative symptoms have on 
medication adherence.  Early resolution of negative symptoms has also been 
linked to poor adherence (Steger et al., 2012).  Other studies have shown that 
ongoing symptoms (Segarra et al., 2012) be that positive symptoms (Pogge et 
al., 2005), early or late resolution of positive symptoms (Steger et al., 2012), 
late resolution of negative symptoms (Steger et al., 2012), symptom severity 
(Robinson et al., 2002, de Haan et al., 2007), concurrent depressive symptoms 
(Barbeito et al., 2013), and ongoing psychopathology (Rabinovitch et al., 2013) 
have no influence on medication adherence.   
3.6.4. Cognitive and Global Functioning 
Other condition-related factors to consider include cognitive and global 
functioning.  Cognition has been defined in the broadest term as ‘‘all processes 
by which… sensory input is transformed, reduced, elaborated, stored, 
recovered, and used’’ (Neisser, 2003).  Evaluation of global functioning in 
mental health focuses on symptom severity or psychological, social, and 
occupational functioning (Gold, 2014).  Global functioning is in itself affected by 
cognitive abilities.  I decided to include cognitive and global functioning as a 
condition, rather than a patient related factor as they are both impacted so 
significantly by psychosis (Rasmussen et al., 2013).  Chen et al. (2005) did not 
determine an association between cognitive function and medication adherence 
(Chen et al., 2005b).  Mutsatsa et al. (2003) found that negative and 
disorganisation syndromes resulted in poorer adherence, although 
disorganisation and reality distortion syndrome were not associated with poor 
adherence in a study by Rabinovitch et al. (2009).  Others have concluded that 
poor premorbid cognitive and executive functioning were significant factors for 
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poor adherence (Robinson et al., 2002).  In a two year prospective study good 
cognitive flexibility resulted in poorer rates of adherence, whilst verbal fluency, 
attention, visual-motor capabilities and verbal and visual memory had no 
influence (Verdoux et al., 2002).  Poor global functioning has also been 
associated with both poor medication adherence (Hill et al., 2010) and good 
adherence (Le Quach et al., 2009).  Evidence is therefore contradictory about 
the impact of cognitive and global functioning on medication adherence in FEP. 
3.6.5. Alcohol Misuse 
The literature also considers the impact of alcohol, cannabis and other illicit 
substances on medication adherence.  Some of the articles include cannabis 
and alcohol in a general category of substance misuse whilst others separate 
them out.  I have chosen to replicate the conventions used in the original 
articles.  Initially, I debated whether these categories fit more closely in the 
section on patient related factors. My reasoning for including them as a 
condition related factor is because it has been estimated that approximately 
40% of people with psychosis misuse substances at some point in their lifetime, 
at least double the rate seen in the general population (NICE, 2011b).  There is 
therefore a strong association between substance misuse and the condition 
itself.  The evidence base in relation to alcohol is split, with two studies showing 
that alcohol misuse negatively impacts on medication adherence (Coldham et 
al., 2002, Kamali et al., 2006) and another two studies highlighting no effect 
(Mutsatsa et al., 2003, Perkins et al., 2006) 
3.6.6. Cannabis Misuse 
Cannabis use has been shown to reduce adherence rates (Coldham et al., 
2002, de Haan et al., 2007, Miller, 2007, Barbeito et al., 2013), although this 
was not replicated in a further study (Perkins et al., 2006).  In a prospective 12 
month study conducted by Faridi et al. (2012), those continuing to use and 
stopping cannabis became less adherent in the first six months of the study. By 
12 months, 40% of those stopping cannabis became adherent with medication 
again compared with 92% who became adherent with medication whilst 
continuing to use cannabis (Faridi et al., 2012).  Whilst this was a study with a 
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relatively small sample size (n=48), it may be that those continuing to use 
cannabis may become more adherent with medication over time to reduce the 
risk of cannabis worsening psychotic symptoms.  Cannabis is one of a number 
of substances liable to misuse, and some studies have assessed the impact of 
substance misuse more globally on medication adherence.  These studies 
considering the impact of substance misuse on adherence in FEP will now be 
reviewed. 
3.6.7. Substance Misuse 
NICE identified that substance misuse is associated with poorer rates of 
medication adherence in those suffering a psychotic illness (NICE, 2011b).  
Whilst some studies in FEP support this (Pogge et al., 2005, Kamali et al., 
2006, Tunis et al., 2007, Le Quach et al., 2009, Hill et al., 2010), others refute it 
(Coldham et al., 2002, Robinson et al., 2002, Mutsatsa et al., 2003, Perkins et 
al., 2006, Lecomte et al., 2008, Rabinovitch et al., 2009, Steger et al., 2012).  
One study linked poor adherence with a greater severity of substance misuse 
disorder, suggesting that adherence may also vary with the extent of substance 
misuse (Wade et al., 2007).  The NICE guidance considers adults as well as 
young people, and given the evidence presented there may therefore be 
differences between cohorts of young adults with FEP and adults with chronic 
psychoses. 
3.6.8. Other Condition Related Factors 
Other condition-related factors may also affect adherence in FEP although the 
evidence is somewhat limited.  Age of onset of illness (Segarra et al., 2012), 
age of admission, baseline depressive symptoms and psychomotor poverty 
(Rabinovitch et al., 2009), or memory changes (Pogge et al., 2005) have not 
been found to affect medication adherence in FEP.  Failure to engage in 
individual therapy has however been shown to be influential (Pogge et al., 
2005). 
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3.7. Treatment Factors affecting adherence  
Having considered condition-related factors, treatment factors that may have a 
direct effect on adherence are now presented.  These factors include patient 
attitudes, side effects, class of antipsychotic and concurrent medication.   
3.7.1. Patient Attitude to Medication 
One of the potential drivers of medication adherence is patient attitude to 
medication.  A few studies have shown that negative medication attitudes result 
in lower adherence rates (Mutsatsa et al., 2003, Hill et al., 2010, Chan et al., 
2014a), although this finding was not replicated by De Haan et al. (2007). 
Patients who felt that medication was beneficial were, surprisingly, no more 
likely to take it than those who found it less beneficial (Hui et al., 2006b).  This 
finding was replicated by Pogge et al. (2005), who found that efficacy of 
medication was not significant when determining medication adherence.  In 
contrast, a grounded theory study considered that efficacy of aripiprazole did 
impact on medication adherence (Hon, 2012).  Failure to identify an association 
between adherence and medication efficacy in some published research may 
be due to the fact that adherence behaviour is multifactorial and decisions are 
influenced by more than one parameter.  This may include, for example, an 
assessment of the relative merits of better symptom control versus the impact of 
side effects on daily living. 
3.7.2. General Side Effects 
Numerous studies have assessed the influence of side effects on antipsychotic 
medication adherence in FEP.  Subjective experiences of medication (de Haan 
et al., 2007) and side effects (Perkins et al., 2006) were found not to have a 
bearing on medication adherence in the two identified studies.  A qualitative 
study by Hon (2012) identified side effects as a potential modifier of medication 
adherence.  Further studies have addressed the impact of differing side effects 
individually and these will now be described. 
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3.7.3. Extrapyramidal Side Effects 
Extrapyramidal side effects is a term used for a group of side effects which 
include tremor, parkinsonian side effects, akathisia, dystonia, muscle rigidity 
and dyskinesia (Tandon and Jibson, 2002).  Akathisia, but not parkinsonian side 
effects, were reported as having an adverse effect on antipsychotic medication 
adherence in one study (Perkins et al., 2006), however another found 
parkinsonian side effects to have a negative impact on adherence (Robinson et 
al., 2002). Other studies failed to shown a significant influence of akathisia 
(Coldham et al., 2002, Pogge et al., 2005), or extrapyramidal side effects 
(Coldham et al., 2002, Novak-Grubic and Tavcar, 2002, Mutsatsa et al., 2003, 
Pogge et al., 2005, Rabinovitch et al., 2009) on FEP medication adherence. 
3.7.4. Weight Gain 
Weight gain is another recognised side effect of some antipsychotic drugs 
(Robson and Gray, 2007), and some patients find it difficult to cope with the 
insatiable appetite and weight gain that may result (Usher et al., 2013).  Studies 
have shown that weight gain can result in poor medication adherence (Pogge et 
al., 2005, Perkins et al., 2006), although this finding has not been consistent 
(Rabinovitch et al., 2009).  In the study by Pogge et al. (2005) the findings 
varied depending on perceived and actual weight gain.  Young people who 
rapidly gained weight gain were poorly adherent to medication.  Perceived 
rather than actual weight gain had no effect on medication adherence. 
3.7.5. Sedation 
Another potential side effect which some patients find troublesome is sedation 
(Dibonaventura et al., 2012).  The only study in FEP to consider the impact on 
adherence found there to be no association (Pogge et al., 2005) between 
adherence and sedation. 
3.7.6. Anticholinergic Side Effects 
Anticholinergic side effects that may be secondary to antipsychotic medication 
include dry mouth, blurred vision, urinary retention and particularly in the elderly 
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confusion, disorientation and memory changes (Mintzer and Burns, 2000).  
Limited evidence suggests that anticholinergic side effects do not impact on 
medication adherence in FEP (Pogge et al., 2005) 
3.7.7. Other Treatment Related Factors 
As well as side effects of antipsychotic medication, the actual antipsychotic 
medication and the form prescribed is also of relevance to medication 
adherence.  The particular medication prescribed was shown to have no 
influence on adherence in FEP in several studies (Novak-Grubic and Tavcar, 
2002, Mutsatsa et al., 2003, Lepage et al., 2010a).  Limited evidence suggests 
that FEP adherence may be better with injectable depot medication rather than 
oral medication (Segarra et al., 2012).  Another study showed greater 
adherence rates with risperidone over olanzapine (Tunis et al., 2007).   
Patients may also be prescribed other medication alongside their antipsychotic 
prescription.  A concurrent prescription for an antidepressant or mood stabiliser 
has also been shown to be of no significance to adherence with antipsychotic 
medication in FEP (Gearing and Charach, 2009). 
Studies also highlight that initial medication behaviours may mirror subsequent 
adherence patterns, with initial medication refusal being predictive of poor 
adherence longer term (Rabinovitch et al., 2009) and following an initial relapse 
(Robinson et al., 2002). 
3.8. Other Factors Affecting Medication Adherence 
On reviewing the evidence for factors affecting medication adherence I 
struggled to assign some findings to the five dimensions proposed by the World 
Health Organisation (WHO).  This is because it is impossible to presume and 
make assumptions about what factors may have impacted on measures of a 
participant’s quality of life or goal attainment.  I have therefore chosen to 
represent these factors of quality of life and goal attainment in a final ‘other 
factors’ category outwith the WHO classification (World Health Organisation, 
2003) described in Section 3.2. 
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A poor quality of life at baseline and follow-up, as determined by use of quality 
of life scales, was shown to reduce medication adherence in FEP (Coldham et 
al., 2002).  In a Grounded Theory study of FEP patients prescribed aripiprazole, 
quality of life as reflected by the parameters of living a ‘normal’ life, being in 
control, having the freedom to make choices, a good social circle and 
independence was one of three factors driving medication adherence  (Hon, 
2012).   
Another aspect directly contributing to quality of life is goal attainment, which 
itself may predict adherence behaviour.  The majority of patients presenting with 
FEP are young with many of their life goals yet to be achieved.  Limited 
evidence suggest that the potential impact of medication interfering with 
attainment of life goals is not a significant predictor of adherence (Perkins et al., 
2006). 
Having outlined factors which may affect adherence with antipsychotic 
medication in FEP, it is also relevant to consider what strategies may improve 
adherence with medication. 
3.9. Strategies to Improve Adherence 
The WHO has proposed interventions that may support adherence across the 
five dimensions of patient, social and economic, health system or team, 
condition and treatment-related factors in several physical health conditions 
such as hypertension, tuberculosis, asthma, cancer and HIV (World Health 
Organisation, 2003).  Patient related interventions for promoting adherence 
across the differing illnesses included setting mutually agreed goals, providing 
incentives, as well as use of memory aids and reminders.  Socioeconomic 
interventions to support adherence included family support and preparedness 
as well as social support.  Education on use of medicines is a useful condition-
related intervention, and treatment interventions include simplification of 
medication regimens, education on the use of medication, education about 
adherence, prescriptions tailored to patient need alongside continual monitoring 
and re-assessment of medication and monitoring of adherence.  Several health 
care and health team factors have been proposed to support adherence across 
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different health conditions.  These include good multidisciplinary care, training in 
educating patients about adherence, ready availability of information for 
patients, staff training in monitoring adherence, good therapeutic relationships, 
management of disease and treatment alongside patients, more intensive 
patient contact, adherence education and training in monitoring adherence 
(World Health Organisation, 2003).  Unfortunately the WHO document did not 
include specific interventions to support adherence in psychotic illness, however 
other studies have considered this.  One strategy commonly quoted as 
improving adherence in psychosis is adherence therapy.   Adherence therapy 
centres around an observation that adherence is driven by a patient’s beliefs 
and involves a patient centred approach that explores and tests patient beliefs 
about treatment, engages in structured medication problem-solving, explores 
ambivalence about taking medication and considers how medication might 
influence goal attainment (Brown et al., 2013).  The evidence base for 
adherence therapy in psychosis is mixed with some studies supporting (Kemp 
et al., 1998, Gray et al., 2004, Maneesakorn et al., 2007), and others not 
supporting this approach (O'Donnell et al., 2003, Gray et al., 2006, Anderson et 
al., 2010).  More recently, a study specifically considering the role of adherence 
therapy in early psychosis evidenced a significant reduction in relapse with the 
intervention (Brown et al., 2013).  Whilst education strategies have been shown 
to increase knowledge about medication and illness, they have not been shown 
to significantly improve adherence in psychosis (Nose et al., 2003a, Brown and 
Gray, 2012).  Such is the importance of the topic, NICE published a clinical 
guideline in 2009 to support medicines adherence and patient involvement in 
decisions about prescribed medication (NICE, 2009b). This guideline 
emphasised the importance of good communication between healthcare 
professionals and patients, provision of relevant information to facilitate 
increased patient involvement in the treatment decision making process and a 
patient centred approach depending on individual attitudes, motivations and 
drivers for good or poor adherence.  This has more recently been reinforced in 
the NICE guideline for medicines optimisation, promoting the safe and effective 
use of medicines to enable the best possible outcomes (NICE, 2015).  Despite 
this, studies have shown that patient and healthcare professional views about 
factors affecting medicines adherence do differ as will now be highlighted.   
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3.10. Patient, Carer and Staff Views on Medication Adherence 
Whilst evidence exists about factors which may impact on antipsychotic 
medication adherence, there are very few studies comparing patient, carer and 
staff views.  Where references exist these tend to focus on those with 
schizophrenia and do not consider FEP separately.  Kikkert et al (2006) 
assessed views of patients, carers and professionals in respect of the 
importance of medication efficacy, side effects, self-management of side 
effects, positive and negative expectations and attitudes to medication, insight, 
information and involvement and professional and non-professional support in 
the promotion of medication adherence.  Whilst there were similarities in the 
ratings between patients and carers, there were key differences between 
patients, carers and staff.  Ratings of the importance to medication adherence 
were made against eighty two statements which could then be collated into ten 
clusters.  Staff designated medication side effects as the second most important 
cluster determining medication adherence but this was rated much lower by 
patients (4th most important cluster) and carers (least important cluster).  
Efficacy of medication was the highest ranked cluster for patients and carers; 
however staff rated this as the fifth most important.  Staff felt that insight was 
the most important cluster determining medication adherence, whereas carers 
rated this second and patients as the third most important cluster.  Healthcare 
professionals also viewed negative medication attitudes and expectations more 
highly than patients and carers, and professional and non-professional support 
and side effects more highly than carers (Kikkert et al., 2006). 
Another qualitative study comparing views of patients with schizophrenia, their 
carers and healthcare providers determined eight themes that influenced 
adherence.  These themes were the environment (lack of support and cost), 
relationships between family and providers, insight and knowledge, symptoms 
and outcomes, side effects, substance misuse, stigma and dosing. Views of 
patients and their healthcare professionals on barriers, facilitators and 
motivators of adherence were assessed and agreement was found in less than 
two thirds of the groupings (Pyne et al., 2006).  This provides further support for 
discrepant views between some patients and the staff supporting their care. 
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In a further study, reasons for medication continuation and discontinuation prior 
to and during a clinical trial were gathered from clinicians’ and patients’ 
perspectives.  Both patients and clinicians ranked poor control of positive 
symptoms as the main reason for medication discontinuation before 
commencement on the study.  During the study the most important reason for 
continuing treatment, as identified by both patients and staff, was that the study 
drug benefitted positive symptoms.  Patients ranked side effects as the highest 
reason for discontinuation of the study drug, whilst staff continued to rank poor 
response of positive symptoms as the highest influence (Ascher-Svanum et al., 
2010). 
Finally, a more recent study compared the attitudes of staff and carers about 
schizophrenia, medication to treat schizophrenia and adherence to the 
medication.  Three variances in opinion emerged between staff and carers.  
Firstly, carers felt that psychiatrists relied too much on information provided by 
patients when assessing adherence with medication. Carers, but not 
psychiatrists, felt that the condition itself affected adherence to medication.  
Finally, a higher proportion of carers (two-thirds) than staff felt that medication 
to treat schizophrenia was detrimental to health (Svettini et al., 2015) 
None of the studies presented above considered views of healthcare 
professionals, patients and carers about adherence with medication in FEP, 
instead focusing on those with chronic psychoses.   
3.11. Summary 
Summarising the findings of my integrative review, it is clear that a large 
proportion of people prescribed antipsychotic medication for FEP do not take 
medication as prescribed by their doctor and this risks detrimental outcomes.  
Evidence shows that medication adherence rates in first episode psychosis 
range from 14.5% (Malla et al., 2008) to 70% (McEvoy et al., 2007, Miller et al., 
2011). Where medication is not taken as prescribed adverse personal, social 
and economic consequences may result.  Evidence suggests that poor 
adherence in FEP may be associated with longer time to, and poorer rates of, 
remission (Malla et al., 2006, Malla et al., 2008, Petersen et al., 2008).  Poor 
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adherence increases the likelihood of relapse (Robinson et al., 1999, Chen et 
al., 2005b, Uçok et al., 2006, Alvarez-Jimenez et al., 2012, Caseiro et al., 
2012), and poorer clinical outcomes (Petersen et al., 2008, Barbeito et al., 
2013).  An increasing body of evidence is available considering factors which 
may affect adherence with medication in FEP.  Much of the evidence is 
conflicting with regards to the patient, social and economic, health system and 
treatment related factors that drive medication adherence and this therefore 
warrants further study so the impact of poor medication adherence in FEP can 
be more fully understood.  Limited evidence in chronic psychosis suggests 
differences in the views of patients, carers and healthcare professionals about 
influential factors impacting medication adherence.  Published studies have not, 
thus far, sought to explore views of patients, carers and healthcare 
professionals about influential factors impacting medication adherence in FEP. 
Upon recognising a lack of published literature comparing patient, carer and 
health professional views of factors affecting antipsychotic medication 
adherence in FEP,   I initially decided to conduct focus groups to obtain 
qualitative information from young people, carers and staff.  Lack of 
engagement with this proposal meant that I ended up taking a detour in my 
qualitative research journey by conducting quantitative survey research.  This 
would provide evidence of whether views were similar or discrepant across the 
three groups and support an assessment of whether any differences may affect 
clinical intervention to support medication adherence.  As described in Chapter 
One, this was a detour in my qualitative research journey due to recruitment 
difficulties.  I have however decided to present the survey research in the next 
chapter as it produced some interesting results in the staff cohort.   
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CHAPTER FOUR.   AN ELECTRONIC SURVEY 
AND A RE-ROUTING OF MY RESEARCH 
JOURNEY 
4.1.  Introduction 
In this chapter, I present my initial plans for the study, my exploration of different 
philosophical worldviews and reflections about the most appropriate worldview 
underpinning the proposed research. I describe the electronic survey I 
undertook to gather data on factors influencing 14-18 year olds’ adherence with 
antipsychotic medication. This chapter details the reasons why I undertook this 
survey, the research framework employed and some of the difficulties that had 
to be overcome.  The research findings, which were subsequently published  
(Ramdour et al., 2015), are presented.  A discussion of how the views of staff 
reflect and contradict conclusions in published literature are then presented, 
along with new findings not represented in similar survey studies of adherence 
in chronic psychoses.  Finally, I outline the reasons why the research approach 
had to be revisited to engage young people in the study, and how this re-routing 
of my research journey subsequently directed the qualitative PhD research 
study. 
4.2. Research Question 
The objectives of this initial research were to explore factors affecting young 
people’s adherence with antipsychotic medication with staff, young people 
prescribed antipsychotic medication between the ages of 14 to 18 and their 
carers. The research questions that underpinned the initial plans for the study 
were as follows: 
  What factors are perceived by healthcare professionals (HCP), carers 
and young people to influence a young person’s adherence to 
antipsychotic medication? 
 Are there differences between HCP, carer and young people’s views? 
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My initial thoughts were that there would be differences in opinions across the 
HCP, carer and service user groups about the factors affecting adherence.  I 
also felt, based on the findings of a similar study in patients with schizophrenia 
(Kikkert et al., 2006), that staff would recognise the importance of insight and 
positive attitudes to medication in maintaining good adherence to medication  
and consider side effects to be one of the predominating determinants of poor 
adherence.   
Having decided upon the research questions to be investigated, a four stage 
research framework was followed in designing the study (Creswell, 2014).  The 
four components research approach, research design, philosophical worldview, 
and research methods will now be explored in more detail, however, a summary 
of the research framework chosen is presented in Table 4.1. 
Table 4.1.  Research Framework Summary 
 
Research Approach Quantitative 
Research Design Survey Research 
Philosophical Worldview Postpositivist 
Research Method Survey 
 
4.3. Research Approach and Design 
The research approach encompasses whether quantitative, qualitative or mixed 
methods research is selected, whilst the research design outlines the inquiry 
which sits beneath the research design. 
The three research approaches, quantitative, qualitative or mixed methods 
research exist at different stages along a continuum (Newman and Benz, 1998).  
Whilst qualitative and quantitative research might be viewed at opposite ends of 
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this continuum, the reality is that whilst a research study might veer towards 
either a qualitative or quantitative approach it can still incorporate aspects of the 
other approach (Crotty, 1998).  As mixed methods research includes aspects of 
both qualitative and quantitative research this sits along the continuum between 
qualitative and quantitative research (Creswell, 2014).  
Qualitative research is used for exploring and understanding meaning of social 
and human experience, seeking answers in relation to how social experience is 
shaped and given meaning (Denzin and Lincoln, 2008).  In this way it can be 
viewed as subjectivist.  Conversely, quantitative research tests objective theory 
by determining links and interdependencies across variables, tending to focus 
on numbers, statistics and analysis of specific variables (Denscombe, 2010).  
Mixed methods research involves the collation of both qualitative and 
quantitative data, to derive more comprehensive meaning than would have 
been obtained using either approach alone (Creswell, 2014).  .   
Initially I debated whether to take a qualitative approach and conduct focus 
groups for the purposes of data collection. Feedback from staff working with 
young people suggested that some patients would be reticent about being 
involved in a group preferring participation on an individual basis.  I therefore 
decided not to use focus groups for the purposes of data collection.   For this 
research study I wanted to measure the strength assigned to different factors 
which may affect adherence, comparing findings across three discrete groups.  
The research being proposed was therefore quantitative in approach.  
 Having decided to take a quantitative approach, I then had to consider the 
research design.  It was suggested by a researcher in children’s health that 
young people are more willing to contribute via electronic forums.  This is 
because their participation is then at a time of their choosing. It does not require 
travel to places they may be unfamiliar with, or for them to interact with people 
they do not know.  It was also suggested that other research studies in young 
people with FEP offered incentives to engagement. This feedback led me to 
decide upon a survey research design enabling electronic survey completion or 
completion of hard copy survey forms.  
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Differences between these three approaches also exist in the philosophical 
worldviews the researcher brings to the study and the research design and 
methods which translate the research approach into practice (Creswell, 2014).   
4.4.  Choosing a Philosophical Worldview 
Worldviews are considered to be ‘a basic set of beliefs that guide action’ (Guba, 
1990).  Thus, in research, they are the philosophical beliefs that a researcher 
brings to a study about the world itself and the nature of research.  
Philosophical beliefs will naturally be influenced by life experience, views of 
others and past research experience (Creswell, 2014).  Other authors have 
coined different terms to detail such beliefs, namely paradigms, epistemologies 
and ontologies, or broadly conceived research methodologies.  I will now 
describe features of the four worldviews most frequently described in research 
literature, with explanation of the thinking behind the worldview ultimately 
chosen being presented last. 
4.4.1.  The Transformative Worldview 
A transformative worldview developed from a recognition by some that post-
positivist assumptions developed theories that did not fit societal features of 
marginalisation, power, justice, oppression and discrimination (Creswell, 2014).  
This worldview is based on an ideal that research needs to confront social 
oppression through political change (Mertens, 2010).  Whilst some young 
people with psychosis may be marginalised and suffer stigma based on the 
judgements and views of often ill-informed others, I do not approach this study 
with a strong argument to support a transformative worldview that young people 
with psychosis are oppressed or that there is a political agenda to be 
challenged which will subsequently impact on their approach to taking 
medication.  On this basis my research cannot be considered to have its roots 
in a transformative worldview.   I also do not instinctively operate or feel at my 
most comfortable working within a transformative worldview. 
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4.4.2.  The Pragmatic Worldview 
A pragmatic worldview is driven by actions, situations and consequences 
(Creswell, 2014).  The aim is to outline the research problem, use all available 
approaches to uncover solutions to the research problem and find out what 
works (Patton, 1990).  Pragmatists also recognise that research always takes 
place in particular contexts; these contexts include social, political, historical or 
other contexts. In order to maximise knowledge obtained and best understand 
the research problem, researchers working within a pragmatic worldview will 
employ numerous approaches often using both quantitative and qualitative 
design (Creswell, 2014).  
In my personal life I tend to take a pragmatic view about many things and family 
and friends would say that one of my most common sayings is ‘What will be will 
be’.  My professional background also lends itself to a pragmatic worldview as 
the world of psychiatry is rarely black and white or clear cut.  Despite this, I still 
felt that a pragmatic worldview did not apply to this research as I felt it was, at 
heart, an exploratory study; it was neither based on an initial theory nor did the 
quantitative research aim to uncover solutions to the problem of medication 
adherence.  The objective of my study was to better understand key influences 
in the hope that this might inform and direct clinical practice. 
4.4.3.  The Constructivist Worldview 
Contrasting with a pragmatic worldview, constructivists believe that individuals 
seek understanding of the world in which they operate based on historical, 
cultural and social experience and in doing so develop varied and numerous 
subjective meanings to explain occurrences based on their background and 
experience (Crotty, 1998).  Social constructivist researchers do not start with a 
theory but instead generate or inductively produce a theory or meaning based 
on open-ended questions and a focus on the contexts in which people live, work 
and interact in order to understand the historical and cultural perspectives.  The 
researcher interprets the data obtained, but in doing so they accept that their 
interpretation will be influenced by their own personal, cultural and historical 
background (Creswell, 2013).  The quantitative research was not intended to 
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introduce open ended questions or inductively produce theory and so did not fit 
a social constructivist worldview. 
4.4.4.  The Post-positivist Worldview 
Positivists hold the view that research is objective and what we know of the 
world can be understood by scientific measurement (Crotty, 1998). Addressing 
one of the criticisms made of positivism, post-positivists extend the thinking 
beyond positivism, acknowledging that we cannot always be certain about 
claims of knowledge when studying human behaviour (Phillips and Burbules, 
2000).  Thus, post-positivism recognises the reality that all methods of 
assessing objective accounts are flawed and so only a partially objective 
account of the world can be developed (Denzin and Lincoln, 2005). Knowledge 
is based on observation and measurement of the objective reality that exists in 
the world and therefore sits more comfortably within a quantitative research 
approach.  A reductionist approach is often applied to reduce ideas into small, 
discrete sets to be further examined.  The researcher begins with a theory, 
collects data to substantiate or refute the theory, and then makes any 
necessary revisions and conducts further tests  (Creswell, 2014).  I felt that this 
worldview sat most comfortably with my proposal to conduct a quantitative 
study intended to measure the importance assigned to medication adherence 
variables by young people, carers and healthcare professionals. 
Having detailed the research approach, research design and underpinning 
philosophical worldview, I will now provide further information about the 
research method used to underpin the survey. 
4.5. Methodology 
In providing an overview of the survey methodology, I firstly detail the process 
employed to design the survey and obtain ethical approval before providing 
more information on the means of sampling the target population.   
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4.5.1.  Survey Design 
Separate surveys were designed and Survey Monkey© was used to obtain the 
views of staff working in EIS and CAMHS, carers and young people. Survey 
content was derived from conclusions in published literature of factors affecting 
antipsychotic medication adherence including insight, medication attitudes, side 
effects and substance misuse (Table 3.1). The content of existing tools such as 
the DAI (Hogan et al., 1983) and the MARS (Thompson et al., 2000) validated 
to assess medication adherence in adults were also considered. A consultant 
psychiatrist also outlined additional factors they felt were of relevance based on 
their observations from clinical practice.  
Survey questions predominantly comprised Likert scales indicating respondent 
agreement with a range of statements. There was also an opportunity to provide 
additional information and comments via use of free text boxes in relation to the 
three most important factors influencing good and poor medication, and specific 
side effects impacting on adherence where this was indicated as promoting 
poor adherence by respondents. 
The electronic surveys were firstly field tested by the researcher, members of 
the supervisory team and a member of staff well versed in the use of Survey 
Monkey within the School of Health at the University of Central Lancashire 
(UCLan).  Content validity was explored with two school teachers, teaching staff 
working with current inpatients aged 14-16, three children aged 12, 16 and 18, a 
school governor and two inpatients aged 14-18 to ensure the young person’s 
survey was relevant and would be easily understood by participants.  Minor 
amendments to language used within the survey were made accordingly to 
ensure comprehension. 
4.5.2.  Ethical Approval 
Ethical approval was obtained from the National Research Ethics Service, 
University of Central Lancashire and Lancashire Care NHS Foundation Trust 
Ethics Committees. 
97 
 
4.5.3.  Survey Sample 
Purposive sampling was utilised in this study. This is a method of non-
probability sampling in which decisions concerning the sample recipients are 
taken by the researcher based upon a range of criteria which may include 
specialist knowledge of the research issue, or capacity and willingness to 
participate in the research (Alasuutari et al., 2009). Sampling was conducted in 
order to distribute the survey to staff with prior and/or current experience 
working with young people with psychosis. The survey was distributed to 184 
multidisciplinary staff working in Lancashire EIS and CAMHS services via the 
staff email distribution lists. These teams were chosen as they both specifically 
target young people with mental health difficulties, including FEP. The online 
survey was also promoted through local team meetings, the hospital website 
and Facebook page and through the hospital Twitter account.  Additionally, the 
mental health charity, Rethink, distributed the survey to its staff within the 
region. Members of the College of Mental Health Pharmacists and the Quality 
Network for Inpatient CAMHS email discussion groups were also invited to 
participate as further means of accessing staff working with the target patient 
population. 
Posters and flyers were designed, advertising links to the surveys.  Hard copies 
were also made available in reception areas, via care coordinators and service 
user and carer participation leads working in the CAMHS service. The surveys 
were also publicised via a number of other different forums (Table 4.2) to 
engage healthcare professionals, young people and their carers.  These posters 
and flyers also referenced the opportunity to enter a draw for gift vouchers on 
completion of the survey.  Whilst this might bring into question motives for 
involvement in the research study, I felt that participants would still engage fully 
and provide vital and robust data for the purposes of my analysis.  Incentives 
were also being offered for the time required for participation in other studies of 
FEP being conducted at the time, and staff indicated that this had supported 
recruitment. 
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Table 4.2.  Forums Used to Publicise the Survey 
4.6. Results 
Whilst it was not possible to estimate the number of people who received the 
survey, completed responses were received from 60 staff.  Demographic 
information is provided in Table 4.3.  Responses from young people and carers 
Mode Forum 
 
Meetings CAMHS staff meetings 
EIS staff meetings 
Preston Mental Health Forum 
 
Websites Lancashire Care NHS Foundation Trust 
Young Minds Very Important Kids (VIK) website 
 
Facebook Lancashire Care NHS Foundation Trust 
Mental Health Foundation 
Young Peoples Mental Health Coalition 
 
Twitter Lancashire Care NHS Foundation Trust 
Mental Health Foundation 
Young People’s Mental Health Coalition 
 
Press release Press contacts of Lancashire Care NHS Foundation Trust 
 
Email 
distribution 
Rethink (North West England) 
College of Mental Health Pharmacists 
Staff distribution lists for EIS and CAMHS services in Lancashire Care NHS 
Foundation Trust 
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were much lower, with only five carers and four young people participating.  
This prevented any meaningful analysis in the patient and carer group and so I 
have chosen to focus purely on the findings from the staff responses. 
Table 4.3.  Staff Demographics 
Characteristic  n (%) 
Age of staff  
 20- 29 8 (13.3%) 
 30- 39 21 (35.0%) 
 40- 49 21 (35.0%) 
 50- 59 9 (15.0%) 
 Not Stated 1 (1.7%) 
Gender  
 Male 22 (36.7%) 
 Female 37 (61.7%) 
 Not Stated 1 (1.7%) 
Ethnicity  
White British 43 (71.7%) 
White Irish 1 (1.7%) 
Indian 5 (8.3%) 
Pakistani 1 (1.7%) 
Chinese 1 (1.7%) 
Any other White background 3 (5.0%) 
Any other Asian background 3 (5.0%) 
Any other ethnic group 1 (1.7%) 
Not stated 2 (3.4%) 
Profession  
Registered Nurse/Registered Nurse and Manager 22 (36.6%) 
Medical Doctor 12 (20.0%) 
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Pharmacist 6 (10.0%) 
STaR*/Healthcare Support Worker 6 (10.0%) 
 Student Nurse 2 (3.3%) 
Psychologist 2 (3.3%) 
Occupational Therapist 1 (1.7%) 
Other 4 (6.8%) 
Not Stated 1 (1.7%) 
Experience  
Less than 2 years 9 (15.0%) 
2- 5 years 24 (40.0%) 
6- 10 years 16 (26.7%) 
Over 10 years 10 (16.7%) 
Not Stated 1 (1.7%) 
*STaR: Support, time and recovery 
When analysing the data, factors were stratified according to how likely the 
individual factors would encourage both good and poor adherence with 
antipsychotic medication. The factors of most importance were those where at 
least 75% of staff ranked this as a very strong or strong influence on medication 
adherence or non-adherence.  Important factors were those where 50- 74% of 
staff ranked this as a very strong or strong influence on medication adherence.  
Factors of lesser importance were the factors where 25-49% of staff ranked this 
as a very strong or strong influence on medication adherence.  If less than 25% 
of staff ranked the factor as a very strong or strong influence, this was deemed 
to be not important. 
Staff felt that the most important factors promoting good antipsychotic 
medication adherence in FEP were insight into the fact that medication would 
make them better and prevent relapse as well as rapport with and the views of 
staff (Table 4.4).  
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Table 4.4.  Factors Promoting Good Medication Adherence (in descending 
order of importance) 
Importance Factor Very Strong or Strong Influence 
(% respondents) 
Most 
Important  
Medication will make them better 93% 
Rapport with staff 85% 
Medication will prevent relapse 83% 
Views of Staff 78% 
Important  To be in control of their life 70% 
To be in control of decisions about 
medication 
68% 
Would be admitted to hospital if they did 
not take medication 
68% 
Medication will help them achieve their 
goals 
68% 
Pressure from family 67% 
Views of family 65% 
Medication will help them think more 
clearly 
63% 
Pressure from staff 57% 
Less 
Important 
Views of friends 47% 
Views of other patients 40% 
Others will realise they are ill if they do 
not take medication 
38% 
Pressure from friends 32% 
Pressure from other patients 30% 
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Not Important Influence of television 18% 
Influence of newspapers of magazines 18% 
Influence of films 18% 
The most important factors impacting on poor medication adherence were felt to 
be poor illness and medication insight, medication side effects and individuals 
exerting personal control (Table 4.5).  
Table 4.5.  Factors Encouraging Poor Medication Adherence (in 
descending order of importance) 
Importance  Factor Very Strong or Strong Influence (% 
respondents) 
Most 
Important 
They are not ill so do not need medication 92% 
Side effects of medication 87% 
Wanting to be in control of their own life 80% 
Medication decisions are up to them and 
nobody else 
78% 
Thinking they only need to take 
medication when they are ill 
78% 
Important Thinking medication may be bad for them 71% 
Thinking medication will not help them get 
better 
71% 
Family have told them not to take 
medication 
66% 
Thinking medication will not prevent 
relapse 
66% 
Others knowing they are ill if they have to 
take medication 
59% 
103 
 
Feeling embarrassed at having to take 
medication 
59% 
Their family do not think they are ill 58% 
Thinking it is unnatural to take medication 51% 
Less 
Important 
They would rather take illicit substances 49% 
They would rather drink alcohol 49% 
Other patients have told them not to take 
medication 
47% 
Thinking medication will prevent 
attainment of goals 
46% 
Influence of newspapers or magazines 44% 
Friends have told them not to take 
medication 
42% 
Some staff think medication is not 
necessary 
39% 
Their friends think they are not ill 36% 
Not 
Important 
Influence of films 24% 
They want to be admitted to hospital 22% 
Influence of television 21% 
48 staff provided further information on the side effects they felt contributed to 
poor medication adherence (Table 4.6).  Weight gain, sedation and 
extrapyramidal side effects were the most cited side effects mediating 
adherence with antipsychotic medication. 
Staff were also given the opportunity to identify their views of the three most 
important factors promoting medication adherence in young people using free 
text options within SurveyMonkey©. Responses were collated, themed by 
response and counted. The three most important factors promoting adherence 
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with medication were felt by staff to be symptom control, to get better and, 
thirdly, hope of a better quality of life. Staff were then asked to describe the 
three most important factors contributing to poor adherence with medication and 
these were again collated and themed. The three most important factors were 
side effects, failure to acknowledge the illness and lack of insight. This mirrors 
the feedback obtained through the targeted questions about medication 
adherence. 
Table 4.6. Side Effects Influencing Adherence with Medication (n=48) 
Side Effect Number of responses 
Weight gain/increased appetite 42 
Sedation/tiredness/drowsiness/lethargy 31 
Extrapyramidal Side Effects 19 
Sexual dysfunction 14 
Hypersalivation 10 
Blunted emotions/affect/thinking/concentration 10 
GI side effects 4 
Neurological/headaches/dizziness 6 
Metabolic 1 
Need for regular blood tests  1 
Reduced motivation 1 
Sweating 1 
Urinary incontinence 1 
White count reduction with clozapine 1 
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Analysis of responses by doctors and registered nurses identified some 
variation in views. Doctors rated the views of family members much more highly 
in promoting adherence than nurses (92% rating it as a very strong or strong 
influence compared with 55% of nurses). Doctors also felt that fear of admission 
encouraged medicines adherence (92% rating it as a very strong or strong 
influence compared with 59% of nurses). Considering factors which are very 
strong or strong mediators of poor adherence, doctors also rated views of staff 
that medication is not necessary more highly than nurses (67% vs. 32%), ideas 
that it is not natural to take medication (75% vs. 41%), that taking medication 
will prevent goal attainment (75% vs.45%) and a preference for cannabis (83% 
vs. 23%) indicating differing views between these groups of healthcare 
professionals. 
4.7. Discussion  
The results presented highlight that from a staff perspective, a number of 
personal, social and treatment factors are influential in promoting adherence 
with antipsychotic medication in FEP. In a population of young people, patient 
insight into the need for medication, positive patient attitudes, relationships with 
staff and family are considered to be important in supporting adherence with 
medication. Side effects are considered a negative influence on medication 
adherence. Substance and alcohol misuse was perceived as having less of an 
impact than some published studies suggest, although doctors recognised that 
cannabis could deter medicines adherence. Media influences were also not 
considered to be strongly influential.  
Published studies in FEP support staff views that patient insight into the need 
for medication is associated with greater rates of adherence (Coldham et al., 
2002, Novak-Grubic and Tavcar, 2002, Mutsatsa et al., 2003, Kamali et al., 
2006, McEvoy et al., 2006a, Perkins et al., 2006, Le Quach et al., 2009, Hill et 
al., 2010, Steger et al., 2012, Chan et al., 2014a). A couple of studies have 
failed to find a link between insight in FEP and medication adherence (de Haan 
et al., 2007, Lecomte et al., 2008). It seems reasonable to assume that when 
young people perceive the need for medication, and potential benefits this may 
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produce they are more likely to take their medication (Perkins et al., 2006). If 
patients are embarrassed that they have to take medication that this can have 
an adverse impact on medication adherence (Hui et al., 2006b). Positive 
attitudes by young people to medication therefore seem to be important in 
determining whether medication is taken or not (Townsend et al., 2009) with 
studies confirming this association (Mutsatsa et al., 2003, Hill et al., 2010, Chan 
et al., 2014a). These findings therefore provide support for the initial hypothesis 
that staff would appreciate the importance of insight and positive medication 
attitudes.  
Participating staff also felt that they themselves were a positive influence on 
medication adherence, suggesting that their role in reinforcing the positive 
benefits of medication and the rapport that they had with the young people 
affected the extent to which medication was subsequently taken. Limited 
published literature supports the importance of a good therapeutic alliance on 
medication adherence in first episode psychosis (De Haan et al., 2007, Tunis et 
al., 2007, Montreuil et al., 2012). One study comparing the views of first episode 
and multiple-episode patients with schizophrenia found that 74% of the FEP 
sample rated the doctor–patient relationship as a strong adherence influence 
compared with only 13% of the multiple episode sample, highlighting the 
importance of forging good therapeutic relationships in early psychosis and 
potentially different adherence drivers in first episode and chronic psychosis 
(Sapra et al., 2014). The doctor–patient relationship was the strongest influence 
on FEP adherence in the study by Sapra et al. (2014); however, only 18% of the 
FEP patients rated the influence of clinicians other than the doctor as highly 
influential. It is possible that this is linked to the fact that doctors prescribe 
medication in the majority of cases, and will as part of the consultation process 
have conversations about medication.  
Staff indicated that family relationships and family perceptions of medication 
were also influential. While these influences were predominantly seen as 
beneficial, with children taking medication either because their parents wanted 
them to or because the young person did not want to worry their parents, there 
was also a view that this influence could be detrimental where family members 
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did not see the need for medication and pressured their child not to take it. 
Published studies considering familial influences on adherence focus on the 
social support provided by families rather than the attitudes of family members 
to medication (Perkins et al., 2006, Rabinovitch et al., 2009, 2013.) This would 
therefore warrant further exploration. Influences of other patients and friends on 
adherence with medication were categorised by staff with lesser importance. 
This is perhaps surprising given the need of many young people to fit in with 
their peer group, and the potential for them to be swayed by their peer group to 
ensure acceptance and popularity.  
Staff responding to the survey, in the main, did not feel as though media 
sources (television, newspapers, magazines or films) had a positive or negative 
influence on medication adherence. One study concluded that negative reports 
in the mass media significantly influenced public acceptability of psychotropic 
medication (Benkert et al., 1997). It is hypothesized that negative 
representations in the media may drive negative attitudes to medication, 
thereby influencing medication adherence, although no studies appear to have 
directly assessed this.  My initial thoughts that media and peer pressure may 
have influenced adherence were not felt to be strong influences on medication 
adherence by staff working more closely with young people with FEP.  
One of the strongest articulated influences on adherence was side effects, with 
87% of respondents indicating that this was a very strong or strong determinant 
of poor adherence with antipsychotic medication. Lack of significant side effects 
was seen to promote adherence with medication, with side effects such as 
weight gain, sedation, sexual dysfunction, hypersalivation and extrapyramidal 
side effects increasing the risk of poor adherence. The highest rated side effect 
of concern was weight gain. The only papers to assess the impact of weight 
gain in first episode psychosis to date have produced conflicting results as to 
whether weight gain adversely affects medication adherence (Pogge et al., 
2005, Perkins et al., 2006, Rabinovitch et al., 2009) and so further research 
would be beneficial. Interestingly, staff views that EPSEs significantly affect 
medication adherence are not supported in published literature (Coldham et al., 
2002, Novak-Grubic & Tavcar 2002, Mutsatsa et al. 2003, Pogge et al. 2005, 
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Perkins et al., 2006, Rabinovitch et al., 2009). The only study to date 
considering the effects of sedation also concluded that there was no effect on 
adherence with antipsychotic medication (Pogge et al., 2005). Survey 
responses received from staff therefore support my initial suggestion that, as is 
the case in schizophrenia, staff may overestimate the impact side effects have 
on medication adherence in FEP.  
Published literature suggests medication adherence rates are lower in those 
who misuse alcohol (Coldham et al., 2002, Kamali et al., 2006), cannabis 
(Coldham et al., 2002, De Haan et al., 2007, Miller et al., 2009, Faridi et al., 
2012, Barbeito et al., 2013) and other substances (Pogge et al., 2005, Kamali et 
al., 2006, Tunis et al., 2007, Hill et al., 2010), a conclusion endorsed by the 
NICE (2011). The evidence base is however mixed as some studies have failed 
to show a link with alcohol (Mutsatsa et al., 2003, Perkins et al., 2006), 
cannabis (Perkins et al., 2006) and substance misuse (Coldham et al., 2002, 
Mutsatsa et al., 2003, Perkins et al., 2006, Lecomte et al., 2008, Rabinovitch et 
al., 2009, Steger et al., 2012). Staff responding to the survey were less 
convinced that alcohol and substance misuse are associated with poor 
adherence to medication, although doctors felt that a preference for cannabis 
affected medication adherence. This may be secondary to differential gaps in 
the evidence base about the potential impact substance use may have on 
adherence across different professional groups.  
The final concept emerging from the staff survey was the importance of 
personal control in determining adherence with medication. It has been 
suggested that young people are in a unique position of being under parental 
control while wanting to exert their independence and autonomy, and that this 
may subsequently influence the decisions they take about medication 
(Townsend et al., 2009). It is therefore postulated that at a time of uncertainty 
and worry when their life may appear to be escalating out of control, medication 
may be seen as one area where that young person can exert total control. 
There is limited evidence from a grounded theory study considering adherence 
with the antipsychotic drug, aripiprazole, that freedom to choose and being in 
control contributes to quality of life parameters that support medication 
109 
 
adherence (Hon 2012). This provides support for one of the founding principles 
of the NICE guideline on medication adherence, namely patient involvement in 
choice and decisions around medication to promote medication adherence 
(NICE 2009). 
4.8. Research Limitations 
The research represents the views of a limited number of staff working with 
young people with a first episode psychosis.  Analysis of the 18 respondents 
providing an address revealed that 12 were from Lancashire and so results from 
a more global sample may or may not differ.  The initial intention was to 
compare staff views with those of young people and carers, however insufficient 
numbers of young people and carers were recruited representing a further 
limitation of the research. 
4.9.  Conclusion 
Despite this being a detour in my qualitative research journey, this research 
represented the first attempt to gather views of patients, carers and staff about 
adherence with medication in FEP, although response rates only enabled 
analysis of staff responses.   
Patient insight into illness and the benefits of medication, as well as positive 
therapeutic alliances, were seen as important determinants of antipsychotic 
adherence in first episode psychosis by staff. Unacceptable side effects were 
considered the strongest deterrent to adherence. The initial proposal that staff 
would recognise the importance of insight and positive medication attitudes and 
overestimate the importance of side effects was therefore proven. Staff also 
under-estimated the importance of forgetfulness in this age group when 
considering factors linked to poor medication adherence.  
The research highlighted key differences in opinions of doctors and nursing staff 
about the importance of family member views and fear of admission in 
promoting adherence.  Differences were also apparent in the importance 
attributed to patient views that medication is not necessary, and that it is not 
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natural to take medication, in predicting medication adherence.  Doctors were 
also more convinced than nursing staff that a perceived or actual detrimental 
effect on goal attainment and preference for cannabis negatively affected 
adherence with medication.  Finally, this research suggests that staff do not 
consider that media influences, such as newspapers and television, affect 
adherence with antipsychotic medication in teenagers. 
Acknowledging that these findings represent the views of only 60 staff, I felt that 
further exploration of this topic was warranted with young people experiencing a 
first episode psychosis. This would allow an examination of whether staff views 
are consonant or dissonant with the views of the young people themselves.  I 
wanted to ensure the voices of young people with psychosis were heard, and 
this required consideration of the best methods to engage those who had taken 
medication as a teenager.  Qualitative studies with this cohort of patients are 
extremely sparse (Charach et al., 2008).  I therefore decided to conduct 
narrative research to support young people telling their medication stories.  This 
narrative research with young people now provides the focus for the remainder 
of this thesis, and in the next chapter I provide an overview of narrative 
research and the approach taken in conducting this research.  
  
111 
 
CHAPTER FIVE.  NARRATIVE RESEARCH 
5.1.   Introduction 
In this chapter, I describe the aim of the narrative research and underpinning 
research questions.  The research framework is then presented with emphasis 
on the research design and methods employed.  Finally, details of how the 
research was approached and conducted are presented, addressing the 
research population, ethical approval, recruitment, data collection and 
assessment of data worthiness.  Reflective entries are included throughout to 
highlight my deliberations about the best way to engage this patient population 
to effectively address the research aim and questions.    
5.2. Research Aim and Questions 
The aim of the research was to obtain stories from young people about their 
antipsychotic medication journey and their views about medication, with the 
intention of exploring what factors promote and discourage adherence with 
antipsychotic medication in a teenage population.  
The specific research questions to be examined were: 
 What influences adherence with medication in the young people studied? 
 How do these influences compare with those affecting young people’s 
adherence with medication for chronic physical illness? 
 Do the young people’s views about medication adherence concur or 
contradict the views of staff who participated in the survey research? 
5.3.  Research Framework  
Having decided upon the research questions to be investigated, the research 
framework for the study then had to be agreed using the framework by Creswell 
(2014) previously described.  A summary of the research framework is 
presented (Table 5.1).  Background information was provided in Chapter Four 
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about the different research approaches and philosophical worldviews, brief 
information is therefore given about the approach and worldview underpinning 
this research.  In the following sections, I then explore in more detail the 
research design and method. 
Table 5.1.  Research Framework 
Research approach Qualitative 
Philosophical Worldview Social Constructivism 
Research Design Narrative Research 
Research Method Autophotography/ Auto Driven Photo 
Elicitation 
For this research study I wanted to explore and understand what taking 
antipsychotic medication meant to young people, and whether there were 
particular influences on whether young people took their medication as 
prescribed or deviated from the prescriber’s intentions.  I was keen for this 
research to be rooted in the views of the participants themselves rather than my 
preconceived ideas or those derived from research literature.  This therefore 
lent itself to a qualitative research approach. 
I also felt that a social constructivist worldview was most relevant to this 
research as the intention was to seek subjective interpretation about what it is 
like to take medication as a teenager and what influences medication 
behaviours.  Having conducted a literature review and worked clinically for 
numerous years with people prescribed antipsychotic medication the reasons 
for good or poor adherence appear to be subjective, complex and multifactorial.  
Historical, cultural and social views are also relevant when considering the topic 
of medication.  Antipsychotic medication was first developed in the 1950s.   
Prior to this there would be no views about the value of antipsychotic 
medication and whether or not it was important to take this.  Advances in 
medicine, knowledge about how antipsychotic medication works, increasing 
awareness of possible side effects and development of novel antipsychotic 
medicines also change people’s perceptions.  By way of an example, the first 
lobotomy was performed in 1935 and was seized upon by psychiatrists globally 
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as a possible cure for certain psychiatric disorders.  The number of procedures 
performed increased annually thereafter, started to decline in the 1950s and 
such procedures are now very rarely performed (Diefenbach et al., 1999).  In 
the 1950s it is possible that a lobotomy was more acceptable to patients than 
taking the first available antipsychotic drug, chlorpromazine, as this was new 
and relatively untested.  More recently there was a view that SGAs were more 
likely to act on negative symptoms and cause less EPSEs, leading to their 
preferential use over FGAs (NICE, 2002a, NICE, 2002b). Subsequently, it has 
been recognised that there is little difference in efficacy between FGA and SGA 
antipsychotics, with the exception of clozapine, and that SGAs are more likely to 
precipitate metabolic syndrome (Lieberman et al., 2005, Jones et al., 2006, 
NICE, 2014).  There is also a social element as adherence rates may be 
improved through good therapeutic relationships (de Haan et al., 2007, Tunis et 
al., 2007).  Thus there are historical, social and cultural influences to medication 
opinion which may subsequently impact on medication adherence. Given this 
historical, social and cultural context, the research was underpinned by a social 
constructivist worldview. 
5.4.  Research Design 
Having decided upon a qualitative approach from a social constructivist 
worldview, the next step was to consider the research design. This involved 
consideration of the designs available and how they would best fit my research 
question, the particularities of my participants and other relevant factors. The 
research design is the type of inquiry to be used within a qualitative, quantitative 
or mixed methods approach.  Creswell (2013) identifies five different qualitative 
research designs, namely phenomenology, grounded theory, ethnography, case 
studies and narrative research.  An understanding of these different designs 
was therefore needed before a decision could be taken on the most appropriate 
design for my particular research study.  
The age of research participants also needed to be considered when deciding 
on the research design.  Undertaking research with young people poses 
particular challenges, especially in sensitive areas such as substance misuse, 
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violence and sexual activities (Drew et al., 2010).  For some young people 
adherence to medication may be a sensitive topic, as they may not want to 
admit to having to take medication or may not want significant others, such as 
their parents, to know that they are not taking medication prescribed for them.  
Historically, difficulties associated with undertaking research with young people 
were overcome by approaching proxies such as parents, teachers and 
healthcare professionals to provide accounts on behalf of young people 
(Santelli et al., 2003). However, more recently the shift has been towards 
research conducted in partnership with young people (Punch, 2002, Santelli et 
al., 2003).  This requires consideration of different ways of gathering data, and 
tailoring of research methods to effectively engage with young people 
(Mauthner, 1997, Pole et al., 1999, Matthews, 2007).  Research that involves 
young people at varying developmental stages needs to appeal to them, 
engage them and encourage discussion of ideas, views and perceptions that 
may not be easy to communicate (Drew et al., 2010).  This led me to explore 
the five different research designs with a view to how they would fit with the 
principles of engaging and promoting young people to take part in the research.  
The approaches I discounted are presented first, with the research approach I 
selected described in more detail at the end. 
5.4.1.  Phenomenology 
A phenomenological approach focuses on lived experience, by seeing things 
through the eyes of others who have experience of the particular phenomenon 
being researched (Denscombe, 2010).  Typically between five and twenty five 
participants are included in a phenomenological research study (Polkinghorne, 
1989).  The findings are then condensed into an essence of ‘what’ they 
experienced, and ‘how’ they experienced it (Moustakas, 1994).  Whilst data 
collection often consists of in-depth, multiple interviews with participants, other 
material can also be included such as taped conversations, poetry, music and 
art (Van Manen, 1990, Creswell, 2013).   
Two questions form the basis for phenomenological explorations, ‘What have 
you experienced in terms of the phenomenon?’ and ‘What contexts or situations 
have typically influenced or affected your experiences of the phenomenon?’  
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(Moustakas, 1994).  These questions are asked to gain a common 
understanding across participants. Researchers are encouraged to put their 
own views and experiences to one side, a process known as ‘bracketing’, so 
that past knowledge does not influence the data interpretation process (Van 
Manen, 1990).  Data analysis is then conducted by highlighting significant 
portions of data (‘horizontalisation’) and developing ‘clusters of meaning’ from 
the statements (Moustakas, 1994).   
Clearly, the research topic of ‘what influences adherence’ sits well with a 
phenomenological approach as there is potentially a common phenomenon of 
being asked to take prescribed medication then making decisions as to whether 
to take it or not.  The numbers required would be achievable and there could be 
common features across participants.  A phenomenological approach was 
taken in another study to explore experiences of young people prescribed 
antipsychotic medication (Murphy et al., 2015a).  In this study ambivalence 
towards medication was evidenced, secondary to a lack of information about 
the illness and medication as well as stigma.  Adherence was affected by this 
lack of knowledge, as well as a pressure to conform to their adolescent culture.  
Whilst a phenomenological approach has already been utilised to explore young 
people’s views about medication, the main concern in taking this approach was 
the need for multiple in-depth interviews with participants given the recruitment 
difficulties encountered in the preliminary research phase.  I felt that young 
people might not want to meet repeatedly with a researcher given the 
commitments of school or college attendance, homework, work and social 
activities.  I therefore needed to consider whether other approaches might 
engage young people more effectively and time-efficiently and so decided to 
explore other designs for my study. 
5.4.2  Grounded Theory 
In grounded theory the emphasis is on development of theory that emerges 
from the data obtained (Dawson, 2009).  The aim is to discover or produce a 
theory from the data, a ‘unified theoretical explanation’ for an outcome (Corbin 
and Strauss, 2008).  Prior knowledge and experience is put aside, in a similar 
way to the bracketing of phenomenology, and the theory is instead produced or 
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‘grounded’ in the data obtained from participants (Strauss and Corbin, 1998).  
Participants are interviewed and the researcher constantly compares data with 
that of previous participants to enable the researcher to formulate ideas and 
generate theory on an ongoing basis.  This process continues until the 
researcher feels that no new information is being gleaned, a stage referred to 
as ‘saturation’ (Dawson, 2009).  Data analysis commences with the 
identification of major categories of information (open coding), with each code 
then being subject to further analysis for sub-categories (axial coding).  From 
this a theory is then developed to describe the interdependencies between the 
categories (selective coding) (Strauss and Corbin, 1990). 
Initially, I had thought about conducting semi-structured interviews as part of a 
grounded theory approach, similar to the method employed in another 
qualitative study of medication adherence in FEP (Hon, 2012).  This study 
explored factors affecting adherence in FEP with a single antipsychotic drug, 
but originality within the context of my PhD would be ensured by exploring 
young people’s views of taking a range of antipsychotic medication.  My 
reasons for discounting this approach centred on the fact that my research aim 
was not about generating theory.  As it is suggested that grounded theory 
studies typically involve around 20 participants (Creswell, 2013), I also felt that 
this would be difficult given that my research involved teenagers who have 
many competing interests and demands.  The survey used in the preliminary 
research phase had failed to gain sufficient interest and I questioned whether 
the same would be true if participants were required to engage purely in an 
interview.  I was concerned that I might not reach a stage of data saturation if 
participant numbers were limited.  Additionally, in Hon’s (2012) grounded theory 
study, the researcher worked in the EIS service, had developed working 
relationships with some of the participants and this would naturally have aided 
recruitment.  Such relationships would not be present in my case and I would 
again need to rely on care coordinators identifying potential candidates for 
interview, a strategy which had not been too successful previously.  I therefore 
continued to explore other designs to find one which most suited the proposed 
study 
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5.4.3.  Ethnography 
Whilst grounded theory approaches are based on the assessment of many 
participants who share the same characteristics which make them suitable for 
the study, they may not be based in the same place or interact so often that 
they develop shared patterns of behaviour.  Ethnographic studies are founded 
on the observation of particular cultural or sub-cultural groups.  The researchers 
often immerse themselves within that cultural group in order to explore and 
understand shared behaviours, values, beliefs and languages thereby  enabling 
in-depth observation and interaction (Silverman, 2010).   
When considering ethnography for my study I acknowledged that the 
participants would all be members of the EIS or CAMHS services and accepted 
that this could be deemed a specific cultural group. However, the young people 
would potentially be from different teams across Lancashire and interaction 
between participants would not have been present to the extent required for an 
ethnographic study.  Not being a full-time member of the EIS or CAMHS teams, 
I also felt that I would not have enough contact time with the young people to do 
justice to this design. Ethnographic studies typically involve the whole of a 
particular group, at least at the outset, and so again this would limit data 
collection as there is no single forum through which all of the young people 
linked to a team meet together. Observation of interactions would therefore not 
be easily facilitated.  Whilst I was interested in relevant cultural influences, this 
was not the driving force being the research.  This therefore led me to then think 
about whether a case study design would be appropriate. 
5.4.4.  Case Studies 
Whilst ethnography seeks to understand how a particular culture might function, 
case study research involves exploration of a phenomenon in a single or few 
cases via extensive, in-depth data collection using a number of different 
mediums e.g. interviews, observation, reports (Denscombe, 2010).  This design 
was not felt to be suitable given the need for extensive data collection via 
different means.  Experience in the exploratory stage of my study highlighted 
the difficulties in getting young people to engage. This would potentially prove 
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more problematic if the young people needed to provide data in a number of 
different formats.  I also questioned how I would choose the participants as this 
design usually involves no more than four or five cases given that analysis 
becomes more dilute with an increasing number of participants (Creswell, 
2013).  I would be relying on care coordinators to identify participants for me 
based on particular criteria, however with such a small number of participants I 
was concerned that the data obtained might not be rich enough to present an 
in-depth picture of the pertinent issues with taking antipsychotic medication.  I 
therefore discounted this approach and moved on to consider the final 
qualitative approach of narrative research. 
5.4.5.  Narrative Research 
Despite the words ‘story’ and ‘narrative’ having different meaning they are often 
used interchangeably (Waziri et al., 1993). A simple definition of a story is 
something told by someone, with a simple definition of a narrative being the 
resulting product after the story has been analysed (Frank, 2010).  Polkinghorne 
(1996) considers narrative as a story within a wider story, with each part linking 
and connecting to each other to impart meaning and understanding. Within this 
research I was interested in the stories young people tell about medication and 
interpreted these stories using narrative techniques. 
The focus of narrative research is the interpretation of stories obtained in 
research, particularly on the meanings people make of what happened (Chase, 
2007).  On this basis, I felt that a narrative research design lent itself to 
understanding motivations for medication acceptance or refusal.  This design 
also sits well with a social constructivist worldview, as stories aid people to 
construct, articulate and understand their social world (Bold, 2011).  Young 
people have stories to tell about their experiences of taking medication, and 
how these experiences affect decisions about whether they take prescribed 
medication or not. I felt very strongly that these stories needed to be heard and 
understood, so this naturally progressed to a view that narrative research was 
the design of choice.   
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Further reading of the topic led me to realise that proponents of  narrative 
research view it in a number of different ways, employing different approaches 
to analysis (Bold, 2011).  Common elements exist in that stories of personal 
experience are gathered, retold based on defined narrative elements and 
rewritten into chronological sequence incorporating the place or setting of the 
storytellers experience (Creswell, 2013).  Through my deliberations of the 
subject, I uncovered a number of different approaches to analysis of narratives 
which can broadly be termed structural, temporal, sociolinguistic and content 
analysis.   
Structural Analysis 
Labov and Waletzky (1997) assess narratives as building blocks of information 
that come together to form a temporal sequence of events.  These individual 
blocks of information provide referential meaning of personal interest, or 
evaluative meaning which links to social context.  Analysis is based on a formal 
approach of linguistic structure whereby parts of sentences are related to what 
happens in the story (Bold, 2011).  Labov and Waletzky contend that a ‘fully-
formed’ narrative displays six core features which form the basis of their 
framework for analysis.  The ‘abstract’ provides information on what the story is 
about and the ‘orientation’ on the context of the story. The ‘complicating action’ 
serves to provide readers with an insight into what happened next, whilst the 
‘evaluation’ highlights the significance of this.  The ‘resolution’ offers information 
on the outcome, and finally the ‘coda’ is a statement returning perspective to the 
here and now (Labov and Waletzky, 1997).  The framework presented  by 
Labov and Waletzky provides a means by which the researcher can identify, 
unpick and compare narratives about particular events whilst presenting the 
information from the viewpoint of the storyteller (Andrews et al., 2008).  Critics 
of this approach argue that not all narratives will fit into this framework as they 
do not contain all six core elements, that the framework does not take into 
account current use of English language or cultural and gender influences on 
storytelling, nor does it allow for use of other means of storytelling such as 
photographs and poetry (Andrews et al., 2008).  Core features may be 
presented in a different order, and stories may intertwine with each other 
120 
 
making the narrative structure more complex than described by the framework 
(Frank, 2010). 
In a similar vein, Burke’s (1945) approach to analyzing narrative is to consider 
five aspects, some of which overlap with those presented by Labov and 
Waletzky.  These five components are the act, scene, agent, agency and 
purpose, or put more simply the What?, When or Where?, Who?, How? and 
Why? (Burke, 1945) 
During the process of data analysis, I did utilise the framework by Labov and 
Waletszky as an introduction to narrative analysis (Appendix 1).  I sometimes 
struggled to identify all aspects outlined in the framework, but was not 
particularly concerned about this as I knew from prior reading that this was one 
of the criticisms of the framework.  Whilst feeling that I was taking a more 
narrative approach, I did not feel that I was critically considering the transcripts.  
This resulted in my exploring other avenues for narrative analysis. 
Temporal Analysis 
Other authors deviate from a structural approach and consider narratives from a 
perspective of the natural passage of time and sequencing of events.  I have 
classified these approaches as temporal analyses.  All of the approaches I will 
describe contain a temporal aspect, although other aspects of narrative are also 
featured.  Clandinin and Connelly (2000), propose that events have a past, 
present and potential future (Clandinin and Connelly, 2000).  Data are analysed 
according to three different categories, continuity (past, present and future) but 
also by interaction (personal and social), and places (physical places or the 
story-tellers places).  Similarly, Cortazzi (1993) proposes three features of a 
narrative which brought together form a plot structure.  Temporality describes a 
sequence of events in time.  Causation considers how one event causes 
another, as assessed by those listening or reading the information.  Finally 
there is the element of human interest, without which there is no narrative 
(Cortazzi, 1993).  Considering the transcripts obtained from the interviews, I 
could clearly see temporal aspects to the stories told and could identify the 
elements of causation and human interest.   
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Sociolinguistic Analysis 
In contrast to all of these viewpoints, a sociolinguistic approach is advocated by 
Gee (1991) who pays more attention to how something is said, analysing 
pauses and other aspects of interrupting speech which serves to present 
information to those listening in distinct segments (Gee, 1991).  Sociolinguists 
may also focus on aspects of conversation such as turn-taking or sequencing 
(Bold, 2011).  I questioned the value of such an approach based on the 
research questions being explored, as I did not feel that the outputs would be 
particularly engaging or have the potential to influence clinical practice.  I also 
do not have a sociolinguistic background so felt I could not do this approach 
justice.  I therefore moved on to consider analysis of the content of stories. 
Content Analysis 
When classifying narrative analysis as a form of content analysis, I understand 
this to mean where the focus of analysis is on the content and meaning of the 
story told. Some authors argue that meaning is more important than the 
structure of a narrative (Clough, 2002, Bolton, 2006) and conduct thematic 
analysis of the data obtained (Bold, 2011).  The key difference between 
thematic analysis and narrative analysis is that narrative analysis starts from the 
perspective of the story teller rather than the analyst, and centres on the 
analysis of events  over time with the intention of producing new meanings 
(Waziri et al., 1993).  Other approaches which could be classed as content 
analysis are those which are based on the plot and genres within stories.   
Having explored the different approaches to narrative analysis, I decided that I 
wanted to concentrate my analysis on the content of the stories, as I felt that 
this would result in richer outputs than a purely structural approach. 
5.5.  Research Method 
Having chosen to use a narrative research design as a means of aiding 
understanding and gaining some insight into potential ways of transforming 
approaches to medication adherence, I still had to decide on the research 
method for gathering, analysing and interpreting the data.  Throughout the 
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research project, I had been keen to try and capture young people’s interest by 
using methods which would harness their imagination and creativity.  This led 
me to explore the role of visual methods of data collection to support this 
research, before finally agreeing on autophotography (auto-driven 
photoelicitation) as a means of gathering data. My reasons for these decisions 
are now detailed along with supporting literature. 
 5.5.1.  Visual Research 
A literature review evaluating the choice and use of visual methods of research 
proposes a number of benefits in using this methodology (Pain, 2012).  
Participants often feel more comfortable and communicative when they are able 
to use visual images as prompts (Banks, 2001, Clark-Ibáñez, 2007, Keller et al., 
2007). Visual methods also facilitate rapport between researcher and participant 
(Gold, 2004, Drew et al., 2010), enhance engagement with the research itself 
(Rhodes and Fitzgerald, 2006) and provide the researcher with insight into 
someone else’s world (Chalfen, 1998, Gold, 2004).  Visual methods are also 
considered a good way of engaging children and young people as they often 
find it easier to express themselves visually (Clark, 2005, Kinney, 2005).  Visual 
methods are seen as a way of redressing the power imbalance between adult 
researchers and children because research is conducted in partnership with the 
children (Clark, 2010, Drew et al., 2010).  Others have concluded that use of 
photographs as a research methodology serves to empower young people and 
helps them articulate sensitive, complicated or difficult topics (Rose, 2001, Pink, 
2006, Thomas, 2009).  Visual data provides a means of including those who 
may find it difficult to contribute because of language difficulties or other 
contextual issues, and can therefore be an important in providing a medium by 
which minority and disadvantaged groups can express their views and feelings 
(Bold, 2011).  Given all of these purported benefits, I therefore decided that a 
visual method of data collection was ideally suited to this research.  This then 
required a decision to be taken about the visual medium which would best suit 
data collection considering the study participants and research questions being 
examined.  
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 5.5.2.  Photographic Research 
Visual research comprises a wide range of data be that drawings, 
advertisements, collages, diagrams, signs or video-recordings, however 
photographs are by far the most common visual aid used (Emmison, 2012).  
Photographs are employed in a number of different ways within research.  
Photographs can be used as a stimulus for interviewing, systematic recording of 
a particular topic such as facial expressions, content analysis of naïve 
photographs whereby additional information is obtained other than that intended 
by the photographer, native image making where indigenous groups take 
photographs and then assess the outputs and documentary photography, or 
narrative visual theory where the visual coefficients of a social organisation are 
explore through photography (Wagner, 1979). 
In contrast, Douglas Harper provides an alternative framework for photographic 
research comprising four categories.  The scientific category is where 
photographs are viewed as storage devices for depicting data for further 
analysis.  In the narrative category, photographs are used to study the process 
of social interaction and life as it unfolds.  When using a reflexive category the 
subject is involved in uncovering meaning of the images.  Finally the 
phenomenological category focuses on elicting personal knowledge though 
photographs which have a personal meaning (Harper, 1988).  Considering 
Harper’s viewpoint and how it applies to this research, whilst the proposed 
research project might initially be viewed as reflexive this is not the case as 
reflexive approaches still involve the researcher taking the images.  The most 
common approach within this category is that of ‘Photo-elicitation’ whereby 
images taken or gathered by the researcher are used as prompts in subsequent 
interviews with participants (Emmison, 2012).  I felt that it was important for the 
young people to take photographs themselves rather than be provided with 
images to then use as a basis for interviews.  By asking young people to 
generate their own images, this would ensure that the personal stories of the 
young people were accurately and comprehensively represented.  The young 
people would present their views about medication, rather than this information 
being based on my thoughts from past experiences and knowledge of the 
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literature.  Considering the framework of Harper presented above, I considered 
that asking young people to take their own photographs would represent both a 
useful scientific and phenomenological approach.   
Autophotography 
The research methodology described, whereby participants take their own 
photographs is referred to as ‘auto-driving’ (Heisley and Levy, 1991) ‘auto-
photography’ (Noland, 2006) or ‘autodriven photo-elicitation’ (Jenkings et al., 
2008).  First used in 1966, when cameras were given to Navajo Native 
Americans to analyse ways in which they viewed and experienced the world 
(Ziller and Rorer, 1985), auto-photography has become more prevalent since 
the advent of affordable, disposable cameras in the 1980s (Thomas, 2009) and 
the availability of cameras on devices such as mobile phones.  This approach 
assumes that photographs have a role and purpose in ‘promoting reflections 
that words alone cannot’ (Clark-Ibáñez, 2007).  The photographs are a means 
of obtaining rich verbal data which then takes priority over the images 
themselves (Drew et al., 2010).  It is suggested that auto-photography may 
more readily allow exploration of personal subject areas (Ziller, 1990).  In young 
people, it has been argued that photographs can provide visual narratives that 
both represent and facilitate further reflection (Olney and Farber, 1995).  It also 
can be a valuable and fun method to use when working with teenagers who lack 
self-esteem (Noland, 2006). Others argue that use of pictures allows 
understanding of ‘self’ to be better represented, as the person taking the 
photographs has the freedom to choose scenes and subjects which best 
represents their opinions on a particular topic (Combs and Ziller, 1977, Ziller 
and Lewis, 1981). Given all these arguments, I felt that the ideal methodology to 
explore this sensitive topic was auto-photography as an approach to in-depth 
interviewing (Drew et al., 2010).  This sits with Harper’s methodology of using 
photographs as interview stimuli (Harper, 1986).  Many young people already 
have mobile phones with cameras and take photographs to post on social 
media sites. I therefore felt that they would be comfortable with the prospect of 
taking photographs to articulate their views about medication.  I hoped that the 
young people would more readily engage in the research because of the artistic 
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element of the photography stage, but I also needed to cater for those situations 
where taking a photograph might be particularly difficult or for situations where 
young people might not be comfortable taking photographs themselves.  For 
this reason, participants were also able to include existing photographs or 
images from sources such as magazines and the internet if they felt they readily 
depicted their feelings about medication.  It was felt that combining these two 
approaches would ensure a richness of data that might not otherwise be 
captured and help ensure the safety of the young people in the study.  
Photographs as Data 
Having decided to use photographs as a means of illustrating medication stories 
and informing subsequent discussions at interview, I was then left to debate 
whether the photographs themselves would be analysed separately and be 
included in the thesis as another form of data.  Within anthropological fields, 
inclusion of images within texts has been more prevalent than within the social 
sciences (Emmison, 2012).  It is suggested that this is because anthropology 
articles are usually describing cultures which may be alien to readers, that 
differences in culture, race and geography allow the reader to more readily 
accept photographs which might otherwise be seen as offensive, and that 
subjects within the photographs are unlikely to protest at being photographed 
because of power imbalance with the photographer (Emmison, 2012).  In 
sociology it is proposed that photographs are less likely to be included in texts 
because a greater emphasis is placed on words to understand or interpret 
social action (Fyfe and Law, 1988), indeed it has been argued that: 
“a photograph depends on caption and textualisation to give it 
authentic and precise social scientific meaning.  In this way it 
loses its autonomy as a photograph, and thus any claim to make a 
contribution ‘in its own right’.  In social science, as in most other 
discipline areas, images need words, whilst words do not 
necessarily need images” (Chaplin, 1994). 
Others have argued that a reluctance to include photographs within sociology 
research texts is based on a concern about the observation, regulation and 
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control of subjects within the photographs (Tagg, 1993).   
Having considered these two opposing viewpoints, I felt that whilst inclusion of 
photographs was not vital, it might at times aid understanding of the concepts 
being articulated and be more engaging to the reader. Conversely, there would 
be no need to include all of the photographs as this might dilute meaning and 
visual impact.  From my reading of the use of visual research, I did however 
recognise a need to avoid self-censorship and be able to provide a reasoned 
argument for inclusion or exclusion of particular photographs within the thesis 
(Emmison, 2012).   
Having articulated the reasons for choosing the different elements of my 
research, and summarised the research framework in Table 5.1, I will now go 
on to describe the research in more detail outlining the target population for the 
study, ethical issues which required consideration and the process by which 
data was collected. 
5.6.  Research Population. 
As already outlined the population being researched was teenagers prescribed 
medication for a psychotic illness.  The inclusion and exclusion criteria are now 
presented to further detail the target population 
5.6.1.  Inclusion Criteria 
To be accepted into the study, participants had to be between 14 and 18 years 
old, have contact with EIS or CAMHS services, and have had experience of 
taking antipsychotic medication.  Alternatively they could be accepted into the 
study if they were over the age of 18 but had been prescribed antipsychotic 
medication at some point between the ages of 14 and 18. 
5.6.2.  Exclusion Criteria 
Participants were excluded if their current mental or physical state precluded 
them from being able to actively participate or give informed consent for 
involvement in the study. 
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5.7.  Ethical Issues  
The nature of the research being conducted, and the intended research 
population, all contributed to the need to explore numerous and complex ethical 
issues.  This section is therefore sub-divided to provide more detailed 
information on research ethics approval, informed consent, mental capacity, 
data management, confidentiality and other ethical issues.   
5.7.1.  Ethics Approval 
As the research was being conducted within the National Health Service, ethical 
approval from the National Research Ethics Service (NRES), Lancashire Care 
NHS Foundation Trust (LCFT) Ethics Committee and the University of Central 
Lancashire (BuSH) Ethics Committee was a pre-requisite to progressing the 
research.  Approval was obtained from NRES and LCFT ethics committees in 
February 2010, with chair’s approval from BuSH in March 2010 based on the 
approval already obtained from NRES and LCFT ethics committees.  The 
NRES and LCFT ethics committees made several requests for amendments to 
submissions and supporting paperwork and these will be outlined in the relevant 
sections below. 
5.7.2.  Informed Consent 
This research study involved participants who were potentially vulnerable on 
two counts, namely their age and the presence of a mental illness.  To 
safeguard the wellbeing of these young people, a number of requirements were 
included through all stages of the research to ensure that it was appropriate for 
that young person to engage in the research, their wellbeing was ensured and 
informed consent to participation obtained.   
When first submitting the paperwork for ethics committee approval, LCFT asked 
that I expand the description regarding assessing capacity to consent.  They 
also wanted further information on what would happen if service users were 
unable to consent, and whether parental consent would be sought.  In response 
to these questions, a decision was taken that assessment of capacity would first 
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be undertaken by the care coordinators of potential research participants. Care- 
coordinators only approached me if the young person was able to give informed 
consent.  The advantage of this initial assessment was that it was undertaken 
by a healthcare professional who knew the young person, their history and 
current mental state.   
I then went with the care coordinator to discuss the research project with the 
potential participant.  This had the advantage that the young person was more 
relaxed at the initial introduction as there was a familiar member of staff 
present.  The young people were given a research information sheet at this 
stage incorporating an expression of interest form (Appendix 2).   
Parental consent was also obtained from parents or guardians of those aged 14 
or 15 through use of a parental research information sheet incorporating a 
parental consent form (Appendix 3).  At the NRES ethics committee meeting, 
the issue of parental consent was also raised and the committee asked that the 
process be revised so that young people aged 14 or 15 consented in writing to 
the researcher approaching their parents or guardian.  The initial intention had 
been to get verbal consent to approach the parents or guardian.  The 
requirement to obtain written parental consent for those aged 14 and 15 was 
included in the patient consent to fulfill the requirements of the ethics 
committee.   
Written consent was gained from the young person at this stage for the 
photography and interview stage (Appendix 4). Verbal consent was reaffirmed 
at the start of the interview stage.  If at any stage informed consent could not be 
assured, the researcher would withdraw the young person from the study.   
At the end of the interview it was made clear that consent for inclusion of some 
or all of the photographs could be withdrawn during the interview or within the 
four week period thereafter.   A photography permission form was also used to 
obtain consent to store the photographs electronically for five years, to include 
the photographs in this thesis, other presentation or academic publications 
(Appendix 5).   
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As well as considering the consent of that young person to participate in the 
research, it was also necessary to consider consent of any other person whose 
photograph might be taken.  If the young person took photographs of other 
people, they had to get those people to sign a model release form (Appendix 6).  
Photographs were then only included in the thesis, publications or any 
presentations if a completed model release form was available. 
5.7.3.  Mental Capacity 
As well as assessing the young person’s ability to provide informed consent, 
consideration also had to be given to mental capacity and whether this would 
impact on any decisions taken about involvement and participation in the study.  
Again care coordinators were only asked to recommend those young people 
who were mentally and physically well enough to actively engage and progress 
the study.  During the interview participants could take a break whenever they 
wished and also terminate the interview at any stage if they felt in any way 
uncomfortable or unwell.  The NRES ethics committee also insisted that I 
contact the care coordinator if concerns about the person’s physical or mental 
wellbeing became evident at any point during the research.  This was made 
clear to participants via the research participant information sheet.   
5.7.4.  Data Management 
Another ethical issue I had to address was that of data management.  To 
ensure data security a number of steps were taken.  Firstly, all manual data 
containing personal details (including photographs) were stored in a locked 
filing cabinet in my work office.  All audio files were transferred to a secure 
password protected computer and then deleted from the audio recorder.  These 
files were password protected.  Any hard copies of transcripts were kept in a 
locked cabinet when not in use, and all electronic copies were password 
protected on a password protected laptop. This was the case for all electronic 
data which was stored on a password protected computer. A password 
protected encrypted memory stick was used to backup data. When not in use 
this was kept in a locked cabinet in my work office.  The CD-Roms containing 
participant photographs were kept in this locked cabinet when not in use.  If 
130 
 
there were occasions where I returned home after an interview and was unable 
to immediately place the recorder/paperwork in my work office, I stored the data 
in a sealed envelope within a locked desk draw in my home office. Finally, all 
personal data (excluding photographs) were to be securely destroyed once it 
was no longer needed. 
5.7.5.  Confidentiality 
Whilst effective data management is one means of ensuring confidentiality, 
there were other aspects of confidentiality to consider as part of the research.  
When detailing narratives obtained from participant stories within the thesis, 
pseudonyms were used to protect identity. Whilst this goes someway to 
protecting confidentiality it cannot guarantee it (Elliott, 2005), as it is possible 
that close friends and family would still be able to recognise the participant 
stories if they were aware that the young person was participating in the study. 
5.7.6.  Other Ethical Issues 
In conducting this research there were other ethical issues I had to consider.  
The age of the participants required particular consideration and, as already 
described, parental consent was obtained for participation of those under 16.  I 
also sent all of the research literature for participants and parents to the 
safeguarding lead for their consideration and comments as part of the 
development process.  They asked that the following statement be included at 
the end of the research protocol in a section on ‘Safeguarding Children’ 
(Appendix 7): 
“Lancashire Care Trust (LCFT) staff have a duty of care to safeguard and 
protect children at risk of harm and neglect from the subsequent negative 
outcomes and enable all children to reach their full potential. Every child 
has the right to be protected from potential significant harm. If at any time 
staff identify concerns for a child/ young persons welfare or believe a 
child is suffering, is at risk of suffering abuse or neglect or has suffered 
abuse or neglect a referral must be made to Children’s Integrated 
Services (CIS) in line with LCFT and Local Safeguarding Children Board 
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Procedures.  The child/ young person’s welfare should remain the central 
concept in any assessment”. 
There was also the potential that participants might disclose sensitive 
information to me, knowing that I was a healthcare professional rather than a 
family member or friend (Rice and Ezzy, 1999).  This was a particular concern 
of the NRES ethics committee, who were keen to understand how I would 
respond if young people disclosed that they were not taking their medication at 
interview.  The committee subsequently required that I inform their doctor or 
care coordinator in the event of such a disclosure.  This requirement was 
therefore added to the participant research information sheet.   I also reinforced 
this verbally with the young person when consenting them to the study so they 
were clear about this responsibility.  Given the requirement to inform the care 
coordinator or consultant if I was concerned about the young person’s mental 
health during any meeting, I did initially wonder whether this would cause the 
young person to deliberately hide such information from me. Following the 
interviews I was left with the impression that this had not been the case, as 
young people seemed comfortable relaying the negatives as well as the positive 
aspects of taking medication.  One young girl disclosed that she wanted to 
reduce her medication during the interview and had a meeting with the 
consultant the following week to discuss this.  Whilst her father administered 
medication, she was in midst of taking her GCSEs and so I was concerned that 
she might try to secrete the medication.  I was relieved that the research 
protocol fully supported my contacting the care coordinator to confirm that she 
was aware of the patient’s wish to reduce the dose and had indeed arranged a 
meeting with the consultant to discuss this.  By requiring me to disclose non-
adherence to the team, the ethics committee ensured that I was not in a 
position described by Duncan et al. (2009) where disclosure of poor adherence 
to medication led to an ethical dilemma because assurances had been given to 
participants that information would not be disclosed to health professionals 
responsible for delivering care. 
Once ethical approval was obtained, I then moved onto the recruitment phase 
of the research. 
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5.8.  Recruitment 
Participants were recruited from EIS and CAMHS tier 3 and 4 services at 
Lancashire Care NHS Foundation Trust (LCFT).  Potential participants were 
informed of the study through posters displayed in reception areas, by care 
coordinators within the community teams, provision of information on discharge 
from an inpatient ward, or through attendance at a young person’s support 
group, ‘The Crew’.  Participant information sheets incorporating expression of 
interest forms (Appendix 2) were provided, along with a parental information 
sheet and consent form (Appendix 3) if the young person was under the age of 
16. 
 5.9.  Data Collection 
Return of expression of interest forms and any associated parental consent 
forms marked the start of the data collection phase.  Data collection progressed 
through a number of sequential phases, namely the introductory meeting, 
photography phase, interview and transcribing stages. 
5.9.1.  Introductory Meeting 
For those who returned an expression of interest form and fulfilled the criteria 
for participation in the study, an introductory meeting was arranged.  At this 
meeting the care coordinator was present to facilitate introduction to the 
researcher and make the young person feel more at ease when meeting 
somebody they had not met before.  During this meeting the study was 
discussed in more detail and the young person was asked to take photographs 
depicting ‘What medication means to me’.  Participants were told that they could 
include both positive and negative aspects of taking their medication.  They 
were informed that the focus was on their personal views and experiences, as 
opposed to that of the wider public, and that the information could be based on 
experiences and hopes in the past, present and/or future. It was made clear that 
up to twenty photographs could be taken, and that other images e.g. from 
magazines, photograph albums or the internet could also be included.  In the 
event of the latter being provided, the researcher sought permission to take a 
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digital photograph of the images submitted if they were not subject to copyright.  
The purpose of the Model Release Form (Appendix 6) was also explained as a 
means of ensuring the consent of all involved.  During the initial meeting, 
participants were given the opportunity to ask any questions and seek further 
clarification.  A consent form was completed for the photography and interview 
phase of the project (Appendix 4).  Participants were informed that their care 
coordinator would be advised of their involvement in the study.  A time frame for 
taking the photographs was agreed between the researcher and the participant, 
usually around four weeks, and if not taking photographs via a personal mobile 
phone, a disposable camera was provided. The cameras were labeled with 
sequential letters of the alphabet so I could identify which research participant 
had taken the photographs when the disposable cameras were returned.  
Information discussed during the meeting was reinforced through provision of a 
photography guidance sheet (Appendix 8).   
5.9.2.  Photography Stage 
After the initial meeting the young person was left to their own devices to take 
their photographs.  Once the photographs had been taken, participants emailed 
the photographs to a university, password protected, email account or posted 
the camera back to the researcher in a pre-paid padded envelope provided. If 
photographs were not returned in the timeframe agreed, I made contact with the 
young person to check that the data collection was progressing, answer any 
further questions and then agree a new timescale for the photographs to be 
returned.   
On receipt of the camera or emailed photographs, I then obtained (a) a set of 
prints for participants, and (b) a CD-ROM of these prints. The participants were 
already aware, and had consented to the fact, that I would look at the 
photographs before sending them back.  This was purely to check that they had 
been developed correctly. Participants had also given consent to the researcher 
having a copy of all photographs on CD-ROM. 
Having checked that the photographs had been developed properly, the 
photographs were returned to the participant on a mounted card.  Participants 
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had to select photographs for discussion, giving the photograph a title.  They 
then had to indicate, through use of adhesive labels provided, whether the 
photograph represented a positive or negative aspect of medication and 
whether the photograph was relevant to the past, present and/or future.  To 
support this stage a photograph selection form was provided (Appendix 9).  
That said, not all of the young people titled and labeled the photographs. 
However, this did not prevent the research from progressing. 
On return of the photographs to the participant, the researcher agreed a 
convenient time and date for an in-depth interview to hear their story about 
taking antipsychotic medication.    
5.9.3.  Interview Stage 
Interviews were conducted at a time and place suggested by the young person.  
If the researcher was going to interview the young person alone, at a site which 
was not trust premises, the Lone Worker Policy for the Trust was followed.  
At the start of the interview, verbal consent was obtained. I clarified whether 
there were any time constraints to the interview, and the participant was 
advised that they could take a break whenever they wished.  Participants also 
completed a form identifying which photographs they gave permission to be 
stored, and/or used in a thesis, and/or used in presentations or exhibitions, 
and/or used in academic publications (Appendix 5).  
During the interview, participants were given the choice of selecting the 
photographs and talking about what the photograph meant, or alternatively 
telling me their medication story and referring to the photographs throughout as 
an illustration of that part of the story.  All but one of the participants chose to go 
through the photographs and tell me what aspect of their journey the 
photograph depicted. This one participant wrote out her story prior to the 
interview and then arranged her photographs sequentially in the order in which 
they appeared in her story. 
Open questions were used to encourage participants to respond in a manner 
they found meaningful (Grace, 1991). If the young person was struggling to 
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articulate their views and thoughts, flash cards were available to support 
discussion about particular factors which might promote or interfere with 
adherence.  These flashcards were derived from the outputs of the preliminary 
research phase which involved staff surveys of factors affecting adherence with 
medication.  During the interviews these flashcards were not used as I felt that 
the young people were depicting their views clearly enough.  Whilst a couple of 
young people were not particularly forthcoming at interview, they did respond to 
additional probing questions and I felt that they would not welcome or 
appreciate use of the flashcards.  Any points of uncertainty during the interview 
were clarified with the participant for the purpose of clarity. To support this 
process an interview prompts sheet was designed (Appendix 10).  This prompt 
sheet was used during the initial interview more as a prompt to the process and 
I did not methodically ask the questions that had not been covered during the 
interview.  This is because I felt it was important for the content of the interview 
to be driven by the young person.  I considered that it may put particular ideas 
in the young person’s mind if I asked targeted questions related to adherence 
factors identified in published literature as being important. 
At the end of the interview participants were given a £10 gift voucher in 
recognition of the time taken to participate in the study.  They were also advised 
that they had a ‘cooling off’ period of one month during which time they could 
contact the researcher and ask for some or all of their data to be removed from 
the study. The audio-recordings of the interviews were then sent for 
transcription soon after completion of the interview to support data analysis. 
5.9.4.  Transcribing Stage 
Interviews from all participants were transcribed verbatim by an external 
transcriber, with the content then checked by myself for accuracy.  Transcripts 
were anonymised and pseudonyms applied to each young person to support 
anonymity. As transcription is such a crucial part of the analytical process, this 
was conducted by a skilled transcriber recommended by a member of my 
supervisory team.  Even with use of an experienced transcriber, there are some 
recognised limitations such that it has been suggested that: 
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“It is now widely accepted that it is all but impossible to produce a 
transcript of a research interview, or any other type of 
conversation, which completely captures all of the meaning that 
was communicated in the encounter itself.  Any transcription of 
speech must therefore be understood as a compromise”  (Elliott, 
2005). 
On receipt of each transcript, the digital recording was analysed alongside the 
transcript repeatedly to confirm data accuracy.  Other safeguards to enhance 
data worthiness were also considered as part of the process. 
5.10.  Data Worthiness 
When undertaking narrative analysis, it is vital that the researcher understands 
the different ways that data might become distorted.  Within this research 
project, there was the potential for this to happen with the images themselves, 
other media images presented, during the interview process and then when 
undertaking data analysis for presentation within the thesis.  I now describe how 
I guarded against this when undertaking the research. 
5.10.1.  Photographs 
When the research participant used the photographs to articulate their story 
about medication, it was essential that I understood as far as possible what was 
being depicted within the photograph, capturing information not just related to 
medication but exploring issues such as the relationships between the 
photographer and other subjects in the photograph and how this might have 
affected the image produced. This is because when using photographs in 
research, they must be assessed giving due consideration to the key criteria of 
authenticity, credibility, representativeness and meaning (Scott, 1990).   
Authenticity cannot really be questioned when using photography, however 
credibility requires more attention given changes that can be made to 
photographs with technology and advances in photographic development.  That 
said, the young person had been involved in the production of the end product, 
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and so even if changes have been made the photograph could still be viewed 
as representing a selective account of reality.  One young person, a keen 
photographer, had planned to make changes to her photographs to make the 
image more visually captivating and to better illustrate the points she was 
making in taking the photographs.  Unfortunately her camera broke during the 
research project and she was therefore unable to produce any photographs for 
inclusion in the research.  All photographs included in the research were 
therefore in their original format and had not been altered in any way. 
In using photographs as a prompt for further exploration the researcher is also 
required to consider criteria of representativeness and meaning, considering the 
historical content in which the photograph was taken, any additional data which 
can be used for triangulation purposes, evidence of themes across different 
photographs and scrutiny of individual photographs to understand texture and 
nuance (Dowdall and Golden, 1989).  This seemed to be a useful approach to 
ensure that the photographs were represented faithfully by the written 
information they generated.  It was important that I clarified the meaning of the 
photographs during the interview rather than making assumptions based on the 
scene being depicted.  Encouraging the young people to title their images also 
supported some basic understanding about what the image was representing. 
In asking further questions about the photographs when their meaning was 
unclear, steps were being taken to ensure the research was robust and faithfully 
represented the young people’s stories of taking antipsychotic medication. 
5.10.2.  The Interview 
The interview also required consideration of data worthiness.  The story told at 
interview will be influenced by the subjective process of reminiscing and 
recreating the story, as well as the memory of those events (Reissman, 1993, 
Bold, 2011). This is highlighted by Webster, who argues that: 
‘narrative is not an objective reconstruction of life- it is a rendition 
of how life is perceived’ (Webster, 2007).   
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It was therefore crucial that I understood the context in which information was 
being supplied, or the context in which events took place, to fully appreciate the 
stories (Clandinin and Connelly, 2000).  During the interview this was achieved 
by asking for points of clarification where there was ambiguity about the 
information being presented. 
Dynamics between the researcher and participant also influence the story being 
told (Bleakley, 2004), as do other factors such as participant motive and the 
intended audience (Wertz, 2011).  I wondered whether my professional 
background as a pharmacist might encourage the young person to talk openly 
about their medication, or whether the young person might say what they 
presumed I wanted to her.  I therefore made it explicit at interview that I wanted 
to know about the bad as well as good things about medication. To encourage 
reflexivity I kept a research diary so I could record relevant information and 
observations which might affect the information being obtained. I also decided 
to use some of the suggestions made by Valerie Yow to ensure I kept an open 
mind during the interview period, asking myself the following questions and 
documenting thoughts in my research diary:  
 What am I feeling about this young person? 
 What similarities and differences between me and the young person 
impinge on this situation? 
 What are the effects on me as I conduct the research and how might my 
reactions be affecting the young person?  (Yow, 1997) 
My reflections on these questions are included in the next chapter where I 
provide an overview of each young person who participated in this research.  
Following data collection, I then moved to analysis of the data which also 
required consideration of data worthiness. 
5.10.3.  Data Analysis 
It is suggested that in the process of retelling a story told by a participant, the 
researcher will pass through at least five levels of representation all of which 
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have the potential to distort information (Reissman, 1993).  Firstly, in attending 
to the experience the researcher may focus on selected aspects of the 
experience to make the account meaningful.  Secondly, when recounting the 
experience, this will be influenced by factors such as personal memory, things 
the storyteller perceives as important, what the storyteller thinks their audience 
will want to hear and the cultural background and influences of the storyteller.  
Different genres may be employed which will have different effects on the 
reader depending on how successfully they attune the reader to the storytellers’ 
perspective. Thirdly, transforming accounts into a script requires interpretation 
thereby lending itself to the possibility of incomplete or selective information 
being presented.  Speech uses features such as inflection, volume, and 
repetition to convey meaning and it is important to report such features as part 
of the transcription process to present a complete picture to the reader.  
Fourthly, when analysing experiences to create a metastory to capture accounts 
of all participants, there is a process of determining the significance of all the 
information presented, editing the information and then re-presenting this as a 
story in itself.  Once again, this process has the potential to distort the final 
product and must be considered as part of the research process to ensure a fair 
representation of data.  Finally, those reading the research will themselves bring 
their own background, personal experiences, values and perceptions into the 
reading of experience and this will influence their own interpretation of the 
information presented (Reissman, 1993).   
It was important to consider all these different aspects of potential data 
distortion and misrepresentation when conducting and analysing the research.  I 
also investigated other ways of evaluating the results of any analysis and 
robustness of the research methodology.  Whatever the focus of analysis, Sikes 
and Gale (2006) have listed several qualities of a good story, namely liminality 
where gaps in the text are introduced so readers can use their own experiences 
to fill in any missing or ambiguous information, transgression when the ensuing 
emotional response, future possibilities and dreams are attended to, evocation 
where readers are emotionally moved by the story presented, complexity, 
creativity and audience engagement (Sikes and Gale, 2006).  Stories are not 
just heard by verbal and written word but by other media such as photographs, 
140 
 
videos, music, drawings provide as was the case in this research study.  
Common features of all of these methods of narration are that they aid humans 
to make sense of things, represent the experience rather than providing that 
experience itself, and seek to transform those involved (Andrews et al., 2008). 
Whilst all of the qualities may not be present in the stories as data, they may be 
more likely to be present in visual data and in the metastory produced by the 
researcher (Bold, 2011).    
Given these common themes of a good story, I decided to evaluate content 
against measures proposed by Sikes and Gale (2006) as I felt that these 
succinctly captured these themes and enabled an assessment as to the 
authenticity of the information presented.  The first measure ‘substantive 
contribution’ considers how the story informs understanding of social and 
cultural life.  ‘Aesthetic merit’ assesses ability of a story to open senses, 
encourage interpretative responses and obtain reactions from the reader.  
‘Reflexivity and participatory ethics’ questions the reflexivity of the researcher 
undertaking the narrative research by exploring aspects such as how the 
narrative was obtained, what could have influenced the text obtained, how this 
was addressed and whether the way in which participants are represented was 
fair and accurate.   ‘Impact’ simply assesses the impact of the narrative on 
those involved.  Finally, ‘near experience’ involves a judgement on whether the 
information presented rings true and offers a fair representation of the events 
described (Sikes and Gale, 2006).  
My reflections on all of these aspects formed part of my research diary and 
contributed in part to my understanding of my position within the research 
project presented in the introductory chapter.  Having presented the means in 
which data can be distorted, and the means of guarding against this, I will now 
detail my approach to the data analysis itself. 
5.11.  Dialogical Narrative Analysis 
My initial approach to data analysis was to read the stories repeatedly, then 
organise the content into codes and sub codes in Excel.  I soon abandoned this 
approach as I found it cumbersome and unwieldy. I also felt that, rather than 
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engaging with the story, I was formulaically going through a process rather than 
considering the underlying meanings to what was being said.  Thus the outputs 
felt more like thematic rather than narrative analysis.   I also struggled to 
engage with the framework for narrative analysis proposed by Labov and 
Waletsky (1997) (Appendix 1) as I felt that this was also not supporting my 
engagement with the stories as I was focusing on uncovering the different 
aspects to a story, such as the abstract, coda, complicating action rather than 
engaging with the content of the story.  An example of how I attempted to use 
the framework by Labov and Waletsky (1997) is included as Appendix 1.  I then 
began to wonder whether the stories from young people about their medication 
experiences would uncover different genres depending on, for example, 
attitudes to medication, insight, internal and external influences on medication 
and subsequent medication taking behaviour. In my wider reading of the topic, I 
came across the concept of dialogical narrative analysis outlined in the book 
‘Letting Stores Breathe: A socio-narratology’ (Frank, 2010).  An outline 
framework is provided as a means of supporting critical analysis of the content 
of the story and its resultant effects.  Dialogical narrative analysis requires 
respect for the initial and obvious understanding of a story, whilst requiring the 
listener to dig more deeply for unspoken meaning.  Questions are proposed to 
support discovering of hidden meaning such as what is as stake for whom?; 
what is narratable?; how do characters hold their own in the story?; what effect 
does the story have on these characters?; what are the elements of fear and 
desire in the story?; and how does the story do the work of memory? (Frank, 
2010).  Having discovered this approach, I decided that dialogical narrative 
analysis would ensure that I did justice to the stories being told, uncovering both 
hidden as well as obvious meaning.  I also felt that it might ultimately support 
identification of different sub-stories and genres. In taking a dialogical stance, I 
not only focused on the aspects outlined above, but considered the different 
capacities of stories present in transcripts as outlined by Frank (2010).  I was 
therefore looking at whether the stories made trouble for characters, how the 
story tested and showcased individual characters, what points of view were 
articulated, whether there was suspense within the story, were there any 
unexpected twists and turns or morals to the story, whether aspects of the story 
resonated with other stories told by participants, were symbiotic relationships 
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evident, did plots and characters change as the story unfolded, what truths were 
told and how my imagination was fired by the story.  I started out by handwriting 
features of the different stories under the headings described above.  In my 
analysis of the first transcript for example, I felt that the stakes for Ameeta were 
being defined as a carer, a nurse, somebody who is ill.  Also at stake was 
Ameeta never being able to get past the dark times.  This stake was redefined 
as her story progressed with Ameeta redefining herself as her own, 
independent person and asserting her right to a brighter future.  Medication 
changed possibilities for Ameeta as by controlling symptoms medication 
enabled her to re-engage with her hobbies, attend college and undertake 
college courses.  This consequently made her feel like a valued member of 
society with a bright future.  She described her life as a ‘life worth living’.  I 
continued to write down by interpretation of the questions posed and the 
capacities outlined by Frank (2010). Having completed this for the first 
transcript, I then checked my interpretations with my supervisory team to 
confirm that I was taking a sensible and reasonable approach and had not 
missed any major concepts.  I continued analysing in this way until my 
confidence with dialogical narrative analysis increased.  Recognising the 
advantages of having a system to organise data more efficiently, I then started 
to code using the quantitative analysis software package MaxQDA 11.  Within 
MaxQDA 11, I structured the codes so that they mirrored the initial narrative 
questions and capacities of stories articulated by Frank (2010).  I also 
introduced additional codes to focus on themes which seemed to be prevalent 
during the interviews held.  Additional codes included emotions linked to 
medication such as happiness, resentment, anger as well as specific themes 
related to medication adherence, including factors promoting or deterring 
adherence, specific side effects and prescribed dose.  When new concepts 
emerged from interviews I went back to previous interviews to check that I had 
not missed similar concepts within the transcripts of earlier participants. For the 
purpose of illustration, when considering the interview transcript for one of the 
participants, Allison, I recognised a new code about doing more things on 
medication.  I realised that I had missed this in earlier transcripts so went back 
to recode these.  Allison had also taken an overdose, a new stake to 
acknowledge in the coding system, and I had missed this when considering 
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Katey’s interview transcript.  In undertaking a process, similar to the constant 
comparison conducted in grounded theory approaches, I ensured robustness of 
the data analysis process. 
Before embarking on an outline of my findings from the data analysis process, I 
will in the next chapter give a brief outline of the young people who participated 
in this research.  Incorporated into this information are relevant aspects taken 
from my research diary to evidence the process by which data worthiness was 
considered.   
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CHAPTER SIX.  AN OVERVIEW OF THE YOUNG 
PEOPLE 
Whilst undertaking this research, I was extremely privileged to meet with and 
hear stories from young people who had met with varying degrees of adversity 
during their teenage years yet had responded to this with courage and 
determination.  I was humbled and inspired when talking to them and therefore 
felt it was important to present an overview of their background, situation and 
stories so others could benefit from this same appreciation of the personal 
circumstances forming the backdrop to their stories.  I have included 
demographic information using pseudonyms about their age, gender, ethnicity 
(Table 6.1), as well as information about the number of 
photographs/images/drawings presented and the length of our interviews (Table 
6.2).  Far more interesting to me, however, is the background information which 
provides an insight into these remarkable young people.  Reflexive entries have 
also been included of my impression of these initial meetings, based on the 
entries in my research diary . 
Table 6.1.  Demographic Information of Young People 
Pseudonym Age Gender Ethnicity 
Ameeta  17 Female Asian-Pakistani 
Victoria 16 Female White-British 
Katey 16 Female White-British 
Allison 20 Female White-British 
Christina 16 Female White-British 
Samantha 18 Female White-British 
Gabriella 17 Female White-British 
Michelle 20 Female White-British 
Stephen 15 Male White-British 
Jonathan 17 Male White-British 
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Table 6.2.  Summary of Data Received 
Pseudonym Interview Duration Number of Images 
Ameeta 25 minutes 43 seconds 8 
Victoria 28 minutes 0 seconds 6 
Katey 45 minutes 45 seconds 13 
Allison 49 minutes 14 seconds 17 
Christina 38 minutes 48 seconds 10 
Samantha Approximately 27 minutes 8 
Gabriella 10 minutes 48 seconds 3 (described) 
Michelle 46 minutes 44 seconds 10 
Stephen 14 minutes 32 seconds 0 
Jonathan 22 minutes 23 seconds 20 (described) 
 
Ameeta 
I was first introduced to Ameeta by her care coordinator at the children’s home 
where she lived.  When we arrived for the morning appointment Ameeta was 
still in bed, and so I spoke to her about the research whilst she was dressed in 
pyjamas and dressing gown and obviously still sleepy.  Quietly spoken and 
appearing quite timid, I wondered whether she was clear about what she 
needed to do and so repeated this a few times in different ways.  During this 
initial meeting I found out that she was doing a European Driving Licence 
Computer course at college; when I next met her she was part way through a 
twelve week programme with the Prince’s Trust and was about to start a 
placement at a nursery school.  Her ambition was to start a Health and Social 
Care Level 3 course. 
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When I turned up to interview Ameeta, the staff at the home took me into the 
office and explained that Ameeta had had a particularly difficult week.  This was 
because another resident, who she had known for some time, had killed 
themself.  I suggested re-arranging, however staff told me that preparing for our 
meeting had been a distraction for her and she had spent a lot of time preparing 
for our discussion.  This included rehearsing with staff what she wanted to say 
at interview as she was worried she had not done the right thing and may not be 
providing relevant information.  I was a little apprehensive about how Ameeta 
would be given the enormity of what she had experienced that week, but was 
extremely thankful that staff had thought to speak to me about this before I saw 
her.  When I went into the lounge, Ameeta had already arranged all the 
photographs on the table and had printed images from the internet as further 
illustrations.  She had also gone to the trouble of writing out her story in an 
exercise book.   
During the interview it became apparent that Ameeta had found things difficult 
during her childhood.  She spoke about being the main carer for her family, 
including two uncles with bipolar disorder, and the stress this caring role placed 
her under.  She spoke of the ‘trauma’ she experienced, how her day to day life 
was very hectic and busy.  Whilst she would previously put a smile on her face, 
deep down she was very low in mood.  When she first started to experience 
psychotic symptoms she did not realise or appreciate what was going on and 
was unable to see a future.  This ultimately culminated in a hospital admission.   
Ameeta was the first person I interviewed as part of this research and I was 
incredibly moved by the efforts she had gone to, particularly in light of the recent 
suicide of a friend.  I was however conscious that my concerns about the recent 
death of a friend prevented my exploration of the ‘trauma’ she repeatedly 
referred to during her childhood.  I took from the discussion that this was in 
relation to family pressures and the caring role she had to assume, however the 
trauma could have extended beyond the information she volunteered at 
interview.  Ameeta was obviously looking forwards and doing everything she 
could to make a brighter future for herself.  She seemed surprised when I told 
her what a fantastic job she had done supporting this research, shyly accepting 
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this praise.  She impressed upon me how determined she was to move forward 
and not look back, doing everything she possibly could to achieve her goals.  I 
came away from the interview desperately wanting her to succeed and achieve 
the goals she had set herself. 
Victoria 
My first introduction to Victoria was at home alongside her care co-ordinator.  
Her sister and grandmother were also present when we visited.  Victoria has an 
autism spectrum disorder and Asperger’s syndrome as well as bipolar affective 
disorder.  She needed help from the care co-ordinator to complete the 
paperwork and this is an aspect I had not considered when preparing for the 
interview.  I was glad that the care coordinator was present as this could 
otherwise have been awkward as I had not realised that she would struggle to 
complete the documentation.  Despite this, I was clear that she was able to 
understand information presented, weigh up the pros and cons of participation 
and provide informed consent.  She also asked why I had put a letter ‘C’ on the 
disposable camera and I had to explain that this was so I could identify who the 
camera was from when it was returned to me.  Again, I was surprised to be 
asked this question as it had not occurred to me that people may question this.  
Victoria has a keen interest in gardening and was really pleased that her father 
had fixed the greenhouse as she had been able to plant some seeds.  She took 
me out to the garden with her care co-ordinator, keen to show us what she had 
been doing in the garden.  She had been busy since the greenhouse had been 
mended planting vegetables, herbs and flowers and was really proud of her 
achievements.  She was well versed in what had been planted telling us the 
names of all the different flowers she was growing.  Not in any way being an 
avid gardener, I was impressed by her knowledge of the different plants and 
flowers in the garden as she was able to name many of them. 
When I next turned up to interview Victoria, I was introduced to her father.  
Victoria was particularly upset that only two of the photographs she had taken 
had turned out, and asked me to take some more photographs on my mobile 
phone to include in the study.  She chose to take photographs of a baby 
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anteater in a book, the contents of the kitchen cupboard and some of the plants 
and vegetables in her garden, explaining that these replicated the photographs 
that had not turned out.  I was having a difficult day as I had learned that 
morning that a family member battling terminal cancer had died.  I had therefore 
spent the morning comforting my mother.  At times during the interview, 
Victoria’s eyes welled up and it looked as though she were fighting not to let the 
tears fall.  This was particularly true when talking about her five month stay in 
hospital and how she thought she would never go home.  I tried to steer the 
conversation back to more positive things when she appeared so upset; this 
may therefore have stilted the interview.  The discomfort I felt at her obvious 
distress may have been due in part to my family bereavement and a wish to 
avoid upsetting topics.   
When I saw Victoria she was also part way through GCSEs and this was 
placing additional stresses on her.  I was pleased that her father was at home, 
making sure he knew I was leaving in case she wanted to talk things through 
after the interview.  I also contacted her care coordinator to explain she had 
been upset during our meeting as I was concerned about her. 
My impression of Victoria was somebody who was struggling to come to terms 
with her numerous conditions.  She was unsure how she really felt about having 
to take medication, but wanted to ultimately stop her medication as she saw 
little benefit in taking it.  She saw herself as somebody who was not ‘normal’ 
and desperately wanted this to change; indeed normality was a recurring theme 
throughout our discussion.  I was left with the overall impression that she was 
struggling to find and assert her identity and had no clear sense of self. 
Katey 
My first meeting with Katey was a little stressful as I turned up to college only to 
find I was at the wrong campus.  I rushed over to the correct site and was 
directed to a meeting room where the care coordinator and Katey were talking.  
Both were incredibly understanding about the mix up but I was very flustered.  
Katey was doing a health and social care course at college, a busy course with 
lots of college hours in the week for lectures.  Katey was an active member of a 
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support group consisting of young people and parents who have used inpatient 
services in the past.  This group work in partnership with inpatient staff and 
managers to develop services, and Katey had been an integral part of the 
project to change the ward catering arrangements to self-catering.  Through her 
involvement with this group, Katey also sat on interview panels for recruitment 
of new inpatient staff.  
Katey lives with her mum, stepfather and two half-siblings.  She has no contact 
with her father, but sees her two brothers at weekend when they come to stay 
at the house.   
Katey had been admitted to hospital on three different occasions due to her 
mental health.  The first admission was because of her eating disorder, with 
subsequent admissions due to depression and anxiety.  Previously prescribed 
antidepressants, at the time of the interview she was prescribed the 
antipsychotic medication risperidone and had been taking this for four months.  
When we met for the interview, Katey was still having days when her mood was 
low and a dose increase of risperidone was being considered because of 
ongoing psychotic symptoms.  Despite this, she was doing well with her college 
course and was thinking about applying to University to start a mental health 
nursing course.   
My impression of Katey was that of a sociable young lady; striving towards a 
career as a nurse.  Despite seeing a lot of positive aspects to her medication, 
she also showed some ambivalence to it and had concerns about her weight 
increasing with an increasing antipsychotic dose.  With her history of an eating 
disorder I felt that this concern was completely understandable. She was taking 
a mature approach by discussing her concerns, monitoring her actions and 
deciding what was and was not acceptable to her. 
Allison 
I first met Allison at a meeting of a local patient and carer support group.  She 
wanted to get involved in the study but was unsure whether she had been on 
antipsychotic medication until another member of the group informed her that 
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she had taken this before.  We subsequently met at the shared accommodation 
where she was living.  Whilst discussing the study and what was required, I was 
struck by the extensive scarring on both her arms due to self-harm. Her eyes 
were constantly moving from side to side making me wonder whether she had a 
form of epilepsy.  She explained that she would soon be moving to alternative 
accommodation as her current placement was dominated by male tenants and 
she wanted to move somewhere with more women.  I subsequently visited her 
at her new house, a converted barn in a rural setting with fabulous views over 
the surrounding countryside.  The house had only opened six weeks previously 
and there was still building work ongoing. The interior was very luxurious with 
an indoor swimming pool, a huge modern kitchen where all the residents 
seemed to congregate and a large dining table at which the interview was 
conducted.  Allison seemed much happier in the new accommodation and 
whilst making tea in the kitchen it was evident that she had bonded with some 
of the other girls who were staying there and enjoyed talking to the other 
residents.   
During the course of the discussion it became apparent that Allison had been in 
hospital for a prolonged period, including a stay on the psychiatric intensive 
care unit (PICU) having absconded from the open ward.  She was discharged to 
her community placement straight from the PICU and found the transition from 
hospital to home particularly difficult.  This culminated in a large, serious 
overdose requiring paramedic intervention and a hospital stay.  Her account of 
the overdose was particularly vivid and she had clearly been frightened by this.   
Subsequent to the overdose, medication had been stopped by the prescriber 
but was being reconsidered due to re-emergent symptoms.  She was very 
selective about who she discussed symptoms and medication with, and did not 
appear to have a relationship with her father or fiancé that allowed her to 
comfortably talk about such topics.  I wondered what was driving the secrecy 
with family members, perhaps a wish to not worry them or concerns about how 
they would react to the information. 
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Christina 
My first meeting with Christina was at the school she attended, her care 
coordinator was present.  Before the meeting, I was given an overview of the 
school and it’s ethos as it is so unique.  Catering for students with social, 
emotional and behavioural difficulties, the school focus is on vocational training 
in areas such as hair and beauty, construction and expressive arts as well as 
teaching more traditional subjects such as Maths, English and Information 
Technology.  I was told that the majority of students were vulnerable, 
disaffected, disengaged or at risk of exclusion from other schools.  On 
admission to the school, an emotional screening tool routinely utilised showed 
that Samantha had high levels of anxiety, depression, explosive anger and 
over-dependence on adults.  Despite this, her school attendance is good and 
she was described as very open, artistic and articulate.  She uses art to express 
her thoughts and feelings about her mental illness and I was encouraged to look 
at her portfolio.  Christina was studying health and beauty and so I was shown 
the salon where they undertook the different treatments.  Medication was stored 
at the school in case her mother forgot to give it to her. Her mother was 
diagnosed with bipolar affective disorder, and this led to her at times forgetting 
to give Christina her medication.   
When I spoke to Christina she was very keen to use her artwork for the project.  
She appeared a little sedated, and her hands and legs were bouncing up and 
down whilst we were speaking.  I wondered whether this was secondary to 
anxiety or side effects of medication.  I left the school anticipating the art work 
she might complete for the research given all of the very positive feedback 
about her outstanding artistic ability.  When the photographs of her artwork 
were subsequently returned, the images leapt out and were very dramatic 
showcasing her amazing talent 
Samantha 
My first impression of Samantha was somebody who was extremely shy.  I 
joined a planned meeting with her care coordinator who had briefly explained 
beforehand the purpose of my visit.  Quietly spoken, Samantha indicated that 
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she was happy to take part in the study on the understanding that she did not 
have to include photographs of herself as part of the study.  She also appeared 
a little startled when I disclosed that the interview would be taped. I had to 
explain that the interview would not be played back to her as she told me she 
did not like hearing her voice on recordings.   
When I interviewed Samantha she had recently got the results of her health and 
social care course and was beaming when she told me that she had got a 
distinction star, double distinction.  Following this achievement, she was 
debating whether her next step would be to undertake an apprenticeship or go 
to university.  She had managed to secure work in the administration 
department of a local school and this was swaying her towards an 
apprenticeship. 
Samantha’s story about the impact of her illness was particularly moving and I 
struggled with how difficult it must have been for her when symptoms were 
particularly troublesome.  The voices she heard meant that she found it difficult 
to leave home, always wanting to ensure that doors and windows were locked 
and family members were safe.  Samantha had also self-harmed in response to 
the voices and taken overdoses of prescribed medication.  Despite this she had 
achieved outstanding course results, showing fierce determination and courage, 
and was thinking about what her next career steps. 
Michelle 
When I met Michelle, with her psychologist at a local GP surgery, she was 
immaculately dressed and made up obviously taking a lot of pride in her 
appearance.  She was bubbly, enthusiastic and really keen to get involved in 
the research.  She was an undergraduate at Leeds University but came home 
regularly so she did not foresee any problems with arranging to be interviewed 
at home.  There was a delay between the initial and follow up meeting as she 
was in her final year and under pressure to complete her dissertation.  Once her 
dissertation was handed in, she became unwell and so again this delayed the 
interview.  When we met she was ecstatic as she had been for an interview the 
day before and been offered a job.  She was working as a youth worker when 
153 
 
we met, but had also successfully undertaken numerous placements as part of 
her university course.   
Michelle was very forthcoming during the interview and again I was struck by 
the adversity and tragedy she had overcome during her childhood.  The trauma 
she disclosed included the murder of a relative when she was still at high 
school.  The interview progressed very well and was helped by the fact that 
Michelle herself had interviewed people as part of her dissertation transcribing 
the interviews herself. 
Gabriella 
Gabriella was the participant I most struggled to engage.   The interview 
seemed particularly difficult and felt a little stilted as Gabriella’s answers were 
brief and not particularly expansive.  I was also nervous around her dogs as one 
kept jumping up at me, and I think this affected my abilities to garner more 
information from Gabriella. I sensed that she was picking up on my discomfort 
around her pets which could also have made her feel less at ease.  She struck 
me as somebody who was very shy with limited social support excepting her 
family.  She clearly loved the menagerie of animals that joined the interview at 
varying stages.  Gabriella was clearly very imaginative and had put a lot of 
thought into the composition of the photographs taken.  Unfortunately her 
camera broke before she had chance to send them so she instead described 
the photographs at interview.  Even when described verbally I could visualise 
how the photographs would have looked as Gabriella described her intentions 
so clearly. 
Stephen 
I first met Stephen at his school, along with his care coordinator.  One of the 
teachers was waiting in reception, keen to speak to the care coordinator about 
her concerns with regards to Stephen’s presentation.  I knew beforehand that 
Stephen struggled at school, for the past nine months he had been at home or 
at a ‘medical school’.  It subsequently transpired that this was the first week 
back at this school and the week had not gone particularly well.  When I 
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subsequently spoke to Stephen, he appeared fairly quiet but pulled faces when 
he learnt he would have to take photos and then have an interview that was 
recorded.  He also did not know what a disposable camera was so I had to 
explain this to him.  He agreed to participate, however his interest seemed 
superficial and I wondered whether he would complete the photographs and 
interview given his obvious unease about this.  A long time passed between the 
initial and final interview as he broke his leg and injured his back in a gardening 
accident.  Because of his injuries the discussion about medication went ahead 
without photographs as he was struggling to take photographs following the 
accident.  His mother joined the interview part way through with Stephen’s 
consent.  She did contribute to the interview, however I did not feel that this 
detracted from the information Stephen provided. Prior to her involvement, I 
was struggling to get Stephen to engage and the interview was feeling 
particularly stilted. This improved when his mother joined the interview.  I was 
conscious however that his mother disclosed some information that Stephen 
himself would not have provided.  This was particularly evident from Stephen’s 
facial expression as his mother spoke of the weight gain he experienced with 
medication.   
Jonathan 
I first met Jonathan in a coffee shop with his care coordinator; he had already 
started to take photographs on his mobile phone as he was on holiday from 
college.  At college he was doing a fine art and photography course and the 
photographs he showed me were excellent and thoughtful images which fired 
my imagination.  He highlighted from the start that he was ambiguous about his 
medication likening it to a ‘mist’.  It was clear from information disclosed that 
Jonathan had ongoing psychotic symptoms.  Jonathan mentioned that this was 
affecting his ability to engage in and progress his fine art as he was struggling 
to find inspiration; this was clearly troubling him.  The time between the initial 
and final interview was also prolonged for Jonathan.  When I first turned up to 
interview him he was suffering from pleurisy and was too unwell to proceed.  
His mother suggested I arrange subsequent meetings through her as Jonathan 
forgot a lot of things.  Jonathan was also unable to send me the photographs he 
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took on his mobile phone as he could not load them onto a computer to send 
via email. 
A Brief Overview of Those who Withdrew from the Study. 
Paul 
Paul was the first person I recruited to the study and he lived in the same 
children’s home as Ameeta.  A few weeks later he was admitted to hospital and 
then on discharge relocated to Scotland which prevented on-going participation. 
Jackie 
Jackie seemed very keen to be involved in the study and had asked to take 
photographs on her own camera as photography was one of her hobbies.  She 
subsequently withdrew from the study as she had to undergo surgery and felt 
unable to continue. 
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CHAPTER SEVEN. RESULTS 
7.1.  Introducing the Results 
Having described the methodology employed during this research, I will now 
outline the results of the narrative analysis.  When coding the interview 
transcripts using Frank’s (2010) outline framework, a metastory of moving from 
darkness to brightness emerged in both the stories told and the photographs 
and drawings used to illustrate the young people’s medication journeys.  Four 
stories were also evident, namely stories of endurance, motivation, control and 
resentment.  Underneath all of these stories were different sub-stories which 
together combined to emphasise the importance of the overarching story to the 
young people involved (see Figure 7.1). 
In presenting the results, I will first discuss the metastory before concentrating 
on the individual stories and their underlying sub-stories.  In presenting the 
results I have deliberately chosen to include illustrative quotes from the young 
people as well as some of the images presented given the time, effort and 
imagination employed to create and/or generate the pictures and the powerful 
responses some of these images and their association stories provoked.  
Permission was sought from the young people to include any of the images of 
themselves within this thesis. 
7.2. The Journey from Darkness to Brightness 
The metastory that emerged from all the stories narrated by the young people, 
albeit to different degrees, was a move from ‘dark times’ where symptoms 
predominated bringing fear, isolation and unpredictability to brighter times of 
happiness, friendships, productivity and hope as medication started to take 
effect and symptoms lessened.  Whilst there was acknowledgement by Ameeta 
and Michelle that other interventions also supported this improvement and a 
degree of doubt by Jonathan and Victoria that these changes were in fact due 
to medication, the other young people directly attributed these positive 
developments to the effects of medication. 
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Figure 7.1.  A Summary of the Overarching Metastory, Stories and their 
Associated Sub-Stories 
 
 
  
Before effective medication regimens were prescribed, many of the young 
people experienced auditory hallucinations of such a negative nature that they 
were worried that harm would come to themselves or their families.  Allison, 
Katey and Michelle were concerned that they would instigate harm with Allison 
explaining: 
“…it was getting to the point they [the voices] were telling me to 
hurt my family as well” (Allison). 
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Ameeta on the other hand was concerned about harm coming to her family 
even though she was not hearing voices instructing her to harm them. As 
Ameeta described: 
“I thought someone close to me would get hurt.  There was a lot of 
paranoia and stuff like that, so they were dark times” (Ameeta). 
The paranoia and associated fear for her family still resonated with Ameeta, 
leading her to take two pictures that she self-titled ‘Trauma and Dark Times’ 
(see Image 7.1).  In doing so, Ameeta directly referenced the darkness of her 
past in both the illustrative quote and self-titled photographs. 
 
Image 7.1.  Photographs by Ameeta “Trauma and Dark Times” 
Psychotic symptoms and the associated fear and darkness this produced 
contributed to the social isolation experienced by the young people.   
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Christina, an extremely talented artist, also spoke about how her drawing style 
was influenced by her emotions and symptoms. Using light pencil when she 
was feeling good and heavy, dark ink when she was not well, she produced a 
very visual representation of her journey between darkness and brightness (see 
Images 7.2 and 7.3).  It should be noted that the titles on all of Christina’s 
drawings were included by Christina herself.  
 
Image 7.2.  A Dark Ink Drawing by Christina “Feeling Confused and 
Unsure” 
 
Image 7.3.  A Light Pencil Drawing by Christina “Feeling on Top of the 
World” 
Christina’s use of dark ink to illustrate ‘feeling confused and unsure’ (see Image 
7.2), mirrors Michelle’s very strong imagery of darkness (likened to living in a 
cave) to describe aspects of her life before medication.  Michelle outlined this 
saying:  
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“…before being on medication and I was in a really dark place you 
don’t really see the world as a positive place or a nice place at all.  
You really kind of – it’s quite a dark place to be in and you don’t 
appreciate things and you don’t want to go out of the house, you 
don’t want to see people, you know.  You just want to kind of stay 
in your cave or in your bed and not interact or see anyone, you 
know, and it’s really difficult because you kind of isolate yourself. 
One thing that the medication has done has made me realise how 
to appreciate things and be able to get up in the morning and go 
out and do things and last summer it was my first year – it was 
four years since I was on medication and I remember taking this 
picture and just appreciating the view and being out in the sun, in 
the air, and in the sun and on the beach.  When I was little my 
mum used to always take me to – [place]- and it always used to 
do me the world of good because I’ve always been quite an 
anxious person.  I’ve always preferred the sun, I’ve always 
preferred things like that and my mum has always taken me to 
places like this to make me feel better.  And it was actually the first 
time I looked up and I was kind of like – ‘I’m starting to appreciate 
the world again” (Michelle). 
Michelle, in the same vein as Ameeta, spoke specifically of darkness when 
illustrating life before taking medication.  Michelle, however, moves on to speak 
of her current enjoyment of life using the illustration of being out in the fresh air 
and sun (see Image 7.4).  The sun also represents brightness and so again 
Michelle’s story contrasts dark and brightness to reflect life before and after 
medication.  
Gabriella was unable to send photographs as her camera broke after she had 
taken them.  She did, however, describe her plans to edit the photographs to 
illustrate her feelings, one photograph being an arm with a capsule resting on it.  
Gabriella explained why she had taken this particular photograph, saying:   
“…the arm is black and white in the background and then the pill 
is quite vibrant colours so it stood out.  That was kind of to 
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represent like colour in black and white symbolising hope (the 
medication) in darkness really” (Gabriella). 
Thus, Gabriella contrasts darkness and brightness through use of the colour 
black to represent darkness, and white to symbolise the hope that medication 
may lighten the darkness.   
 
Image 7.4.  A Photograph by Michelle about Appreciating Life Again. 
Both Ameeta and Jonathan used the metaphor of ‘light at the end of the tunnel’ 
to signify the importance of medication in symptom control and recovery, with 
Jonathan describing the photo taken on his mobile phone as follows: 
“I was sat in the back seat of the car and I just kind of saw this 
mist and the whole thing was just very, it was kind of a light at the 
end of the tunnel kind of thing because you see the light shining 
on to it, and that was kind of how I was hoping the medication was 
going to go.  I was eventually going to reach the end of this kind of 
period of darkness.  You can see the trees covering up most of 
the ground and then just that (the light) at the end” (Jonathan). 
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Jonathan, like Gabriella, is also talking about the hope that medication will end 
the darkness in his life.  He acknowledges that he has not reached that stage 
yet, and is indeed doubting that he ever will, saying: 
“I think I am just going to have to deal with this forever or at least 
for a while  more, but I will be able to cope with it a lot better” 
(Jonathan). 
Hope that medication would also improve symptoms was also a strong 
motivating factor for young people starting to take medication.  Katey spoke 
about her reasons for taking medication when it was first prescribed despite her 
fears about side effects, saying: 
“The hope that it would get better, yes, because I didn’t really 
speak to my family about what was going on and when they did 
find out they were like quite shocked and they wanted it all to stop.  
So I thought the medication is there to help me really if I take it 
then it will stop and then I could help and then they won’t be 
worried.  So I carried on taking it in the hope that it would get 
better” (Katey). 
Whilst Jonathan does not feel that medication has been strongly instrumental in 
helping his illness, stating early on in his interview that medication has neither 
helped nor hindered him, he goes on to acknowledge the possibility that 
medication may have been one of the strategies that has helped reduce the 
intensity of his auditory hallucinations when he talks about: 
“…this strange submerged world which was just voices in my 
head and spending time on my own and drugs and all the strange 
things.  I don’t know if I got out of that on my own or if aripiprazole 
helped.  But these days they [the voices] are at a more 
manageable level, just a very low background noise most of the 
time.  Although I still get episodes where I freak out and become 
very loud and I see things and get paranoid and suffer from 
delusions” (Jonathan). 
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Jonathan continues to take medication because he is not experiencing side 
effects that concern him. I think there is also an element of his continuing to 
take medication in the hope that the darkness ends and the light starts shining 
brightly. This is evidenced when Jonathan describes a picture of the light 
shining through his bedroom curtains, as he says: 
“It’s like it is a bit hopeful, it’s like a very hopeful thing to be on 
medication, you are just hoping at the end of the day, there’s 
nothing sure and that’s what this is about, it’s a very dark room 
where you get a bit of light.  It’s like the meds are trying to break 
through.  The light trying to get through curtains is like the meds 
trying to get through to my head I suppose, just hopeful, wishful 
thinking” (Jonathan). 
Jonathan also referred to his visual hallucinations as having a different quality to 
real images.  He explained that his hallucinations were very dark and not fully 
formed, contrasting with real and actual images that he could see more clearly 
than the hallucinations.  In doing this he highlighted another aspect to the 
imagery of darkness.   
All of the young people spoke of the positive difference medication made to 
their symptom control and how this positively impacted on their vocational, 
educational, social or emotional quality of life.  This may not have been 
immediately obvious to Jonathan, Victoria and Christina, who at times 
expressed ambivalence about medication, however they all highlighted positive 
aspects to medication at varying points in their stories.  Victoria and Christina 
highlighted the role medication had in facilitating discharge from hospital, and 
Jonathan wondered whether medication had played a role in reducing the 
intensity of his voices whilst recognising that medication had played a part in 
bringing a focus to his life. Jonathan, whilst expressing ambivalence about 
medication on several occasions at both the initial meeting and interview, was 
obviously still hoping that medication would reduce the intensity of his voices 
further.  Whilst Gabriella’s symptoms had lessened on medication she did not 
talk about how this had subsequently impacted on her quality of life, other than 
to express her happiness that the voices were less intense and intrusive.  This 
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is perhaps more indicative of the difficulties I had engaging Gabriella in 
discussion and getting her to expand on information beyond what her 
photographs were illustrating.  Ameeta, Victoria, Allison, Christina, Samantha 
and Michelle all acknowledged that medication had supported them to get out of 
the house more. For Ameeta (see image 7.5) and Victoria this had enabled 
them to participate in their respective hobbies of baking and gardening.   
 
Image 7.5.  A Photograph by Ameeta about Enjoying Baking 
Being able to leave the house more often also facilitated increased social 
activities and contact with friends for Ameeta, Allison, Christina, Samantha and 
Michelle.  This social contact brought brightness and happiness to their lives, 
contrasting with the dark times of social isolation.   
As well as positive impacts socially, medication had also resulted in positive 
educational and vocational journeys.  For Katey, Victoria, Christina, Samantha 
the medication had helped them through the stress of exams.  Whilst Victoria 
and Christina felt that they would have managed as well without the medication, 
the other young people clearly felt that the medication had been instrumental in 
their exam success and subsequent ability to progress to college, university or a 
career.  These young people were certainly experiencing brighter times and the 
prospect of brighter futures with the positive impacts of the medication.  
Samantha clearly stated that she would not have finished her health and social 
care course without the antipsychotic medication.  She could not concentrate at 
college because of the voices and so had to study in a separate room with 
support staff to keep her focused on the work at hand.  She also missed some 
college having to attend the accident and emergency department because she 
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frequently cut her arms in response to the voices.  Samantha ended up getting 
distinction star and double distinction on the course, an achievement she felt 
would have been unattainable before being prescribed medication.   These 
outstanding results have enabled her to consider whether to go to university or 
do an apprenticeship, and she is currently working in the administration 
department at a local primary school to have a taster of an apprenticeship.  For 
Ameeta, the medication had been beneficial in supporting her to undertake 
vocational qualifications and start a placement with the Prince’s Trust.  She was 
very positive about the direction her life had taken and was very much looking 
to a brighter future, explaining:  
“I managed to see a bright future for me moving forward and 
pictured myself, pictured a life worth living”  (Ameeta). 
This quote by Ameeta captures the journey she sees herself on, moving 
forwards towards the brightness of a life worth living.   
Medication had also had a positive emotional impact, with Ameeta, Allison, 
Katey, Michelle and Samantha speaking of how much happier they were on 
medication. This was particularly evident when Katey said: 
“I’m happy that I’m on it [medication], I’m happy that it makes me 
happy and I can carry on and do whatever and – I don’t know, I’m 
just happy” (Katey). 
Samantha also spoke of being happy now that she was in control of the voices 
rather than the voices being in control of her, taking a photograph of nature and 
a blue sky to illustrate her happiness and contentment (see Image 7.6) 
Whilst the participants were predominantly in a bright and happy phase of their 
lives when I met them, they were however realistic in recognising that there 
would always be good and bad days.  Whilst these bad days may resemble a 
brief journey back to the dark times, there appeared to be an acknowledgment 
that the bad days would be more manageable and not of the magnitude or 
duration of the darkest times when the illness was at its most severe.  This view 
was crystallised in the heartfelt words of Ameeta when she pronounced that ‘the 
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stress-free fairytale just doesn’t exist’. Christina felt that medication was not 
helping her voices to the extent that she wanted, and she continued to have 
intermittent dark days when she struggled to ignore the numerous voices inside 
her head.  Whilst Victoria recognised that medication had helped in her 
discharge from hospital, she still wanted to stop her medication and resented 
the fact that she was being told to remain on it whilst she finished her GCSE 
exams.  She was struggling to embark on the journey towards her idea of a 
brighter time when she would no longer need to take medication. She was also 
helpless in her ability to control the pace of that journey as decisions were being 
taken for her.  Thus, there was still an edge of darkness to Victoria’s story that 
prevailed more obviously than in the stories told by the other young people.   
 
Image 7.6.  A Photograph by Samantha to Illustrate Happiness 
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Although reducing components of stories down into factors in a table could be 
seen as reductionist, summaries of the dark and bright aspects to the stories 
told by participants are provided in Tables 7.1 and 7.2 and will be outlined in 
more detail throughout the chapter.   
Table 7.1.  Elements of Darkness in Individual Stories 
Element of 
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Being a carer           
Being like family 
members 
          
Being on 
medication 
          
Childhood trauma           
Dependence on 
medication 
          
Dependence on 
others 
          
Eating disorder           
Feeling alone           
Feeling different           
Harm coming to 
others 
          
Helplessness           
Hospital 
admission 
          
Medication 
ineffective 
          
Recklessness           
Secretiveness           
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Self-harm           
Side effects           
Stigma           
Struggling with 
identity 
          
Symptoms            
 
In considering the socio-narratological components of the young people’s 
stories, the elements of darkness (see Table 7.1) equate with the forces of fear 
within individual stories, whilst the elements of light (see Table 7.2) could be 
viewed as the forces of desire.  This metastory of darkness and brightness also 
fired my imagination as I thought and reflected upon how it must be living with 
psychotic symptoms, fearful of how you might respond to the symptoms or 
being terrified of leaving the house.  To me the young people’s descriptions 
made it feel like it was an awful experience.   
The four stories that underpin the young people’s journey from darkness to 
brightness can also be categorised according to dark and light, with stories of 
endurance and resentment representing darker stories than the brighter stories 
of motivations and taking control.  These stories will now be discussed in more 
depth. 
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Table 7.2.  Elements of Brightness in Individual Stories 
Element of 
Brightness  
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Being a ‘normal’ 
teenager 
          
Being happy           
Career ambitions           
Discharge from 
hospital 
          
Engaging in 
education 
          
Engaging in 
hobbies 
          
Healthier lifestyle           
Improved 
relationships 
          
Independence           
Looking to a 
brighter future 
          
Openness           
Socialising            
Support networks           
Taking control           
Volunteering           
7.3.  Stories of Endurance 
The stories told by the young people evidenced different aspects of endurance 
related to past experiences, illness and medication.  Endurance evident in past 
experiences predominantly involved having to deal with trauma and illness.  
170 
 
There was also endurance in managing symptoms and the bad days that 
inevitably formed a feature of the young people’s lives.  Once medication was 
initiated there was then the endurance of waiting for medication to help 
symptoms, managing side effects, taking medication for life and taking 
medication despite ambivalence about the same.  These stories of endurance 
outline some of the features of the capacity for stories to make trouble or deal 
with trouble for those involved.  They highlight some of the stakes such as fears 
of not being able to participate in teenage activities, loss of independence, 
readmission and worries about relapse that these young people had to deal 
with. In some cases the stories also describe how these stakes were overcome. 
7.3.1.  Stories about Dealing with Past Trauma 
Several young people spoke about past traumas experienced in their formative 
years.  Ameeta did not go into specific detail about her traumatic experiences, 
and given her fragility when interviewed I consciously chose not to explore this 
in more detail. My impression from what she did say at interview was that the 
trauma was related to her home life and the associated caring responsibilities 
for her family, as well as her own symptoms of psychosis, low mood and 
suicidal ideation prior to her receiving input from mental health services.  
Ameeta spoke of the impact this trauma had on her when she said:. 
“I experienced a lot of trauma.  My day to day life was very hectic 
and busy.  I would put a smile on my face but deep down I was 
very low in mood.  I had a lot of emotions inside me that I couldn’t 
explain.  I had reached the point where I no longer saw a purpose 
for me in life which was when I first began to experience 
psychosis without realising or fully understanding what was truly 
going on”  (Ameeta) 
Michelle also talked about trauma, particularly in relation to a family member 
who was murdered when she was fourteen years old.  She spoke about how 
medication, along with cognitive behavioural therapy, had helped her to 
overcome the ongoing difficulties this was creating and to respond differently to 
bereavement, she explained:   
171 
 
“In my life I’ve suffered with a lot of trauma and trauma which at 
twenty years old, the trauma that I’ve gone through is not what 
normal people at twenty-one would go through.  It’s things that 
you see on the TV and you’d go – that would never happen to my 
family, and you’d kind of not think about it but it does happen.  
And one thing that I struggled with before my medication is 
overcoming those traumas and I took bereavement really bad, I 
found it very hard.  I find attachment very hard, you know letting 
someone go.  I used to have thoughts of, because I’d so many 
traumas, I was pushing my mum away because I was so scared 
that she might die that I did not want to be close to her.  And one 
thing that I feel being on medication has done is I was on 
medication when my grandad died last year and I felt like I was a 
lot calmer when it came to the death” (Michelle). 
Michelle chose a photograph of herself as a baby with her grandfather as the 
image to support this part of her interview (see Image 7.7). 
 
 
 
 
 
 
 
 
 
Image 7.7.  A Photograph of Michelle with her Grandfather 
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Some of the young people’s vivid accounts of their psychotic symptoms could 
also be considered traumatic.  I present these as a separate substory of 
endurance because of the ongoing efforts required in resisting and managing 
symptoms. 
7.3.2.  Stories about Resisting Symptoms 
Having already detailed some of the difficulties young people faced resisting 
voices that told them to harm family members, there are also other stories 
related to enduring ongoing symptoms which merit consideration.   
Christina still hears three voices and when they are all speaking at once she 
finds this hard to manage, becoming in her own words “spaced out”, feeling as 
though everything is rushing past her, that she is not part of the world, that 
everything is “blurry” and there is too much going on in her head (see Image 
7.8). 
 
Image 7.8.  A Drawing by Christina “Too Much Going on in my Head” 
Katey had periods of low and high mood which she found particularly difficult to 
deal with, and Victoria also found the mania a particularly troublesome feeling 
that she worried would never be controlled and she would therefore never be 
able to leave hospital.  Katey described the impact her variable mood had on 
her willingness to take medication when she said: 
“it was just becoming really overwhelming and I was just 
struggling with everything and it was getting worse every day so 
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whenever they said – “Oh we can give you medication to try and 
make this stop”, I was willing to do it”.  (Katey) 
At the time I interviewed Allison, she was not prescribed any medication as it 
had been previously withdrawn by her doctor following an overdose.  More 
recently, symptoms had returned and an appointment had been arranged to 
discuss medication being restarted.  Whilst the voices had not got to the stage 
of instructing her to harm her family, they were instructing her to harm herself; 
she was managing, with effort, to resist.   
Other young people were also managing with ongoing symptoms, their goal 
being to have manageable symptoms rather than being symptom free.  For 
Samantha she was content that the voices were quieter and she could ignore 
them as they no longer called out her name.  Michelle, Ameeta and Allison also 
spoke of being able to cope with the voices better since being prescribed 
medication. Michelle told of a particular trip to the beach with her mum on a 
sunny day when she was able to resist symptoms, saying : 
“I would not eat, I would not do anything you know, and people 
would not want to be in my company because it was very 
negative.  I was not a very positive person to be around.  I 
remember this day and thinking: ‘I’m up and I’m not listening to 
those voices and I’m having a good day’.  (Michelle) 
When I spoke to Jonathan, his views of his ongoing symptoms were slightly 
different in that he viewed them very much as part of himself and contributed to 
who he was as a person.  He therefore did not direct his efforts towards 
resisting symptoms.  He was pleased that the voices and visions were more 
manageable, but was unsure how much medication was responsible for this.  
When describing a photograph he had taken of a sky to depict his ongoing 
symptoms, Jonathan captured how he viewed his symptoms and the illness as 
the cloudy part of himself, explaining: 
“This is on a good day, this is just the sun and the clouds and the 
clouds are like my illness.  They are still there but they kind of 
174 
 
make me whole as like a person as well as it being a nice day.  
You’ve got to have some clouds haven’t you?”(Jonathan). 
Jonathan was not alone in still experiencing bad days and this was another 
element of endurance the young people had to manage. 
7.3.3.  Stories about Accepting the Bad Days 
Even accounting for the fact that some young people have to live with ongoing 
symptoms, most of the people were realistic and recognised that there would be 
good as well as bad days, irrespective of whether this was linked to their illness.  
There was therefore an element in most stories of enduring the bad days and 
employing coping mechanisms to get through them.   
Ameeta, Christina and Michelle all focused on thinking about the good days to 
get them through the bad.  For Ameeta, she looked at her memories book when 
she needed to focus on positive aspects of her life proclaiming a need to “live in 
the present and create new ones [memories] for the future because it’s the 
good times that get you through the worst”.  Michelle had kept all of the thank 
you cards received from her university placements to remind herself of how far 
she had come and how much she could achieve (see Image 7.9), whilst 
Christina tried to remember all of the positive aspects to her life including her 
family and friends who were always there to help her through difficult times.   
 
Image 7.9.  A Photograph of Michelle’s Thank You Cards 
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Allison had a wall in her bedroom covered in inspirational quotes that she could 
read when she was having a bad day.  She also had one of her favourite quotes 
tattooed on her arm so she could glance down and remind herself that there 
would always be bad days and life was about learning to embrace these.  
Allison’s tattoo proclaimed: 
“It’s not about waiting for a storm to pass it’s about learning to 
dance in the rain”.  (Allison). 
I had not heard this quote before, but for me this captured the essence of how 
many of the young people interviewed were approaching and accepting their 
illness with bravery, courage and determination to move forwards.  It also 
captured how the young people continued with their lives whilst waiting for 
medication to control symptoms.  For this reason, I incorporated part of this 
quote into the title of this thesis as it seemed to eloquently represent the 
essence of a successful journey towards a brighter and happier future. 
7.3.4.  Stories about Waiting for Medication to Work 
Another endurance story central to the stories told was about how the young 
people had to wait until medication started to work. Ameeta, Allison, Samantha 
and Stephen felt that medication took longer to work than they expected.  Staff 
had explained the delayed response to Ameeta and Samantha so they were 
aware that the effects would not be immediate, however Stephen clearly lacked 
awareness about this as his mother explained: 
“Right at the beginning because I think they weren’t instant, I think 
he expected to take a tablet and to like instantly feel happy.  And 
because he was not getting that and because his mood was so 
low as well we went through a bit of a bad time where – that’s it, 
there’s no point  taking it because it’s not doing any good for me, 
so what’s the point of taking it and he did not take it.  Everybody 
else could tell a difference except for Stephen.  So you had a very 
firm talking to did not you, by [the care coordinator] and a few 
others at school and you know, various other people, who said – 
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“Look, you know, you can’t tell a difference but  everybody else 
can and it does take some time”.  So you’re pretty good now aren’t 
you. It’s not very often that he forgets because I have to take it out 
for him you know and leave it on the side.  But right at the 
beginning he was a bit of a devil for not taking it” (Stephen’s 
mother). 
 Allison also spoke of the time it took for medication to get into her system and 
start to improve symptom control, saying: 
“…it takes time to get into your system because obviously you 
can’t just take it one night and then, you know, and obviously you 
feel better and everything.  I think it took about three or four 
months to get into my system”.  (Allison) 
Four of Samantha’s photographs were imaginatively taken to display the time it 
takes for medication to take effect, showcasing a series of photographs of a 
daffodil blooming from bud to fully opened flower with time (see Image 7.10). 
       
Image 7.10.  Photographic Series by Samantha about Waiting for 
Medication to Work 
For some young people, the medication they were initially prescribed did not 
effect the desired improvement of symptoms.  This led to alternative 
antipsychotic medications being tried.  This requirement to switch antipsychotic 
medication introduced a longer delay as the young people concerned endured 
ongoing symptoms whilst waiting to be prescribed medication that would control 
their symptoms.  Ameeta was prescribed Olanzapine and Risperidone before 
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finally improving with aripiprazole.  Katey spoke of being prescribed lots of 
different medications that did not help and Christina also did not respond 
positively to Olanzapine, saying:   
“I used to have a bad day pretty much every day with Olanzapine.  
I did not really have many good days”.  (Christina) 
Gabriella also had to endure a lot of different antipsychotics before finally going 
back to the first antipsychotic prescribed, risperidone. This seemed to result in 
fewer side effects the second time around.  She outlined her journey through 
these different medication trials, explaining: 
“I was put on risperidone which gave me a few side-effects so 
they put me onto aripiprazole then the aripiprazole was not really 
doing anything and things had really got worse so they put me on 
amisulpide and then when that was not doing anything either they 
put me back on risperidone, because that was the one that 
seemed to do a lot more than the others”.  (Gabriella) 
For others, medication was changed because of side effects, and side effects 
represented another story of endurance that I will now consider. 
7.3.5.  Stories about Dealing with Side Effects 
Once medication was prescribed and starting to take effect, many of the young 
people then had to endure a range of side effects due to their antipsychotic 
medication.   
For every young person except Ameeta and Jonathan, weight gain was 
something that they had found particularly troublesome.  Victoria spoke about 
how she was always hungry when she was first prescribed medication and 
would “eat and eat and eat” resulting in weight gain and Michelle also indicated 
how unhappy she was with the amount of weight she gained when she first 
started on medication.  Michelle included a photograph of numerous chocolate 
bars to illustrate this aspect of her medication journey (see image 7.11).  Katey 
also felt more hungry and gained weight when she was first prescribed 
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risperidone.  This was directly responsible for her stopping taking medication for 
about a month.  Katey had previously been admitted with an eating disorder and 
so she was particularly conscious about her weight and body image.  Her eating 
disorder had been of such a concerning magnitude that she described at 
interview being at “death’s door” because of this, and so she like all of the other 
young people experiencing weight gain worked hard to counteract this side 
effect.  Despite stopping medication because of the weight gain Katey resumed 
taking the risperidone as she was terrified that the symptoms would return.   
 
Image 7.11.  A Photograph by Michelle about Weight Gain 
Ongoing symptoms were an issue when I saw Katey at interview and a dose 
increase of risperidone was being considered.  When discussing her feelings 
about the plan to increase the dose, her attitude was that she was going to try 
the higher dose and assess the impact on her weight, explaining: 
“I am going to try it (medication) and then if I do put on weight I’m 
going to stop because it’s – I’d rather not put on weight and 
struggle a little bit than put it on and maybe not see a benefit at 
all”.  (Katey) 
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Allison spoke of how she gained weight very quickly on olanzapine and this was 
the reason medication was subsequently changed to quetiapine.  Allison also 
had a history of eating disorder and spoke about how she felt like a completely 
different person because she had gained so much weight on medication.  
Olanzapine was deliberately commenced because she was underweight but 
Allison spoke of how resisting feelings of hunger at this stage in her life made 
her proud.  She did however start to eat when she felt hungry as staff in the 
hospital told her ‘she would be admitted to an eating disorders unit if she failed 
to gain weight’.  Allison therefore had to endure the weight gain so she could 
avoid transfer to an eating disorders unit.  Allison included two photographs of 
herself before and after she had gained weight to illustrate the difference, and a 
before and after photograph was also included by Michelle who was also very 
conscious of her image and how she looked to other people (see Image 7.12).   
 
 
 
 
 
 
 
 
 
Image 7.12.  A Photograph by Michelle to Illustrate Weight Gain 
Gabriella and Christina also had to endure weight gain on antipsychotic 
medication with Christina bemoaning: 
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“it’s a lot of weight, I was a size six and now I’ve gone up to a size 
fourteen”  (Christina) 
When interviewing the participants, the last two interviews were with the only 
two young men who completed the study.  Prior to these interviews, I did 
wonder whether weight gain would be a concern for these men as it had been 
such a striking feature in the stories of all the young women except Ameeta.  
Stephen initially spoke of how he had no side effects with his risperidone. 
However, after his mother joined the interview she spoke of how he had gained 
weight on medication and did not like this.  Stephen looked at his mother in 
embarrassment when this was mentioned with his expression questioning why 
she had brought this up.  I was therefore left with the impression that this was a 
sensitive subject for Stephen.  The only side effect Jonathan mentioned was a 
hand tremor with aripiprazole.  It is however notable that the side effect profile 
for aripiprazole is very appealing to those concerned about weight gain as it is 
less likely than other antipsychotics to cause this. 
Sedation was the second most prevalent side effect discussed at interview.  
Victoria was particularly concerned about the impact that this had on her daily 
activities describing how sometimes she went out for a long walk but was too 
tired to finish it, having to return home sooner that she wanted (see Image 
7.13). 
Michelle was also worried about how she would get up for her new job each 
morning when she confided: 
“This has been the biggest problem with having my medication, 
sleeping.  Before medication I had insomnia really bad, would not 
sleep, would not go to bed, it was awful.  My medication makes 
me sleep straight away [she gives a little laugh] knocks me out 
completely but I can’t get up in the morning anymore without 
having six alarms across my room”.  (Michelle) 
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Image 7.13.  A Photograph by Victoria Representing Sedation 
Christina spoke of wanting to stay in bed all day at times, and whilst this did not 
particularly concern her it meant that her mother had to constantly shout at her 
to get up for school.  Some of this was related to medication, however, she also 
recognised that if she was having a bad day this also impacted as she would 
think that there was no point getting up as nothing would make her feel better 
(see Image 7.14). 
 
Image 7.14.  A Drawing by Christina “Feel Like Staying in Bed” 
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Allison also noted the effects sedation had, enduring this at the start of 
treatment but eventually recognising that the sedation was lessening as her 
body adapted to the new medication.  Allison explained: 
“…when I first started taking it I felt tired constantly, all the time, 
proper like lethargic like where you can’t be bothered doing 
anything because you are that tired.  But as time went on it 
lessened quite a lot, it was not as bad.  It still made me a little bit 
tired but not as much as it did at first”.  (Allison) 
Other side effects were also mentioned at interview albeit less frequently.  
Katey, Christina and Jonathan all mentioned having tremors with their 
medication.  Samantha experienced galactorrhoea and did not at first realise 
that fluid expression from the nipples could be secondary to medication.  She 
managed this initially by always wearing jackets to hide the problem, however 
on reading the patient information leaflet and recognising this was because of 
the amisulpride she spoke to her psychiatrist and the medication was changed.  
Gabriella had a photosensitivity reaction to risperidone and developed a rash on 
her hands.  When Christina took her aripiprazole at night it caused insomnia but 
this was easily managed by taking the dose earlier in the day.  Allison 
experienced cold sweats, headaches and also felt that a return of her seizures 
could have been related to medication.  The young people in the study therefore 
experienced and endured a wide range of side effects related to their 
antipsychotic medication but employed different strategies to manage these, 
displaying high levels of agency. 
As well as young people having to endure the side effects of medication there 
was also another medication aspect to endurance because of the length of time 
antipsychotic medication has to be taken for which will now be explored. 
7.3.6.  Stories about Taking Medication for Life 
During the interviews with young people discussions arose at times about the 
length of time they might have to take their antipsychotic medication.  Most did 
not want to contemplate the possibility that they might have to take this long 
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term or for life.  Michelle was one of the oldest participants at 20, and when 
asked what key messages she would have for teenagers about to start taking 
antipsychotic medication for the first time her response was: 
“I just think that if I could give advice to anyone, which I’d love to, 
it’s like not being scared about going onto things like 
antipsychotics because they are not forever and they will help”.  
(Michelle) 
Both Allison and Samantha did not like to think that they would be on 
antipsychotic medication for life, but indicated that if this was the case then they 
would accept this because the alternative of living with psychotic symptoms was 
too hard to imagine.  This was explained by Allison who said: 
“I don’t want to be someone who takes medication for the rest of 
their life, then I think to myself, if it’s going to help then it’s worth 
it”.  (Allison) 
Gabriella also highlighted this as an issue when describing another photo she 
had taken prior to her camera breaking, detailing: 
“…one of them [the photographs] was a dinner plate with a pile of 
pills on it and a knife and fork and it was quite a simple picture.  
Well they are all quite simple pictures really, and it was to 
symbolise like having to take the pills every day and how it’s 
something that we have to do and people don’t really realise that.  
It’s like a regular thing.  It affects how we live really because like 
you’ve got to eat to survive so like eating the pills is what I was 
going for”.  (Gabriella) 
As well as the possibility of having to take medication for life, Allison, Katey and 
Michelle also spoke of their fears of becoming physically and/or psychologically 
dependent on medication with Allison saying: 
“I think to myself I don’t want to end up getting addicted to it if you 
know what I mean.  Some people get addicted to prescribed drugs 
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don’t they to the point where they need to keep taking them?”  
(Allison) 
There is therefore an element of endurance about continuing to take medication 
despite fears of dependence, however, this again is driven by a wish to have 
manageable symptoms.  Some young people also continued to take medication 
despite their ambivalence as will now be discussed. 
7.3.7.  Stories about Taking Medication Despite Ambivalence 
Another aspect of endurance in the stories was highlighted by Victoria, Christina 
and Jonathan who continued to take medication despite a view that it was not 
particularly benefitting their symptom control and illness.  All three young people 
were unclear whether medication was helping with their illness.  For Christina 
and Jonathan this opinion was driven by the fact that they had ongoing and 
seemingly frequent symptoms.  Jonathan in particular spoke about being 
“ambiguous” about medication representing his view that whilst he was not 
finding medication particularly troublesome to take, he still had ongoing 
symptoms.  Jonathan was not sure whether medication had been in anyway 
helpful in reducing the intensity of the symptoms, or whether this was because 
he was spending less time on his own and had stopped using illicit drugs.  He 
was particularly vocal about this saying: 
“All of them [the photos] have this ambiguous kind of nature I 
would say because that’s how I feel about my medicine, I just feel 
ambiguous.  This is just like your average day in quite a serene 
place.  I suppose that’s how I feel about the meds, not here or 
there, just, you know” (Jonathan).  
Christina also continued to endure taking medication despite ongoing symptoms 
and views that it was not helping, she explained: 
“I can see their lips moving but I’m hearing the voices in my head 
but the voices just overwhelm me so I can’t really hear what they 
are saying……I just – [pause] I feel as if it’s – [pauses again – 
longer this time] I don’t know – like just why me, why do I have to 
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take it, why?  Because in my eyes I don’t feel like it’s making that 
much of a difference so I think like - why should I still be taking 
this when it’s not making that much of a difference?” (Christina). 
Christina also presented how disaffected she feels about taking medication in 
one of her drawings (see Image 7.15).   
 
Image 7.15.  A Drawing by Christina “Fed Up of Taking Medication” 
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Victoria’s ambivalence and resentment towards her medication appeared not to 
be driven by ongoing symptoms.  Whilst she seemed to acknowledge that she 
was manic when admitted to hospital and takes medication to prevent mood 
swings, she did not feel that she was ill anymore and was therefore struggling to 
understand why she should continue to take the medication.  At times, Victoria 
also attributed her admission to a breakdown and mood swings to normal 
teenage behaviour, proclaiming: 
“I don’t think that there’s anything wrong with me.  I might have 
mood swings and I might be autistic but there’s nothing wrong with 
that.  I mean before I had my breakdown I was perfectly fine” 
(Victoria).   
Victoria was very clear during the interview that she did not think medication 
was natural and did not agree with taking it.  Whilst in hospital she felt that 
medication was a poison but put this down at interview to her paranoid 
symptoms. However, she still does not want to take medication explaining: 
“I don’t agree with taking medication, I don’t think it’s natural really 
and I shouldn’t have to so as soon as possible I want to be off it” 
(Victoria). 
Her endurance is particularly evident throughout all of the stories as she is 
continuing to take medication despite these strongly held opinions.  This may be 
because her father gives her the medication as he was annoyed when she 
forgot a dose soon after her discharge from hospital.  Victoria is very close to 
her father and depends on his support and help, so perhaps her motivation to 
continue taking medication is related to a wish to avoid worrying her father.  
These substories of endurance represent some of the darker stories told.  
However, the young people also told brighter medication stories, including 
stories of motivation which will now be considered.    
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7.4.  Stories of Motivation 
Throughout individual stories there were also a number of different motivating 
factors to continue taking prescribed medication.  Whilst these may not have 
been apparent to the young person at initiation of treatment, the positive 
outcomes resulting from improved symptom control in each individual case 
became motivating factors for ongoing adherence with antipsychotic 
medication.  These positive outcomes secondary to improved symptom control 
with medication incorporated stories of being well, stories of staying well, stories 
about being a ‘normal’ teenager, and stories about having a bright future. These 
components again reflect the forces of desire that emerged from individual 
stories.  Whilst the young people may not always have been able to foresee the 
positive impact that medication would make in their lives when starting to take it, 
recognising how medication had enhanced their quality of life was a strong 
motivating factor in their continuing to take the medication.  
7.4.1.  Stories of Being Well 
Fundamental to young people’s views about medication was the extent to which 
they recognised that medication had played a part in improving symptoms and 
assisting their journey to recovery.  Christina and Jonathan were more 
ambivalent about medication because they were still symptomatic, however, 
most young people had noticed a marked improvement in symptoms with 
medication and this was their primary motivation for continuing to take it.  Whilst 
Joanthan still had hope that medication would support recovery, Ameeta and 
Gabriella recognised that medication had been instrumental in their recovery.  
One of Ameeta’s photographs depicted how her recovery was achieved by 
taking small steps and a mindset that there was no going back (see Image 
7.16.). 
Ameeta and Katey were apprehensive about going on medication at first.  For 
Ameeta her apprehension revolved around the fact that she had previously 
cared for relatives who were on medication for mental illness, and was worried 
medication would make her feel empty; devoid of emotion or feeling.  Because 
of her paranoid ideation, Ameeta was also concerned that harm would come to 
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family members if she took medication. It was seeing other people in hospital 
progressing that made Ameeta want to improve her own situation by taking 
medication.  As Ameeta herself explained: 
“…when I went into hospital I saw other people and they were 
progressing really well, and I wanted to become like that” 
(Ameeta). 
 
Image 7.16.  A Picture by Ameeta “Recovery” 
For Katey, her reluctance was understandable because she had never taken 
medication before and it was something new.   Ultimately it was a wish to be 
well that motivated her to take the medication. 
Allison, Ameeta, Christina, Jonathan, Michelle and Samantha all continued to 
experience symptoms although they spoke of medication making the symptoms 
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less frequent, quieter or more manageable.  This in itself was a sufficient 
motivator to continue the medication, as Michelle says: 
“…and, you know, medication has made these voices a lot more 
quieter and it’s made me want to get up in the morning, get 
changed, have a shower, you know, where I would not have a 
shower, I would not, I’d stay in bed” (Michelle). 
For those young people who recognised the positive impact of medication on 
their symptom control, a further motivation to take medication was to remain 
well.   
7.4.2.  Stories of Staying Well 
In Ameeta’s, Katey’s and Samantha’s stories it was evident that they dreaded 
the possibility that the dark times (when they were previously unwell) may 
return.   
Whilst Victoria spoke at length of how she no longer felt the need to take 
medication she did, at times, say things which supported the role of medication 
in relapse prevention, saying ‘if they take it off me now then I might go manic 
again’. 
Allison spoke of how she and other friends had in the past stopped medication 
as they felt better and did not need it, highlighting a lack of awareness of the 
role of medication in preventing relapse.  They eventually resumed medication 
when their illness worsened as the positive aspects of medication at this stage 
then outweighed the negative aspects, highlighting the dynamic nature of 
medication adherence.  Allison described: 
“…when I first got put in hospital when I was seventeen and I was 
taking meds then but that was only antidepressants, but when I 
got out of hospital I thought – ‘Oh no I’m fine now, I don’t have to 
take them’.  Then obviously because you think that you are better 
you don’t need them when obviously it’s the medication that’s 
making you feel better.  I think quite a lot of friends that I’ve got 
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like when I was younger, quite a lot of them said that to me, they’d 
stopped taking them when they felt better but then about three or 
four, no about two or three weeks later, they’d start to feel worse 
again.  But that’s why I stopped taking mine” (Allison). 
For Ameeta, Allison, Christina, Katey and Victoria another important aspect of 
remaining well was avoiding the need to go back into hospital.  Allison had 
absconded during her admission because of a wish to get out of hospital 
resulting in her being placed in a Psychiatric Intensive Care Unit.  Ameeta and 
Victoria also spoke of how uncomfortable they felt being observed by staff on 
the ward, with Ameeta likening this to the television show – ‘The Cube’- where 
the television audience are peering into a glass box where the contestant is 
sitting (see Image 7.17).  This image also represents the loneliness Ameeta felt 
whilst an inpatient, mirroring the emotions expressed by Christina when she 
was also admitted to hospital.  Katey summed up the motivation of staying well 
and avoiding readmission when she explained that going back into hospital is 
her “worst fear”.   
 
Image 7.17.  A Photograph by Ameeta to Represent “Feeling Alone” 
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Being admitted to hospital because of poor mental health sets teenagers apart 
from their peers, and another motivation evident in the stories was a stated wish 
to be a ‘normal’ teenager. 
7.4.3.  Stories of Being a ‘Normal’ Teenager 
Accepting that people’s views of what a ‘normal’ teenager is vary, the word 
‘normal’ was still commonly used during the interviews with the young people.  
This was in a variety of contexts from doing normal teenage activities, wanting 
to be free of symptoms to wanting to be like their peers who were not mental ill 
engaging in usual teenage activities.  This appeared to be driven by a wish to 
feel and be viewed like other teenagers without mental health difficulties.  Whilst 
not all of the young people interviewed felt that they had experienced stigma 
because of their mental illness, for Michelle and Katey this had been a ‘source 
of trouble’ within their individual stories.  This was reflected in a drawing Katey 
included which was her way of making a statement about not being crazy (see 
Image 7.18). 
 
Image 7.18.  A Drawing by Katey “I Am Not Crazy”. 
 Michelle also spoke of the stigma still associated with mental illness saying: 
“I think stigma is a big thing which is still around with mental 
health, you know, if you tell someone, if you say the word 
‘psychosis’ to someone they will always think, maybe - oh you 
might go and kill someone or you might be a bit crazy - you know, 
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and they don’t understand the underlying issues and the ins and 
out of it, you know” (Michelle). 
Taking medication had supported this wish to be ‘normal’ in a number of ways, 
by allowing the young people to go out and spend more time with friends, to 
strengthen and develop friendships and be accepted by their friends, to remain 
at school or college and to become more independent.  Medication had enabled 
Ameeta, Michelle and Samantha to leave the house more and this had meant 
that they were able to spend more time with family and friends.  Katey and 
Allison had become closer to family members having previously deliberately 
distanced themselves from family because of the content of their auditory 
hallucinations.  Allison’s fiancé had told her of the positive difference medication 
had made to Allison’s personality and consequently their relationship.  
Stephen’s relationships with his friends had also strengthened as he was kinder 
to them. 
Improvement in symptoms had also enabled Katey, Michelle and Samantha to 
remain at university and college.  When the voices were at their worst, 
Samantha had to study in a separate room with support staff to keep her 
focused on the work at hand.  As the symptoms improved with medication, 
concentration abilities increased and this resulted in Samantha re-integrating 
into lessons with other classmates.  Similarly, Katey had also not attended 
school but an education centre.  Katey described the impact this had when 
saying: 
“Before I went to college I did not go to school.  I went to an 
education centre for a couple of hours a day and I did not do a lot 
there, I did not get on with the people there really.  So by going to 
college I’ve been able to like talk to people my own age and just 
laugh and just do normal things   and go out and that’s helped a 
lot as well” (Katey). 
Michelle also spoke of how she could have left university after her first year 
because her mood was so low and she was struggling to concentrate and 
attend lectures.  Medication had been instrumental in her remaining at 
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university, increasing her attendance at lectures, obtaining positive feedback 
from her work placements and ultimately in facilitating her completion of the 
degree course. 
Whilst accepting the role of medication in making the young people feel ‘normal’ 
for Christina, Katey, Samantha, Gabriella and Victoria the fact that they had to 
take medication was stigmatising and set them apart from their peers.  This was 
highlighted by Gabriella who explained:   
“…it [medication] helps, but obviously it makes you feel a bit 
different from everybody else but it’s alright taking it I think” 
(Gabriella). 
Despite this, these young people continued to take medication with the majority 
of them believing it to be instrumental in ensuring a brighter future for them. 
7.4.4.  Stories of a Brighter Future 
As well as the motivation of being a ‘’normal’ teenager, there was also the 
motivation of a brighter future which many teenagers naturally aspire to. For 
Ameeta, Allison, Katey, Michelle, Samantha, this brighter future was very much 
centred around educational and vocational achievements.  A brighter future was 
not just measured however by educational and vocational attainment, but 
socially and emotionally through a desire to be happy and to have strong 
relationships. 
When I saw Ameeta, she had written her medication story out in advance and 
was the only young person to use the story rather than the photographs as the 
starting point for the discussion about medication.  The opening line of her story 
was very poignant with Ameeta saying: 
“In life you have a choice being the victim or being the survivor but 
sometimes it’s not as easy as that”  (Ameeta). 
The plot of Ameeta’s story was therefore very focused upon survival against the 
odds and claiming victory over her illness.  Ameeta also used a saying (see 
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Image 7.19) she obtained from the internet to illustrate her opinion of how best 
to move forwards towards a brighter future further emphasising a ‘plotline’ of 
victory over illness.   
 
Image 7.19.  A Photograph by Ameeta “Moving Forwards” 
Ameeta’s notion of victory and a brighter future was focused on always looking 
forwards, making something of herself, seeing a brighter future, having a life 
worth living and being independent.  Samantha’s story also had a similar plot of 
claiming victory over her illness when she expressed her happiness that she 
now controlled the voices rather than the voices controlling her.  Samantha was 
deliberating about whether the next phase of her life would involve university or 
completing an apprenticeship, whilst Katey was very clear that her goal was to 
go to University saying: 
“I’m planning to go to university soon and I can do that now that 
I’m on my medication and everything’s under control.  Without it I 
don’t think I’d be able to think about that” (Katey). 
Christina was very excited about starting A-levels at college the following year 
so she could continue her art work.  Allison’s ambition was to have a career, 
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whilst Michelle had just obtained her first job having finished her degree course 
at University.  A brighter future for many of the young people involved was 
dependent on educational and vocational attainment which is to be expected in 
young people of school and college age.  There was a sense that for many they 
were on the start of an exciting journey, as summed up with Katey saying: 
“I was curious about what was going to happen and now I’m more 
curious as to what is going to happen in the future.  Since I’ve 
been taking medication I’m more able to do things” (Katey). 
Another ‘force of desire’ evident in the stories of the majority of young people 
interviewed was about being happy, and this formed another subjective 
measure of a bright future.  Allison specifically linked happiness and a brighter 
future in the same sentence saying: 
“I was more happy in myself and stuff, I was actually looking 
forward to the future” (Allison). 
For Allison, Katey and Samantha it was evident that their idea of happiness was 
also measured in strong personal relationships and wide social circles.  Allison 
was looking forward to her future with her fiancé, Samantha was very happy in 
the company of her siblings and Katey was enjoying a better relationship with 
friends, family and her boyfriend.  Whilst Stephen and Jonathan both noted 
improved relationships with family and friends, it was less evident from their 
interviews how they subjectively measured happiness and so assumptions 
cannot be made that these positive relationships influenced their level of 
happiness.  This may be because the interviews with Jonathan and Stephen 
were shorter and they were more centred around the medication itself rather 
than the emotions and feelings taking medication engendered in them.   
Gabriella’s measure of happiness was that her symptoms were getting better, 
and this was mirrored by all of the young women except Victoria and Christina.  
Gabriella was planning to draw a smiley face on a Paracetamol tablet to 
illustrate her happiness that she was moving towards recovery, whilst Katey 
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also used one of her photographs to visually represent how happy she was (see 
Image 7.20). 
 
Image 7.20.  A Photograph by Katey “Happy” 
Happiness was also attributed to stronger relationships that developed as 
symptoms improved secondary to antipsychotic medication.   
7.4.5.  Stories of Strong Relationships 
Many young people also directly attributed medication to improving their social 
circle and strengthening their relationship.  In response to thoughts of harming 
family members, Katey and Allison withdrew from family members.  Smantha, 
Katey and Michelle spent most of their time isolated in their bedrooms as this is 
where they felt most safe.  As medication began to take effect and symptoms 
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lessened young people became more sociable with others and were able to go 
out of the house more.  This resulted in stronger relationships with family and 
friends. Samantha was particularly happy that she now had her first boyfriend 
and talked of how this would not have been possible before medication.  
Samantha explained that she would not have been able to leave the house to 
meet up for a date during the dark days when the voices were controlling her 
and limiting her ability to leave the house.  Michelle and Stephen also both 
commented on how friends were more willing to spend time with them because 
of the positive impact medication had made on their demeanour, with Stephen 
explaining: 
“Yes like when I was not on them [the tablets] I’d be very annoyed 
and mean with them [his friends] but now that I’m on them people 
just think I’m just a right nice person” (Stephen). 
As well as improving relationships with friends, Katey, Allison, Samantha and 
Michelle also highlighted that it had resulted in a journey towards better familial 
relationships.  They were increasingly able to interact and engage more with 
their family members and this closer contact had subsequently brought 
brightness to their lives.  For Katey this had resulted in a closer relationship with 
her younger brothers, with her outlining: 
“I was really, really close to my two brothers, I spent all my time 
with them when we were younger, then whenever I got poorly I 
spent less and less time with them.  My mum and dad are 
divorced so they live with my dad during the week and then with 
my mum at the weekend and I live with my mum full-time.  I don’t 
have any contact with my dad so I don’t get to spend a lot of time 
with them either.  But now I’m more confident around them and I 
spend more time with them and to go out and just to wind each 
other up… I enjoy spending time with them now… it’s fun” (Katey).   
The positive impact medication effected on social relationships and the young 
peoples’ subsequent levels of happiness was a motivation to continuing 
adhering to the antipsychotic medication. 
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All of these stories of motivation reflect particular forces of desire within the 
young people’s stories.  They also introduce an element of suspense with the 
hope that these individual goals are attained and highlight the individual stakes 
that are central to the stories should they not be reached.  Other elements 
which could have been presented in this section include independence, 
confidence and involvement. I have however decided to explore these under a 
separate heading of control, as the stories highlighted young people who were 
both in control and lacked control of their life and destiny and this seemed to 
merit its own story. 
7.5.  Stories of Control 
When hearing the young people’s stories it was evident that whilst most were 
taking control of their individual story, some seemed powerless to effect 
change.  In narrative terms, this was illustrative of the degree of agency within 
each story.  Within this section I will consider subsets of control in relation to 
making positive choices, asserting independence, being dependent and being 
open about mental health. 
7.5.1.  Stories about Making Positive Choices 
Stories about making positive choices are evident in many of the individual 
accounts already recited.  One of the key positive choices the young people 
made was to actually take their prescribed antipsychotic medication, and the 
young people showed high levels of agency with regards to this.  Poor 
adherence was most commonly unintentional adherence with Christina, 
Jonathan, Samantha, Victoria and Stephen admitting to having forgotten to take 
the occasional dose of medication.  
In addition to taking medication, the young people actively welcomed and 
utilised the support mechanisms available to them.  All remained in contact with 
their mental health team and gained support from their family, friends or 
children’s home staff.   Others sought help and support elsewhere.  For Ameeta 
this support was provided by the crisis team and charities such as Mind and the 
Samaritans, whilst Christina gained a lot of support from her youth worker and 
199 
 
the youth club she attended.  Katey was a dynamic member of a patient and 
carer support group, petitioning for healthier meals for young inpatients and 
subsequently supporting the introduction of self-catering on the inpatient wards.  
Katey also interviewed people applying for mental health jobs on the young 
person’s inpatient unit, positively utilising her previous experiences as an 
inpatient.  With support, Ameeta was becoming more assertive in taking control 
of her life, being driven by a wish to have a positive future, make something of 
herself and not having to rely on others to care for her.  Support was also 
helping the other young people interviewed continue their daily activities and 
work towards their amibitions for their future. 
Other young people also spoke of the positive coping mechanisms they 
employed when they were having a bad day.  Many of these have previously 
been described; time spent doing hobbies, reading memory books or favourite 
quotes, focusing on good times or seeking out support from friends and family.  
A couple of the young people were also undertaking additional treatments with 
Christina actively engaged in art therapy and Michelle receiving ongoing 
support and treatment through Cognitive Behavioural Therapy sessions. 
Another feature of making positive choices was shown by Katey, Michelle and 
Jonathan in their renouncement of previously reckless behaviour.  Michelle in 
particular spoke of how she put herself in danger by going out, spending lots of 
money on alcohol and not thinking about her personal safety when she first 
went to University.  This had impacted negatively on her attendance at lectures. 
However, with the introduction of medication things changed for the better with 
Michelle saying: 
“Before I was on medication my lifestyle was very reckless.  I’d  
drink a  lot, I’d go out a lot with my friends, I  did not really have a 
care, I was quite, safety was not a thing that I’d thought about 
really, you know.  I would not care really, like I would not think 
about my own safety. I’d do stuff and not think of the 
consequences doing it and one thing that medication did do was 
settle me down a lot in that sense” (Michelle).   
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Following the introduction of medication, Michelle described how she became 
calmer.  This led to her making positive choices to spend her money on other 
things she enjoyed such as shopping, and to take care of her body by adopting 
a healthier lifestyle.  
One of the other young people leading a reckless lifestyle was Jonathan, who 
admitted putting people who wanted to buy illicit drugs in contact with drug 
dealers in a nearby city.  He spoke of doing this as his head was instructing him 
to do it, but this all stopped after the police came to his house to speak to him 
and his parents about it. Jonathan spoke of how it was this visit by the police 
that made his parents realise he was unwell, prompting them to seek support 
from mental health services. 
Allison and Katey also displayed features of reckless behaviour when they took 
large overdoses.  Katey repeatedly stopped taking antidepressant medication to 
store it up for an overdose, saying: 
“I’m not very reliable whenever it comes to medication.  When I 
was first put on medication, anti-depressants, I was on them for 
about six months and I decided to take a lot of them and overdose 
on them.  So my medication was locked away from me for about 
two years and in that time I stopped taking my medication three 
times and started building them up to take another overdose but I 
was always being found out about it” (Katey). 
Whilst Katey had repeatedly stopped taking antidepressants to self-harm, she 
had not overdosed on antipsychotic medication.  Allison was not prescribed 
medication when I saw her as this had been stopped following a large and 
serious overdose when she was feeling low and felt that life was no longer 
worth living.  Allison took an overdose of twenty quetiapine 200mg tablets mixed 
with fluoxetine but someone walked in whilst she was taking the overdose and 
called an ambulance.  She described the subsequent events disclosing: 
“I was that out of it, I did not even know, because I remember 
sitting in my bedroom and the ambulance people came up and I 
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said to her – ‘Can I go to bed?’.  She [ambulance staff] said ‘ –
[participant] if you go to sleep you are not going to wake up’.  
Because I think my pulse was at a hundred and sixty I think it was, 
and then I thought if I go to sleep, because I did not want to be 
here anyway.  Then she said to me – ‘Just let me search online 
what these tablets can do to you’, and then she searched it and 
her face just dropped, and I was like – is it a bad thing?  Because I 
was really confused, because I think she was waiting for someone 
else to come up, another colleague of hers or something, and I 
started to get really drowsy to the point where I couldn’t even 
dress myself or anything.  Anyway I went to go into the ambulance 
and I nearly fell but then I felt, you know like I did in hospital when 
I was about to have a fit, so then I thought I was going to have a fit 
again but I did not, and we got to A&E and I stood up to walk in 
and she says ‘It’s alright love, I’ll push you in’, you know in the 
bed.  But then I don’t remember even going into A&E, the next 
minute they were shining like a light on my eyes going – ‘Wake up 
Michelle’ you know in resus, and then I ended up conking out 
again and then the next minute when I woke up I was on a ward at 
about three o’clock in the morning thinking, ‘Where?’ (Allison). 
Allison was adamant that she would never take another overdose again as it 
had been such a dreadful experience.  She did however also explain that staff 
at her supported accommodation would administer medication and observe her 
talking it so she could not secrete medication and take a further overdose.  This 
left me wondering whether she herself was acknowledging the possibility that 
she could overdose again. 
Whilst Allison, Katey, Jonathan and Michelle had all displayed reckless 
behaviour, they had also all been proactive in making positive choices to 
renounce these harmful activities. 
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7.5.2.  Stories of Proactivity with Medication 
Another way young people were proactive and positively exerted control was by 
becoming more informed about medication, taking a more active role in decision 
making in relation to medication and side effects, and accepting responsibility 
for taking medication.   
Samantha became very proactive having previously forgotten doses of 
medication, and subsequently placed her medication into a dosette box each 
week which she could then leave on her bedside cabinet.  The dosette box 
meant that her siblings and the dog could not accidentally take the medication 
from the bedside cabinet and allowed her to see at a glance whether she had 
taken her medication (see Image 7.21).  She had also established a routine 
around taking medication after her breakfast. 
 
Image 7.21.  A Photograph by Samantha of her Medication Dosette Box 
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Side effects to medication were a major stake that some young people had to 
manage and overcome.  These experiences were also linked to fears that side 
effects may return with planned dose changes and changes to prescribed 
medication.   
The most common side effect highlighted was weight gain.  It was, however, 
most prevalent in the Katey’s and Allison’s stories.  Katey and Allison both had 
a history of an eating disorder requiring admission to an eating disorders unit or 
intervention to prevent admission to an eating disorders unit.  For these two 
young women they were particularly concerned about experiencing a relapse of 
their eating disorder as this would then potentially result in one of their fears 
being realised, namely admission to an eating disorder unit and being tube fed.  
This was evident with Allison saying: 
“I think they knew that I had issues with eating because it was on 
my notes as well that I’d been to eating disorder services and 
places, but, I don’t know, all they kept saying to me was, ‘Oh 
you’ve got to eat, you’ve got to eat or you are going to get put into 
an eating disorder unit’.  So then I think I thought to myself - I’ve 
got to start eating to get better because that’s the last place I want 
to be, because I don’t want to be tube fed or anything.  But then 
as time went on, especially when I got out was when, you know, I 
felt the worst because of how much weight I’d put on”  (Allison). 
The side effects were proactively managed and overcome in a number of 
different ways by the people who took part.  For Allison, Katey and Michelle 
weight gain was limited by adopting a healthier lifestyle where they were 
conscious about what they ate. Katey, Michelle, Stephen and Victoria increased 
their physical activity by gardening, walking and exercising as Katey explained: 
“I’ve started to be a lot more conscious about what I’m eating and 
how much and starting to exercise a little bit more now” (Katey). 
Another side effect caused by medication was sedation.  This was invariably 
managed by wake up calls from parents, although Michelle had employed a 
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more practical solution by having numerous alarm clocks across her bedroom 
so she has to get out of bed to turn them off (see Image 7.22). 
 
Image 7.22.  A Photograph by Michelle of Managing Sedation 
The medication regimen was changed due to the side effects experienced by 
Allison, Christina, Samantha and Gabriella.  Their willingness to discuss side 
effects with the care team is evidence of high levels of agency and resulted in 
their side effects lessening or disappearing.  Katey spoke of how delighted she 
was when staff listened about her weight gain and changed her medication, 
perhaps reflective of previous experiences of being coerced by staff into eating 
to avoid admission to an eating disorders unit alongside a lack of understanding 
about her fears of gaining weight. 
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Despite the wide range of side effects experienced by the young people 
studied, it is noteworthy that side effects rarely resulted in intentional 
nonadherence.  It was evident in the stories told that the young people 
dynamically balanced the impact of side effects against the impact medication 
was having on symptoms and as a result of this continued to take their 
medication.  There was only one instance where side effects did directly affect 
medication adherence; Katey stopped risperidone because of weight gain.  She 
did then make a conscious decision to restart the medication as she was 
terrified about what would happen, explaining: 
“I have always gone back to doing it because of the fear of what’s 
going to happen if I don’t take it….just losing control completely 
and ending up back in hospital”  (Katey). 
Another way young people took control of their medication was by becoming 
more informed about it.  When Samantha first started to experience 
galactorrhoea she did not realise this was due to medication.  It was only when 
she read the medication information leaflet that she recognised this and was 
then able to discuss the problem with her psychiatrist and switch to an 
alternative antipsychotic.  She had not read the information leaflet when initially 
prescribed the medication and took responsibility for this herself.  She indicated 
that she would not normally read the medication information leaflets as it can 
put you off taking medication.  Samantha also had not taken much notice when 
information about her medication was provided by the healthcare team.  
Christina asked me during the interview how her medication worked and what it 
was supposed to do, and Allison spoke of how a lack of information about 
medication resulted in her not wanting to take it, saying: 
“I got put back in hospital for taking an overdose because they’d 
changed it again (the medication) to something else which I did 
not know what it was.  Then I found it was for people that were 
psychotic but then I did not believe I was psychotic so I did not 
want to take it” (Allison). 
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Ameeta appeared the most informed about her illness and medication, talking 
about the impact of stress on symptoms, medication working to correct 
chemical imbalances as well as environmental and genetic contributors to 
illness.  Interestingly, Christina and Victoria seemed least informed about their 
medication and they were the young people who displayed the greatest degree 
of ambivalence towards their medication.  During the interview Christina 
explained: 
“This is like feeling confused and unsure about my medication like 
why?  Confused about what it’s actually meant to do and stuff like 
that.  I’m unsure about what it’s meant to do because I don’t really, 
no-one’s really explained to me what it’s meant to do.  My mum 
said it’s supposed to like calm me down and control the voices but 
no-one has really told me, like the doctors or owt like that, they’ve 
not really explained what it’s meant to do so I don’t really know.  
So I couldn’t really say whether it’s working or it’s not working 
because I don’t know what it’s meant to do, if you know what I 
mean.  I don’t – [slight pause, hesitancy as if searching for right 
words] I feel like it’s affecting me a little bit like I can control it [the 
psychosis] more but I don’t know if that’s myself or the medication 
because I don’t know what it’s meant  to do” (Christina). 
Despite feeling that she did not have enough information about how medication 
worked and what it was supposed to do, Christina had not been proactive in 
seeking out this information perhaps highlighting a lack of independence relying 
instead on others to provide this information contrasting with some of the other 
young people who were demonstrating increasing levels of independence. 
7.5.3.  Stories of Independence 
Medication facilitating increasing levels of independence was another story of 
control that emerged.  Ameeta, Katey, Michelle and Samantha all attributed 
their levels of independence in part to medication as they were able to socialise 
and attend further education courses.  Ameeta proclaimed during the interview 
that she was going to continue to be assertive in making her life her own, whilst 
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Katey spoke of the impact medication had on her ability to undertake her Health 
and Social Care college course saying: 
“It’s made me a lot more independent, I’m able to go to college by 
myself and oversee my work and manage my time, and able to 
work as well, and without my medication I would not be able to do 
any of that” (Katey). 
Katey also used a photograph of a cat to depict her independence, given that 
cats are often perceived as independent animals (see Image 7.23). 
 
Image 7.23.  A Photograph by Katey of Independence 
Contrasting with these stories of independence, there were however features of 
dependence prevalent in other stories. 
7.5.4.  Stories of Dependence 
Whilst medication for some young people brought about an increased level of 
independence, for Allison, Christina, Stephen and Victoria medication reinforced 
their dependence on others.  All four young people were given medication by a 
parent or carer because they had previously forgotten to take their medication.  
Christina also had a back up supply of medication at school so teachers could 
give medication if her mother also forgot. The fact that a parent administered 
medication did not seem to bother Stephen and for Allison this was a condition 
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of her placement in supported accommodation. However, this was a source of 
irritation for Christina and Victoria, Christina said: 
“I’ve got like a little routine going, my mum’s got me in a routine, 
she   gets up and wakes me up and makes me go down for 
breakfast and makes me have my tablets and get ready for 
school.  I think I want to learn – get a chalkboard or something like 
that though, so I can have more independence to remind me to 
take my tablets or something like that because I’m going to 
college this year and I just think I should.  I don’t know why – I feel 
like I should, it’s my, like not decision, like it’s my – what do you 
call it?.....my responsibility” (Christina). 
The language used by Christina was particularly interesting as there was a 
strong sense of her being made to take her tablets against her wishes.  I 
therefore wondered whether she would take medication if this was her 
responsibility, or whether she would stop the medication as she also did not feel 
it was helping her symptoms.  Victoria also felt she was being disadvantaged  
by taking medication as she wanted to go on a particular residential course and 
could not go as there was nobody able to administer her medication.  Victoria 
therefore had no control over this situation which was a source of frustration for 
her. 
7.5.5.  Stories of Openness 
Another way in which young people seized control was by being more open 
about their illness and the fact that they had to take medication.  Initially there 
appeared to be a reluctance to disclose this information because of fears about 
stigma and how others would then perceive them.  This was very articulately 
expressed by Michelle saying: 
“it’s quite a secretive world I think because you don’t like people 
knowing what’s going on and why you are taking tablets.   You 
don’t really tell people about these tablets because, you know, 
they could look up the name online and see what it is” (Michelle). 
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Whilst nobody other than Gabriella’s mother knew that she took medication for 
a mental illness, Jonathan and Samantha had always been very open about 
this.  Jonathan had never experienced stigma and held the view that if people 
responded negatively this was not worth worrying about, saying: 
“No I never minded it I never cared what people thought.  I 
suppose it just was not important to me, if someone did not like it 
then I would not be friends with them you know” (Jonathan). 
Samantha also felt a responsibility to talk about mental illness and her 
medication and actively encouraged people to ask questions so they could be 
more informed about mental health issues. 
Contrasting with this high degree of openness, Allison, Christina, Katey and 
Michelle were more selective about who was aware that they took medication.  
Whilst initially more secretive about this, they had chosen to disclose to close 
friends that they took medication as their mental health improved.  In the case 
of Christina this was driven in part by external factors given side effects that 
were apparent to others and she also had to decline sleepovers at friends’ 
houses as she needed her mother to administer medication and get her ready 
in the morning.  Allison had spoken to a close friend she met in hospital about 
her illness and medication, but was reluctant to confide in her fiancé and family.  
I was surprised about this and wondered whether this was driven by a fear of 
how they would react if they knew the full extent of her symptoms, whether it 
was through a desire to prevent them worrying, or a view that they would not be 
able to understand what she was going through.  Allison also refused to go 
sleepovers as other people would then realise that she was prescribed 
medication and she was concerned about what people would think if they knew 
she heard voices.  Whilst Katey had disclosed to other people at college that 
she took medication, this appeared to have had negative consequences as she 
talked of having few friends at college as people did not understand what was 
wrong, felt that she was ‘crazy’ and that they needed to be wary of her.  She 
seemed to be the young person most affected by stigma from others. 
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7.6.  Stories of Resentment 
The final story that emerged was that of resentment.  The young people felt 
different from their peers because they had to take medication, they felt that this 
set them apart and singled them out as being different to other young people. 
7.6.1.  Stories of Resentment at Being Ill and Taking Medication 
Whilst most young people interviewed had noticed some positive difference with 
medication there was understandably an element of frustration that they had to 
deal with the symptoms and subsequent impact on their lives that the illness 
brought.  Victoria appeared to lack insight into the fact that she was unwell, 
however this varied throughout the interview when she at times acknowledged 
her illness and at other times attributed her difficulties to normal teenage issues.  
There was however an underlying current of resentment from Allison, Christina, 
Gabriella, Jonathan, Michelle, Samantha and Stephen about their mental illness 
although they had learnt to accept this.  This resentment was not overtly 
expressed but was felt as an undercurrent to their stories. 
Whilst acknowledging the role medication had played in controlling symptoms 
and therefore supporting an outward appearance of ‘normality’ to others, there 
was also resentment for some about having to take medication to be able to do 
things their friends could do without medication.  Allison, Katey, Michelle, 
Samantha and Victoria all felt this way, with Christina saying: 
“One time I forgot, well a few times I forgot then one time – I’m fed 
up of taking it!  So I just thought to myself – I don’t need to take it 
anymore, because when I’m having a good day you don’t, you 
think to yourself – I don’t need it anymore, when you’re not 
hearing voices and things like that.  Sometimes I’ll just stop and 
then I’ll wake up in the morning and they won’t be there and I’ll be 
like – I don’t need to take it  today so I’ll not take it for a few days 
and then have a big come-down a few days later and they’ll come 
back and it will all come back ten times worse.  But sometimes I 
get fed up with taking medication because none of my friends take 
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anything and it’s like – why?   Why me?  You know what I mean, 
why does it have to happen to me” (Christina).   
For most young people one of their goals was to be able to reduce and 
ultimately stop medication.  The dose prescribed was also in the cases of 
Michelle and Katey linked to their assessment of how dependent they were on 
the medication with Katey saying: 
“I felt more that I had to rely on the medication because I had to 
take such a high dose, I did not like being dependent on it.  I don’t 
like being dependent on medication.  I hate taking medication and 
it just broke me up a bit it’s like – ‘why have I got to depend on 
medication to get through like day to day tasks?”  (Katey) 
The sense of resentment about having to take medication was most strongly 
expressed by Victoria and appeared to be driven by a couple of factors.  Firstly, 
Victoria had little ability to influence her position and this was the basis of some 
of her resentment.  Despite wanting to come off her medication because of a 
view that it was not benefiting her and was unnecessary, she kept being told by 
staff that she had to maintain her current medication regimen until after her 
exams.  Secondly, her father administered her medication and so she had no 
ability to exert her wish not to take medication unless she directly defied her 
father.  Victoria’s close relationship with her father meant she did not wish to 
worry or upset him, thus she seemed helpless to be able to exert her 
independence and desire to stop taking the medication.  This all contributed to a 
difficult interview where I was concerned that she may start crying at any 
moment, such was the level of her distress at having to continue taking 
medication. 
7.6.2.  Stories of Resentment about Feeling Different 
The final resentment factor that Allison, Christina, Katey, Michelle, Samantha 
and Victoria expressed was feeling different because of their illness and the fact 
that they had to take medication.  Victoria, a keen gardener, illustrated this 
difference by taking a photograph of two different plants, a heather and a phlox, 
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that stood side by side outside her greenhouse (see Image 7.24).  Whilst initially 
appearing to be a single plant, closer examination reveals two different, 
adjacent plants of similar size. The heather has purple flowers whilst the phlox 
has more distinctive white flowers.   
 
Image 7.24.  A Photograph by Victoria about Feeling Different 
When speaking about her friends Katey said: 
“I think they’ve got more of an understanding now.  I am the same 
as everybody else, I just have different coping mechanisms and I 
respond to stress in different ways” (Katey). 
This highlights the way Katey is trying to normalise her situation as no two 
people can be the same.  This desire to feel normal had also been the basis for 
Christina and Katey to have missed doses of antipsychotic medication.  Doses 
had been missed on days where symptoms had not been evident, however, 
fear of symptoms returning or deterioration in mental state invariably led to 
medication being resumed.  As Katey explained:  
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“There have been times when I’ve not wanted to take it because I 
don’t – I’ve been – ‘oh I really don’t want to take my medication 
today, I just want to be normal for a day’, and I have gone a 
couple of days without taking it but I have always gone back to 
doing it because of the fear of what’s going to happen if I don’t 
take it” (Katey). 
Whilst a lot of stories represented a move from darkness to brightness these 
resentments still brought an element of darkness to the happiness displayed by 
most of the young people. 
7.7.  Conclusion 
In outlining the findings from my research I have described how the main stories 
emerging from the young people in relation to medication were of endurance, 
motivation, control and resentment.  Descriptions, quotes and images have 
been used to reinforce aspects of these four stories to give the reader a feel for 
the traumas, struggles, strength, determination and achievements within the 
individual stories.  Many of the stories told contributed to a metastory of a 
journey from darkness to brightness, and the words within this metastory were 
supplemented by supporting visual images of light and dark.  An element of 
darkness still remained with some resentment evident about the need to take 
medication to stay well and be able to do ‘normal’ teenage activities.   Even 
where young people accepted their illness and the need for medication there 
was still a frequent refrain running through the stories, namely ‘Why’?  Christina 
summed up the views of many when she said ‘Why me, why do I have to take it, 
why?’. It became evident that young people were consciously or subconsciously 
balance the positive and negative aspects of medication when making decisions 
about whether to take medication as prescribed.  In balancing stories of 
motivation and control against stories of endurance and resentment, the young 
people were making dynamic decisions about medication adherence in 
response to their current situation and personal opinions.   
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CHAPTER EIGHT. DISCUSSION 
8.1.  Introduction 
In this chapter, I will start by reflecting upon how the stories of endurance, 
motivation, control and resentment contribute to the concept of dynamic 
medication adherence.  The young people involved in this research balanced 
the positive and negative aspects of medication when making decisions about 
whether to take medication as prescribed. The relative balance of these 
different aspects varied with time and circumstance, meaning that adherence 
was dynamic rather than static.  These medication decisions were driven by the 
balance of brighter stories of motivation and control against darker stories of 
endurance and resentment. Examples of the way young people balanced these 
aspects is provided throughout the chapter.  This shifting and responsive 
approach to adherence reflects many aspects of dynamic medication 
adherence (de Haan et al., 2007, Le Quach et al., 2009), however my 
interpretation is more complex bringing into the equation specific stories of 
motivation and control versus endurance and resentment.  At its most simple, 
the balance of these four stories and their dynamic impact on medication 
adherence can be represented pictorially (see Figure 8.1).  In doing so, I 
acknowledge that this is a simple illustration of a complex relationship. 
Therefore, the complexity of these relationships will be further explored in the 
rest of the chapter under the broad headings exploring motivation and control 
and then exploring endurance and resentment.  Within these sections I will 
provide evidence to support my deliberations from stories presented in the 
previous chapter, whilst weaving in capacities of stories that were deeply tied up 
with the factors that promoted and/or prevented the young people’s medication 
adherence.  Capacities are the narrative equipment of stories, they are the core 
features which make the stories breathe, work and act (Frank, 2010).  The 
capacities that will be considered are trouble, character, points of view, 
suspense and imagination (Frank, 2010); when these capacities are presented 
in the discussion, they are presented in italicized text. A capacity for trouble is 
the way in which a story may deal with trouble, or make trouble, for those 
involved in the story.  Stories showcase, probe and challenge peoples’ 
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character.  Individuals may embrace, resist or fail to recognise the character in 
which they are cast within the story.  Stories also present points of view which 
make particular viewpoints more compelling and credible to the audience.  
Within stories aspects of suspense make the stories exciting, dramatic and 
engaging.  Endings of stories are never assured so there is always an element 
of drama as the story unfolds and draws to a conclusion.  Even when the told or 
written story has concluded, the story continues to breathe as it lives on in the 
continuing retelling of the story.    Finally stories have the capacity to arouse 
imagination and emotions.  Stories can make the unseen visible to others who 
have not been cast in similar stories (Frank, 2010). All of these capacities 
combine to make stories a powerful tool in the engagement and education of 
others. 
Figure 8.1. Pictorial Representation of Dynamic Adherence (with stories of 
motivation and control in balance with stories of resentment and 
endurance) 
 
Narrative elements of tone, temporality and agency will also be highlighted 
throughout the chapter. I will link the stories to research and evidence 
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underpinning from the literature on young people with both mental and chronic 
physical illness.  Studies of adherence in chronic physical illness are introduced 
where published research in adolescents with mental health is limited or absent.  
My discussion examines where the findings from extant literature reflect or 
contradict my findings about antipsychotic medication adherence in 
adolescents.  As part of this element of the discussion, I also compare the views 
of young people in the study and the opinions of health professionals from my 
survey research.  This will all evidence how young people actively balance the 
positive and negative aspects of medication; in doing so they are, in the words 
of one young person, ‘Learning to Dance in the Rain’.   
8.2.  Stories of Brightness 
Stories of motivation and control represented the brighter aspects of young 
people’s medication journeys.  All of the sub-stories of motivation (being well, 
staying well, being a ‘normal’ teenager, having a brighter future and stronger 
relationships), and all but one of the sub-stories of control (making positive 
choices, proactivity with medication, independence and openness) represented 
positive consequences of taking medication.  Narratively the tone of these 
stories was therefore positive and presence of these stories was more likely to 
dynamically shift medication behaviour towards good adherence.  The one 
exception was dependence, a sub-story of control with a more negative tone 
which in some circumstances, such as fear of being addicted to medication, 
could dynamically result in poorer adherence with medication.  These sub-
stories will now be explored in more detail. 
8.2.1.  Becoming and Staying Well 
A wish to reach a stage in their medication journey where the young person was 
well, and then remained well, represented the most significant driver to take 
prescribed medication and was an important contributor to dynamic medication 
adherence.  This is because the most dominant capacity for trouble within all of 
the stories told was the illness and associated symptoms.  Symptoms such as 
hallucinations and paranoid delusions resulted in some of the darkest times for 
the young people and were typified by fear, isolation and admission to hospital.  
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In some cases the young people talked of recklessness and found this 
behaviour to be troublesome.  The young people frequently made reference to 
darkness when describing this stage of their medication journey leading me to 
try and imagine the difficulties of living with the darkness of psychosis.  In 
exploring the literature on darkness and light, I found two particular articles were 
of real value.  The first was a study exploring women’s experiences during the 
first few days of a postpartum psychosis (Engqvist and Nilsson, 2013).  I found 
this article interesting as the emergent theme of ‘Shades of Black with a Ray of 
Light’ had some resonance with the young people interviewed as part of my 
study and the metastory of a journey from darkness to brightness.  The 
mother’s darkness centred on themes of lack of sleep, no longer wanting the 
baby, thoughts of harming themselves and/or their child and being in an ‘unreal’ 
world.  This unreal world was described variously as being in a vacuum, having 
strange feelings in their heads, feeling part of a mystery where everything rolled 
around without making sense, being in total turmoil and feeling confused, 
insecure and fearful.  One woman described how things seemed so unreal she 
felt that she must be dead.  Family member accounts were of their loved one 
being lost in the world and totally absent (Engqvist and Nilsson, 2013).  The 
feelings of confusion, fear and turmoil described by these women were also 
evident in the stories of young people in my study, with a descriptor of darkness 
also applied. The ray of light in the mother’s stories was not overly apparent 
within the journal article, however the ray of light for the young people 
participating in my research was ‘hope’.  Hope of recovery, hope of a brighter 
future and a good quality of life.  Further context to the darkness of psychosis 
was evidenced in a second article, a personal account of schizophrenia.  This 
account described the empty spaces of blocked thoughts, a tortured mind and 
fear of a brain which “torments me in times of psychosis, always threatens me, 
and seems to always be laughing at me, scorning my vulnerability…. I am alone 
with my darkness” (Ruocchio, 1991).  Many young people also described the 
fear and torment of psychotic symptoms and it is therefore unsurprising that the 
young people’s predominant reason for taking medication was in the hope that 
symptoms would reduce and hopefully disappear.   
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Seven participants noted a dramatic improvement in symptoms with medication 
and their lives became brighter as a result; this became a key motivating factor 
to continue to adhere to medication as they dynamically balanced their quality 
of life before medication when symptomatic, against their quality of life once 
medication started to take effect and symptoms reduced. This resonates with 
staff opinion in my earlier published survey research. Ninety three percent of the 
60 survey respondents highlighted a wish to get better as the strongest 
motivator for medication adherence, with relapse prevention the third strongest 
motivator to take medication (Ramdour et al., 2015). A wish to be well and 
remain well is also evidenced in the literature as positively influencing 
medication adherence.   Evidence from four studies in EIS concluded that 
perceived medication efficacy is positively associated with medication 
adherence (Hui et al., 2006a, Perkins et al., 2006, Le Quach et al., 2009, Hon, 
2012) mirroring the views of most young people in this study. In the study by Le 
Quach et al. (2009), perceived benefit of medication and a desire to avoid 
relapse of illness were the predominating subjective reasons for good 
adherence to antipsychotic treatment at two year follow up, showing the 
importance young people assign to medication efficacy.  This reflects my 
research findings as a positive influence of medication on symptom control, 
leading to an improved and sustained benefit on mental wellbeing, was the 
strongest subjective reason for young people continuing to adhere to 
antipsychotic medication (Ramdour et al., 2015). However, the published 
evidence base is not overwhelmingly supportive. There is one published study 
which failed to replicate an association between subjective experiences of 
medication, including perceived benefits of medication, and subsequent 
adherence (de Haan et al., 2007).  The authors questioned whether inclusion of 
research participants dependent on cannabis had influenced their findings.  In 
my study nobody disclosed cannabis use although participants were not directly 
questioned about this as part of the research.  It could be that young people 
misusing cannabis may perceive benefits of medication differently to those not 
using cannabis.  Improvement in mood, reduction in daily stresses and ease in 
socialisation are cited as a reason for using cannabis by some people 
experiencing psychosis (Dekker et al., 2009, Archie et al., 2013).  It could 
therefore be argued that people prescribed medication who also use cannabis 
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may struggle to attribute improvement in symptoms to either medication or 
cannabis.   
Whilst seven young people clearly recognised the positive difference resulting 
from antipsychotic medication, there were three young people who more 
obviously struggled to perceive benefits of medication. The tone to their stories 
was more negative.  These three young people still continued to take 
antipsychotic medication, albeit forgetting to take the occasional dose. Negative 
perceptions of efficacy did not consistently affect medication adherence.  
Subjective efficacy of medication was not ultimately a strong determinant of 
these three young people’s medication adherence, contradicting the findings of 
other published literature (Hui et al., 2006b, Perkins et al., 2006, Tunis et al., 
2007, Hon, 2012)   This could be because in two of the three cases, young 
people were given medication by a parent or school teacher limiting their 
abilities to influence adherence.  In the other case the young person 
dynamically balanced any inconvenience cause by the medication against 
positive benefits, and as he was not finding the medication troublesome he 
continued to take it.  This young person was still hopeful that medication would 
improve symptoms, however he was arguably showing low levels of agency in 
continuing to take the prescribed medication when he felt it was not helping his 
mental state.  There was no indication that he was proactively seeking 
alternative medication or different treatment options. 
8.2.2.  Being a ‘Normal’ Teenager 
Another story of motivation that was prevalent within many of the young 
people’s stories was a wish to be a ‘normal teenager’.  When examining this in 
more detail, it became apparent that the young people’s views of normality were 
very much linked to their stories of a brighter future; going to college or 
university, getting a job, having a good social life, having positive and sustaining 
relationships with family and friends.  Considering published literature, living a 
normal life was one of the factors linked to poor medication adherence in 
another study of FEP (Hon, 2012). This has also been demonstrated to 
influence adherence in other chronic health conditions such as chronic kidney 
disease (Johnson et al., 2008), cystic fibrosis (Dziuban et al., 2010), diabetes 
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(Auslander et al., 2010), epilepsy (Kyngäs, 2000b) and organ transplants 
(Simons et al., 2010, Taylor et al., 2010), with young people expressing a 
yearning to forget that they have an illness (Rhee et al., 2009).  Whilst my study 
provides evidence that a desire to feel normal may lead to intermittent poor 
adherence, further evidence from a larger population sample is needed to 
support or refute this.  The fact that most young people spoke of their desire to 
feel ‘normal’ but continued to consistently take medication, despite in some 
cases a degree of ambivalence towards medication, was an unexpected finding.  
This is because ambivalence is usually associated with poor medication 
adherence (Laakso, 2012) and taking medication is often seen as something 
that sets young people with FEP apart from their peers (Ng et al., 2011).  This 
provides another example of the way in which the young people in my study 
balanced the positive and negative aspects of taking prescribed medication, 
namely their desire to feel ‘normal’ or ‘recovered’ against their ambivalence 
towards medication.  The concept of recovery in psychosis is measured across 
dimensions of clinical and social recovery as well as from subjective accounts of 
personal and existential recovery (Lam et al., 2011).  From a psychiatric 
perspective, recovery means that symptoms are well managed, cognition is 
preserved and adherence to medication is assured (Link and Phelan, 2001, 
Brown et al., 2008, Ng and Klimidis, 2008).  From a patient perspective 
recovery from FEP is achieved when there is no longer a need to be prescribed 
antipsychotic medication and when the young person feels ‘normal’ (Ng et al., 
2011).  This therefore introduces a complex dynamic for young people with FEP 
who may measure recovery by not being prescribed medication, or alternatively 
by feeling normal because symptoms of the illness have been effectively 
controlled by medication.  It is probable that antipsychotic medication supports 
and enhances a young person’s sense of normality if their medication results in 
a reduction in symptoms such as hallucinations, delusions and social 
withdrawal. This was particularly highlighted by one young person in my study 
who spoke about being noticeable different to other people because of the way 
she behaved and the content of her conversation, and spoke of the social 
isolation that resulted from this obvious sign of difference. The ultimate goal for 
most young people in the study was for antipsychotic medication to be 
withdrawn, possibly seeing this as a sign of recovery as proposed by Ng et al 
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(2011).  Another sign of recovery could also be optimism about, or achievement 
of, a brighter future. 
8.2.3.  Having a Brighter Future 
One story of motivation that was constant throughout all stories was goal 
attainment. This was fundamental to the young people’s desire to have a bright 
future and feel ‘normal’.  Adolescence is naturally a time of forming close friends 
and romantic relationships, focusing on school achievement and future career 
goals, establishing autonomy, developing a sense of personal identity and 
setting and pursuing goals (Holmbeck, 2002, Schwartz and Drotar, 2006, Modi 
et al., 2009, Schwartz and Parisi, 2013).    Goals have been shown to not only 
facilitate wellbeing and purpose in life but direct human actions (Pervin, 1989, 
Emmons et al., 1998, Little, 1998).  It is therefore unsurprising that in an 
adolescent age group, goal attainment may direct actions in relation to young 
people’s adherence with medication.  The young people in this study had shown 
tenacity and fight under difficult circumstances in their pursuit of these goals, 
demonstrating personal qualities of ambition.  Many had already been victorious 
in achieving some of their goals such as completing exams and attending 
college and university.  Medication for mental illness has been shown to 
positively impact on success and acceptance into the college community, 
empowering the students (Kranke et al., 2013). Several young people in my 
study specifically mentioned that they would never have been able to go to 
college or university had it not been for their medication, supporting the findings 
of Kranke et al. (2013).   Young people were also attaining goals in other non-
academic domains by engaging in hobbies, overcoming eating disorders and 
increasing their levels of independence.  They were striving forwards on a 
journey towards the brightness of a career, sustained romantic relationships 
and other incremental personal goals displaying high levels of agency in their 
pursuit of these goals.  This was another maintaining factor promoting 
medication adherence and introduced a further element of suspense wondering 
whether the young people would attain all of the goals they had set themselves.  
Interference with life goals has been shown not to affect medication adherence 
in one study in FEP (Perkins et al., 2006), however, patients were twice as likely 
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to have persisted with treatment for six months if the medication was facilitating 
fulfillment of life goals in another study in FEP (Tunis et al., 2007).  The findings 
from my study support the suggestion that where antipsychotic medication is 
seen to support goal attainment, this becomes a motivating factor to persist with 
antipsychotic medication.   
Whilst personal goals were a motivating factor for adherence in the young 
people studied, it is also important that illness and treatment goals are set by 
those suffering chronic illness as this is beneficial in promoting disease 
management and maintaining and enhancing well-being and quality of life 
(Barlow, 1996, Altemeier, 1997, Bradley et al., 1999).  Goal setting in children 
and adolescents is particularly important given the prevalence and challenges 
of managing a chronic illness at a young age (Schwartz and Drotar, 2006).  As 
already described the prevalent illness goal for the young people involved in my 
study was recovery.  A further illness goal for some young people was 
avoidance of hospital admission.  Treatment goals were also apparent with the 
young people expressing a desire for manageable side effects.  They also 
wanted to be prescribed as low a dose of medication as possible to control their 
symptoms, with their ultimate treatment goal being to reduce and stop 
medication.  
It is also important to ensure that young people understand the nature and 
implications of their illness and goals, and the impact this has on illness 
management (Bauman, 2000). Treatment or illness related goals may need to 
be modified as the young person grows and matures (Madsen et al., 2002), and 
the presence of the illness itself may in itself compromise attainment of  
identified goals (Seiffge-Krenke, 1998).  One young person in my study initially 
failed to get a placement to study A-level art because she did not have the pre-
requisite number of GCSEs.  This is because the pressure of exams made the 
tremors caused by medication much worse, making it physically more difficult to 
complete work in the exam. The voices she continued to hear also proved a 
distraction when sitting exams. Accessing educational and vocational training 
can be more difficult for those diagnosed with a mental illness (Russell and 
Lloyd, 2004) but with support from her family and care coordinator, she had 
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successfully challenged this and obtained a college placement.  In doing so, 
she had to accept that she would have to progress her art A-level differently to 
other students with more individual support provided by college staff outside of 
the usual classes.  Whilst this decision would enable this young person to 
continue her studies, it was also in some ways fostering social exclusion.  
Social exclusion occurs when someone wants to participate in key activities of 
the society in which they live but are unable to do so for reasons beyond their 
control (Burchardt et al., 2002).  This young person already struggled with her 
identity and felt different to her peers because of her illness and need for 
medication. In accepting this college placement she had to accept that she 
would be treated differently to most other students at college because of her 
ongoing psychotic symptoms. She would be socially excluded by being taught 
individually away from her peers when she would prefer to progress her studies 
as other students on the course.  Another young person had attended an 
education centre as a younger teenager because of her illness and the 
difficulties this caused her at school.  She eventually started college, which in 
itself was a huge personal achievement.  This young person was also singled 
out for individual study away from the wider college class because of florid 
psychotic symptoms, however, as medication improved symptom control she 
was subsequently able to reintegrate into college classes to be taught alongside 
her peers.  There was therefore a degree of flexibility in the approach used 
depending on the young person’s presentation and this flexibility in approach 
has been identified as key to supporting academic attainment in those with 
mental illness (Weiner, 1998). The illness in both cases had the potential to 
compromise attainment of personal goals however the young people were 
showing themselves to be resilient characters in responding to the presenting 
barriers. 
Goal attainment was identified in my study as a significant motivation for good 
medication adherence in young people prescribed antipsychotic medication.  
This is supported by limited published research.  One study has argued that 
medication adherence is an outcome of desire in adolescents with mental 
illness (Longhofer and Floersch, 2010).  If young people have no desires then 
they are less likely to adhere to medication.  There is also a complex dynamic 
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between desire and disappointment when children and adolescents have to 
additionally factor in the desire of their parents or guardians and others with 
authority to promote medication adherence.  Longhofer and Floersch (2010) 
identified three types of desire and disappointment relevant to adolescent 
adherence with medication for mental illness, namely instrumental desire, 
concordant desire and conditional desire.  Instrumental desire relates to the 
immediate effects produced by medication adherence; disappointment results if 
medication does not produce the desired results leading to alternative strategies 
such as psychotherapy or relaxation classes being sought (Longhofer and 
Floersch, 2010). Examples of instrumental desire were evident in my research 
in several ways, in the way medication reduced exam stresses for some of the 
young people involved, the way taking medication reassured family members 
and the way medication enabled discharged from hospital. Concordant desire is 
where individuals taking medication actively desire the expected outcomes.  If 
the desired outcome is not achieved then the individual seeks a change in dose 
or a switch to alternative medication rather than an alternative treatment 
strategy as is the case in instrumental desire (Longhofer and Floersch, 2010).  
In my research, all of the young people wanted their symptoms to improve after 
being prescribed medication so they felt less anxious, confused and fearful.  
Some young people were using additional treatment interventions such as 
psychological therapy, but such therapies were never in place of medication.  
Even where medication had not produced the intended response, doses had 
been increased or alternative antipsychotic medications tried.  The young 
people were all evidencing concordant desire.  Finally, conditional desire is 
where medication fails, the desire for the medication disappears and the 
individual gives up on medication (Longhofer and Floersch, 2010).  Whilst three 
young people felt to a certain extent failed by their medication, as it had not 
resulted in the desired effect, none had completely abandoned their medication.  
Hence, there were no examples of conditional desire in my study.   
Given the limited evidence base about the importance of goal attainment to 
medication adherence in adolescents with mental illness (Perkins et al., 2006, 
Tunis et al., 2007), I sought to assess the evidence base in adolescents with 
chronic physical illness and adults.  Research on the impact of goal setting in 
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adolescents with a chronic health condition is limited (Schwartz and Drotar, 
2006),  with one study of adolescents with cancer reporting that those with 
future-orientated goals were more likely to be perfectly adherent to medication 
regimens (Hullmann et al., 2015).  Goal setting in adults has been shown to 
promote health-related changes in behaviour (Strecher et al., 1995), 
management of chronic illness (Bradley et al., 1999) and wellbeing (Echteld et 
al., 2001, Pinquart et al., 2005, Schwartz and Drotar, 2006).  There is therefore 
some supporting literature in chronic physical illness to evidence the benefit of 
goal setting not only with medication adherence but across wider domains. 
8.2.4.  Developing Stronger Relationships 
As well as considering attainment of personal goals, normality was also 
assessed in the strength of the young person’s social relationships and abilities 
to socialise with others with young people consistently reporting improved 
relationships as a result of their antipsychotic medication.  Social isolation is 
common in those experiencing psychosis (Judge  et al., 2008). Some young 
people lose friends in the early years of psychosis, preferring to spend time with  
those in mental health services who are more likely to understand what they are 
going through, or fearing rejection because of their psychosis (MacDonald et al., 
2005).  Developing relationships takes courage particularly for those with 
psychosis; one recent study highlighted that 70% of participants avoided close 
personal relationships because they anticipated discrimination (Brain et al., 
2014). As already detailed, this fear of discrimination was evident in the stories 
of some of the young people who took part in my study.  Despite these fears, it 
is evident that young people at risk of or experiencing psychosis desire 
relationships, be those relationships friendly or intimate (Ben-David et al., 
2014).  The majority of young people in the study had overcome fears of 
stigmatisation and discrimination, disclosing to close friends details of their 
illness and developing new relationships.  One young person was delighted that 
she had recently started seeing her first boyfriend, and another also spoke 
about the support received from his girlfriend.  Seven participants spoke about 
becoming more sociable and developing stronger relationships as medication 
took effect and symptoms receded.  This reflects findings from other studies 
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evidencing a beneficial effect of medication adherence on social relationships 
(Kane, 2013, Svettini et al., 2015).  The young people with strong relationships 
and an active social life spoke of how happy this made them feel; this 
represented another motivating story for medication adherence.  Their stories 
were much brighter than the young people with limited social contact with their 
peers.   
In contrast to those young people who had good and varied social support, two 
of the young people involved in my study appeared to be loners, reliant on 
family members or pets for companionship.  These two young people both 
struck me as being particularly despondent with their current situation; 
loneliness was a dark aspect of their current circumstances.  It is however 
known that those suffering a first episode psychosis can report loneliness 
particularly where they lack a confidant (Sündermann et al., 2013) and are more 
likely than those without psychosis to have a smaller social circle and fewer 
friends (Macdonald et al., 2000).  There was an element of suspense within 
these young people’s stories as I wondered whether their social circle would 
expand or whether this loneliness would remain. 
As well as improving relationships with friends and peers, many young people 
participating in the research also held a positive point of view that taking 
medication had improved their relationships with family members.  This was 
directly linked to the receding of hallucinations telling them to harm family 
members, but was also a consequence of their increased ease socialising and 
spending time with family members.  Key literature considering medication 
adherence in adolescents with long term physical or mental illness considers 
the impact that family and friends can have on rates of adherence, either by 
supporting the young person or if necessary prompting and administering 
medication. Some literature suggests that familial involvement supports 
adherence (Kyngäs, 2000a, Kyngäs, 2000b, Coldham et al., 2002, Rabinovitch 
et al., 2009, Rhee et al., 2009).  In my study, three young people’s adherence 
was associated with the support provided to take their medication by family 
members or teachers providing confirmatory evidence that social support can 
improve medication adherence.  In contrast, other studies provide evidence that 
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family dynamics may also be the basis for poor adherence if the home 
environment is troubled or adolescents rebel against their parents by not taking 
medication (Mulvaney et al., 2008, Hommel and Baldassano, 2010, Taylor et 
al., 2010, Wamboldt et al., 2011).  There was no evidence that the adherence of 
young people in my study was negatively affected by family dynamics.  In a 
recent study considering schizophrenia from the point of view of the carer, 46% 
of carers indicated that their family member taking medication had greatly 
improved their relationships with the carer (Svettini et al., 2015) .  This research 
provides original, confirmatory evidence from the perspective of the young 
person that medication improves the quality of relationships, not only with family 
members but with friends and peers.   This in turn provides young people with 
strong motivation to adhere to medication and maintain these relationships.   
8.2.5.  Making Positive Proactive Choices  
In taking medication, the young people were making a positive choice in 
attempting to control their symptoms so they could move to a brighter phase in 
their lives.  Two young people independently chose to use medication reminder 
aids as a prompt to taking medication; in doing so they were again making 
positive choices, demonstrating proactivity with medication and high levels of 
agency.  Whilst this study has predominantly focused on the contribution 
medication made to the management of their illness, the young people also 
stated that medication was not the only reason why their illness had improved.  
The importance of psychological and psychosocial intervention was highlighted, 
as well as their personal determination in resisting and managing the dark 
symptoms of their illness.  Psychological and psychosocial intervention have 
been demonstrated as effective treatment modalities and are recommended in 
national guidelines as components of a gold standard approach to the 
management of FEP and schizophrenia (NICE, 2009a, NICE, 2011a).  In FEP it 
is recommended that antipsychotic medication is used alongside psychological 
therapy such as cognitive behavioural and family therapy; antipsychotic 
medication can enhance effectiveness of the psychological intervention (NICE, 
2013). In accessing and engaging with psychological therapies as well as 
prescribed medication, these young people were doing all they could to 
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increase their chance of recovery. Positive choices and proactivity were 
evidenced in the way young people also used positive coping strategies such as 
memory books, distraction, meaningful activity and support from staff, family 
and friends to manage the dark days when ongoing symptoms were more 
intrusive or they felt more stressed or upset. The young people were using 
many different strategies, including adhering to medication, to maximise and 
maintain health and wellbeing and avoid relapse. They were displaying high 
levels of agency in the different approaches used to manage and control 
symptoms.  Strength, courage, determination and resourcefulness were 
evidenced in the way these young people approached and managed their 
illness.  Given this there was naturally an element of suspense in the stories 
they told with a sense of hoping they would remain well and wondering whether 
they would relapse in the future.   
8.2.6.  Independence and Dependence 
As many young people’s symptoms lessened and social functioning improved, 
their medication journey naturally led them towards brighter times of increasing 
independence.  Young people explicitly stated that without medication they 
would not have been able to go to college or university, complete exams or 
think about future career ambitions.  Taking effective medication shortens DUP 
which is itself linked to better social and vocational outcomes in measures such 
as occupational and social functioning and attainment (Inoue et al., 1986, 
Larsen et al., 1996, Barnes et al., 2000).  This was evidenced in my study by 
independence resulting from exam success, vocational learning and the 
undertaking of work based placements.  The reported benefits of social 
integration (Drake et al., 2000), social functioning (Barnes et al., 2008) and 
social networks (Helgason, 1990, Tirupati et al., 2004, Jeppesen et al., 2008). 
were apparent in the developing social relationships of most young people and 
the increased time spent socialising with friends.  This introduced further levels 
of independence from their families as the young people spent more time away 
from their home environment.  Medication adherence was directly associated 
with an increased level of independence, evidenced by improved occupational, 
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vocational and social functioning.   This independence presented a motivating 
factor to take medication. 
Whilst independence was a brighter story of control, at the opposite end of the 
spectrum dependence presented trouble for some young people.  Dependence 
was referenced in two ways, through reliance on other people to administer 
medication or physical and psychological dependence on antipsychotic 
medication.  This represented a darker aspect of medication for the young 
people involved and the tone of these stories was therefore negative.  Five of 
the ten young people interviewed admitted to forgetting doses of medication.  
Published research shows that forgetfulness is one of the most common factors 
for poor adherence in adolescents with chronic illness. One systematic review 
concluded that unintentionally forgetting medication was the second highest 
reported reason for poor adherence across a number of different illness and 
studies (Hanghøj and Boisen, 2014).  With five young people forgetting to take 
their medication, this was the highest single reported reason for poor adherence 
in my study.  Studies in asthma (Buston and Wood, 2000, Velsor-Friedrich et 
al., 2004, Naimi et al., 2009, Rhee et al., 2009, Wamboldt et al., 2011), cystic 
fibrosis (Rosina et al., 2003, Gray et al., 2012) and type 2 diabetes (Mulvaney et 
al., 2008, Rothman et al., 2008)  highlight that patients with these conditions 
frequently forget doses of medication, with some studies suggesting that this 
happens in 53% of adolescents diagnosed with these conditions (Rothman et 
al., 2008, Rhee et al., 2009, Dziuban et al., 2010).  Medication forgetfulness 
was also found in 84.8% of patients with inflammatory bowel disease (Gray et 
al., 2012), more than 55% of patients with severe hemophilia (De Moerloose et 
al., 2008) and by between 30% and 56% of patients with kidney, heart or liver 
transplants (Simons and Blount, 2007, Zelikovsky et al., 2008, Simons et al., 
2009, Simons et al., 2010).  My finding that five of the ten young people 
admitted to forgetting occasional doses of medication is therefore broadly 
similar to the findings in young people with chronic physical illness.  
For three young people in my study, medication forgetfulness resulted in 
medication oversight by a parent or teacher increasing their dependence on 
others and limiting the opportunity for these young people to stop taking their 
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medication.    Published research in physical illness suggests that parents may 
have difficulties passing the responsibility for taking medication over to their 
children, and that this impacts negatively on the adolescents strive for 
autonomy and self-management of their illness (De Moerloose et al., 2008, 
Mulvaney et al., 2008, Taylor et al., 2010, Mulvaney et al., 2011, Wamboldt et 
al., 2011).  It has however also been suggested that whilst young people may 
feel uncomfortable being given medication by a parent, that not being monitored 
can also be viewed as a sign of parents who ‘do not care’ (Wamboldt et al., 
2011).  Some young people with chronic health conditions have reported not 
receiving adequate support from parents (Kyngäs, 2000a, Kyngäs, 2000b, 
Mulvaney et al., 2008), with some young people expressing a fear of asking 
parents for help with their medication regimen (Bullington et al., 2007).  One 
young person in my study wanted to exert her autonomy by stopping her 
medication, but did not want to worry her father by doing so.  The fact that her 
father was insistent on administering medication introduced an element of 
resentment as all she wanted to do was exert her independence and make her 
own decisions about taking medication (Taylor et al., 2010).   Contrasting with 
this viewpoint, another young person who had medication administered 
welcomed this support, seeing it as a sign of caring by a mother who herself 
struggled with mental illness (Wamboldt et al., 2011).   
Considering the fact that young people cited forgetfulness as the most common 
reason for poor adherence with antipsychotic medication, I was interested in 
assessing staff opinion of the importance of medication forgetfulness. Only four 
people responding to the staff survey highlighted forgetfulness as a reason for 
poor adherence, showing some discrepancy with the young people’s accounts.  
Staff were not directly questioned about forgetfulness in the survey, and so staff 
had to indicate this as a potential adherence factor through free text boxes; 
results may have been different had a specific question about forgetfulness 
been included. Whilst five young people reported that they just forgot to take 
their medication at times, they gave no further reasons for this.  With hindsight, 
this is something I wish that I had explored further as there are many 
contributory factors as to why adolescents with chronic illness may forget their 
medication.  These include unexpected changes to the young person’s 
231 
 
schedule (Hommel and Baldassano, 2010, Taylor et al., 2010, Wamboldt et al., 
2011), distractions due to other activities (Rothman et al., 2008), not being at 
home to take the medication (Zelikovsky et al., 2008, Gray et al., 2012) and 
social commitments such as parties (Mulvaney et al., 2011).   
Another feature of dependence was in the fact that the young people had to 
take medication to get better and remain well.  Whilst medication had been 
instrumental in improving symptoms for most young people, the goal for all was 
to be able to reduce and stop medication.  Current guidance suggests that 
medication should be continued for one to two years following remission from a 
first episode of psychosis (NICE, 2013).  A recent study of 174 experienced 
healthcare professionals working in early psychosis indicated that over 75% of 
clinicians felt that a plan of antipsychotic withdrawal would be considered in 
more than 60% of patients whose symptoms had remitted.  This medication 
discontinuation could take place within 12 months of symptom remission as only 
31% of respondents felt that medication should continue for at least 12 months 
following recovery (Thompson et al., 2015).  This suggests that there is 
potential for the young people to achieve their goal of discontinuing medication.    
One young person said she would continue to take medication for life if needed, 
as she never wanted to return to the dark times when she was being controlled 
by voices, however she still hoped that she would be able to manage without 
medication in the longer term.  The possibility of medication discontinuation in 
itself introduces a further element of suspense in their stories due to the 
potential for relapse. 
One young person interviewed was concerned about the possibility of physical 
dependence on the antipsychotics.  Whilst antipsychotics are generally not 
considered addictive, it is recommended that they are withdrawn gradually over 
several weeks to prevent discontinuation syndromes (Goudie, 2000).  The 
possibility of addiction was however of real concern to this young person and so 
she was encouraged to have an open discussion with her care team about her 
concerns. 
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8.2.7.  Stories of Openness 
As these young people became better, achieved their goals and started to 
socialise more, many became more open with close friends about the fact that 
they had a mental illness and were prescribed medication.  At the darkest points 
of their journey they would have feared such disclosure, concerned that friends 
would label them ‘crazy’.  This is a natural reaction to the stigma still present in 
relation to mental illness (Murphy et al., 2015a).  A stigmatised person has been 
defined as someone who expects to be rejected as a friend, employee, 
neighbor, or intimate partner, and to be devalued as less trustworthy, intelligent 
and competent by most people owing to his or her mental illness (Link and 
Phelan, 2001). Self-stigma is evident when a person accepts these prejudicial 
views and internalises these negative perceptions which then impacts on their 
self-esteem (Corrigan and Watson, 2002). Psychosis and schizophrenia remain 
the most stigmatised mental health conditions, with those diagnosed with the 
illness often labeled unfairly as dangerous and unpredictable (Thornicroft et al., 
2009).  Stigmatising attitudes towards people with mental illness are also 
common in adolescents (Reavley and Jorm, 2011).  When young people’s 
attitudes to a range of mental health disorders were explored through case 
studies, adolescents indicated a higher degree of unpredictability in the case 
study of psychosis and a greater likelihood of the adolescents distancing 
themselves socially from somebody who presented in this manner (Reavley and 
Jorm, 2011).  It is therefore not unexpected that young people in this study were 
initially careful about disclosure of their psychosis to their peer group, fearing 
the negative responses, stereotyping and discriminatory actions that may result 
(Hinshaw, 2005, Moses, 2010).  Other studies have also shown that the general 
public and mental health staff prefer to maintain social distance from those with 
psychosis (Corrigan et al., 2002), contributing to the sense of social isolation felt 
by young people with psychosis and impacting on their willingness to seek 
support.  One-fifth of college students failing to seek treatment for their mental 
health needs cited worries about what others would think as a major reason for 
this reluctance to seek support from services (Pedersen and Paves, 2014).  
Other studies would, however, suggest the majority of young adults think it 
acceptable for care from mental health services to be sought, and would not 
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think any less of the person for doing so (Eisenberg et al., 2009, Lally et al., 
2013, Pedersen and Paves, 2014).  In my study one young person was 
incredibly open with friends, colleagues and the general public encouraging 
them to ask questions about her illness and the medication she took.  When this 
was explored further she indicated a personal role in reducing stigma by 
encouraging debate and discussion with others about mental illness.  In doing 
so, she was displaying herself as a courageous, trail blazing character within 
her own story. 
In exploring these stories of motivation and control, other illustrations are also 
provided about how the young people’s characters are both tested and 
displayed.  The first young person I interviewed spoke about how everybody 
has a choice whether they become bitter or better, broken or made, victim or 
victor; these aspects of character were evident in other young people’s stories.  
The idea of people with illness being a victim, being bitter or broken fits with 
Frank’s (1995) description of a wounded storyteller (Frank, 1995).  Frank 
himself is a wounded storyteller having recovered from a heart attack and 
cancer (Frank, 2002) and sought to obtain illness narratives from others, 
ultimately proposing three different narrative types of chaos, restitution and 
quest associated with illness (Frank, 1995).  Chaos narratives are evidenced in 
stories of people overwhelmed by their illness, unable to remove themselves 
from it.  One bad thing after another happens within chaos narratives, and the 
storyteller is stuck in an unrelenting present.  Restitution narratives are apparent 
where storytellers identify with the illness as a disruption to their happy, healthy 
lives.  Storytellers feel that will get better quickly, soon reverting back to their 
pre-illness self.  Finally, quest narratives are illustrated in stories where the 
person who is ill seeks to use their experiences for the benefit of themselves 
and others (Frank, 1995).  The young person who spoke about having a choice 
of becoming a victim or victor had clearly made a choice to become victorious. 
Previously seeing herself as a victim because of her caring responsibilities, the 
pressures at home and her illness, the earlier illness narrative was one of 
chaos.  She subsequently re-engaged with hobbies, spent more time going out 
with friends, felt comfortable seeking help when needed from staff and services 
and was undertaking college and vocational courses to support a future career 
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and to help others.  Her illness narrative had moved from one of chaos to quest.  
Other young people had also been victorious overcoming the chaos of serious 
eating disorders and/or episodes of self-harm to move to a position of stability 
and brightness.  Whilst the majority of young people were still symptomatic, 
they were managing these symptoms without resorting to the previous darkness 
of self-harm and social isolation.  Other young people were doing well at college 
or university having previously isolated themselves because of symptoms; 
some had achieved excellent exam results despite missing some of their 
education through illness whilst others were considering career paths actively 
seeking out a brighter future.  Many young people were interested in pursuing a 
career with young people or a career in health and social care, feeling that their 
personal experiences could be used positively for the benefit of others.  This 
also provides examples of quest narratives described by Frank (1995) within the 
young people’s stories.  These stories show personal characteristics of 
determination, resilience and courage in pursuit of personal goals.   
Literature evidences that those vulnerable to psychosis vary in their ability to 
cope with everyday life stressors (Goh and Agius, 2010), with psychiatric 
symptoms emerging or worsening when the individual’s vulnerability threshold 
to cope with stressors is exceeded (Pruessner et al., 2011).  Individuals 
vulnerable to psychosis also vary in their degree of resilience to stressors 
(Drvaric et al., 2015).  Resiliency may be influenced by individual ability to cope 
with emotions and difficult situations (Johnson et al., 2010), self-esteem and 
coping skills (Pruessner et al., 2011).  It has been suggested that positive 
coping skills and resiliency protect against high levels of psychosocial stress 
(Drvaric et al., 2015).  Many of the young people with brighter stories of 
motivation and control evidenced personal characteristics of resilience and 
positive coping strategies.  Several young people spoke of the trauma and dark 
times experienced in their past.  One young person in particular presented an 
excellent account of how she had overcome this trauma and darkness, moving 
away from the family environment she found so difficult, seeking help from 
healthcare professionals and staff at the children’s home, using positive coping 
strategies such as memory books and meaningful activity and taking small 
steps towards a brighter future.  I also propose that medication had a role in 
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increasing these young people’s resilience, although it has been suggested that 
medication does not impact on levels of stress (Pruessner et al., 2011). My 
reasoning for this is that many young people spoke about being more able to 
cope with ongoing voices when prescribed medication.  Some young people 
also recognised that medication had made them calmer and better able to 
respond to difficult situations.  
Whilst the majority of young people could be considered victors in overcoming 
the darkness in their lives, Victoria seemed to have cast herself as a victim 
within her own story. People with illness may often present themselves as 
victims, reflecting a dominant cultural perception of people with illness as 
‘victims’ requiring care and often resulting in a passive response to illness 
(Frank, 1995).  Resenting the fact that she was prescribed medication and 
could not reduce this until after her exams, questioning her illness and 
portraying a sense of annoyance and anger at her personal circumstances, this 
young person came across as a young woman struggling with her identity and 
actively resisting being cast in her story as a character who was ill.  There was 
considerable conflict within her story as she debated with herself whether she 
was ill or not and whether she was ‘normal’ or not.  She appeared to have little 
capacity to influence her own situation, displaying low levels of agency.  Her 
character appeared broken when I saw her, and recounting her story caused 
her to become upset and almost tearful.  There was however a sense that this 
desolation could change in the future as she attempted to move forward on her 
medication journey, exerting more personal control of her destiny by actively 
seeking agreement from healthcare professionals to reduce her medication.   
This young person’s story also evidences the concept of dynamic adherence.  
Whilst she spoke about certain positive aspects to medication, these were 
related to her time in hospital when she actively recognised symptoms of mania 
and could see the impact medication had on controlling manic symptoms and, 
ultimately, facilitating discharge.  The balance of positive and negative aspects 
of medication was very much in favour of her taking medication.  Following 
discharge home and return to college, the balance had shifted towards more 
negative stories of medication endurance and resentment manifesting in her 
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desire to withdraw medication. As is the case in dynamic medication adherence, 
this young person’s decisions were being driven by life circumstance and 
personal beliefs (Krummenacher et al., 2014).  Her willingness to take 
medication had altered because she no longer saw a role for medication in 
reducing the threat of illness and relapse. This attitudinal change is captured in 
one of the most  commonly used models to explain variance in adherence 
behaviour, a modification of the Health Beliefs Model (Becker, 1979).  This 
model focuses on three dimensions.  The first dimension is the individual’s 
readiness to undertaken the recommended sick-role behaviour i.e. to take 
prescribed medication.  This first dimension comprises a number of factors 
namely, motivations such as willingness to seek help and accept medical 
intervention, value of illness threat reduction such as perceived susceptibility of 
relapse and the probability that medication adherence will reduce the threat of 
illness (Becker, 1979).  Changes in this dimension were apparent between the 
young person’s admission to hospital and the young person’s current position of 
having spent time living back at home without needing hospital admission.  This 
young person was less willing to undertake the recommended sick-role 
behaviour.  The second dimension involves psychosocial variables which may 
alter beliefs and attitudes in the first dimension.  This second dimension 
includes variables such as cultural influences, therapeutic relationships, social 
support and previous experiences of healthcare environments (Becker, 1979).  
This dimension had remained static for the young person between the time of 
hospital admission to the time she participated in the study.  The final dimension 
of the model, sick role behaviours, include those behaviours associated with the 
individual’s acceptance of his or her illness, including adherence to medication 
(Becker, 1979).  This young person had become less accepting of her illness 
with time and circumstance.  An individual’s medication adherence is directly 
linked to the patient’s readiness to take prescribed medication as well as 
psychosocial factors (Rickles, 2010) as outlined in the Health Beliefs Model.  
Psychosocial influences and readiness to take medication vary with time and 
circumstance, and so this model also supports the concept of dynamic 
medication adherence.   
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As well as stories of motivation and control, such as being well, staying well, 
being a normal teenager and being open about both illness and medication, 
darker stories of endurance and resentment were also evidenced in other young 
people’s stories.  These will now be explored further. 
8.3.  Stories of Darkness 
Stories of endurance and resentment represented stories of darkness in the 
young people’s medication journeys. All of the sub-stories of endurance 
(dealing with trauma, resisting symptoms, accepting the bad days, waiting for 
medication to work, dealing with side effects, taking medication for life and 
despite ambivalence), and all of the sub-stories of resentment (being ill, taking 
medication and feeling different) represented more negative consequences of 
both the illness itself and taking medication.  The tone of these stories was 
therefore negative and they represented the darker sources of trouble evident in 
the young people’s journeys.  Whilst presence of these stories may instinctively 
be considered to dynamically influence behaviour towards poor medication 
adherence, this rarely proved to be the case in the young person undertaking 
this research as bright stories of motivation and control outweighed the darker 
stories of endurance and resentment. 
8.3.1.  Trauma 
Two young people specifically spoke of the trauma they endured in their earlier 
life and attributed medication, in part, to helping them overcome this.  
Psychological and psychosocial intervention had also been instrumental in 
helping these young people move beyond the trauma and develop coping 
strategies for the future should they find themselves in similar situations, as 
recommended in national guidance (NICE, 2013).  They were displaying high 
levels of self-efficacy in coping with these stresses, as evidenced in other 
studies (Macdonald et al., 1998, Schmidt et al., 2014).  The young people had 
shown great strength of character in dealing with these traumas, moving 
forwards to a brighter point in their lives.  Whilst not every young person spoke 
specifically of past trauma, all of the young people talked about the nature of the 
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symptoms of their illness necessitating prescribing of antipsychotic medication.  
This represented another story of endurance. 
8.3.2.  Symptoms and ‘Bad Days’ 
For six young people in this study, their psychotic symptoms were such that 
they had to endure voices telling them to harm other people and/or themselves.  
They were fearful of these voices and their abilities to resist them; when the 
voices were at their darkest and strongest the young people isolated 
themselves to avoid acting on these instructions to harm others.  This safety 
behaviour has been suggested by other authors as a component of a cognitive 
model for hallucinations (Beck and Rector, 2003).  Individuals are less likely to 
respond to command hallucinations to harm others than they are to respond to 
hallucinations to harm themselves (Beck-Sander et al., 1997). This was 
evidenced in my study with some young people unable to resist command 
hallucinations to harm themselves but never acting on instructions to harm 
others. This self-harm manifested in either self-mutilation or medication 
overdoses. The young people who did self-herm aligned these behaviours to 
the darker aspects of their journey.  That some young people participating in 
this research had resorted to self-harm is not surprising. One study conducted 
in the UK found that 11% of those diagnosed with FEP self-harmed in the 
period between symptom onset and engagement with services (Harvey et al., 
2008).  Other studies have suggested that the incident of self-harm may be 
even higher (Proctor et al., 2004, Falcone et al., 2008). One can only imagine 
the difficulties these young people faced enduring and resisting these 
symptoms; all displayed great courage and determination in doing so.  The 
introduction of medication had in most cases resulted in a quieting of the voices 
but they rarely disappeared completely.  The young people did report finding 
their voices more manageable and easier to resist.  This finding is in keeping 
with published literature which suggests that a significant number of people 
have persistent psychotic symptoms (Livingstone and Wykes, 2010).  Some 
authors have suggested that up to 50% of people with psychosis can have 
ongoing symptoms despite taking medication (Fowler et al., 1999).  The young 
people were realistic in their opinion that there would always be bad days but 
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had been proactive in the way they approached these dark days, using coping 
strategies and interventions which reminded them of brighter times. 
8.3.3.  Waiting for Medication to Work 
When medication was first prescribed, four young people found that it took 
longer to take effect than they had anticipated.  Two had been informed about 
the delayed effect of medication, however for one young person this lack of 
information resulted in poor adherence as he was expecting an immediate 
response and stopped taking medication because he felt it was not working.  
This highlights the importance of providing information such as how long 
medication will take to work (up to six weeks), as highlighted in NICE guidance 
(NICE, 2009b).  The narrative aspect of temporality is also reflected in the 
stories of the young people waiting for medication to take effect.  They all 
unanimously stated that medication had taken longer to work than they have 
anticipated, even when this delayed response had been highlighted by 
healthcare professionals.   As well as wondering whether any positive effects of 
medication would be apparent, the young people also had to consider the 
possibility that they may experience side effects of medication.   
8.3.4.  Medication Burden 
Medication burden is a term used to capture a number of inconveniences in 
relation to medication, including the number and size of tablets, side effects and 
palatability of medication to be taken. It has the potential to interfere with 
patients’ daily lives, affect wellbeing and risk medication-related difficulties 
(Mohammed et al., 2016).  In my study, side effects were the most prominent 
feature of medication burden.  Once medication was prescribed, all but one of 
the young people had to endure side effects of medication.  This is not 
unexpected given that children and adolescents are more sensitive to the 
effects, including side effects, of antipsychotic medication (Correll, 2011).  
Reviewing published literature, side effects have been demonstrated as 
impacting adversely on medication adherence in FEP in some studies 
(Robinson et al., 2002, Pogge et al., 2005, Tunis et al., 2007, Opjordsmoen et 
al., 2010, Hon, 2012). Other studies in FEP have concluded that side effects do 
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not influence medication adherence (Coldham et al., 2002, Novak-Grubic and 
Tavcar, 2002, Mutsatsa et al., 2003, Perkins et al., 2006).  Side effects of 
medication have also been associated with poor medication adherence in 4% of 
patients with cancer (Hullmann et al., 2015), 7% of adolescents with cystic 
fibrosis (Dziuban et al., 2010), 14% of patients with inflammatory bowel disease 
(Greenley et al., 2010), 18% of young people with asthma (Rhee et al., 2009), 
and 16% and 27% of adolescents with transplants (Simons and Blount, 2007, 
Simons et al., 2010).  These studies in physical illness provide evidence to 
support the fact that side effects of medication can at times result in poor 
adherence with medication, although the relative importance of this may vary 
across different chronic physical health conditions.   
The most common side effect highlighted by the young people in my study was 
weight gain, followed by sedation and EPSEs.  Weight gain is a recognised side 
effect in children and adolescents treated with antipsychotic medication, as 
evidenced by a recent systematic review (Almandil et al., 2013).  Published 
literature about the impact of weight gain on antipsychotic medication 
adherence is mixed, with one study in FEP suggesting an adverse association 
(Pogge et al., 2005) and a further study concluding there is no association 
between weight gain and antipsychotic medication adherence (Rabinovitch et 
al., 2009).  In my study, seven young people mentioned that they had gained 
weight due to prescribed medication. In my earlier published survey research, 
staff identified weight gain as the side effect most likely to affect medication 
adherence, with 42 respondents specifically highlighting this as a factor for poor 
medication adherence (Ramdour et al., 2015). Despite this, there was only one 
occasion where this resulted in poor adherence with medication.  In this 
instance the young person, who had a history of eating disorder, stopped 
medication because of weight gain; she later resumed taking it, fearful that 
symptoms would worsen, she would end up in hospital, unable to attend college 
and achieve her goal of becoming a mental health nurse.  This provides another 
example of dynamic adherence, in that whilst taking medication the weight gain 
dominated her thoughts tipping the balance towards poor adherence.  Once she 
stopped taking medication, the fears of relapse and the impact this would have 
on her future goals overtook the concerns about weight gain, swinging the 
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balance in the opposite direction towards better adherence.  This reflects the 
findings of Tunis et al. (2007), that young people with psychosis are more likely 
to persist with treatment where this is viewed as supporting goal fulfillment 
(Tunis et al., 2007).  The young people also spoke about strategies they had 
adopted to manage the weight gain, largely exercise and healthy eating. 
Pharmacological strategies such as a change or dose reduction of medication 
had also been employed in some instances.  Several systematic reviews and 
meta-analyses support pharmacological (Fiedorowicz et al., 2012, Mizuno et al., 
2014, Zheng et al., 2015)  and/or non-pharmacological strategies (Álvarez-
Jiménez et al., 2008, Das et al., 2012) such as lifestyle and behavioural 
interventions, to manage antipsychotic-induced weight gain. The interventions 
being utilised to manage antipsychotic weight-gain by the young people and 
their care team were therefore appropriate. 
Sedation was another side effect cited as problematic by five young people in 
my study.  Thirty one staff responding to the survey research felt that sedation 
adversely affected medication adherence (Ramdour et al., 2015).  Despite 
these views, none of the young people in this study were poorly adherent to 
medication as a consequence of sedation.  This mirrors findings in published 
research of FEP (Pogge et al., 2005).  Once again, the young people 
complaining of sedation employed proactive interventions to manage this side 
effect, using numerous alarm clocks set around the bedroom so they would 
have to get out of bed to switch them off or ensuring wake-up calls from a 
parent who persisted until the young person arose from their bed. 
Extrapyramidal side effects were the third most frequent side effect, reported by 
three young people in the study and listed as a potential modifier of adherence 
by 19 staff responding to the survey research (Ramdour et al., 2015).  The 
EPSEs took the form of tremors, however again young people continued to take 
medication despite the inconvenience resulting from the tremors.  My finding 
that EPSEs had no effect on medication adherence reflects the conclusions of 
most published studies in FEP (Coldham et al., 2002, Novak-Grubic and 
Tavcar, 2002, Mutsatsa et al., 2003, Pogge et al., 2005, Rabinovitch et al., 
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2009), although one study (Robinson et al., 2002) did suggest an association 
between EPSEs and poor medication adherence. 
In my study, other aspects of medication burden such as tablet size, number of 
medications and their taste was not reported to have any impact on adherence 
in young people taking antipsychotic medication.  This conflicts with published 
literature in chronic physical health conditions where there is a suggestion that 
medication burden, other than side effects, also negatively impact medication 
adherence.  It has been suggested that adolescents may not adhere to 
medication because of complicated regimens (Rosina et al., 2003, Bullington et 
al., 2007, Rhee et al., 2009, Dziuban et al., 2010, Hommel and Baldassano, 
2010), the taste of the medicine (Bullington et al., 2007, Simons and Blount, 
2007, Zelikovsky et al., 2008, Modi et al., 2009, Simons et al., 2009, Dziuban et 
al., 2010, Simons et al., 2010, Gray et al., 2012) and the size of the tablets 
(Simons and Blount, 2007, Simons et al., 2009, Simons et al., 2010).  This did 
not feature as a concern in this research study.  The greatest number of 
medications taken by a young person for their mental illness was two 
medications, once or twice daily, via the oral route. When compared with 
regimens for some physical health conditions such as organ transplants and 
type 2 diabetes, the prescribed regimens for young people in this study could 
therefore be considered relatively straightforward. This has likely influenced the 
lack of impact the medication regimen had on medication adherence.  It could 
however be a further example of balancing symptom control against aspects of 
medication burden such as the complexity of the regimen or the number of 
medications or doses prescribed. 
In summary, despite experiencing significant side effects, all of the young 
people were proactive in their management of medication burdens employing 
lifestyle, behavioural and practical strategies such as exercise, healthy eating, 
alarm clocks and wake up calls to overcome side effects; they were also willing 
to discuss treatment options with health professionals when other strategies did 
not have the required impact on side effects.  The young people displayed high 
levels of agency in their management of side effects; by employing different 
strategies to manage these side effects the young people were indeed 
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‘Learning to Dance in the Rain’.   My research findings complement published 
studies in FEP that weight gain, sedation and EPSEs are not significant factors 
for poor adherence with medication.  Had the young people’s responses to 
these side effects been passive, rather than proactive, then the findings may 
have differed as the balance between the positive effects of medication and the 
negative impact of side effects would have differed.  When comparing the 
findings about side effects from the young people’s stories with the survey 
responses from health professionals, health professionals appeared to over-
estimate the impact of medication side effects on adherence emulating the 
findings of another published study (Kikkert et al., 2006).  Side effects of 
medication, particularly weight gain, sedation and EPSEs were cited by staff as 
the second most common reason for poor adherence (Ramdour et al., 2015). 
This was not reflected in the young people’s stories highlighting a need for 
further staff awareness in this area.  
8.3.5.  Taking Medication for Life 
Despite various stories of endurance related to medication, the young people in 
my study continued to take it.  They also had to contemplate the possibility that 
they may have to endure taking medication long term.  Whilst most young 
people held a point of view that they would only be on medication in the short 
term, and the ultimate aim in all cases was to be able to reduce and stop 
medication, there was recognition by most young people that medication was 
still needed at the current time.  Only one young person was adamant that she 
could manage without medication and resented the fact that she could not stop 
it.  It also has to be acknowledged that at various times in the young people’s 
journeys they held more negative points of view reflecting the dynamic 
perspective to medication attitudes. At times the young people felt that they 
were not ill and did not need medication, or were better and therefore no longer 
needed to take medication. Three young people all narrated this as a feature of 
their individual stories, although with two young people this was associated with 
previous experiences of being prescribed antidepressant medication rather than 
currently prescribed antipsychotic medication.   My findings did indicate that 
whilst poor insight into illness and the need for medication may be a factor in 
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adolescent medication adherence, this was more commonly associated with 
adherence to previously prescribed antidepressant medication. Only one young 
person admitted not taking antipsychotic medication because she felt well, was 
having a good day and thought she could manage without the medication, 
displaying a lack of insight.  Insight has been shown to be a significant 
determinant of medication adherence in studies of FEP, be that in domains of 
illness awareness (Mutsatsa et al., 2003, Segarra et al., 2012, Chan et al., 
2014a), need for treatment (Mutsatsa et al., 2003, Perkins et al., 2006) or 
overall insight (Coldham et al., 2002, Mutsatsa et al., 2003, Kamali et al., 2006, 
McEvoy et al., 2006a, Segarra et al., 2012). Results from the staff survey also 
highlighted staff awareness of the potentially negative impact of poor insight on 
medication adherence.  Ninety two percent of staff indicated that young people 
thinking they were not ill resulted in poor adherence, making this the most 
important factor for poor adherence in the views of staff.  Whilst there is 
evidence in published literature to support these health professional views 
(Coldham et al., 2002, Mutsatsa et al., 2003, Kamali et al., 2006, McEvoy et al., 
2006a, Le Quach et al., 2009, Hill et al., 2010, Segarra et al., 2012, Steger et 
al., 2012, Rabinovitch et al., 2013), the fact that poor insight contributed to poor 
adherence in only one young person in my study cannot be viewed as strong 
evidence to support the link between insight and medication adherence.  This 
lack of association reflects findings from one other published study (Lecomte et 
al., 2008).  In recognising that my finding contradicts the majority of literature in 
relation to the negative impact of poor insight on medication adherence in FEP, 
it must be acknowledged that this research was conducted in a small sample of 
young people who had been selected by care coordinators; this may have 
influenced the results with care coordinators unwittingly or preferentially 
selecting those with more insight.   
Another factor which may have influenced levels of insight was the extent to 
which health professionals had discussed illness and prescribed medication 
with the young people.  One young person did not initially feel that she needed 
quetiapine as nobody had explained that her experiences were secondary to 
psychotic symptoms.  Upon realising that it was an antipsychotic medication, 
her first reaction was to say that she did not need it as she was not psychotic.  
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Another young person felt that she was taken more seriously in adult services 
than in CAMHS and was helped to understand her illness more.  Published 
literature has shown that where young people feel they are being treated like a 
child who cannot take care of themselves this can impact negatively on their 
self-management of illness (Rhee et al., 2009).  When Michelle was treated like 
an adult and was given information about her illness and why staff felt 
medication was necessary she accepted medication, providing support to this 
argument.  The importance of provision of information about medication and 
patient involvement in medication decisions is given in NICE guidelines relating 
to psychosis (NICE, 2013, NICE, 2014), medicines adherence (NICE, 2009b) 
and medicines optimisation (NICE, 2015).  Studies show that lack of information 
from, or inadequate communication with doctors, has in particular been 
perceived as a lack of support by adolescents with chronic physical illness 
(Kyngäs, 2000a, Kyngäs, 2000b, Rosina et al., 2003, Swarztrauber et al., 2003, 
Mulvaney et al., 2008, van Dellen et al., 2008, Taylor et al., 2010, Wamboldt et 
al., 2011), with a frequent refrain from mothers and children in one study being 
that doctors were cold and impersonal communicating more with their computer 
than their patient (van Dellen et al., 2008). A recent qualitative study of young 
people’s experiences of taking medication also highlighted that a lack of 
knowledge about antipsychotic medication affected decisions about 
commencing, taking and continuing medication (Murphy et al., 2015a).  It is 
therefore important that prescribers and other healthcare professionals provide 
adequate information in a suitable format to support adherence with medication 
(NICE, 2009b).   
Lack of awareness about how medication worked and its function was evident 
in another young person, and may have been implicated in her ambivalence to 
medication.  A couple more young people continued to endure taking 
medication despite a degree of ambivalence towards it.  One young person had 
not noticed dramatic improvement in symptom control and was therefore 
ambivalent about benefits, however side effects were not troublesome so he 
was happy to continue taking it.  Had side effects been of more concern to him, 
it is likely that this would have swung the balance between positive and 
negatives towards poorer adherence.  
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Another young man admitted to not taking the occasional dose of medication 
purely because he was in a dark, bad mood. Some studies in physical illness 
suggest that teenage defiance can be a root cause of poor adherence with 
medication (Mulvaney et al., 2008, Rhee et al., 2009, Hommel and Baldassano, 
2010, Taylor et al., 2010, Wamboldt et al., 2011, Gray et al., 2012).  This refusal 
to take medication because of a bad mood could be viewed as an act of 
defiance, a way of exerting personal control or indeed as a symptom of his 
illness.  Adolescence is a time of developing a clearer sense of self, gaining 
increasing levels of independence and taking control of personal, emotional and 
financial matters, however it also introduces some challenges such as exerting 
authority, taking risks and demanding rights (Christie and Viner, 2005).  Staff 
responding to the preliminary research questionnaire felt that personal control 
was an important mediator of medication adherence, reflecting limited findings 
in published literature of young people experiencing a mental illness (Townsend 
et al., 2009).   Eighty percent of staff felt that a wish to be in control of their own 
life was a very strong or strong influence on poor adherence, with 78% similarly 
highlighting a view that all medication decisions are solely up to them (the 
young person) as having a very strong or strong influence on poor adherence 
with antipsychotic medication.  Adolescents may exert their authority by refusing 
to take medication long term, however further research is warranted to explore 
this within the specific topic area of psychosis in young people.   
8.3.6.  Being Ill, Taking Medication and Feeling Different 
Finally, another prevailing capacity of trouble within the young people’s stories 
was their feeling different from their peers because they were ill and had to take 
medication.  Considering the evidence base in adolescents taking antipsychotic 
medication, there appears to be no published literature to date directly 
considering whether feeling different directly impacts on medication adherence 
in young people prescribed antipsychotics.  In one published qualitative study of 
medication adherence in FEP, ‘living a normal life’ was identified as being an 
influential measure of quality of life.  Quality of life was then shown to affect 
adherence with the antipsychotic medication aripiprazole.   It is probable that 
feelings of difference may impact on ‘living a normal life’ thereby influencing 
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antipsychotic medication adherence in FEP (Hon, 2012).  In a further qualitative 
study, pressure to conform to their peer group was highlighted to affect young 
people’s decisions about medication adherence (Murphy et al., 2015a).  It is 
possible that this pressure to satisfy their peer group may be linked to a 
requirement or desire to be like their peers rather than standing out as different. 
The young people in my study most often storied resentment to both the illness 
and medication.  Coming to terms with psychosis has been identified as an 
important stage in recovery (Waite et al., 2015).  It has been argued that grief 
and mourning for losses engendered by the illness, and hopelessness about 
having a bright and viable future with the illness, are an important part of 
coming to terms with a diagnosis of psychosis (Wittmann and Keshavan, 2007).   
It is therefore not unexpected that such stories of resentment were evident in six 
young people’s stories.  One point of view expressed on several occasions was 
‘Why Me?’, as young people struggled to come to terms with their illness.  They 
compared their situation to friends who were not mentally ill and who did not 
need medication to be able to undertake usual teenage activities.  The illness 
and requirement to take medication set them apart from their peers and made 
them feel different; these aspects of their stories not only outlined their 
resentment but were narrated in negative, dark tones.   
Studies in HIV (Veinot et al., 2006), cystic fibrosis (Dziuban et al., 2010) and 
sickle cell disease (Modi et al., 2009) highlight that feeling different can directly 
contribute to poor adherence with medication regimens.  This finding has also 
been replicated in type 2 diabetes (Mulvaney et al., 2008, Auslander et al., 
2010), chronic kidney disease (Kemp et al., 1998, Johnson et al., 2008) and 
liver transplants (Taylor et al., 2010).  Whilst there is a reasonable evidence 
base to support the positive association of feeling different on poor adherence 
across a range of different physical health conditions, this association was not 
apparent in my study. Whilst six young people spoke of feeling different 
because they were prescribed medication, only one young person stopped 
taking medication for a few days because of her ‘desire to be normal’. They did 
not speak of any pressure from their peers to stop medication, although other 
published literature suggests that pressure to conform to peers can affect 
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medication adherence (Murphy et al., 2015a). Young people appeared to 
balance how taking medication set them apart from their peers against how 
improved symptoms secondary to medication supported an outward 
appearance of ‘normality’ to their peer group.  This supposition is evident in the 
example of one young person who was, by her own admission, noticeably 
different to peers because of her topics of conversation and behaviour.  Being 
on medication brought some normality and brightness into her life as she was 
able to move to college from an education centre and was better able to interact 
with other college students.  She stopped medication on occasion because it 
made her feel different to others but then resumed it because of her wish to 
remain at college and retain her independence. This story again provides 
evidence that adherence with antipsychotic medication is dynamic.   
As feeling different contributed to intermittent adherence in only one young 
person, there is no strong evidence from my research that feeling different 
results in poor adherence with medication.  The consequences of feelings of 
difference or ‘wishes to be normal’ are worth further exploration in future 
studies.   
Young people can also feel different to their peers because of hospital 
admissions.  For five young people this represented another aspect of trouble 
within their stories.  Although one young person who had been admitted to 
hospital on three separate occasions recounted two admissions in a positive 
light, she also had an admission that she found particularly difficult.  All of the 
other young people admitted to hospital spoke about how difficult they found 
this experience and how desperate they were to be discharged back home.  
The troubles associated with hospital admission were linked to the young 
people being away from their usual home environment, feeling isolated from 
family and friends, feeling under constant observation from staff on the ward 
and also a genuine fear and dislike about hospitalisation.  Studies in children 
have identified fears of hospital admission linked to familial separation and 
feeling alone (Coyne, 2006, Wilson et al., 2010).  As well as the loneliness 
resulting from a hospital admission, children also miss school, the loss of 
independence and limited abilities to undertake activities (Bossert, 1994, 
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Coyne, 2006, Lindeke et al., 2006).  Children have also expressed a dislike of 
hospital admission because of unfamiliarity of the environment (Coyne, 2006).  
The reasons the young people in this study found hospital admission dark and 
troublesome are therefore corroborated by published research.  Whilst some 
young people highlighted that their worst fear was readmission, none of the 
young people concerned directly attributed a fear of readmission to their 
continued adherence with medication.  I propose that this is another 
subconscious motivator for medication adherence linked to young people taking 
medication to stay well.  This is not something that is readily evidenced in 
published studies and could be explored in future research.   
Finally, as already briefly discussed, a particular source of resentment was the 
illness itself and need for the young people to have to take medication.  Studies 
have found that teenagers with asthma (Buston and Wood, 2000, Rhee et al., 
2009, Wamboldt et al., 2011), diabetes (Mulvaney et al., 2008, Auslander et al., 
2010, Mulvaney et al., 2011) and cystic fibrosis (Dziuban et al., 2010) are often 
embarrassed about disclosing their illness to friends and peers.  Other studies 
in diabetes (Mulvaney et al., 2011), solid organ transplants (Bullington et al., 
2007, Simons and Blount, 2007, Simons et al., 2010), chronic kidney disease 
(Johnson et al., 2008) and asthma (Naimi et al., 2009) have found that 
teenagers are reluctant to take medication in front of their friends.  Whilst the 
majority of evidence suggests that people with chronic health conditions dislike 
feeling different from their friends and want to be able to undertake usual 
teenage activities, there is also some evidence that adolescents may feel 
special and unique because of their illness, poorly adhering to medication 
fearing rejection if they were to become well (Bullington et al., 2007).  
Comparing these findings in chronic physical illness with the young people in 
my study, all of the young wanted to recover and so there was no evidence that 
people were intentionally non-adherent to remain ill.  Young people with 
psychosis have similar concerns to adolescents with chronic physical illness 
about friends being aware of their illness, or knowing that they take medication. 
I propose that these concerns may be even more challenging for young people 
with psychosis due to the ongoing stigma about mental illness (Kranke et al., 
2010, Gerlinger et al., 2013).  It was clear from the young people’s stories that 
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they were fearful of the reactions they would get following such disclosure.  
They were worried that people would consider them ‘crazy’ or dangerous; they 
were fearful of being stigmatised because of their mental illness.  This concern 
about stigma is also evidenced in a qualitative study of other young people 
prescribed antipsychotic medication (Murphy et al., 2015a).  A systematic 
review concluded that fears of dangerousness due to mental illness is the most 
significant reason why the public maintain social distance from those with a 
mental illness (Mertika et al., 2006). A recent narrative study identified that 
young children who had a parent with a mental illness were aware of social 
stigma and therefore avoided disclosure about their parent’s mental illness, 
(Murphy et al., 2015b) providing further support for childhood awareness of 
stigma.  Given this awareness of social stigma around mental illness at such a 
young age, and the link with rejection and personal devaluation, it is not 
surprising that the young people in this study were not always willing to disclose 
details of their illness and medication to close friends.  They were even more 
reluctant to discuss this openly with peers.  Two young people were more 
willing to discuss their illness and medication openly, with one young girl in 
particular seeing it as a personal responsibility to encourage questions with the 
aim of reducing the stigma around mental illness.  She showed great bravery 
and courage in being so willing to discuss her illness, reflecting how far she had 
come in her journey from the dark past of isolating herself at home, fearful of 
leaving the house or interacting with others.   
8.4. Summary 
In conclusion, the young people were balancing individual stories of motivation 
and control against stories of resentment and endurance when making 
decisions about medication.  Medication adherence was dynamic, with the 
relative balance of these positive and negative aspects of medication 
influencing subsequent adherence behaviour.  All were displaying high levels of 
agency in overcoming the symptoms of their illness, journeying away from the 
dark times of uncontrollable, distressing symptoms, social isolation and fear 
towards a brighter future of independence, happiness and success.   
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CHAPTER NINE.  CONCLUSION 
Having presented my findings and discussion, this final chapter provides details 
of my original contribution to knowledge, strengths and limitations of the 
research, implications for practice and suggestions for further research.  I 
conclude by summarising what these young people’s stories can teach us as 
health professionals and people. 
9.1. Original Contribution 
When embarking on this research, I felt that there was a need to hear stories 
from young people about their medication journeys in order to understand their 
perspectives of what it was like to take antipsychotic medication.  In undertaking 
this research, I have made an original contribution in a number of different 
ways.  Firstly, this is the only study to my knowledge to use auto-photography to 
explore medication adherence in any form of mental illness within published 
literature.  It is also the only study which uses narrative research methodology 
to obtain views about medication adherence in mental illness that I have been 
able to find in published literature.  Focusing specifically on adolescents, there 
are limited published qualitative studies addressing antipsychotic medication 
(Hon, 2012, Murphy et al., 2015a).  One study used a grounded theory 
approach with FEP patients prescribed the antipsychotic medication, 
aripiprazole (Hon, 2012).  A further study took a phenomenological approach to 
explore antipsychotic medication experiences of young people (Murphy et al., 
2015a).  The research undertaken in my study used a narrative, rather than a 
grounded theory or phenomenological, research approach and participants 
could be prescribed any antipsychotic medication between the ages of 14 and 
18 to meet the inclusion criteria.  
The findings also represent an original contribution to knowledge.  On analysing 
the young people’s individual stories, a metastory emerged whereby the young 
people journeyed from a place of darkness to brightness as medication took 
effect and psychotic symptoms lessened.  Such a metastory has not been 
referenced in published literature of young people with psychosis prescribed 
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antipsychotic medication.  Four key stories became apparent; stories of 
endurance, stories of motivation, stories of control and stories of resentment.  
Adherence behaviour depended upon the relative balance of motivation and 
control (promoting adherence) versus endurance and resentment (potentially 
deterring adherence).  Where young people could appreciate that medication 
was helping to control symptoms, improve quality of life, contribute to goal 
attainment and facilitate independence they were willing to endure more of the 
negative aspects of medication such as side effects and feeling different.  This 
was because the perceived benefits of medication outweighed the drawbacks of 
medication.  Where this balance swung the other way, and drawbacks 
outweighed the perceived benefits, resentment increased towards the 
medication.  Medication efficacy was the predominating aspect promoting 
adherence with medication as this was fundamental to stories of motivation and 
control such as being well, staying well, feeling ‘normal’, having a bright future 
and being independent.  Forgetfulness was the most common reason for poor 
adherence, mirroring findings in adolescents with chronic physical illness. The 
research findings also suggest that medication burden including complicated 
medication regimens or unpalatable medicines were not a feature of poor 
adherence in adolescents prescribed antipsychotic medication, contrasting with 
findings in research of adolescents with chronic physical illness.  Finally, the 
research provides original evidence that strengthening relationships with family, 
partners and friends as a consequence of taking prescribed medication is a 
motivator to continued use of antipsychotic medication in adolescents. Other 
studies consider the impact social support has on medication adherence in FEP 
(Malla et al., 2002a, Perkins et al., 2006, Gearing and Charach, 2009, 
Rabinovitch et al., 2009, Rabinovitch et al., 2013) and this usually reflects 
whether somebody is available to provide support or prompt and administer 
medication.  Some literature also suggests that antipsychotic medication can 
adversely affect young people’s relationships (Murphy et al., 2015a).  My study 
provides new evidence that indirect effects of medication on social support 
through strengthening relationships and widened social circles encourages 
future adherence with antipsychotic medication. 
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9.2.  Strengths and Limitations 
In conducting this research, I sought at all times to approach it in a way which 
ensured rigour and would promote confidence in the research findings.  As with 
all research, there were strengths and limitations in the research design and 
methodology which will now be outlined. 
Strengths 
One of the key strengths of this research is the use of a novel qualitative 
approach to explore antipsychotic medication adherence in adolescents.  Many 
medication adherence studies take a quantitative approach, measuring 
adherence and then comparing with demographic data and results of tools to 
assess features such as insight and attitudes to medication.    Thus, there is an 
element of limiting results according to the measures being assessed.  In asking 
young people to tell their story of their medication journey, I was trying to 
capture all of the information they themselves found relevant.  The information 
they provided was in no way restricted through use of semi-structured 
interviews, rating scales or tools.  I also feel that the young people were more 
willing to participate as they were controlling the information provided at 
interview and felt more comfortable and at ease telling their story rather than 
answering lots of questions in an interview schedule. 
The involvement of care coordinators in electing young people who were able 
and willing to take part and give informed consent and in introducing me to the 
young person was a further strength of the research.  This is because the young 
people felt more relaxed being introduced to me by somebody they knew.  I also 
feel that involvement of the care coordinators ultimately led to high quality 
information being provided by the young people concerned, as the care 
coordinators selected those who would understand and engage well with the 
research design and method.  Only two young people dropped out of the 
research and this was due to factors outwith their control, namely relocation to 
another country and the need for an operation. 
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Thirdly, I feel that the young people concerned engaged well with the 
autophotography aspect of the research.  Whilst I did not always end up 
receiving hard copies of photographs taken, the images and illustrations and 
even the would-be images employed by the young people were incredibly 
imaginative.  These images introduced an additional layer by which to 
understand the young person and their story.  The images also increased the 
impact of the stories told by offering a visual representation.  All but one of the 
young people chose to go through the photographs one by one at interview and 
tell me why they had taken the photograph and what it represented.  This 
allowed them to easily structure the information provided; the photographs 
provided prompts to the information they wanted to give.  Only one young 
person presented the information as a story from beginning to end of her 
medication journey, and she had written this down beforehand so as not to 
forget and to make things easier at interview. The young people, in the main, 
seemed at ease talking about their photographs and could spend most of the 
interview looking at the photographs rather than me if this made them feel more 
at ease.  I think this all contributed to the young people being more open and 
talkative at interview than they may otherwise have been.  Focusing discussions 
around what the photographs meant made it easier for young people to discuss 
their views and feelings; the original intentions of using a visual methodology to 
engage young people in the research was incredibly effective.  Despite 
struggling at times to engage one young person in discussion about her illness 
and medication, she became much more animated when describing the 
photographs she had taken.  She had been very creative in capturing these 
images and was keen to edit the images so they became an even stronger 
representation of her story.  Unfortunately her camera broke and she was 
unable to share these pictures.  She was however able to describe the 
photographs in considerable detail incorporating her ideas about how she had 
planned to edit the photographs using different colours and photographic 
effects.  This highlights the strength of the methodology chosen as this young 
person was still able to engage in discussions about her medication despite the 
photographs being physically absent. She still chose to focus her discussion 
around the images taken rather than just recount her medication story to me.   
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Finally, I think that the narrative approach combined with use of visual imagery 
enabled a more meaningful appreciation of what taking antipsychotic 
medication meant to the young people involved.  Without the combination of 
both narrative analysis and autophotography, it is possible that the metastory of 
a journey from darkness to brightness may not have been as readily apparent.  
The images themselves provided evidence of the contrast between darkness 
and brightness and this enabled this concept to naturally emerge during 
discussions about the images.  
Limitations 
As well as significant strengths to the research, there were also a number of 
limitations.  Whilst previously arguing that involvement of care coordinators was 
a strength of the research, some might also say that their involvement led to a 
degree of participant selection that otherwise would not have occurred.  This 
may have introduced a degree of bias, as it is possible that those young people 
agreeing to participate may have been those who had more insight or were 
more adherent due to positive experiences of taking medication.  To defend 
against this, it was made clear through written and verbal information that I 
wanted to hear the good and bad stories around medication.  If the information 
was overwhelming positive at interview, I directly asked whether they had ever 
experienced any negative things in relation to medication.  In the images 
presented, and verbal information provided, the young people were willing to 
disclose negative features of medication and so I do not think that this concern 
was realised. 
It was also a requirement of the ethics committee that young people be 
informed that their care coordinator or doctor would be contacted if they 
disclosed at interview that they were not currently taking prescribed medication. 
I was required to disclose any concerns about mental state should they be 
evident during my interactions with the young people.  I was initially concerned 
that this may encourage people not to speak openly about poor adherence, but 
again this did not materialise with the young people still disclosing past reasons 
for not taking medication.  Nobody disclosed that they were not currently taking 
medication, however, I felt that this was probably a reflection of current 
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adherence behaviour.  I was concerned that one young person may not take 
medication as she was so disaffected by it, however her father was 
administering medication and so I was reassured that this was being monitored 
and she was taking it.  In the end I was relieved that the ethics committee had 
required these additions to the research proposal, as I did on one occasion 
approach a care coordinator when somebody became upset at interview talking 
about past and current experiences. 
It could also be argued that some young people may not have been willing to 
engage in the research as they felt that this required a degree of artistic ability.  
I propose however that the advantages of using visual research approaches 
outweighed this.  Some young people did at times find it difficult to take 
photographs to explain certain concepts, however in these instances they 
resorted to the internet and obtained relevant images online.  One young 
person did struggle to imagine the pictures he could take to illustrate his 
medication journey.  I therefore had to explain and give examples during further 
telephone conversations.  This young person did not take any photographs in 
the end, as he sustained significant injuries in a gardening accident and so was 
housebound for a long period.  In hindsight, I think this also provided him with a 
feasible excuse to cover up the fact that he did not really understand what was 
required, however he was still able to participate in the research without 
providing photographs. 
On reflection, I was also unrealistic in my expectation that the young people 
would return their photographs within the agreed timescale without prompting.  
Numerous follow up telephone calls, emails and text messages were required 
before photographs were returned, and during some of these conversations it 
became apparent that the young person had not started to take photographs.  
The need to devote time and energy to taking the photographs may have put 
some off engaging with the research.  Other factors which may have also 
detracted from participation include the need to be interviewed, for the interview 
to be recorded and to speak to somebody about medication who they had only 
met during a brief interview.  That said, I think the fact that I was not working in 
257 
 
any of the teams the young people attended meant that they may have seen me 
as more independent and therefore been more open during interview.   
Finally, there are limitations in the sample recruited as all young people were in 
contact with services in Lancashire.  Findings may therefore have differed had 
the sample been more geographically spread.  The sample was predominantly 
female (80%) and Caucasian (90%).  The stories may differ to stories told by 
young people from a different population. However, it should also be 
acknowledged that the young people’s stories are bound by context, time and 
memory. 
9.3.  Implications for Practice 
Having considered both the strengths and limitations of the research, I will now 
consider implications for practice based on the research findings.  I propose that 
it is important for healthcare professionals to explore and understand young 
people’s individual medication stories, not only to effectively engage them in 
ongoing discussion but to monitor and promote medication adherence.  I also 
suggest that there are advantages to using narrative research approaches as 
an innovative means of providing a person-centred approach to medication 
adherence.  Recent national drivers encourage and promote medicines 
optimisation, ‘a person-centred approach to safe and effective medicines use, to 
ensure people obtain the best possible outcomes from their medicines’ (NICE, 
2015).  A key principle in medicines optimisation is seeking to understand the 
patient’s experience (RPSGB, 2013).  Medical narrative is shifting away from 
the physician’s narrative towards greater emphasis on the patient narrative 
(Morris, 2000), with narratives now being perceived as a helpful means of 
understanding the individual, person-specific meaning, context and perspective 
of illness (Greenhalgh and Hurwitz, 1999). Narrative medicine has been defined 
as “medicine practiced with… narrative skills of recognising, absorbing, 
interpreting, and being moved by the stories of illness” (Charon, 2006).  In 
telling these stories, the patient describes the life of their own illness in their 
own words (thus providing insight into past and current experiences), their 
sense of suffering, how this feels to the patient and those close to them, their 
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experience of symptoms, indeed anything that is of relevant to their own 
particular story (Kalitzkus and Matthiessen, 2009, Frank, 2010). The cathartic 
experience of telling stories and having healthcare professionals actively listen 
and absorb what is being said has the potential for the patient to find healing 
(Rian and Hammer, 2013).  It has also been demonstrated to reduce anxiety 
(Freeman, 1991) and increase general wellbeing (Brooker and Duce, 2000).  
For the healthcare professional, narrative medicine has also demonstrated 
improvements in team unity and perception of other people’s perspectives, 
whilst reducing stress and compassion fatigue (DasGupta et al., 2006, Sands et 
al., 2008).  Thus narrative medicine has the potential to enhance the experience 
of patient and professional alike, and may influence outcomes through co-
creation of illness stories, the mutual understanding developed through the 
story-telling process and the resultant improved patient-professional 
relationship. Whilst acknowledging that not all patients will feel comfortable or 
ready to recount their individual illness stories, I consider that the practice of 
narrative medicine, and more specifically narrative pharmacy, has the potential 
to ensure healthcare professionals become truly patient-centred in their 
response to illness for the benefit of both self and patient, thereby improving 
outcomes including adherence with medication. Asking young people to 
describe their medication journey is an effective way of exploring relevant 
motivators and detractors of medication adherence.   
Staff should also explore relevant features of endurance, motivation, control and 
resentment with young people to promote open discussion about the positive 
and negative aspects of taking medication.  Staff should not make assumptions, 
for example that significant side effects will naturally equate with poor 
adherence.  In exploring stories of endurance, motivation, control and 
resentment, healthcare professionals need to consider the relative balance of 
positive and negative aspects of medication with the young people themselves.  
In doing so healthcare professionals will gain an appreciation of individual 
motivations and goals which may promote and deter medication adherence.   
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Finally, adherence needs to be frequently explored with young people as 
adherence behaviour is rarely static, instead varying dynamically with time, 
circumstance and attitude.   
9.4.  Proposals for Future Research 
In undertaking this research it became apparent that published qualitative 
research in this topic and with this patient population is scarce.  This therefore 
warrants further attention and qualitative studies with participants from a wider 
geographical footprint should be undertaken.   
Future research in young people with mental illness, and healthcare 
professionals supporting them, could seek to determine whether narrative 
evidence based medicine approaches result in improved outcomes compared 
with treatment as usual.  Such research could take the form of two patient 
groups whose baseline medication adherence is assessed using both 
subjective and objective measures of adherence.  Additional assessment scales 
of other factors which may affect medication adherence, such as attitudes to 
medication and insight, would also be prudent.  One group would then receive 
treatment as usual, whilst the other group would also be the recipient of 
narrative evidence based medicine approaches.  Repeat measures of 
adherence and assessment scales could then be undertaken to assess for any 
changes in adherence, insight and attitudes across the two patient groups. 
Research with staff could also assess whether narrative evidence based 
medicine approaches increase job satisfaction, reduce stress and improve team 
cohesiveness in those working with young people experiencing psychosis. 
Research could also explore whether goal-setting could improve adherence to 
medication in those with FEP.  One patient group would receive treatment as 
usual. The other group would additionally set goals and measure progress 
against these goals over time.  Baseline and repeat measures of adherence 
could then determine whether goal setting provided any benefit in terms of 
improved adherence with medication. 
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Having provided suggestions for future research, I conclude this thesis with my 
reflections on what the young people’s stories can teach us both as healthcare 
professionals and people. 
9.5.  What These Stories Teach Us as Healthcare Professionals 
and People 
In undertaking this research using visual and narrative approaches, young 
people felt comfortable recounting their individual stories.  Findings from these 
stories have already been presented and discussed. I would however like to 
suggest that the most encouraging and life-affirming moral learning evident 
throughout the young people’s stories is that they can succeed, despite the 
utmost stress, trauma and adversity, attaining their individual goals.  Their 
success and determination should provide encouragement to everybody, 
whether they are suffering a mental illness or not.  One young person 
highlighted that you can start with nothing and make something of yourself; that 
it is all about taking small steps in the right direction to get to your goal.  Positive 
journeys from darkness to brightness were evidenced through the young 
people’s stories, despite set-backs along the way.  These amazing young 
people were all ‘Learning to Dance in the Rain’. 
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APPENDICES. 
Appendix 1.  Labov and Waletsky framework 
This is outlined by using an excerpt from Ameeta’s story. 
Feature Example Reflections 
Orientation From a young age I was piling 
things on top of me, living at 
home which is very difficult for 
me, and I felt I was the primary 
person responsible for my family 
Pressure being placed on 
an individual at such a 
young age.  Cultural 
expectations of a caring 
role for females. 
Complicating 
action 
I experienced a lot of trauma.  My 
day to day life was very hectic 
and busy 
Ameeta didn’t fully 
expand on the trauma.  I 
did not delve further as 
she had just lost a friend 
to suicide. 
Evaluation I would put a smile on my face 
but deep down I was very low in 
mood 
How Ameeta was feeling 
had gone unrecognised 
partly due to her 
determination not to 
outwardly display how 
she was feeling. 
Evaluation I had reached the point where I 
no longer saw a purpose in life 
The anxiety, stress and 
fear that must be present 
when you are 
experiencing psychotic 
symptoms but don’t 
understand or recognise 
them for what they are. 
Evaluation which was when I first started to 
experience psychosis, without 
realising or fully understanding 
what was truly going on 
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Resolution It was then, when I reached the 
point when I was unable to see a 
future, which led to my admission 
to hospital 
What it must be like to be 
admitted to an inpatient 
mental health unit at such 
a young age 
Coda It was at that point I started to 
take medication and 
antipsychotic medication 
Medication was only 
commenced in hospital 
presenting a delay in 
treatment of psychosis. 
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Appendix 2.  Research information sheet 
                               
 
Research Information Sheet for Service Users. 
 
‘What taking medication means to me’ 
 
January 2013 
 
Thank you for taking an interest in our project. My name is Sonia Ramdour and 
I am a pharmacist with the Lancashire Care NHS Foundation Trust.  I am 
currently carrying out a research project with the early intervention service, child 
and adolescent mental health service and the University of Central Lancashire 
and I am looking for volunteers to help me with this.  This study is wanting to 
hear stories from young people who have taken medication at some time 
between the ages of 14 and 18.  We want to find out more about what taking 
medication means to people when they are teenagers. 
 
You are being invited to take part in this study.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss 
it with others if you wish.  Ask us if there is anything that is not clear, or if you 
would like more information.  Take time to decide whether or not you wish to 
take part.  Thank you for reading this. 
 
What is the purpose of the study? 
 
I am wanting to explore what taking medication for psychosis means to young 
people.  It is hoped that by understanding more about this we will be able to 
provide more suitable information and help for young people prescribed this 
medication and their families  
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Why have I been chosen? 
There is very little information on this topic particularly in the 14 to 18 year old 
age group.  We are therefore concentrating on patients in this age group who 
have current contact with early intervention or CAMHS (child and adolescent 
mental health) services. 
 
Who is organising and funding the study? 
This study is funded by the Pharmacy Department of the Lancashire Care NHS 
Foundation Trust and has been organised by the Pharmacy Department, the 
Early Intervention Service and researchers from the University of Central 
Lancashire. 
 
Do I have to take part? 
You are free to agree or refuse to take part in this study and your decision will 
not in any way affect your relationship with your doctors or nurses or your 
subsequent treatment. If you did decide to take part you would be free to 
withdraw at any time without giving a reason or your care being affected 
 
What would I have to do? 
If you took part in this study you would be asked to take some photographs 
representing what taking medication for your mental wellbeing means to you.  
You would take these photographs on a disposable camera we would give you or 
on your mobile phone.  If you took photographs of other people you would also 
need to ask them to complete a form giving permission for the photograph to be 
used in the study. We would not use photographs with people in them unless we 
had their permission to do so. 
You would then email the photographs to me or send the disposable camera 
back in the prepaid envelope provided.  Any mobile phone charges incurred 
sending the photographs straight from your phone will not be reimbursed, 
however there would be no cost to you if you are using a disposable camera or 
sending them as attachments to an email from a computer.   
Once I have had the photographs developed I would then send them back to you.   
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I would then contact you and arrange a meeting to discuss the photographs in 
more detail. Please see the diagram below for further information about how this 
would happen. 
 
What are the risks or benefits to me? 
There are no risks but it would involve you giving up some of your time and may 
cause you to think about unpleasant experiences you have had in the past with 
medication.  
If you agreed to take part in the study 
you would choose whether to take 
photographs on your mobile phone or 
on a disposable camera that we would 
give you 
Once you had taken all of your photgraphs 
(maximum of 20), you would email them to 
me from your mobile phone or post the 
disposable camera back to me 
I would get the photographs developed, 
post them back to you, and arrange to meet 
you 
Before the meeting, you would need to 
label the photographs.  I would provide the 
labels for you to do this and instructions on 
how to label the photographs 
I would meet you to talk about the 
photographs and what taking medication 
means to you 
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There may be no immediate direct benefit to you, although you may find it 
helpful to share your experiences and find out what others think about taking 
medication.  We hope that your feedback will help us examine and evaluate our 
services for the future 
 
Is the study confidential? 
Yes, anything you say or write would remain confidential.  Any information we 
hold about you pertaining to this study will be held securely and destroyed at 
the end of the research study. 
 
Would anyone else know I was taking part? 
Staff from the Early Intervention or CAMHS service may talk to you about the 
research study so you know about it.  You do not have to take part in it if you do 
not want to, and this will not affect the service you receive from them.  If you are 
14 or 15, then we will have to contact your parents or guardians before you can 
take part in the study.  We will ask you to complete a form giving the phone 
number of your parents/guardian so that we can call them and confirm that they 
are happy for you to take part.  They will also need to complete a parental 
consent form.   
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study completely at any time or withdraw 
particular photographs or information you have provided up to four weeks after 
the meeting to discuss them.   
 
What will happen to the results of this study? 
It is intended that the results of this study will guide further research on different 
ways to provide information on medication to encourage and support people in 
the 14 to 18 year age group to take their prescribed medication.  It is anticipated 
that the anonymised results will be published as a journal paper and be 
presented at conferences.  The research will also form part of my PhD thesis.  
You will not be personally identified in these documents although direct quotes 
from the information obtained may be used.  The results will be discussed within 
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the early intervention service and a summary of the main findings will be sent to 
those participants who request feedback.   
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called 
a Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by North West 12 Research Ethics 
Committee (Lancaster).  It has also been reviewed by the Lancashire Care NHS 
Foundation Trust Ethics Committee and the Ethics Committee at the University 
of Central Lancashire.    
 
What if there is a problem? 
If you have worries about any aspect of this study, you should ask to speak to 
Professor Joy Duxbury who is leading this study [telephone number 01772 
895110].  She will do her best to answer your questions and address any 
concerns. If you are still unhappy and want to complain formally, you can do this 
using the Lancashire Care NHS Foundation Trust Complaints Procedure Details 
can be obtained from the Complaints Manager, Sceptre Point, Sceptre Way, 
Walton Summit, Bamber Bridge, Preston PR5 6AW.  Telephone 01772 695316) 
 
Further information 
If you have any further questions please feel free to ask and if you think of 
anything later on, you can contact me at: 
Sonia Ramdour, Guild Lodge, Guild Park Hospital, Whittingham, Preston PR3 
2AZ or by telephoning 01772 406640. 
 
If I am not in the office please leave a message on the answer phone and I will 
contact you as soon as I am able 
 
You should keep a copy of this information for future reference.    
 
Thank you for considering whether you want to be involved in the study. 
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Expression of Interest Form 
 
Study about ‘What taking antipsychotic means to me’. 
 
Name: 
 
Age:    
  
Address: 
 
 
 
Telephone number: 
 
Email: 
 
Please tick which of the following statement/s applies: 
 
I am currently a patient with the early intervention or CAMHS service  
 
 
I attend the support group ‘The Crew’        
 
 
I am aged 14-18 and currently taking antipsychotic medication  
 
 
I am over 18 and was prescribed antipsychotic medication at some  
point between the ages of 14-18 
 
 
I am aged 14 or 15, and know that my parents/guardian will have to agree  
to me taking part in the study.  Their contact details are as follows: 
 
Name of Parent/Guardian……………………………………………. 
 
Telephone number of Parent/Guardian…………………………… 
 
 
I have read the information leaflet and am interesting in being involved in 
the study  
 
 
Signed_____________________________Date _____________________ 
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Please return this form using the following FREEPOST address: 
 
 Sonia Ramdour 
Medication study (Pharmacy) 
Clinical Governance Network Team 
FREEPOST RSAK-2BJS-JJCE 
Po Box 592 
Preston 
  PR5 6XT 
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Appendix 3.  Parental information and consent form 
                                                   
Research Information Sheet for Parents/Guardians of 14 and 15 year olds 
‘What taking antipsychotic medication means to me’ 
January 2013 
Thank you for taking an interest in our project. My name is Sonia Ramdour and 
I am a pharmacist with the Lancashire Care NHS Foundation Trust.  I am 
carrying out a research project with the Early Intervention, Child and Adolescent 
Mental Health (CAMHS) services and the University of Central Lancashire and I 
am looking for volunteers to help me with this.  This study is looking at what 
young people think about antipsychotic medication.  
Your child is interested in taking part in this study but we need your permission 
for them to do this.  Before you decide, it is important for you to understand why 
the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear, or if you would like more information.  Take 
time to decide whether or not you wish them to take part.  Thank you for reading 
this. 
What is the purpose of the study? 
I want to hear stories from young people about what taking medication means 
for them.  By doing this, I hope to have a greater understanding about the 
decisions young people make in deciding whether or not to take medication for 
their mental health difficulties.  It is hoped that by understanding more about 
what young people think, and by hearing their stories, we will be able to provide 
more suitable information for patients and carers about medication 
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Why have they been chosen? 
There is very little information on this topic particularly in the 14 to 18 year old 
age group.  We are therefore concentrating on patients in this age group who 
have current contact with the Early Intervention or CAMHS service. 
Who is organising and funding the study? 
This study is funded by the Pharmacy Department of the Lancashire Care NHS 
Foundation Trust and has been organised by the Pharmacy Department, the 
Early Intervention service and researchers from the University of Central 
Lancashire. 
Do they have to take part? 
You and your child are free to agree or refuse to take part in this study and this 
decision will not in any way affect your relationships with the doctors or nurses 
or your childs subsequent treatment. If you did decide they could take part they 
would be free to withdraw at any time without giving a reason or your care being 
affected.  You can also withdraw them at any time without giving a reason or 
their care being affected 
What would they have to do? 
In the first part of this study we conducted a medication survey to get some 
information on what influences whether people choose to take or not take 
medication prescribed for psychosis.  We now want to get more in-depth 
information about this from young people, and plan to do so by asking them to 
take photographs about what taking antipsychotic means to them.  We will then 
arrange a meeting with your child so they can tell us what the photographs 
mean, and tell us their story about taking antipsychotic medication. 
We have given you this leaflet as your child has indicated a wish to take part in 
the study.  If you agree to them taking part, you will then need to complete the 
form at the end of this leaflet and return it using the freepost address provided.  
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What are the risks or benefits to them? 
There are no risks but it would involve them giving up some of their time and 
may cause them to think about unpleasant experiences they have had in the 
past with medication.  
There may be no immediate direct benefit to your child, although they may find 
it helpful to share their experiences and find out what others think about taking 
medication.  We hope that their feedback will help us examine and evaluate our 
services for the future 
Is the study confidential? 
Yes, anything your child says or writes would remain confidential.  Nobody will 
be able to identify your child from any information we include in publications, 
presentations or the research thesis.  Any information we hold about your child 
will be destroyed at the end of the research study. 
Would anyone else know they were taking part in the study? 
Staff from the Early Intervention or CAMHS service may talk to your child about 
the research study so they know about it.  Your child does not have to take part 
in it if they do not want to, and this will not affect the services received from the 
Early Intervention or CAMHS service.  If you do not wish them to take part then 
this will also in no way affect the service received by the team.  Their care 
coordinator and consultant will be informed that they are taking part in this 
study. 
What will happen if they don’t want to carry on with the study? 
They are free to withdraw from the study at any time.  If they withdraw from the 
study, we will use the data collected up to the point that they withdraw unless 
we are told otherwise. 
What will happen to the results of this study? 
It is intended that the results of this study will guide further research on different 
ways to provide information on medication to encourage and support people in 
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the 14 to 18 year age group to take their prescribed medication.  It is anticipated 
that the results will be published as a journal paper and included in a research 
thesis, but your child will not be personally identified although direct quotes from 
the information obtained may be used.  The results will be discussed within the 
Early Intervention Service and a summary of the main findings will be sent to 
those participants who have asked for feedback. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called 
a Research Ethics Committee, to protect participants’ interests. This study has 
been reviewed and given favourable opinion by North West 12 Research Ethics 
Committee (Lancaster).  It has also been reviewed by the Lancashire Care NHS 
Foundation Trust ethics committee and the ethics committee at the University of 
Central Lancashire.    
What if there is a problem? 
If you or your child have a concern about any aspect of this study, you should 
ask to speak to the Principal Investigator for this study, Professor Joy Duxbury 
[telephone number 01772 895110].  Any concerns will be looked at by 
Professor Duxbury, however If you remain unhappy and wish to complain 
formally, you can do this using the Lancashire Care NHS Foundation Trust 
Complaints Procedure Details can be obtained from the Complaints Manager, 
Sceptre Point, Sceptre Way, Walton Summit, Bamber Bridge, Preston PR5 
6AW.  Telephone 01772 695316) 
Further information 
If you have any further questions please feel free to ask and if you think of 
anything later on, you can contact me at Sonia Ramdour, Guild Lodge, Guild 
Park Hospital, Whittingham, Preston PR3 2AZ or by telephoning 01772 406640. 
If I am not in the office please leave a message on the answer phone and I will 
contact you as soon as I am able. You should keep a copy of this information 
for future reference.   Thank you for considering whether you want your child be 
involved in the study 
328 
 
 
 
Study Number: 09/H1015/77 
 
Parental Consent Form for Service Users Aged 14 and 15 
 
Factors influencing teenage adherence with antipsychotic medication                                                                                                                   
 
Please initial box 
 
I confirm that I have read and understand the information 
sheet dated January 2013 (version 3) for the above 
study and have had the opportunity to ask questions. 
 
I understand that my child’s participation is voluntary and  
that they are free to withdraw at any time, without giving any  
reason and  without their medical care being affected. 
 
I understand that my child will be asked to take photographs  
for this study. 
 
I consent to use of digital audio-recording during the interview  
 
I give consent to the use of direct quotes my child may make  
during the interview and understand that their name will 
not be included alongside these quote 
 
I understand that their care coordinator and consultant will 
be informed of their involvement in the study 
  
I agree to them taking part in the above study.                                          
 
I understand that relevant sections of data collected during the 
study may be looked at by individuals from the University of  
Central Lancashire, from regulatory authorities or from the  
Lancashire Care NHS Foundation Trust, where it is relevant to  
my taking part in this research.  I give permission for these  
individuals to have access to this data. 
 
 
Name of child (Please Print)  ……………………………………………          
   
Name of parent (Please Print)……………………………….Date……                  
 
Signature of Parent ……………………………………………………… 
 
Please return in the FREEPOST ENVELOPE provided 
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Appendix 4.  Consent form 
 
 
CONSENT FORM 
‘What taking antipsychotic medication means to me’ 
Please initial below only if you agree with the statements. Please ask if you are 
unclear or have any questions. Please also print your name, sign and date the 
form below. 
               Initials 
1. I have read and understood the information sheet for this 
study  
2. I have had the opportunity to ask questions about the study  
and these have been answered to my satisfaction 
 
 
3. I understand that my participation is entirely voluntary and that 
I am free to withdraw at any time 
 
 
4. I understand that if there are concerns about my mental health 
during any meetings with the researcher, that they may have 
to contact my care coordinator or a member of my mental 
health team 
 
 
5. I understand that if I disclose that I am not currently taking my 
medication, the researcher will be obliged to discuss this with 
my care coordinator.     
 
 
 PHOTOGRAPHY PHASE 
  
6. I agree to comply with the guidelines given in the ‘Photograph 
guidance sheet for participants’ document 
 
 
7. I agree for the researcher to view these photographs after 
development and for a CD-Rom to be produced so the 
researcher can view these on her computer 
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______________________ 
Researcher’s name                                  
 
_____________________ 
Researcher’s signature 
 
Date ________________      
 
8.  I agree to a selection of these photographs being used in the 
PhD thesis/ subsequent publications and/or presentations as 
stated in the ‘Photograph Use Permission Form’. I also 
understand that I can request for certain photographs NOT to 
be used. 
 
 
 INTERVIEW PHASE 
  
9. I agree to the interview being audio recorded 
  
10. I understand that quotes of what I have said in the interview 
may be used in the thesis and in presentations and 
publications. I understand that my name will not be used and 
the quotes will be anonymised 
 
 
11. I agree to take part in the above study 
 
 
 
 
____________________________ 
Participant’s name                                  
 
____________________________ 
Participant’s signature 
 
Date  _________________                          Date  ____ _____   
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Appendix 5.  Photography permission form 
 
Photograph Use Permission Form 
‘What taking antipsychotic medication means to me’ 
Photograph 
number 
Stored electronically 
for 5 years 
Thesis 
publication 
Presentations/ 
exhibition 
Academic 
publications 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
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I consent to the following photographs being used for the stated purpose. 
 
Participant Name     Researcher Name 
 
Participant signature     Researcher Signature 
 
Date       Date 
  
16     
17     
18     
19     
20     
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Appendix 6.  Model release form 
 
Model Release Form 
‘A research project’ 
Your photograph has been taken by __________________   as part of a 
research project they are participating in. This project is being undertaken jointly 
by the Lancashire Care NHS Foundation Trust and the University of Central 
Lancashire, Preston. 
Please sign below to state that you are happy for the following: 
 I consent to this photograph being used as part of the research 
study and thesis about the study. 
 I consent to this photograph being used in a range of academic 
publications. 
 I consent to this photograph being use in an exhibition or oral 
presentation 
 I consent to this photograph being stored on a secure computer at 
the University of Central Lancashire or Lancashire Care NHS 
Foundation Trust for up to 5 years. 
 I understand that I will not be identified by name in any of the 
above. 
 
Name  __________________________________ 
Date  __________________________________ 
Signature __________________________________ 
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Appendix 7.  Research protocol 
 
 
Research Protocol   
 
An Exploration of Perceptions affecting medication adherence in young 
people in early intervention services with a diagnosis of psychosis. 
 
Protocol Author:  Sonia Ramdour, Lead Pharmacist Central Lancashire. 
Protocol date:  March 2014. 
 
Introduction. 
Medication is an important intervention in the management of mental health 
illness and has significant mental health benefits for the individual. If a service 
user does not take medication as prescribed, this may adversely impact in the 
short and long-term through ongoing symptoms, and poorer response to 
medication the longer the duration of untreated illness. 
 
Antipsychotic medication has been shown to be effective in the treatment of 
schizophrenia but the importance of medication in the prevention of relapse has 
been reviewed by a number of authors (Davis et al. 1993; Gilbert et al.1995; 
Hogarty 1993). Hogarty in 1993 reviewed the effectiveness of antipsychotic 
medication in preventing relapse and showed that relapse rates in the first year 
following hospitalisation can be reduced from 70% to 40% by the use of 
antipsychotic medication (Hogarty 1993). Davis et al carried out a meta- 
analysis of 35 double blind studies comparing maintenance treatment with 
placebo in 3,720 chronic schizophrenic patients. The results showed that 
patients who do not receive antipsychotics are more likely to relapse within 
three years with relapse rates of 55% in those patients randomized to placebo 
treatment as compared to 21% in the antipsychotic treatment group (Davis et al. 
1993).  Gilbert et al reviewed the effect of antipsychotic withdrawal from an 
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analysis of 66 studies involving the withdrawal of medication, which included 
4365 patients. The mean cumulative relapse rate was 53% in those patients 
withdrawn from medication over a period of 9.7 months compared to 16% in 
those maintained on antipsychotic treatment (Gilbert et al. 1995). Whilst there 
are several factors which impact on the validity of these types of reviews e.g. 
lack of diagnostic details, the absence of a standardised definition of “relapse”, 
the inclusion of conditions that would not be diagnosed as schizophrenia using 
contemporary criteria and lack of clarity around duration and dose of medication 
in the preceding episode, it is clear that there are significant risks to individuals 
who choose not to take their antipsychotic medication.  
 
Gilbert el al. in their review examined factors that may predict relapse but 
rejected them however Baldessarini et al. further analysed the evidence 
reviewed by Gilbert et al and provide a list of predictive risk factors with 
antipsychotic withdrawal e.g. gradual discontinuation of treatment, lower 
prescribed dose of antipsychotic.   
 
The issue of whether maintenance treatment is required by all patients with a 
diagnosis of schizophrenia has been reviewed by the NICE schizophrenia 
guidelines. It is reported that around 20% of patients will only experience a 
single episode. Identifying this patient group is however not possible and 
therefore the NICE guidelines have concluded that pharmacological relapse 
prevention should be considered for every patient who is diagnosed with 
schizophrenia (NICE 2002). 
 
Whilst many clinicians would consider medication efficacy with regards to the 
balance of improved symptoms vs. adverse effects, a broader concept has 
been suggested which also takes into consideration factors important to the 
individual prescribed the medication. Such factors may relate to issues of 
tolerability, ability to live independently, physical health and other quality of life 
measures (Thomas 2007). It has been suggested that effectiveness of 
medication is characterised by four different outcome categories: symptoms of 
the disease, burden of treatment, burden of illness and health and wellness 
(Nasrallah et al, 2005). In isolating the individual factors that may impact upon 
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treatment adherence it is therefore important to consider that these should not 
be viewed in isolation but as part of a complex interdependence which overall 
improves the quality of life for individual patients with a diagnosis of 
schizophrenia. 
 
Services users, carers and healthcare professionals within early intervention 
services may have a variety of views, or personal experience, of why there is 
often a reluctance to take prescribed medication for mental illness and these 
views need to be sought in a systematic, evidenced based way to inform 
discussion about future interventions and information provision. It has been 
suggested in existing research that people need to recognise a benefit from 
taking medication and that side effects can influence decisions around whether 
or not to take medication as prescribed. It is anticipated that research focused 
on views of this younger age group, their carers and professionals working with 
them may guide interventions which would hope to positively impact on 
adherence rates with medication in the future.  The 14 to 18 year age group has 
been neglected in research of this type to date, and therefore it is important to 
consider their views as they may differ from those individuals who are older. 
 
PHASE ONE 
Objectives. 
 
The objectives of phase one of this study are as follows: 
1. To explore factors that are perceived as influencing service user’s adherence 
to medication  
2. To assess whether there are differences in the views of healthcare 
professional (HCP's), carers and service users  
3. To consider whether the three groups have different perceptions of what 
constitutes a benefit from medication 
4.  To inform discussion about future interventions and provision of information 
that may positively impact on adherence rates with medication in this 14 to 18 
year old age group. 
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Participants. 
 
Inclusion Criteria. 
1. Service users aged 14 to 18 who have been referred to the early intervention 
service or child and adolescent mental health (CAMHS) services for 
assessment and/or treatment  
2. Carers of a 14−18 year old who has current contact with the early 
intervention or CAMHS service  
3. Staff currently working within early intervention or CAMHS services 
 
Exclusion Criteria. 
1. Those unable to participate and/or give valid consent due to physical or 
mental health problems 
2. Service users under the age of 14 or over the age of 18 
3. Those caring for someone who is under 14 or over 18  
4.  Staff not currently working within early intervention or CAMHS services  
 
Sample and recruitment. 
Participants will be recruited from early intervention and child and adolescent 
mental health services (CAMHS) tier 3 and 4 services within Lancashire Care 
NHS Foundation Trust as follows: 
 
Phase One 
 Posters advertising the initial study questionnaire will be displayed in key 
areas e.g. clinic waiting areas.   
 Flyers will be given to care coordinators so they can pass them on to 
patients and carers on their case load who fulfill the inclusion criteria for 
the study.    
 Likewise, reception staff will give flyers to those fulfilling the criteria who 
attend outpatient clinics.  
 Staff will receive a flyer via staff email distribution lists.   
 The questionnaire will also be publicised on the trust website, twitter and 
facebook pages 
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The questionnaire may also be publicised via links from mental health charities 
to the trust website page, and also via ‘retweets’ from mental health charities 
who are signed up to receive tweets from the trust twitter page. 
 
Participation will be optional. 
 
Design of the study. 
Participants will be asked to complete an anonymous questionnaire designed to 
assess perceptions of and influences on medication adherence.  Separate 
questionnaires will be completed by staff, service users and carers although 
content will be broadly similar excepting demographic information (further 
information is detailed below).  These questionnaires have been designed using 
‘Survey Monkey’ and will be accessible to participants online via weblinks to the 
Survey Monkey website or as a hard copy. 
 
An overview of the research, including objectives and information on what will 
happen with the data collected, will be included at the start of the questionnaire 
 
Limited demographic information will be obtained as follows: 
 Age (completion of this question is optional) 
 Sex (completion of this question is optional) 
 Ethnicity (completion of this question is optional) 
 Whether the participant has ever been prescribed medication for 
psychosis 
 Whether they are a patient aged 14 to 18 who has had contact with EIS 
or CAMHS services.  
 Whether they are a carer of someone aged 14-18 in contact with the EIS 
or CAMHS service,  If so they will be asked whether their child/guardian 
has ever been prescribed antipsychotic medication  
 Whether they are a healthcare professional currently working with EIS or 
CAMHS services.  Is so they will be asked their profession and the length 
of time they have worked in CAMHS or EIS 
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Once the questionnaire has been completed all participants will have the option 
of entering into a draw for one of five £15 vouchers per participant group (HMV, 
Waterstones or iTunes).  Contact details will need to be provided if the 
participant wants to be entered into the draw so winners can be sent the 
vouchers.   Participants will also be given the following options: 
 To take no further part in the research 
 To become a member of an electronic focus group  
 To meet the researcher on an individual basis to discuss their views in 
more detail 
 To invite the researcher to a support group they are involved with to 
discuss issues with the group  
 
Those expressing an interest in the focus groups, e-forum or meeting with the 
researcher will have to provide information so the researcher can contact them.  
A participant information sheet and consent form will then be provided 
electronically or by post.  If they want to proceed they will be asked to return a 
hard copy of the consent form using the freepost address specified.  Those 
aged 14 and 15 will also be required to provide a phone number for their 
parent/guardian.  The researcher will then phone to validate that the 
parent/guardian is aware of their child’s wish to become involved in the study 
and provide a parental consent form for completion.   
 
Once all consent forms have been received the participants expressing an 
interest in the electronic focus group (e-forum) will be registered on the secure, 
private, password protected UCLAN community website which is maintained 
and supported by UCLAN and is endorsed by their ethics committee in the 
faculty of health.   Registration will enable access to the relevant medication 
adherence e-forum depending on whether they are a service user aged 14 or 
15, a service user aged 16-18, a carer or healthcare professional.  A code of 
conduct for users of the site is already established and enforced.  The 
researcher will pose questions about medication adherence on the site and 
participants will then have the opportunity to respond.  The administrator and 
researcher will have editing rights to the forum in the event of inappropriate 
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content being posted e.g. excessive swearing.  The forum will be closed at a 
time when the researcher feels that no new information is being obtained. 
 
Once consent forms have been received for those wanting to participate in a 
one to one interview, the participant will be contacted and a time and place to 
meet arranged.  The Lancashire Care NHS Foundation Trust lone worker policy 
will be followed by the researcher.  The interview will take the form of a semi-
structured interview recorded to allow transcription.  The recording will be stored 
securely in a locked cabinet within a locked room and deleted at the point that 
the research study ends.   
 
Additionally, focus groups may be conducted with attendees of current patient 
and carer forums across Lancashire.  Members will be provided with details of 
the study and focus group in advance and have the option to participate in the 
focus group or not attend.  Consent forms will be completed by any attendees. 
 
Respondents to the questionnaire can also invite the researcher to attend 
existing service user and carer groups in North West England to conduct a 
focus group.  These will be conducted as described above. 
 
Those participating in the focus groups, e-forum or discussions with the 
researcher will be entered into a draw for the opportunity to win one iPad should 
they so wish. 
 
Proposed method of analysis. 
This mixed methods study will explore the factors perceived as influencing 
willingness to take medication in this population of service users using the 
following: 
1. Results of the questionnaire 
2. Focus group outputs (electronic and face to face) 
3. Transcripts of semi-structured interviews 
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Ethical Issues and potential risks of participation in the study. 
In designing this study, the very young age of the service user group has 
required particular attention.  Where participants are aged 14 or 15, parental 
consent for involvement in any one to one interviews or focus groups (including 
those which will be conducted electronically) will be a pre-requisite. Any 
interviews and focus groups will take place outside of school hours so that 
involvement in the study will not mean patients missing school.   
 
It is hoped that potential participants will be keen to complete the questionnaire 
either electronically or as a paper copy, as this can be done quickly in a 
convenient location e.g. home.  Youngsters may be more willing to engage in 
electronic focus groups as they in the main embrace such technology. 
Electronic forums will support those youngsters who are not confident in face to 
face interactions with others.  A reminder of the need for confidentiality will be 
issued at the start of any focus group and if required during any focus group 
discussions by the facilitator.  There will be the option to leave at any point 
during the focus group or interview if the participant does not feel able to 
continue their involvement. Care coordinators will be informed in the event that 
there are concerns about a service users or carer’s mental state at interview or 
during a face to face focus group. If healthcare professionals need additional 
support, this will be provided by existing mechanisms in place in the trust. 
 
Participation is entirely voluntary and no-one will be disadvantaged if they 
choose not to participate.  No participant will be financially disadvantaged by 
their involvement.   
 
PHASE TWO 
 
Objectives. 
The objectives of this study are as follows: 
1. To further explore factors that are perceived by young people as influencing 
service user’s adherence to medication using autophography 
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2.  To inform discussion about future interventions and provision of information 
that may positively impact on adherence rates with medication in this 14 to 18 
year old age group. 
 
Participants. 
 
Inclusion Criteria. 
1. Service users of the early intervention service or child and adolescent 
mental health (CAMHS) services, or service users who attend the 
support group ‘The Crew’ who have taken antipsychotic medication at 
some point between the ages of 14 and 18 inclusive 
 
Exclusion Criteria. 
1. Those unable to participate and/or give valid consent due to physical or 
mental health problems 
2. Service users who were not prescribed antisychotic medication at some point 
between the ages of 14 and 18 inclusive 
 
Sample and recruitment. 
Participants will be recruited from early intervention and child and adolescent 
mental health services (CAMHS) tier 3 and 4 services within Lancashire Care 
NHS Foundation Trust or from the support group ‘The Crew’ initially.   
 
Posters will be displayed in reception areas advertising the second phase of the 
research, which will require young people to take photographs about what 
taking medication means to them and then discuss this topic with the 
researcher.  Care coordinators in CAMHS and early intervention services will 
identify young people aged 14-18 who are likely to participate and then arrange 
a joint visit with the researcher to discuss the research, provide an information 
sheet and expression of interest form to be returned to the researcher at the 
meeting or in a freepost envelope provided.  Staff in younger persons inpatient 
units will also be asked to identify those young people approaching discharge 
who may wish to be contacted about the research after discharge.  The 
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researcher will meet these young people on the ward before discharge and ask 
their permission to contact them about possible participation in the research 
three months post-discharge.  The researcher will also attend any relevant 
patient forums in the community with the approval of the forum facilitator.  The 
research will be discussed at a meeting in the presence of the forum facilitator 
and information sheets and expression of interest forms provided as above.  
The expression of interest form will require provision of contact details for 
parents and guardians for those aged 14 and 15.  The parent/guardian will be 
contacted by the researcher, the study discussed and a parental information 
sheet incorporating a parental consent form provided.  The research study will 
only progress in those aged 14 and 15 on receipt of the parental consent form. 
 
Design of the study. 
In the second phase of the study, the first twelve young people returning 
expressions of interest forms will be contacted and a meeting arranged to 
discuss the study in more detail.  They will be asked to take photographs 
depicting ‘what medication means to me’.  Participants will be told that this can 
include both positive and negative aspects of medication.   Participants will be 
reminded that the focus is on their own personal views and experiences, as 
opposed to that of the wider public, and will be informed that they can focus on 
experiences and hopes in the past, present and/or future. Participants will be 
told that they can take ‘real life’ photographs, or collect other images, for 
example, from photo albums, magazines etc. If such images are presented then 
the researcher will seek permission to take a digital photograph of those 
images.   
 
During this meeting participants will be given the chance to ask any questions, 
be asked to sign a consent form for the photography and interview phase of the 
project and if not taking photographs via a personal mobile phone they will be 
provided with a disposable camera. They will also be made aware of the 
importance of getting written permission before taking photographs of other 
individuals and will be provided with copies of the Model Release Form to 
facilitate this. 
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A time frame for this stage will be agreed between the researcher and the 
participant but it is anticipated to be approximately 4 weeks. Once the 
photographs have been taken participants will email the photographs to a 
university email account or post the camera back to the researcher in a pre-paid 
padded envelope provided. The researcher will obtain (a) a set of prints for 
participants, and (b) a CD-Rom copy of these prints for the researcher. The 
participant will have been made aware and consented to the fact that the 
researcher will look at these photographs before sending them back to check 
that they have developed correctly. Participants will also consent to the 
researcher having a copy of all photographs on CD. In addition participants will 
be sent instructions alongside their photographs regarding the next stage of the 
process which will outline the need to select and label those photographs they 
wish to discuss. 
 
Once the photographs have been returned to the participant the researcher will 
call and arrange a convenient time and date for an in-depth interview where 
participants will be asked to talk about their experiences of taking medication. 
Before the interview, participants will be asked to verbally reaffirm their consent 
to the interview phase of the project. Participants will also complete a form 
identifying which photographs they give permission to be stored for 5 years, 
and/or used in a thesis, and/or used in presentations or exhibitions and/or used 
in academic publications. During the interview, participants will be asked to talk 
about their experiences of taking medication, before being asked to talk 
specifically about the photographs they have taken. They will be asked 
questions to explore whether any of the information provided promotes 
medication adherence or interferes with it.  They will also be asked specific 
questions based on findings of the staff survey to enable any concurring or 
discrepant views to be discussed.  At the end of the interview they will have a 
final opportunity to add anything else they consider appropriate.  
 
It is anticipated that the interview could take up to one hour, although 
participants will be made aware that they can take a break whenever they wish 
and/or finish earlier than expected. At the start of each interview the interviewer 
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will negotiate how much time the participant has available for the interview and 
tailor the process accordingly. All recordings will be transcribed verbatim for 
later analysis. After the interview, participants will be thanked for their time and 
be presented with a £10 gift voucher in recognition of their input. They will also 
be advised that they have a ‘cooling off’ period of one month during which time 
they can contact the researcher and ask for some or all of their data to be 
removed from the study.  
 
Summary of the process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 At the start of the interview, verbal consent is reaffirmed.  Permission is obtained 
to audio-record the interview.  The interview is then conducted in line with the 
interview prompts sheet.  At the end of the interview the photograph use 
permission form is completed.  If the person has disclosed that they are currently 
not taking medication the care coordinator will be informed.  The young person 
will be made aware of this disclosure 
 
The young person is contacted and a meeting with the researcher arranged.  At 
this meeting the photography stage is explained in detail.  A photography 
guidance sheet is provided along with a model release form for completion by 
anyone they photograph.  Consent is assessed and the consent form completed.  
A disposable camera is provided where this is the preferred method to take 
photographs. The consultant and care coordinator are informed of their 
involvement in the study. 
 
On receipt of expression of interest form, the researcher contacts the 
parent/guardian of those aged 14 and 15.  The young person will not be 
contacted again until written parental consent is received  
 
Potential participants are approached by researcher and a member of staff who 
knows them.  Information sheet and expression of interest form is provided 
tial participants are approached by researcher and a 
member of staff who knows them.  Information sheet and 
expression of interest form is provided 
The researcher contacts the participant and arranges a date, time and venue for the 
interview 
 
The researcher returns the developed photographs to the young person mounted 
on cards. Printed labels are included so they can give the photographs a title, 
identify whether the image represents a positive or negative aspect of taking 
medication, and indicate whether the photograph is relevant to the past, present 
and/or future before the interview.  A photograph selection form is provided so 
they are clear about what they need to do with the photographs before the 
interview.   
 
The researcher arranges for the photographs to be developed along with a CD-
Rom of the photographs 
 
The young person takes up to 20 photographs and then returns them to the 
researcher 
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Proposed method of analysis. 
Narrative analysis of in-depth interviews conducted with young people 
participating in the auto-photography part of the study 
 
Ethical Issues and potential risks of participation in the study. 
In designing this study, the very young age of the service user group has 
required particular attention.  Where participants are aged 14 or 15, parental 
consent for involvement in this phase of the study will be a pre-requisite. Any 
interviews will take place outside of school hours so that involvement in the 
study will not mean patients missing school, college or work.   
 
Young people participating in the auto-photography part of the study will in the 
main have been identified by their care team as being able to participate in the 
study and give the necessary informed consent.  Alternatively, they will be 
community patients attending a patient forum facilitated by a member of staff.  
They will be given clear instruction about what images they can use e.g. from 
magazine or the internet, and be told that they can only include images of other 
people with their written consent on the model release form.  If this is not 
available then the images will not be included in the research. Additionally, any 
images deemed by the researcher to be inappropriate will be excluded from the 
research and the young person informed of the reasons for this.  Young people 
will provide written consent at the start of the study to the photography and 
subsequent interview and will provide further verbal consent at the interview 
stage.  They will be able to withdraw at any point during the study and also 
withdraw all or part of their images during and up to four weeks after their 
interview.   
 
Participation is entirely voluntary and no-one will be disadvantaged if they 
choose not to participate.   
 
Safeguarding Children 
Lancashire Care Trust (LCFT) staff have a duty of care to safeguard and protect 
children at risk of harm and neglect from the subsequent negative outcomes 
and enable all children to reach their full potential. Every child has the right to 
347 
 
be protected from potential significant harm.  If at any time staff identify 
concerns for a child/ young persons welfare or believe a child is suffering, is at 
risk of suffering abuse or neglect or has suffered abuse or neglect a referral 
must be made to Children’s Integrated Services (CIS) in line with LCFT and 
Local Safeguarding Children Board Procedures.  The child/ young person’s 
welfare should remain the central concept in any assessment 
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Appendix 8.  Photography guidance sheet 
 
Photograph Guidance Sheet for Participants 
‘What taking antipsychotic medication means to me’ 
This sheet will provide you with further details regarding the steps you need to 
take in this stage of your participation in my study. Please don’t let this guidance 
sheet put you off taking part. It just gives you some useful information. If you 
have any further questions, or experience any difficulties in undertaking this 
task, please contact me (Sonia Ramdour) on 01772 406640 or 
SJRamdour@uclan.ac.uk  
What should I take photographs of? 
I would like you to think about what taking antipsychotic medication means to 
you, both the good and bad things. I would like you to take up to 20 
photographs which you believe represent your views about antipsychotic 
medication. You can focus on what this means in the present, past and/or 
future.  There is no right or wrong way to do this and everyone who takes part in 
the study will take different pictures.  When taking these photographs please 
remember that some might be used in my thesis, in articles, or at conferences. 
You have the right to tell me that I cannot use certain photographs in this way. 
Do I need to obtain permission before taking photographs of people? 
It is important that when you take your photographs that you respect the privacy 
of other people. Please do not take a picture of someone who does not wish to 
be photographed. If you are taking a photograph of an individual, please ask 
them to sign a Model Release Form (or their parent/guardian if they are under 
the age of 16) – included in this pack 
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If you are taking a picture of a group of people who could be identified, it would 
be good to let them know that this photograph may be used in a range of 
academic publications/conference presentations.  
Can I use old photographs? 
Yes it is fine to use some old photographs if you want to. You may already have 
some photographs which you think represent your views on taking medication. I 
will request permission from you to take a photograph of these pictures using a 
digital camera. Please do take at least some new photographs, and then you 
can talk about both the old and new photographs in the interview stage of this 
project. 
Can I use other resources? 
Again it is fine to use resources such as pictures of things you would struggle to 
photograph yourself. A picture of this from a magazine or the internet would be 
fine. Again I will ask permission to take a photograph of these using a digital 
camera. 
How long do I have to take these photographs? 
I will give you four weeks to take the photographs and either email the 
photographs or post the camera back to me. However, if you feel you need a 
longer period of time then that is also fine – we can discuss this after the initial 
four week period. 
What do I do once I have taken my photographs? 
Once you have taken up to 20 photographs please email them to me at 
SJRamdour@uclan.ac.uk if you have taken them on your mobile phone.  If you 
have taken photographs on the disposable camera then return the camera to 
me in the pre-paid padded enveloped I have provided for you marked ‘Private 
and Confidential’. The camera will have your participation number on the front 
so I am able to identity whom the photographs belong to.  
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What happens next? 
Once I have received the camera or email, I will get the photographs developed.  
I will check the photographs to ensure they have developed properly and I will 
post the photographs to you with additional instructions. I will also keep a copy 
of your photographs (on CD-Rom) so I can use them in my study.  
Please look through the photographs and remind yourself why you took each 
one. I will telephone you a few days after sending the photographs to arrange a 
time for us to meet again and for you to talk to me about the photographs you 
have selected.  
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Appendix 9.  Photography Selection Form 
 
Photography Selection Form 
‘What taking antipsychotic medication means to me’ 
Dear 
Please find enclosed the photographs you recently took as part of my research 
study. You will notice that these have been mounted onto card ready for the 
next step of the process.  
I will be in touch shortly to organise a time/date for us to explore these 
photographs in detail. However, in preparation for this meeting it would be really 
helpful if you could take a short amount of time to do the following: 
1. Remove any photographs which you do not wish to include in the 
discussion. 
2. Add any additional photographs/images to the spare cards (use a 
paperclip if you do not wish to stick these down) 
3. For each photograph write a title which briefly explains what this is. 
4. Please also use the stickers I have include in the pack to help label the 
photograph. You will find the following labels 
a. Positive aspects (of taking antipsychotic medication) 
b. Negative aspects (of taking antipsychotic medication) 
c. Past (i.e. this relates to the past) 
d. Present (i.e. this relates to the present) 
e. Future (i.e. this is relevant to the future) 
f. Some blank labels for if you need more 
Please attach all labels that apply to the photograph.  
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I have included an example to illustrate this titled ‘Sleepiness’.  If this is not 
clear or you have any questions, please do not hesitate to contact me on 01772 
406640 or SJRamdour@uclan.ac.uk (Monday – Friday 9am – 5pm please). I 
will be in contact within the next week to arrange a time/date for my interview 
with you. 
Best wishes, 
 
 
Sonia Ramdour 
Pharmacist and Research student 
 
Title: Sleepiness.................................... 
 
 
NEGATIVE 
ASPECTS 
PAST 
PRESENT 
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Appendix 10.  Interview Prompts 
Before the interview begins I need to check a few things with you. 
1. Have you read and understood the information sheet? Do you have any 
questions? 
2. Briefly explain the format of the interview – what they can expect. 
3. Ask if they are happy to verbally reaffirm consent taken at photograph 
stage 
4. How long do you have for this interview? Any time constraints? Explain 
that we will have a break half way through and that they may pause or 
stop at any point. 
5. Ask permission to audio-record the interview 
6. Check if there are any last minute questions. 
7. Ask the participant to sort the photographs in order of importance. 
Now we can get started on the interview. 
1. Can you start by telling me  little bit about yourself 
2. As you know I am wanting to hear your story about taking antipsychotic 
medication.  Please can you tell me your story about taking this 
medication using the photographs you have taken.  When you do this it 
would be great if you could also include the title you have given the 
photograph. I would like you to tell me your story in as much detail as 
you can. I will not interrupt you but I may take some notes in order to ask 
you some questions later. 
3. Wait until the participant appears to have finished speaking and prompt 
them if there is anything else they would like you add. 
4. Ask about any shifts in views about antipsychotic medication  
5. If prompts are needed to obtain more information then consider the 
following: 
 Ask participants to expand on why they chose the particular titles for any 
photographs where it has not been explained/is not self evident. 
 Consider past/present/ future pictures and explore any shifts in view 
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6. Probe more in relation to what motivates them to take their medication 
and if there is anything that makes them think about not taking 
medication. 
7. Ask them to pick out three sort cards which for them are really important 
in terms of taking medication.  Ask them to tell a story about the 
particular cards chosen. 
 What other people think about medication 
 Pressure to take or not take medication 
 Wanting to be in control 
 Media e.g. internet, tv, magazines, newspapers 
 Wanting to be well 
 Achieving my goals 
 Side effects 
 Admission to hospital 
 I’m not ill 
 I’m embarrassed 
 Medication won’t help 
 Medication is bad for you 
 I’m better now 
 
8. I would just like to give you a final opportunity to say anything else you 
feel may be relevant to taking antipsychotic medication 
Thank them for their time.  Give voucher.  Complete photography use 
permission form if not already completed.  Remind them that they can withdraw 
any photographs over the next four weeks by contacting me.  Ask whether they 
would want written feedback on key findings from the study 
 
 
